
 <table border="1">
  		<tr>
  			<th>
  				Generic Name
  			</th>
  			<th>
  				Trade Name
  			</th>
  			<th>
  				Date Designated
  			</th>
  			<th>
  				Orphan Designation
  			</th>
  			<th>
  				Orphan Designation Status
  			</th>
  			<th>
  				FDA Orphan Approval Status
  			</th>
            
	  			<th>
	  				 Approved Labeled Indication
	  			</th>
				
				
				
	  			<th>
	  				Marketing Approval Date
	  			</th>
	  			<th>
	  				Exclusivity End Date
	  			</th>
				
				<th>
	  				Exclusivity Protected Indication *
					(Shown for approvals from Jan. 1, 2013, to the present)
	  			</th>
			
  			<th>
  				Sponsor Company
  			</th>
  			<th>
  				Sponsor Address 1
  			</th>
  			<th>
  				Sponsor Address 2
  			</th>
  			<th>
  				Sponsor City
  			</th>
  			<th>
  				Sponsor State
  			</th>
  			<th>
  				Sponsor Zip
  			</th>
  			<th>
  				Sponsor Country
  			</th>
			
			<th>
  				CF Grid Key
  			</th>
			
  		</tr>
    
	
  		<tr>
  			<td>
  				Liothyronine sodium injection
  			</td>
  			<td>
  				Triostat
  			</td>
  			<td>
  				07/30/1990
  			</td>
  			<td>
  				Treatment of myxedema coma/precoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of myxedema coma/precoma.
	  			</td>
				
	  			<td>
					
						12/31/1991
					
	  			</td>

	  			<td>

					
					12/31/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				SmithKline Beecham Pharmaceuticals
  			</td>
  			<td>
  				One Franklin Plaza
  			</td>
  			<td>
  				P.O. Box 7929
  			</td>
  			<td>
  				Philadelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				046090
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation Factor IX (human)
  			</td>
  			<td>
  				AlphaNine
  			</td>
  			<td>
  				07/05/1990
  			</td>
  			<td>
  				For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/31/1990
					
	  			</td>

	  			<td>

					
					12/31/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alpha Therapeutic Corporation
  			</td>
  			<td>
  				5555 Valley Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Los Angeles
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90032
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				045890
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Epoetin alfa
  			</td>
  			<td>
  				Epogen
  			</td>
  			<td>
  				07/01/1991
  			</td>
  			<td>
  				Treatment of anemia associated with HIV infection or HIV treatment.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of AZT-induced anemia in HIV infected patients.
	  			</td>
				
	  			<td>
					
						12/31/1990
					
	  			</td>

	  			<td>

					
					12/31/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				1840 Dehavilland Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				056490
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				levoketoconazole
  			</td>
  			<td>
  				Recorlev
  			</td>
  			<td>
  				03/09/2012
  			</td>
  			<td>
  				Treatment of endogenous Cushing's syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative
	  			</td>
				
	  			<td>
					
						12/30/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Strongbridge Dublin Limited
  			</td>
  			<td>
  				Suite 206, Fitzwilliam Hall
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dublin 2
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D02 T292
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				364412
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin for injection
  			</td>
  			<td>
  				Nutropin
  			</td>
  			<td>
  				03/23/1989
  			</td>
  			<td>
  				Treatment of short stature associated with Turner's syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of growth failure associated with Turner syndrome.
	  			</td>
				
	  			<td>
					
						12/30/1996
					
	  			</td>

	  			<td>

					
					12/30/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				460 Point San Bruno Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				012686
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin
  			</td>
  			<td>
  				Humatrope
  			</td>
  			<td>
  				05/08/1990
  			</td>
  			<td>
  				Treatment of short stature associated with Turner syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.
	  			</td>
				
	  			<td>
					
						12/30/1996
					
	  			</td>

	  			<td>

					
					12/30/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				045090
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Dornase alfa
  			</td>
  			<td>
  				Pulmozyme
  			</td>
  			<td>
  				01/16/1991
  			</td>
  			<td>
  				To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function.
	  			</td>
				
	  			<td>
					
						12/30/1993
					
	  			</td>

	  			<td>

					
					12/30/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				460 Point San Bruno Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				048090
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antithrombin III (human)
  			</td>
  			<td>
  				Thrombate III
  			</td>
  			<td>
  				11/26/1984
  			</td>
  			<td>
  				For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/30/1991
					
	  			</td>

	  			<td>

					
					12/30/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bayer Corporation
  			</td>
  			<td>
  				Pharmaceutical Division, Biological Products
  			</td>
  			<td>
  				400 Morgan Lane
  			</td>
  			<td>
  				New Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06516
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				004084
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Botulinum toxin type A
  			</td>
  			<td>
  				Botox
  			</td>
  			<td>
  				03/22/1984
  			</td>
  			<td>
  				Treatment of strabismus and blepharospasms
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)
	  			</td>
				
	  			<td>
					
						12/30/1989
					
	  			</td>

	  			<td>

					
					12/30/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Allergan, Inc.
  			</td>
  			<td>
  				2525 Dupont Drive
  			</td>
  			<td>
  				P.O. Box 19534
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92713
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				000483
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Mesna
  			</td>
  			<td>
  				Mesnex
  			</td>
  			<td>
  				11/14/1985
  			</td>
  			<td>
  				For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/30/1988
					
	  			</td>

	  			<td>

					
					12/30/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Degussa Corporation
  			</td>
  			<td>
  				65 Challenger Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ridgefield Park
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07660
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				008685
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ifosfamide
  			</td>
  			<td>
  				Ifex
  			</td>
  			<td>
  				01/20/1987
  			</td>
  			<td>
  				Treatment of testicular cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer.
	  			</td>
				
	  			<td>
					
						12/30/1988
					
	  			</td>

	  			<td>

					
					12/30/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Pharmaceutical Research Institute
  			</td>
  			<td>
  				5 Research Parkway, P.O. Box 5100
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wallingford
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06492
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				017786
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tranexamic acid
  			</td>
  			<td>
  				Cyklokapron
  			</td>
  			<td>
  				12/03/1985
  			</td>
  			<td>
  				For use in patients with congenital coagulopathies undergoing surgical procedures, e.g. dental extractions
  			</td>
  			<td>
  				Designated/Approved/Withdrawn
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with hemophilia for short term use (2 to 8 days) before and after tooth extraction to reduce or prevent hemorrhage abd reduce the need for replacement therapy
	  			</td>
				
	  			<td>
					
						12/30/1986
					
	  			</td>

	  			<td>

					
					12/30/1993
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia Inc.
  			</td>
  			<td>
  				P.O. Box 16529
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Columbus
  			</td>
  			<td>
  				Ohio
  			</td>
  			<td>
  				43216
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				008885
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; and treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. 
	  			</td>
				
	  			<td>
					
						12/29/2014
					
	  			</td>

	  			<td>

					
					12/29/2021
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis (CF) in patients age 6 years and older who have an R117H mutation in the CFTR gene.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Iloprost inhalation solution
  			</td>
  			<td>
  				Ventavis
  			</td>
  			<td>
  				08/17/2004
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms
	  			</td>
				
	  			<td>
					
						12/29/2004
					
	  			</td>

	  			<td>

					
					12/29/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CoTherix, Inc.
  			</td>
  			<td>
  				5000 Shoreline Court
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				186904
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Bexarotene
  			</td>
  			<td>
  				Targretin
  			</td>
  			<td>
  				06/18/1999
  			</td>
  			<td>
  				Treatment of cutaneous T-cell lymphoma.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.  
	  			</td>
				
	  			<td>
					
						12/29/1999
					
	  			</td>

	  			<td>

					
					12/29/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eisai, Inc.
  			</td>
  			<td>
  				300 Tice Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Woodcliff Lake
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07677
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				124699
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Aprotinin
  			</td>
  			<td>
  				Trasylol
  			</td>
  			<td>
  				11/17/1993
  			</td>
  			<td>
  				For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/29/1993
					
	  			</td>

	  			<td>

					
					12/29/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bayer Corporation
  			</td>
  			<td>
  				Pharmaceutical Division
  			</td>
  			<td>
  				400 Morgan Lane
  			</td>
  			<td>
  				West Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06516
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				066992
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Satumomab pendetide
  			</td>
  			<td>
  				Oncoscint CR/OV
  			</td>
  			<td>
  				09/25/1989
  			</td>
  			<td>
  				Detection of ovarian carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.
	  			</td>
				
	  			<td>
					
						12/29/1992
					
	  			</td>

	  			<td>

					
					12/29/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cytogen Corporation
  			</td>
  			<td>
  				600 College Road East
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				036789
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Botulinum toxin type A
  			</td>
  			<td>
  				Botox
  			</td>
  			<td>
  				03/22/1984
  			</td>
  			<td>
  				Treatment of strabismus and blepharospasms
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)
	  			</td>
				
	  			<td>
					
						12/29/1989
					
	  			</td>

	  			<td>

					
					12/29/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Allergan, Inc.
  			</td>
  			<td>
  				2525 Dupont Drive
  			</td>
  			<td>
  				P.O. Box 19534
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92713
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				000483
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bedaquiline
  			</td>
  			<td>
  				SIRTURO
  			</td>
  			<td>
  				01/10/2005
  			</td>
  			<td>
  				Treatment of active tuberculosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
	  			</td>
				
	  			<td>
					
						12/28/2012
					
	  			</td>

	  			<td>

					
					12/28/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Janssen Research & Development, LLC
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				199304
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				clofarabine
  			</td>
  			<td>
  				Clolar
  			</td>
  			<td>
  				02/07/2002
  			</td>
  			<td>
  				Treatment of acute lymphoblastic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens
	  			</td>
				
	  			<td>
					
						12/28/2004
					
	  			</td>

	  			<td>

					
					12/28/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				4545 Horizon Hill Blvd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Antonio
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				78229
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				153201
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Filgrastim
  			</td>
  			<td>
  				Neupogen
  			</td>
  			<td>
  				07/17/1995
  			</td>
  			<td>
  				For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in the mobilization of hematopoietic progenitor cells into the peripheral blood collection by leukapheresis.
	  			</td>
				
	  			<td>
					
						12/28/1995
					
	  			</td>

	  			<td>

					
					12/28/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				1840 Dehavilland Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				089395
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				Lynparza
  			</td>
  			<td>
  				10/11/2018
  			</td>
  			<td>
  				Treatment of pancreatic cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
	  			</td>
				
	  			<td>
					
						12/27/2019
					
	  			</td>

	  			<td>

					
					12/27/2026
					
					
	  			</td>

				<td>
					Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P.O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				655318
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid
  			</td>
  			<td>
  				01/29/2004
  			</td>
  			<td>
  				Treatment of myelodysplastic syndromes
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities
	  			</td>
				
	  			<td>
					
						12/27/2005
					
	  			</td>

	  			<td>

					
					12/27/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				180303
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Porfimer sodium
  			</td>
  			<td>
  				Photofrin
  			</td>
  			<td>
  				06/06/1989
  			</td>
  			<td>
  				For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Photodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy.
	  			</td>
				
	  			<td>
					
						12/27/1995
					
	  			</td>

	  			<td>

					
					12/27/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				QLT Phototherapeutics, Inc.
  			</td>
  			<td>
  				Lederle Laboratories
  			</td>
  			<td>
  				401 North Middletown Road
  			</td>
  			<td>
  				Pearl River
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10965
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				035589
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Immune globulin intravenous, human
  			</td>
  			<td>
  				Gamimune N
  			</td>
  			<td>
  				02/18/1993
  			</td>
  			<td>
  				Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For prophylaxis of children with clinical or immunologic evidence of human immunodeficiency virus to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization, and to increase the time free of serious bacterial infections.
	  			</td>
				
	  			<td>
					
						12/27/1993
					
	  			</td>

	  			<td>

					
					12/27/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bayer Corporation
  			</td>
  			<td>
  				Pharmaceutical Division, Biological Products
  			</td>
  			<td>
  				400 Morgan Lane
  			</td>
  			<td>
  				New Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06516
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				070592
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Altretamine
  			</td>
  			<td>
  				Hexalen
  			</td>
  			<td>
  				02/09/1984
  			</td>
  			<td>
  				Treatment of advanced adenocarcinoma of the ovary.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.
	  			</td>
				
	  			<td>
					
						12/26/1990
					
	  			</td>

	  			<td>

					
					12/26/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Medimmune Oncology, Inc.
  			</td>
  			<td>
  				One Tower Bridge
  			</td>
  			<td>
  				100 Front Street, Suite 400
  			</td>
  			<td>
  				West Conshohocken
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19428
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				000983
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Modafinil
  			</td>
  			<td>
  				Provigil
  			</td>
  			<td>
  				03/15/1993
  			</td>
  			<td>
  				Treatment of excessive daytime sleepiness in narcolepsy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.
	  			</td>
				
	  			<td>
					
						12/24/1998
					
	  			</td>

	  			<td>

					
					12/24/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cephalon, Inc.
  			</td>
  			<td>
  				145 Brandywine Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				West Chester
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19380
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				073793
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sterile talc powder
  			</td>
  			<td>
  				Sclerosol Intrapleural Aerosol
  			</td>
  			<td>
  				09/18/1995
  			</td>
  			<td>
  				Treatment of malignant pleural effusion.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of recurrence of malignant pleural effusions in symptomatic patients.
	  			</td>
				
	  			<td>
					
						12/24/1997
					
	  			</td>

	  			<td>

					
					12/24/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Sciarra Laboratories, Inc.
  			</td>
  			<td>
  				485-09 South Broadway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Hicksville
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				11801
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				091595
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Histrelin acetate
  			</td>
  			<td>
  				Supprelin Injection
  			</td>
  			<td>
  				08/10/1988
  			</td>
  			<td>
  				Treatment of central precocious puberty.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of central precocious puberty.
	  			</td>
				
	  			<td>
					
						12/24/1991
					
	  			</td>

	  			<td>

					
					12/24/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Roberts Pharmaceutical Corp.
  			</td>
  			<td>
  				Meridian Center III
  			</td>
  			<td>
  				6 Industrial Way West
  			</td>
  			<td>
  				Eatontown
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07724
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				016986
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nusinersen
  			</td>
  			<td>
  				Spinraza
  			</td>
  			<td>
  				04/18/2011
  			</td>
  			<td>
  				Treatment of spinal muscular atrophy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of spinal muscular atrophy in pediatric and adult patients
	  			</td>
				
	  			<td>
					
						12/23/2016
					
	  			</td>

	  			<td>

					
					12/23/2023
					
					
	  			</td>

				<td>
					Treatment of spinal muscular atrophy in pediatric and adult patients
				</td>
			
  			<td>
  				Biogen, Inc
  			</td>
  			<td>
  				225 Binney Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				336711
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				coagulation factor XIII A-subunit (recombinant)  
  			</td>
  			<td>
  				TRETTEN
  			</td>
  			<td>
  				11/06/2003
  			</td>
  			<td>
  				Prophylaxis of bleeding associated with congential factor XIII deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.  
	  			</td>
				
	  			<td>
					
						12/23/2013
					
	  			</td>

	  			<td>

					
					12/23/2020
					
					
	  			</td>

				<td>
					Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.  
				</td>
			
  			<td>
  				Novo Nordisk, Inc.
  			</td>
  			<td>
  				800 Scudders Mill Rd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Plainsboro
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08536
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				174803
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Nitric oxide
  			</td>
  			<td>
  				INOmax
  			</td>
  			<td>
  				06/22/1993
  			</td>
  			<td>
  				Treatment of persistent pulmonary hypertension in the newborn.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
	  			</td>
				
	  			<td>
					
						12/23/1999
					
	  			</td>

	  			<td>

					
					12/23/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mallinckrodt Hospital Products
  			</td>
  			<td>
  				1425 U.S. 206
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bedminster Township
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07921
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				074493
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Rifabutin
  			</td>
  			<td>
  				Mycobutin
  			</td>
  			<td>
  				12/18/1989
  			</td>
  			<td>
  				Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.
	  			</td>
				
	  			<td>
					
						12/23/1992
					
	  			</td>

	  			<td>

					
					12/23/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Adria Laboratories, Inc.
  			</td>
  			<td>
  				P.O. Box 16529
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Columbus
  			</td>
  			<td>
  				Ohio
  			</td>
  			<td>
  				43216
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				041989
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Benzoate and phenylacetate
  			</td>
  			<td>
  				Ucephan
  			</td>
  			<td>
  				01/21/1986
  			</td>
  			<td>
  				For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/23/1987
					
	  			</td>

	  			<td>

					
					12/23/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ImmunexImmunex
  			</td>
  			<td>
  				2525 McGaw Avenue
  			</td>
  			<td>
  				P.O. Box 19791
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92623
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				011385
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Mitoxantrone HCl
  			</td>
  			<td>
  				Novantrone
  			</td>
  			<td>
  				07/13/1987
  			</td>
  			<td>
  				Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/23/1987
					
	  			</td>

	  			<td>

					
					12/23/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Lederle Laboratories
  			</td>
  			<td>
  				Division of American Cyanamid Company
  			</td>
  			<td>
  				401 N. Middletown Road
  			</td>
  			<td>
  				Pearl River
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10965
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				019287
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Teriparatide
  			</td>
  			<td>
  				Parathar
  			</td>
  			<td>
  				01/09/1987
  			</td>
  			<td>
  				Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/23/1987
					
	  			</td>

	  			<td>

					
					12/23/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Rhone-Poulenc Rorer Pharmaceuticals, Inc.
  			</td>
  			<td>
  				500 Arcola Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Collegeville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19426
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				014486
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cysteamine enteric coated
  			</td>
  			<td>
  				PROCYSBI
  			</td>
  			<td>
  				10/24/2006
  			</td>
  			<td>
  				Treatment of cystinosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older. 
	  			</td>
				
	  			<td>
					
						12/22/2017
					
	  			</td>

	  			<td>

					
					12/22/2024
					
					
	  			</td>

				<td>
					Treatment of nephropathic cystinosis in pediatric patients 1 year of age to less than 2 years of age.
				</td>
			
  			<td>
  				Horizon Therapeutics USA, Inc.
  			</td>
  			<td>
  				150 S. Saunders Road
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Lake Forest
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60045
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				231006
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				01/23/2013
  			</td>
  			<td>
  				Treatment of Stage IIb to IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
	  			</td>
				
	  			<td>
					
						12/22/2014
					
	  			</td>

	  			<td>

					
					12/22/2021
					
					
	  			</td>

				<td>
					Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
				</td>
			
  			<td>
  				Bristol-Myers Squibb Co.
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				387612
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin (rDNA origin)
  			</td>
  			<td>
  				Nutropin Depot
  			</td>
  			<td>
  				10/28/1999
  			</td>
  			<td>
  				Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term treatment of growth failure due to a lack of adequate endogenous growth hormone secetion for once- or twice-a-month administration.
	  			</td>
				
	  			<td>
					
						12/22/1999
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				115098
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tobramycin for inhalation
  			</td>
  			<td>
  				TOBI
  			</td>
  			<td>
  				10/13/1994
  			</td>
  			<td>
  				Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of cystic fibrosis patients with P.aeruginosa.
	  			</td>
				
	  			<td>
					
						12/22/1997
					
	  			</td>

	  			<td>

					
					12/22/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mylan Specialty LP
  			</td>
  			<td>
  				781 Chestnut Ridge Road
  			</td>
  			<td>
  				Regulatory Affairs-Greenbag Road
  			</td>
  			<td>
  				Morgantown
  			</td>
  			<td>
  				West Virginia
  			</td>
  			<td>
  				26505
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				084494
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Dronabinol
  			</td>
  			<td>
  				Marinol
  			</td>
  			<td>
  				01/15/1991
  			</td>
  			<td>
  				For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of anorexia associated with weight loss in patients with AIDS.
	  			</td>
				
	  			<td>
					
						12/22/1992
					
	  			</td>

	  			<td>

					
					12/22/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Unimed Pharmaceuticals, Inc.
  			</td>
  			<td>
  				901 Sawyer Rd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Marietta
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				054890
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cromolyn sodium
  			</td>
  			<td>
  				Gastrocrom
  			</td>
  			<td>
  				03/08/1984
  			</td>
  			<td>
  				Treatment of mastocytosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/22/1989
					
	  			</td>

	  			<td>

					
					12/22/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fisons Corporation
  			</td>
  			<td>
  				755 Jefferson Rd., P.O. Box 1710
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rochester
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				14603
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				001183
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ethanolamine oleate
  			</td>
  			<td>
  				Ethamolin
  			</td>
  			<td>
  				03/22/1984
  			</td>
  			<td>
  				Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/22/1988
					
	  			</td>

	  			<td>

					
					12/22/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				QOL Medical
  			</td>
  			<td>
  				4445 North Highway A1A, 241
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Vero Beach
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				32963
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				001484
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
	  			</td>
				
	  			<td>
					
						12/21/2020
					
	  			</td>

	  			<td>

					
					12/21/2027
					
					
	  			</td>

				<td>
					treatment of cystic fibrosis (CF) in patients age 4 months and older who have one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to ivacaftor potentiation based on in vitro data and identified in the approval on December 21, 2020.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Ave
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				elexacaftor, tezacaftor, and ivacaftor; ivacaftor
  			</td>
  			<td>
  				Trikafta
  			</td>
  			<td>
  				08/29/2018
  			</td>
  			<td>
  				Treatment of Cystic Fibrosis 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data
	  			</td>
				
	  			<td>
					
						12/21/2020
					
	  			</td>

	  			<td>

					
					12/21/2027
					
					
	  			</td>

				<td>
					treatment of cystic fibrosis in patients aged 12 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on in vitro data.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				647618
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tezacaftor/ivacaftor; ivacaftor
  			</td>
  			<td>
  				Symdeko
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of cystic fibrosis (CF)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence
	  			</td>
				
	  			<td>
					
						12/21/2020
					
	  			</td>

	  			<td>

					
					12/21/2027
					
					
	  			</td>

				<td>
					treatment of cystic fibrosis (CF) in patients age 6 years and older who have at least one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to tezacaftor/ivacaftor based on in vitro data and identified in the approval on December 21, 2020
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				577517
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ansuvimab-zykl
  			</td>
  			<td>
  				EBANGA™
  			</td>
  			<td>
  				05/08/2019
  			</td>
  			<td>
  				Treatment of Ebola Virus Disease 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection
	  			</td>
				
	  			<td>
					
						12/21/2020
					
	  			</td>

	  			<td>

					
					12/21/2027
					
					
	  			</td>

				<td>
					treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection
				</td>
			
  			<td>
  				Ridgeback Biotherapeutics, LP
  			</td>
  			<td>
  				3480 Main Highway, Unit 402
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Miami
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33133
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				683019
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ravulizumab-cwvz
  			</td>
  			<td>
  				ULTOMIRIS
  			</td>
  			<td>
  				01/04/2017
  			</td>
  			<td>
  				Treatment of paroxysmal nocturnal hemoglobinuria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
	  			</td>
				
	  			<td>
					
						12/21/2018
					
	  			</td>

	  			<td>

					
					12/21/2025
					
					
	  			</td>

				<td>
					ULTOMIRIS™ is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
				</td>
			
  			<td>
  				ALEXION PHARMACEUTICALS, INC.
  			</td>
  			<td>
  				121 SEAPORT BLVD
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				513015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Dasatinib
  			</td>
  			<td>
  				Sprycel
  			</td>
  			<td>
  				11/18/2005
  			</td>
  			<td>
  				Treatment of Philadelphia-positive acute lymphoblastic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
	  			</td>
				
	  			<td>
					
						12/21/2018
					
	  			</td>

	  			<td>

					
					12/21/2025
					
					
	  			</td>

				<td>
					SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O Box 5326
  			</td>
  			<td>
  				Mailstop C 4065
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08542
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				214605
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tagraxofusp-erzs
  			</td>
  			<td>
  				ELZONRIS
  			</td>
  			<td>
  				06/06/2013
  			</td>
  			<td>
  				Treatment of blastic plasmacytoid dendritic cell neoplasm 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
	  			</td>
				
	  			<td>
					
						12/21/2018
					
	  			</td>

	  			<td>

					
					12/21/2025
					
					
	  			</td>

				<td>
					ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
				</td>
			
  			<td>
  				Stemline Therapeutics, Inc.
  			</td>
  			<td>
  				750 Lexington Avenue
  			</td>
  			<td>
  				11th floor
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10022
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397413
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				hydroxycarbamide (hydroxyurea)
  			</td>
  			<td>
  				Siklos
  			</td>
  			<td>
  				07/24/2013
  			</td>
  			<td>
  				Treatment of sickle cell disease in patients under 18 years of age
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crisis
	  			</td>
				
	  			<td>
					
						12/21/2017
					
	  			</td>

	  			<td>

					
					12/21/2024
					
					
	  			</td>

				<td>
					To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age amd older, with sickle cell anemia with recurrent moderate to severe painful crisis
				</td>
			
  			<td>
  				Addmedica Laboratories
  			</td>
  			<td>
  				37 rue de Caumartin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Paris
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				400413
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selexipag
  			</td>
  			<td>
  				Uptravi
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH
	  			</td>
				
	  			<td>
					
						12/21/2015
					
	  			</td>

	  			<td>

					
					12/21/2022
					
					
	  			</td>

				<td>
					For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH
				</td>
			
  			<td>
  				Actelion Pharmaceuticals Ltd
  			</td>
  			<td>
  				Gewerbestrasse 16
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Allschwil   
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				304810
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				anakinra
  			</td>
  			<td>
  				Kineret
  			</td>
  			<td>
  				08/19/2010
  			</td>
  			<td>
  				Treatment of cryopyrin-associated periodic syndromes 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of neonatal-onset multisystem inflammatory disease (NOMID)
	  			</td>
				
	  			<td>
					
						12/21/2012
					
	  			</td>

	  			<td>

					
					12/21/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Swedish Orphan Biovitrum AB (publ)
  			</td>
  			<td>
  				SE-011276
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Stockholm
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				312110
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				teduglutide [rDNA origin]; teduglutide [rDNA origin]
  			</td>
  			<td>
  				GATTEX; GATTEX
  			</td>
  			<td>
  				06/29/2000
  			</td>
  			<td>
  				Treatment of short bowel syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support
	  			</td>
				
	  			<td>
					
						12/21/2012
					
	  			</td>

	  			<td>

					
					12/21/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Pharmaceuticals U.S.A., Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				126999
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lomitapide
  			</td>
  			<td>
  				Juxtapid
  			</td>
  			<td>
  				10/23/2007
  			</td>
  			<td>
  				Treatment of homozygous familial hypercholesterolemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
	  			</td>
				
	  			<td>
					
						12/21/2012
					
	  			</td>

	  			<td>

					
					12/21/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Aegerion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				101 Main St., Suite 1850
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				245907
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Botulinum toxin type A
  			</td>
  			<td>
  				Botox
  			</td>
  			<td>
  				08/20/1986
  			</td>
  			<td>
  				Treatment of cervical dystonia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.
	  			</td>
				
	  			<td>
					
						12/21/2000
					
	  			</td>

	  			<td>

					
					12/21/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Allergan, Inc.
  			</td>
  			<td>
  				2525 Dupont Drive
  			</td>
  			<td>
  				P.O. Box 19534
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92623
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				009885
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nitric oxide 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				06/18/2012
  			</td>
  			<td>
  				Treatment of persistent pulmonary hypertension in newborns
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.
	  			</td>
				
	  			<td>
					
						12/20/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				VERO BIOTECH
  			</td>
  			<td>
  				387 Technology Circle, Suite 125 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Atlanta
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30313 
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				368512
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Brilliant Blue G Ophthalmic Solution 0.025% 
  			</td>
  			<td>
  				DORC ILM-Blue
  			</td>
  			<td>
  				07/31/2012
  			</td>
  			<td>
  				For use as an aid in ophthalmic surgery by selectively staining the internal limiting membrane
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).
	  			</td>
				
	  			<td>
					
						12/20/2019
					
	  			</td>

	  			<td>

					
					12/20/2026
					
					
	  			</td>

				<td>
					Indicated to selectively stain the internal limiting membrane (ILM)
				</td>
			
  			<td>
  				Dutch Ophthalmic Research Center International BV
  			</td>
  			<td>
  				P.O. Box 43
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Zuidland
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Netherlands
  			</td>
			<td>
  				341811
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pegaspargase
  			</td>
  			<td>
  				Oncaspar; Asparlas
  			</td>
  			<td>
  				10/20/1989
  			</td>
  			<td>
  				Treatment of acute lymphocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
	  			</td>
				
	  			<td>
					
						12/20/2018
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Servier Pharmaceuticals LLC
  			</td>
  			<td>
  				200 Pier Four Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				039589
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				01/23/2013
  			</td>
  			<td>
  				Treatment of Stage IIb to IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
	  			</td>
				
	  			<td>
					
						12/20/2017
					
	  			</td>

	  			<td>

					
					12/20/2024
					
					
	  			</td>

				<td>
					Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
				</td>
			
  			<td>
  				Bristol-Myers Squibb Co.
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				387612
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				macimorelin acetate
  			</td>
  			<td>
  				Macrelin
  			</td>
  			<td>
  				05/14/2007
  			</td>
  			<td>
  				Diagnosis of growth hormone deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the diagnosis of adult growth hormone deficiency
	  			</td>
				
	  			<td>
					
						12/20/2017
					
	  			</td>

	  			<td>

					
					12/20/2024
					
					
	  			</td>

				<td>
					For the diagnosis of adult growth hormone deficiency.
				</td>
			
  			<td>
  				Novo Nordisk Inc.
  			</td>
  			<td>
  				800 Scudders Mill Road
  			</td>
  			<td>
  				P.O. Box 846
  			</td>
  			<td>
  				Plainsboro
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08536
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				225506
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				treprostinil
  			</td>
  			<td>
  				Remodulin;Orenitram
  			</td>
  			<td>
  				06/04/1997
  			</td>
  			<td>
  				 Treatment of pulmonary arterial hypertension.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
	  			</td>
				
	  			<td>
					
						12/20/2013
					
	  			</td>

	  			<td>

					
					12/20/2020
					
					
	  			</td>

				<td>
					For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
				</td>
			
  			<td>
  				United Therapeutics Corp.
  			</td>
  			<td>
  				55 T.W. Alexander Dr.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				105197
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Varicella Zoster Immune Globulin (Human)
  			</td>
  			<td>
  				VARIZIG
  			</td>
  			<td>
  				11/07/2006
  			</td>
  			<td>
  				Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella
	  			</td>
				
	  			<td>
					
						12/20/2012
					
	  			</td>

	  			<td>

					
					12/20/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cangene bioPharma, Inc.
  			</td>
  			<td>
  				155 Innovation Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Winnipeg
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				228006
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Balsalazide disodium
  			</td>
  			<td>
  				Colazal
  			</td>
  			<td>
  				08/12/2005
  			</td>
  			<td>
  				Treatment of pediatric patients with ulcerative colitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older.  Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.
	  			</td>
				
	  			<td>
					
						12/20/2006
					
	  			</td>

	  			<td>

					
					12/20/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Salix Pharmaceuticals, Inc.
  			</td>
  			<td>
  				400 Somerset Corporate Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				208205
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sorafenib
  			</td>
  			<td>
  				Nexavar
  			</td>
  			<td>
  				10/08/2004
  			</td>
  			<td>
  				Treatment of renal cell carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with advanced renal cell carcinoma
	  			</td>
				
	  			<td>
					
						12/20/2005
					
	  			</td>

	  			<td>

					
					12/20/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bayer Pharmaceutical Corporation
  			</td>
  			<td>
  				400 Morgan Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				West Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06516
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				185204
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution
  			</td>
  			<td>
  				Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio
  			</td>
  			<td>
  				07/18/1997
  			</td>
  			<td>
  				Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.
	  			</td>
				
	  			<td>
					
						12/20/2002
					
	  			</td>

	  			<td>

					
					12/20/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Baxter Healthcare Corporation
  			</td>
  			<td>
  				Renal Division
  			</td>
  			<td>
  				1620 Waukegan Road
  			</td>
  			<td>
  				McGaw Park
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				105697
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				glatiramer acetate
  			</td>
  			<td>
  				Copaxone
  			</td>
  			<td>
  				11/09/1987
  			</td>
  			<td>
  				Treatment of multiple sclerosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
	  			</td>
				
	  			<td>
					
						12/20/1996
					
	  			</td>

	  			<td>

					
					12/20/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Teva Pharmaceuticals USA
  			</td>
  			<td>
  				1510 Delp Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kulpsville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19443
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				024087
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Interferon gamma 1-b
  			</td>
  			<td>
  				Actimmune
  			</td>
  			<td>
  				09/30/1988
  			</td>
  			<td>
  				Treatment of chronic granulomatous disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/20/1990
					
	  			</td>

	  			<td>

					
					12/20/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Horizon Therapeutic Ireland DAC
  			</td>
  			<td>
  				Connaught House, 1st Floor
  			</td>
  			<td>
  				1 Burlington Road
  			</td>
  			<td>
  				Dublin 4
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				029788
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tacrolimus
  			</td>
  			<td>
  				Envarsus XR
  			</td>
  			<td>
  				12/20/2013
  			</td>
  			<td>
  				Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.
	  			</td>
				
	  			<td>
					
						12/19/2018
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Veloxis Pharmaceuticals, Inc.
  			</td>
  			<td>
  				1001 Winstead Drive
  			</td>
  			<td>
  				Suite 310
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27513
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				407113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				12/28/2016
  			</td>
  			<td>
  				Treatment of Merkel cell carcinoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma
	  			</td>
				
	  			<td>
					
						12/19/2018
					
	  			</td>

	  			<td>

					
					12/19/2025
					
					
	  			</td>

				<td>
					KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma
				</td>
			
  			<td>
  				Merck, Sharp, and Dohme Corp.
  			</td>
  			<td>
  				351 North Sumneytown Pike
  			</td>
  			<td>
  				UG2D-027
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				548216
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				 Lynparza 
  			</td>
  			<td>
  				05/15/2018
  			</td>
  			<td>
  				Treatment of Fallopian Tube Cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.
	  			</td>
				
	  			<td>
					
						12/19/2018
					
	  			</td>

	  			<td>

					
					12/19/2025
					
					
	  			</td>

				<td>
					Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced fallopian tube cancer who are in complete or partial response to first-line platinum based chemotherapy.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				417613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				 Lynparza 
  			</td>
  			<td>
  				05/15/2018
  			</td>
  			<td>
  				Treatment of primary peritoneal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.
	  			</td>
				
	  			<td>
					
						12/19/2018
					
	  			</td>

	  			<td>

					
					12/19/2025
					
					
	  			</td>

				<td>
					Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				419013
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				Lynparza
  			</td>
  			<td>
  				10/16/2013
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.
	  			</td>
				
	  			<td>
					
						12/19/2018
					
	  			</td>

	  			<td>

					
					12/19/2025
					
					
	  			</td>

				<td>
					Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancer who are in complete or partial response to first-line platinum based chemotherapy.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				409213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bosutinib
  			</td>
  			<td>
  				Bosulif
  			</td>
  			<td>
  				02/24/2009
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				BOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML).
	  			</td>
				
	  			<td>
					
						12/19/2017
					
	  			</td>

	  			<td>

					
					12/19/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
				</td>
			
  			<td>
  				Pfizer Inc.
  			</td>
  			<td>
  				445 Eastern Point Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Groton
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06340
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				274808
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				voretigene neparvovec-rzyl
  			</td>
  			<td>
  				LUXTURNA
  			</td>
  			<td>
  				03/18/2015
  			</td>
  			<td>
  				Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician
	  			</td>
				
	  			<td>
					
						12/19/2017
					
	  			</td>

	  			<td>

					
					12/19/2024
					
					
	  			</td>

				<td>
					Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal distrophy.  Patients must have viable retinal cells determined by a treating physician.
				</td>
			
  			<td>
  				Spark Therapeutics, Inc.
  			</td>
  			<td>
  				3737 Market Street
  			</td>
  			<td>
  				Suite 1300
  			</td>
  			<td>
  				Philadelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19104
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				466414
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rucaparib
  			</td>
  			<td>
  				Rubraca
  			</td>
  			<td>
  				07/31/2012
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies
	  			</td>
				
	  			<td>
					
						12/19/2016
					
	  			</td>

	  			<td>

					
					12/19/2023
					
					
	  			</td>

				<td>
					As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies
				</td>
			
  			<td>
  				Clovis Oncology, Inc.
  			</td>
  			<td>
  				5500 Flatiron Parkway
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Boulder
  			</td>
  			<td>
  				Colorado
  			</td>
  			<td>
  				80301
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				374712
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				Lynparza
  			</td>
  			<td>
  				10/16/2013
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy
	  			</td>
				
	  			<td>
					
						12/19/2014
					
	  			</td>

	  			<td>

					
					12/19/2021
					
					
	  			</td>

				<td>
					Use as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				409213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				imatinib mesylate
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				11/01/2001
  			</td>
  			<td>
  				Treatment of gastrointestinal  stromal tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).  
	  			</td>
				
	  			<td>
					
						12/19/2008
					
	  			</td>

	  			<td>

					
					12/19/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				149201
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Filgrastim
  			</td>
  			<td>
  				Neupogen
  			</td>
  			<td>
  				11/07/1990
  			</td>
  			<td>
  				Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with severe chronic neutropenia.
	  			</td>
				
	  			<td>
					
						12/19/1994
					
	  			</td>

	  			<td>

					
					12/19/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				1840 Dehavilland Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				049390
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				anakinra
  			</td>
  			<td>
  				Kineret
  			</td>
  			<td>
  				06/29/2020
  			</td>
  			<td>
  				Treatment of Deficiency of IL-1 Receptor Antagonist 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
	  			</td>
				
	  			<td>
					
						12/18/2020
					
	  			</td>

	  			<td>

					
					12/18/2027
					
					
	  			</td>

				<td>
					treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
				</td>
			
  			<td>
  				Swedish Orphan Biovitrum AB (PUBL)
  			</td>
  			<td>
  				Tomtebodavägen 23A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Stockholm
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				745420
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selinexor
  			</td>
  			<td>
  				Xpovio
  			</td>
  			<td>
  				01/05/2015
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
	  			</td>
				
	  			<td>
					
						12/18/2020
					
	  			</td>

	  			<td>

					
					12/18/2027
					
					
	  			</td>

				<td>
					for the treatment of adult patients with multiple myeloma who have received at least one prior therapy,  excluding adult patients covered by Xpovio's previous indication for multiple myeloma approved on July 3, 2019
				</td>
			
  			<td>
  				Karyopharm Therapeutics, Inc.
  			</td>
  			<td>
  				85 Wells Avenue, Suite 210
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Newton
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02459
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				459014
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				osimertinib
  			</td>
  			<td>
  				Tagrisso
  			</td>
  			<td>
  				09/04/2014
  			</td>
  			<td>
  				Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						12/18/2020
					
	  			</td>

	  			<td>

					
					12/18/2027
					
					
	  			</td>

				<td>
					adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				445214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				KEYTRUDA
  			</td>
  			<td>
  				11/19/2012
  			</td>
  			<td>
  				Treatment of Stage IIB through IV malignant melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with unresectable or metastatic melanoma.
	  			</td>
				
	  			<td>
					
						12/18/2015
					
	  			</td>

	  			<td>

					
					12/18/2022
					
					
	  			</td>

				<td>
					Initial treatment of patients with unresectable or metastatic melanoma
				</td>
			
  			<td>
  				Merck, Sharp & Dohme Corp.
  			</td>
  			<td>
  				351 North Sumneytown Pike 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				381012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Fludarabine phosphate oral tablets
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				12/18/2007
  			</td>
  			<td>
  				Treatment of B-cell chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen
	  			</td>
				
	  			<td>
					
						12/18/2008
					
	  			</td>

	  			<td>

					
					12/18/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Sanofi-Aventis U.S., Inc.
  			</td>
  			<td>
  				55 Corproate Drive
  			</td>
  			<td>
  				P. O. Box 5925
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				250607
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				efgartigimod alfa-fcab
  			</td>
  			<td>
  				Vyvgart
  			</td>
  			<td>
  				09/20/2017
  			</td>
  			<td>
  				Treatment of myasthenia gravis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
	  			</td>
				
	  			<td>
					
						12/17/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				argenx BV
  			</td>
  			<td>
  				Industriepark Zwijnaarde 7
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Zwijnaarde
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				9052
  			</td>
  			<td>
  				Belgium
  			</td>
			<td>
  				527316
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				voxelotor
  			</td>
  			<td>
  				Oxbryta
  			</td>
  			<td>
  				12/29/2015
  			</td>
  			<td>
  				Treatment of sickle cell disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older
	  			</td>
				
	  			<td>
					
						12/17/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Global Blood Therapeutics, Inc.
  			</td>
  			<td>
  				181 Oyster Point Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				499715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Trimetrexate glucuronate
  			</td>
  			<td>
  				Neutrexin
  			</td>
  			<td>
  				05/15/1986
  			</td>
  			<td>
  				Treatment of Pneumocystis carinii pneumonia in AIDS patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.
	  			</td>
				
	  			<td>
					
						12/17/1993
					
	  			</td>

	  			<td>

					
					12/17/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Medimmune Oncology, Inc.
  			</td>
  			<td>
  				One Tower Bridge
  			</td>
  			<td>
  				100 Front Street, Suite 400
  			</td>
  			<td>
  				West Conshohocken
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19428
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				014286
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lanreotide acetate
  			</td>
  			<td>
  				Somatuline Depot
  			</td>
  			<td>
  				08/25/2011
  			</td>
  			<td>
  				Treatment of neuroendocrine tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival
	  			</td>
				
	  			<td>
					
						12/16/2014
					
	  			</td>

	  			<td>

					
					12/16/2021
					
					
	  			</td>

				<td>
					Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival
				</td>
			
  			<td>
  				Ipsen Biopharmaceuticals, Inc.
  			</td>
  			<td>
  				106 Allen Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Basking Ridge
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07920
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				347811
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				anti-inhibitor coagulant complex
  			</td>
  			<td>
  				FEIBA 
  			</td>
  			<td>
  				04/12/2013
  			</td>
  			<td>
  				Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors
	  			</td>
				
	  			<td>
					
						12/16/2013
					
	  			</td>

	  			<td>

					
					12/16/2020
					
					
	  			</td>

				<td>
					Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				One Baxter Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				West Lake Village
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91362
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				393913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Levocarnitine
  			</td>
  			<td>
  				Carnitor
  			</td>
  			<td>
  				07/26/1984
  			</td>
  			<td>
  				Treatment of primary and secondary carnitine deficiency of genetic origin.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92)
	  			</td>
				
	  			<td>
					
						12/16/1992
					
	  			</td>

	  			<td>

					
					12/16/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Leadiant Biosciences, Inc.
  			</td>
  			<td>
  				9841 Washingtonian Blvd
  			</td>
  			<td>
  				Suite 500
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20878
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				001584
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				abatacept
  			</td>
  			<td>
  				Orencia
  			</td>
  			<td>
  				12/26/2017
  			</td>
  			<td>
  				Prevention of graft versus host disease 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor
	  			</td>
				
	  			<td>
					
						12/15/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Co.
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				614117
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				budesonide
  			</td>
  			<td>
  				Tarpeyo
  			</td>
  			<td>
  				05/17/2010
  			</td>
  			<td>
  				To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) > or = 1.5 g/g
	  			</td>
				
	  			<td>
					
						12/15/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Calliditas Therapeutics AB
  			</td>
  			<td>
  				26B Wallingatan
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Norrmalm
  			</td>
  			<td>
  				Stockholms län
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				305710
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pasireotide
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				08/25/2009
  			</td>
  			<td>
  				Treatment of acromegaly
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients  with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option
	  			</td>
				
	  			<td>
					
						12/15/2014
					
	  			</td>

	  			<td>

					
					12/15/2021
					
					
	  			</td>

				<td>
					Treatment of patients  with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Bldg 104, 3K28
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				288609
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				plerixafor
  			</td>
  			<td>
  				Mozobil (r)
  			</td>
  			<td>
  				07/10/2003
  			</td>
  			<td>
  				For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma
	  			</td>
				
	  			<td>
					
						12/15/2008
					
	  			</td>

	  			<td>

					
					12/15/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				500 Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				167903
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Hydroxocobalamin
  			</td>
  			<td>
  				Cyanokit
  			</td>
  			<td>
  				11/25/2003
  			</td>
  			<td>
  				Treatment of acute cyanide poisoning
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment on known or suspected cyanide poisoning
	  			</td>
				
	  			<td>
					
						12/15/2006
					
	  			</td>

	  			<td>

					
					12/15/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				SERB, S.A.
  			</td>
  			<td>
  				480 Avenue Louise
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Brussels
  			</td>
  			<td>
  				Brussels
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Belgium
  			</td>
			<td>
  				177403
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Levocarnitine
  			</td>
  			<td>
  				Carnitor
  			</td>
  			<td>
  				09/06/1988
  			</td>
  			<td>
  				Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.  
	  			</td>
				
	  			<td>
					
						12/15/1999
					
	  			</td>

	  			<td>

					
					12/15/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Leadiant Biosciences, Inc.
  			</td>
  			<td>
  				9841 Washingtonian Blvd
  			</td>
  			<td>
  				Suite 500
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20878
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				027888
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin for injection
  			</td>
  			<td>
  				Nutropin
  			</td>
  			<td>
  				11/18/1996
  			</td>
  			<td>
  				As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/15/1997
					
	  			</td>

	  			<td>

					
					12/15/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				460 Point San Bruno Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				100396
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Clofazimine
  			</td>
  			<td>
  				Lamprene
  			</td>
  			<td>
  				06/11/1984
  			</td>
  			<td>
  				Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/15/1986
					
	  			</td>

	  			<td>

					
					12/15/1993
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceutical Corporation
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				002684
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				romiplostim
  			</td>
  			<td>
  				Nplate
  			</td>
  			<td>
  				03/27/2003
  			</td>
  			<td>
  				Treatment of immune thrombocytopenic purpura
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
	  			</td>
				
	  			<td>
					
						12/14/2018
					
	  			</td>

	  			<td>

					
					12/14/2025
					
					
	  			</td>

				<td>
					Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				Mail Stop: 27-2-D
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				165402
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				raxibacumab
  			</td>
  			<td>
  				ABthraxTM
  			</td>
  			<td>
  				11/12/2003
  			</td>
  			<td>
  				Treatment of anthrax
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, 
	  			</td>
				
	  			<td>
					
						12/14/2012
					
	  			</td>

	  			<td>

					
					12/14/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Human Genome Sciences, Inc.
  			</td>
  			<td>
  				14200 Shady Grove Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockville
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20850
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				175503
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pasireotide
  			</td>
  			<td>
  				Signifor
  			</td>
  			<td>
  				07/24/2009
  			</td>
  			<td>
  				Treatment of Cushing's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative
	  			</td>
				
	  			<td>
					
						12/14/2012
					
	  			</td>

	  			<td>

					
					12/14/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Bldg 104, 3K28
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				288709
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ponatinib
  			</td>
  			<td>
  				Iclusig
  			</td>
  			<td>
  				11/20/2009
  			</td>
  			<td>
  				Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.  
	  			</td>
				
	  			<td>
					
						12/14/2012
					
	  			</td>

	  			<td>

					
					12/14/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ARIAD Pharmaceuticals Inc.
  			</td>
  			<td>
  				26 Landsdowne Steet
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				294809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ponatinib
  			</td>
  			<td>
  				Iclusig
  			</td>
  			<td>
  				11/20/2009
  			</td>
  			<td>
  				Treatment of chronic myeloid leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.  
	  			</td>
				
	  			<td>
					
						12/14/2012
					
	  			</td>

	  			<td>

					
					12/14/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ARIAD Pharmaceuticals Inc.
  			</td>
  			<td>
  				26 Landsdowne Steet
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				294709
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Thyrotropin alfa
  			</td>
  			<td>
  				Thyrogen
  			</td>
  			<td>
  				08/03/2001
  			</td>
  			<td>
  				Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer
	  			</td>
				
	  			<td>
					
						12/14/2007
					
	  			</td>

	  			<td>

					
					12/14/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				One Kendall Square
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				142301
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				riluzole oral suspension
  			</td>
  			<td>
  				Tiglutik
  			</td>
  			<td>
  				09/15/2016
  			</td>
  			<td>
  				Treatment of amyotrophic lateral sclerosis (ALS).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
	  			</td>
				
	  			<td>
					
						12/13/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Italfarmaco SpA
  			</td>
  			<td>
  				54 Via dei Lavoratori
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cinisello Balsamo
  			</td>
  			<td>
  				Lombardia
  			</td>
  			<td>
  				20092
  			</td>
  			<td>
  				Italy
  			</td>
			<td>
  				508715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				prothrombin complex concentrate (human)
  			</td>
  			<td>
  				Kcentra
  			</td>
  			<td>
  				12/27/2012
  			</td>
  			<td>
  				Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.  
	  			</td>
				
	  			<td>
					
						12/13/2013
					
	  			</td>

	  			<td>

					
					12/13/2020
					
					
	  			</td>

				<td>
					Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.  
				</td>
			
  			<td>
  				CSL Behring
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				305310
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sapropterin
  			</td>
  			<td>
  				Kuvan
  			</td>
  			<td>
  				01/29/2004
  			</td>
  			<td>
  				Treatment of hyperphenylalaninemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.
	  			</td>
				
	  			<td>
					
						12/13/2007
					
	  			</td>

	  			<td>

					
					12/13/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				BioMarin Pharmaceutical, Inc.
  			</td>
  			<td>
  				105 Digital Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				181503
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antithrombin III (human)
  			</td>
  			<td>
  				ATnativ
  			</td>
  			<td>
  				02/08/1985
  			</td>
  			<td>
  				For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/13/1989
					
	  			</td>

	  			<td>

					
					12/13/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia & Upjohn AB
  			</td>
  			<td>
  				Lindhagensgatan 133
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Stockholm
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				005084
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				golodirsen
  			</td>
  			<td>
  				VYONDYS 53
  			</td>
  			<td>
  				05/22/2018
  			</td>
  			<td>
  				Treatment of Duchenne muscular dystrophy (DMD) 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
	  			</td>
				
	  			<td>
					
						12/12/2019
					
	  			</td>

	  			<td>

					
					12/12/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
				</td>
			
  			<td>
  				Sarepta Therapeutics, Inc.
  			</td>
  			<td>
  				215 First Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				636818
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mepolizumab
  			</td>
  			<td>
  				NUCALA
  			</td>
  			<td>
  				07/14/2011
  			</td>
  			<td>
  				Treatment of Churg-Strauss Syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA)
	  			</td>
				
	  			<td>
					
						12/12/2017
					
	  			</td>

	  			<td>

					
					12/12/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA)
				</td>
			
  			<td>
  				GlaxoSmithKline LLC
  			</td>
  			<td>
  				Corporation Service Company
  			</td>
  			<td>
  				1250 S. Collegeville Rd.
  			</td>
  			<td>
  				Collegeville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19426
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				345111
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				aripiprazole
  			</td>
  			<td>
  				Abilify
  			</td>
  			<td>
  				01/25/2006
  			</td>
  			<td>
  				Treatment of Tourette's syndrome 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients with Tourette's 
	  			</td>
				
	  			<td>
					
						12/12/2014
					
	  			</td>

	  			<td>

					
					12/12/2021
					
					
	  			</td>

				<td>
					Treatment of pediatric patients with Tourette's 
				</td>
			
  			<td>
  				Otsuka Pharmaceutical Development
  			</td>
  			<td>
  				and Commercialization
  			</td>
  			<td>
  				1st Floor
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				207905
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mecasermin rinfabate
  			</td>
  			<td>
  				Iplex
  			</td>
  			<td>
  				05/17/2002
  			</td>
  			<td>
  				Treatment of growth hormone insensitivity syndrome (GHIS)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone
	  			</td>
				
	  			<td>
					
						12/12/2005
					
	  			</td>

	  			<td>

					
					12/12/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Insmed, Inc.
  			</td>
  			<td>
  				10 Finderne Ave
  			</td>
  			<td>
  				Building 10
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				156302
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Riluzole
  			</td>
  			<td>
  				Rilutek
  			</td>
  			<td>
  				03/16/1993
  			</td>
  			<td>
  				Treatment of amyotrophic lateral sclerosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with amyotrophic lateral sclerosis.  Riluzole extends survival and/or time to tracheostomy.
	  			</td>
				
	  			<td>
					
						12/12/1995
					
	  			</td>

	  			<td>

					
					12/12/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Rhone-Poulenc Rorer Pharmaceuticals, Inc.
  			</td>
  			<td>
  				500 Arcola Road, P.O. Box 1200
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Collegeville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19426
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				072792
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Leucovorin
  			</td>
  			<td>
  				Leucovorin calcium
  			</td>
  			<td>
  				12/08/1986
  			</td>
  			<td>
  				For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
	  			</td>
				
	  			<td>
					
						12/12/1991
					
	  			</td>

	  			<td>

					
					12/12/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Immunex Corporation
  			</td>
  			<td>
  				51 University Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				016786
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				uridine triacetate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				05/01/2009
  			</td>
  			<td>
  				An antidote in the treatment of 5-fluorouracil or capecitabine poisoning
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration
	  			</td>
				
	  			<td>
					
						12/11/2015
					
	  			</td>

	  			<td>

					
					12/11/2022
					
					
	  			</td>

				<td>
					For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration
				</td>
			
  			<td>
  				Wellstat Therapeutics Corp.
  			</td>
  			<td>
  				14200 Shady Grove Road
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Rockville
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20850
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				273808
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				alectinib
  			</td>
  			<td>
  				Alecensa
  			</td>
  			<td>
  				01/27/2015
  			</td>
  			<td>
  				Treatment of ALK-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
	  			</td>
				
	  			<td>
					
						12/11/2015
					
	  			</td>

	  			<td>

					
					12/11/2022
					
					
	  			</td>

				<td>
					Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)
  			</td>
  			<td>
  				1 DNA Way, MS #355E
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				462814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Daclizumab
  			</td>
  			<td>
  				Zenapax
  			</td>
  			<td>
  				03/05/1993
  			</td>
  			<td>
  				Prevention of acute renal allograft rejection.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive  regimen that includes cyclosporine and corticosteroids.
	  			</td>
				
	  			<td>
					
						12/10/1997
					
	  			</td>

	  			<td>

					
					12/10/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				067692
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ursodiol
  			</td>
  			<td>
  				URSO 250
  			</td>
  			<td>
  				06/20/1991
  			</td>
  			<td>
  				Treatment of patients with primary biliary cirrhosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/10/1997
					
	  			</td>

	  			<td>

					
					12/10/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Aptalis Pharma US, Inc.
  			</td>
  			<td>
  				100 Somerset corporate Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				022187
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Calcium acetate
  			</td>
  			<td>
  				Phos-Lo
  			</td>
  			<td>
  				12/22/1988
  			</td>
  			<td>
  				Treatment of hyperphosphatemia in end stage renal failure.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						12/10/1990
					
	  			</td>

	  			<td>

					
					12/10/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fresenius Medical Care North America
  			</td>
  			<td>
  				920 Winter Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				031588
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				recombinant von Willebrand factor (rhVWF)
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				11/23/2010
  			</td>
  			<td>
  				Treatment of von Willebrand disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease (VWD)
	  			</td>
				
	  			<td>
					
						12/08/2015
					
	  			</td>

	  			<td>

					
					12/08/2022
					
					
	  			</td>

				<td>
					Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD)
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				650 E. Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				322210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sebelipase alfa
  			</td>
  			<td>
  				Kanuma
  			</td>
  			<td>
  				07/01/2010
  			</td>
  			<td>
  				Treatment of lysosomal acid lipase deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency
	  			</td>
				
	  			<td>
					
						12/08/2015
					
	  			</td>

	  			<td>

					
					12/08/2022
					
					
	  			</td>

				<td>
					Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency
				</td>
			
  			<td>
  				Alexion Pharmaceuticals
  			</td>
  			<td>
  				100 College Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06510
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				309410
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bortezomib
  			</td>
  			<td>
  				Velcade
  			</td>
  			<td>
  				05/30/2012
  			</td>
  			<td>
  				Treatment of mantle cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.  
	  			</td>
				
	  			<td>
					
						12/08/2006
					
	  			</td>

	  			<td>

					
					12/08/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Millennium Pharmaceuticals, Inc.
  			</td>
  			<td>
  				40 Landsdowne Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				226106
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Botulinum toxin type B
  			</td>
  			<td>
  				Myobloc
  			</td>
  			<td>
  				01/16/1992
  			</td>
  			<td>
  				Treatment of cervical dystonia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients  with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
	  			</td>
				
	  			<td>
					
						12/08/2000
					
	  			</td>

	  			<td>

					
					12/08/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Soltice Neurosciences, LLC
  			</td>
  			<td>
  				4010 Dupont Circle
  			</td>
  			<td>
  				Suite L-07
  			</td>
  			<td>
  				Louisville
  			</td>
  			<td>
  				Kentucky
  			</td>
  			<td>
  				40207
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				064791
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fomepizole
  			</td>
  			<td>
  				Antizole
  			</td>
  			<td>
  				12/22/1988
  			</td>
  			<td>
  				Treatment of methanol or ethylene glycol poisoning.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis 
	  			</td>
				
	  			<td>
					
						12/08/2000
					
	  			</td>

	  			<td>

					
					12/08/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Par Pharmaceuticals, Inc
  			</td>
  			<td>
  				1 Ram Ridge Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Chestnut Ridge
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10977
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				033388
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Amifostine
  			</td>
  			<td>
  				Ethyol
  			</td>
  			<td>
  				05/30/1990
  			</td>
  			<td>
  				For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.
	  			</td>
				
	  			<td>
					
						12/08/1995
					
	  			</td>

	  			<td>

					
					12/08/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Medimmune Oncology, Inc.
  			</td>
  			<td>
  				One Tower Bridge
  			</td>
  			<td>
  				100 Front Street, Suite 400
  			</td>
  			<td>
  				West Conshohocken
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19428
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				042789
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bendamustine for 50ml admixture
  			</td>
  			<td>
  				Bendeka
  			</td>
  			<td>
  				07/02/2014
  			</td>
  			<td>
  				Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
	  			</td>
				
	  			<td>
					
						12/07/2015
					
	  			</td>

	  			<td>

					
					12/07/2022
					
					
	  			</td>

				<td>
					Treatment of patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen
				</td>
			
  			<td>
  				Eagle Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Tice Blvd
  			</td>
  			<td>
  				Suite 315
  			</td>
  			<td>
  				Woodcliff Lake
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07677
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				430314
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bendamustine for 50 ml admixture
  			</td>
  			<td>
  				Bendeka
  			</td>
  			<td>
  				07/02/2014
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with chronic lymphocytic leukemia (CLL).  Efficacy relative to first line therapies other than chlorambucil has not been established. 
	  			</td>
				
	  			<td>
					
						12/07/2015
					
	  			</td>

	  			<td>

					
					12/07/2022
					
					
	  			</td>

				<td>
					Treatment of patients with CLL
				</td>
			
  			<td>
  				Eagle Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Tice Blvd
  			</td>
  			<td>
  				Suite 315
  			</td>
  			<td>
  				Woodcliff Lake
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07677
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				431814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				02/09/2006
  			</td>
  			<td>
  				Therapeutic treatment of patients with ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi
	  			</td>
				
	  			<td>
					
						12/06/2016
					
	  			</td>

	  			<td>

					
					12/06/2023
					
					
	  			</td>

				<td>
					Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				216405
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				11/23/2010
  			</td>
  			<td>
  				Treatment of fallopian tube carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi
	  			</td>
				
	  			<td>
					
						12/06/2016
					
	  			</td>

	  			<td>

					
					12/06/2023
					
					
	  			</td>

				<td>
					Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				318010
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				11/02/2010
  			</td>
  			<td>
  				Treatment of primary peritoneal carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi
	  			</td>
				
	  			<td>
					
						12/06/2016
					
	  			</td>

	  			<td>

					
					12/06/2023
					
					
	  			</td>

				<td>
					Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				317810
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				collagenase clostridium histolyticum
  			</td>
  			<td>
  				XIAFLEX
  			</td>
  			<td>
  				03/12/1996
  			</td>
  			<td>
  				Treatment of Peyronie's disease. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.  
	  			</td>
				
	  			<td>
					
						12/06/2013
					
	  			</td>

	  			<td>

					
					12/06/2020
					
					
	  			</td>

				<td>
					Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.  
				</td>
			
  			<td>
  				Auxilium Pharmaceuticals, Inc.
  			</td>
  			<td>
  				640 Lee Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Chesterbrook
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19087
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				095496
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				denosumab
  			</td>
  			<td>
  				XGEVA
  			</td>
  			<td>
  				09/11/2013
  			</td>
  			<td>
  				Treatment of hypercalcemia in malignancy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To treat hypercalcemia of malignancy refractory to biphosphonate therapy.  
	  			</td>
				
	  			<td>
					
						12/05/2014
					
	  			</td>

	  			<td>

					
					12/05/2021
					
					
	  			</td>

				<td>
					To treat hypercalcemia of malignancy refractory to biphosphonate therapy.  
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				MS 17-2-C
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				404213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ruxolitinib 
  			</td>
  			<td>
  				Jakafi
  			</td>
  			<td>
  				03/26/2010
  			</td>
  			<td>
  				Treatment of polycythemia vera
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.  
	  			</td>
				
	  			<td>
					
						12/04/2014
					
	  			</td>

	  			<td>

					
					12/04/2021
					
					
	  			</td>

				<td>
					Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.  
				</td>
			
  			<td>
  				Incyte Corporation
  			</td>
  			<td>
  				1801 Augustine Cut-Off
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				302310
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Human plasma coagulation Factor VIII and human plasma von Willebrand Factor
  			</td>
  			<td>
  				Wilate
  			</td>
  			<td>
  				04/18/2007
  			</td>
  			<td>
  				Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated
	  			</td>
				
	  			<td>
					
						12/04/2009
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Octapharma USA, Inc.
  			</td>
  			<td>
  				121 River Street
  			</td>
  			<td>
  				12th Floor
  			</td>
  			<td>
  				Hoboken
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07030
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				234106
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cytomegalovirus immune globulin (human)
  			</td>
  			<td>
  				CytoGam
  			</td>
  			<td>
  				08/03/1987
  			</td>
  			<td>
  				Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2)  Prophylaxis of CMV disease associated transplantation of kidney (all other), lung, liver, pancreas and heart.    
	  			</td>
				
	  			<td>
					
						12/04/1998
					
	  			</td>

	  			<td>

					
					12/04/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CSL Behring LLC
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				P. O. Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				015386
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fomepizole
  			</td>
  			<td>
  				Antizole
  			</td>
  			<td>
  				12/22/1988
  			</td>
  			<td>
  				Treatment of methanol or ethylene glycol poisoning.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion.
	  			</td>
				
	  			<td>
					
						12/04/1997
					
	  			</td>

	  			<td>

					
					12/04/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Par Pharmaceuticals, Inc
  			</td>
  			<td>
  				1 Ram Ridge Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Chestnut Ridge
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10977
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				033388
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				11/19/2012
  			</td>
  			<td>
  				Treatment of Stage IIB through Stage IV malignant melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection
	  			</td>
				
	  			<td>
					
						12/03/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Merck, Sharp & Dohme Corp.
  			</td>
  			<td>
  				351 North Sumneytown Pike 
  			</td>
  			<td>
  				P.O. Box 1000
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				381012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				berotralstat
  			</td>
  			<td>
  				ORLADEYO™
  			</td>
  			<td>
  				11/01/2017
  			</td>
  			<td>
  				Treatment of C1-inhibitor-dependent angioedema (including prevention and treatment of attacks)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older
	  			</td>
				
	  			<td>
					
						12/03/2020
					
	  			</td>

	  			<td>

					
					12/03/2027
					
					
	  			</td>

				<td>
					prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older
				</td>
			
  			<td>
  				BioCryst Pharmaceuticals, Inc.
  			</td>
  			<td>
  				4505 Emperor Blvd
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Durham
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27703
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				607617
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				blinatumomab
  			</td>
  			<td>
  				Blincyto
  			</td>
  			<td>
  				05/16/2008
  			</td>
  			<td>
  				Treatment of acute lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 
	  			</td>
				
	  			<td>
					
						12/03/2014
					
	  			</td>

	  			<td>

					
					12/03/2021
					
					
	  			</td>

				<td>
					Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Dr.
  			</td>
  			<td>
  				Mail Stop 17-2-A
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				255707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab
  			</td>
  			<td>
  				Rituxan
  			</td>
  			<td>
  				06/13/1994
  			</td>
  			<td>
  				Treatment of non-Hodgkin's B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy
	  			</td>
				
	  			<td>
					
						12/02/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way, MS 242
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				079793
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Alpha1-proteinase inhibitor (human)
  			</td>
  			<td>
  				Prolastin
  			</td>
  			<td>
  				12/07/1984
  			</td>
  			<td>
  				For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.
	  			</td>
				
	  			<td>
					
						12/02/1987
					
	  			</td>

	  			<td>

					
					12/02/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bayer Corporation
  			</td>
  			<td>
  				Pharmaceutical Division, Biological Products
  			</td>
  			<td>
  				400 Morgan Lane
  			</td>
  			<td>
  				New Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06516
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				003084
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tasimelteon
  			</td>
  			<td>
  				Hetlioz
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older
	  			</td>
				
	  			<td>
					
						12/01/2020
					
	  			</td>

	  			<td>

					
					12/01/2027
					
					
	  			</td>

				<td>
					Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older. 
				</td>
			
  			<td>
  				Vanda Pharmaceuticals, Inc.
  			</td>
  			<td>
  				9605 Medical Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockville
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20850
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				301410
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tasimelteon
  			</td>
  			<td>
  				Hetlioz LQ
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age
	  			</td>
				
	  			<td>
					
						12/01/2020
					
	  			</td>

	  			<td>

					
					12/01/2027
					
					
	  			</td>

				<td>
					Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age
				</td>
			
  			<td>
  				Vanda Pharmaceuticals, Inc.
  			</td>
  			<td>
  				9605 Medical Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockville
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20850
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				301410
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pralsetinib
  			</td>
  			<td>
  				Gavreto
  			</td>
  			<td>
  				05/26/2020
  			</td>
  			<td>
  				Treatment of RET-fusion, RET-mutation, and TRKC-positive poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
	  			</td>
				
	  			<td>
					
						12/01/2020
					
	  			</td>

	  			<td>

					
					12/01/2027
					
					
	  			</td>

				<td>
					Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080-4990
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				728519
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ecallantide; ecallantide
  			</td>
  			<td>
  				Kalbitor; Kalbitor
  			</td>
  			<td>
  				02/04/2003
  			</td>
  			<td>
  				Treatment of angioedema
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older
	  			</td>
				
	  			<td>
					
						12/01/2009
					
	  			</td>

	  			<td>

					
					12/01/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Pharmaceuticals USA, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				160802
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin (r-DNA)
  			</td>
  			<td>
  				Zorbtive
  			</td>
  			<td>
  				03/06/1995
  			</td>
  			<td>
  				For use alone or in combination with glutamine in the treatment of short bowel syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of short bowel syndrome in patients receiving specialized nutritional support
	  			</td>
				
	  			<td>
					
						12/01/2003
					
	  			</td>

	  			<td>

					
					12/01/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				EMD Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				080394
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				carfilzomib
  			</td>
  			<td>
  				Kyprolis
  			</td>
  			<td>
  				01/18/2008
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and hyaluronidase-fihj and dexamethasone
	  			</td>
				
	  			<td>
					
						11/30/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Onyx Therapeutics, Inc.
  			</td>
  			<td>
  				249 East Grand Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				252507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				elotuzumab
  			</td>
  			<td>
  				Empliciti
  			</td>
  			<td>
  				09/01/2011
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies
	  			</td>
				
	  			<td>
					
						11/30/2015
					
	  			</td>

	  			<td>

					
					11/30/2022
					
					
	  			</td>

				<td>
					Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies
				</td>
			
  			<td>
  				Bristol-Myers Squibb Co.
  			</td>
  			<td>
  				P.O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				348411
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Thyrotropin alpha
  			</td>
  			<td>
  				Thyrogen
  			</td>
  			<td>
  				02/24/1992
  			</td>
  			<td>
  				As an adjunct in the diagnosis of thyroid cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.
	  			</td>
				
	  			<td>
					
						11/30/1998
					
	  			</td>

	  			<td>

					
					11/30/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				One Kendall Square
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				063191
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Naltrexone HCl
  			</td>
  			<td>
  				Trexan
  			</td>
  			<td>
  				03/11/1985
  			</td>
  			<td>
  				For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						11/30/1984
					
	  			</td>

	  			<td>

					
					11/30/1991
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				DuPont Pharmaceuticals
  			</td>
  			<td>
  				E.I. Du Pont De Nemours & Co.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19880
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				006085
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pafolacianine
  			</td>
  			<td>
  				Cytalux
  			</td>
  			<td>
  				12/23/2014
  			</td>
  			<td>
  				Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer
	  			</td>
				
	  			<td>
					
						11/29/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				On Target Laboratories, LLC
  			</td>
  			<td>
  				1282 Win Hentschel Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				West Lafayette
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				47906
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				458714
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tacrolimus extended-release capsules 
  			</td>
  			<td>
  				Astagraf XL
  			</td>
  			<td>
  				10/04/2016
  			</td>
  			<td>
  				Prevention of rejection in kidney, liver or heart transplant in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients
	  			</td>
				
	  			<td>
					
						11/29/2018
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Astellas Pharma Global Development, Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				534516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cabozantinib
  			</td>
  			<td>
  				Cometriq
  			</td>
  			<td>
  				11/29/2010
  			</td>
  			<td>
  				Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of progressive, metastatic medullary thyroid cancer (MTC).  
	  			</td>
				
	  			<td>
					
						11/29/2012
					
	  			</td>

	  			<td>

					
					11/29/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Exelixis, Inc.
  			</td>
  			<td>
  				1851 Harbor Bay Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Alameda
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94502
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				297109
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				amifampridine phosphate
  			</td>
  			<td>
  				FIRDAPSE
  			</td>
  			<td>
  				11/12/2009
  			</td>
  			<td>
  				Treatment of Lambert-Eaton Myasthenic Syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				FIRDAPSE® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
	  			</td>
				
	  			<td>
					
						11/28/2018
					
	  			</td>

	  			<td>

					
					11/28/2025
					
					
	  			</td>

				<td>
					FIRDAPSE® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
				</td>
			
  			<td>
  				Catalyst Pharmaceuticals, Inc.
  			</td>
  			<td>
  				355 Alhambra Circle
  			</td>
  			<td>
  				Suite 1250
  			</td>
  			<td>
  				Coral Gables
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33134
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				295309
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				gilteritinib
  			</td>
  			<td>
  				XOSPATA
  			</td>
  			<td>
  				07/13/2017
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia (AML)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						11/28/2018
					
	  			</td>

	  			<td>

					
					11/28/2025
					
					
	  			</td>

				<td>
					XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Astellas Pharma US, Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				587217
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Eflornithine HCl
  			</td>
  			<td>
  				Ornidyl
  			</td>
  			<td>
  				04/23/1986
  			</td>
  			<td>
  				Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						11/28/1990
					
	  			</td>

	  			<td>

					
					11/28/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoechst Marion Roussel
  			</td>
  			<td>
  				P.O. Box 9627
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kansas City
  			</td>
  			<td>
  				Missouri
  			</td>
  			<td>
  				64134
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				013586
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				larotrectinib 
  			</td>
  			<td>
  				VITRAKVI
  			</td>
  			<td>
  				05/09/2017
  			</td>
  			<td>
  				Treatment of solid tumors with NTRK-fusion proteins
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				VITRAKVI® is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.
	  			</td>
				
	  			<td>
					
						11/26/2018
					
	  			</td>

	  			<td>

					
					11/26/2025
					
					
	  			</td>

				<td>
					VITRAKVI® is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.
				</td>
			
  			<td>
  				Bayer HealthCare Pharmaceuticals Inc.
  			</td>
  			<td>
  				100 Bayer Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whippany
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07981
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				578317
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab
  			</td>
  			<td>
  				Rituxan
  			</td>
  			<td>
  				06/13/1994
  			</td>
  			<td>
  				Treatment of non-Hodgkin's B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma
	  			</td>
				
	  			<td>
					
						11/26/1997
					
	  			</td>

	  			<td>

					
					11/26/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way, MS 242
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				079793
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				naxitamab-gqgk
  			</td>
  			<td>
  				DANYELZA®
  			</td>
  			<td>
  				06/24/2013
  			</td>
  			<td>
  				Treatment of neuroblastoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy
	  			</td>
				
	  			<td>
					
						11/25/2020
					
	  			</td>

	  			<td>

					
					11/25/2027
					
					
	  			</td>

				<td>
					treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy
				</td>
			
  			<td>
  				Y-mAbs Therapeutics, Inc.
  			</td>
  			<td>
  				750 3rd Avenue
  			</td>
  			<td>
  				9th Floor
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				399613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				setmelanotide
  			</td>
  			<td>
  				Imcivree
  			</td>
  			<td>
  				11/27/2017
  			</td>
  			<td>
  				Treatment of leptin receptor deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
	  			</td>
				
	  			<td>
					
						11/25/2020
					
	  			</td>

	  			<td>

					
					11/25/2027
					
					
	  			</td>

				<td>
					Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
				</td>
			
  			<td>
  				Rhythm Pharmaceuticals, Inc.
  			</td>
  			<td>
  				222 Berkeley St. Suite 1200
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02116
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				613717
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				setmelanotide
  			</td>
  			<td>
  				Imcivree
  			</td>
  			<td>
  				04/04/2016
  			</td>
  			<td>
  				Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
	  			</td>
				
	  			<td>
					
						11/25/2020
					
	  			</td>

	  			<td>

					
					11/25/2027
					
					
	  			</td>

				<td>
					chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
				</td>
			
  			<td>
  				Rhythm Pharmaceuticals, Inc.
  			</td>
  			<td>
  				222 Berkeley St. Suite 1200
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02116
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				514815
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Voxelotor
  			</td>
  			<td>
  				OXBRYTA
  			</td>
  			<td>
  				12/29/2015
  			</td>
  			<td>
  				Treatment of sickle cell disease (SCD).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
	  			</td>
				
	  			<td>
					
						11/25/2019
					
	  			</td>

	  			<td>

					
					11/25/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
				</td>
			
  			<td>
  				Global Blood Therapeutics, Inc.
  			</td>
  			<td>
  				171 Oyster Point Blvd
  			</td>
  			<td>
  				Suite 300
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				499715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Octreotide
  			</td>
  			<td>
  				Sandostatin LAR
  			</td>
  			<td>
  				08/24/1998
  			</td>
  			<td>
  				Treatment of acromegaly.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.
	  			</td>
				
	  			<td>
					
						11/25/1998
					
	  			</td>

	  			<td>

					
					11/25/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				114598
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Octreotide
  			</td>
  			<td>
  				Sandostatin LAR
  			</td>
  			<td>
  				08/24/1998
  			</td>
  			<td>
  				Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.
	  			</td>
				
	  			<td>
					
						11/25/1998
					
	  			</td>

	  			<td>

					
					11/25/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				114698
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Octreotide
  			</td>
  			<td>
  				Sandostatin LAR
  			</td>
  			<td>
  				08/24/1998
  			</td>
  			<td>
  				Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of profuse watery diarrhea associated with VIPoma.
	  			</td>
				
	  			<td>
					
						11/25/1998
					
	  			</td>

	  			<td>

					
					11/25/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				116898
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Oprelvekin
  			</td>
  			<td>
  				Neumega
  			</td>
  			<td>
  				12/17/1996
  			</td>
  			<td>
  				Prevention of severe chemotherapy-induced thrombocytopenia. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						11/25/1997
					
	  			</td>

	  			<td>

					
					11/25/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genetics Institute, Inc.
  			</td>
  			<td>
  				87 Cambridge Park Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02140
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				096796
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Atovaquone
  			</td>
  			<td>
  				Mepron
  			</td>
  			<td>
  				09/10/1990
  			</td>
  			<td>
  				Treatment of AIDS associated Pneumocystis Carinii Pneumonia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.
	  			</td>
				
	  			<td>
					
						11/25/1992
					
	  			</td>

	  			<td>

					
					11/25/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Inc.
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				048890
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				necitumumab
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				11/20/2015
  			</td>
  			<td>
  				Treatment of squamous non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. 
	  			</td>
				
	  			<td>
					
						11/24/2015
					
	  			</td>

	  			<td>

					
					11/24/2022
					
					
	  			</td>

				<td>
					Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer.  PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				33 ImClone Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Branchburg
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08876
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				418213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				maribavir
  			</td>
  			<td>
  				Livtencity
  			</td>
  			<td>
  				06/07/2011
  			</td>
  			<td>
  				Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet
	  			</td>
				
	  			<td>
					
						11/23/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Pharmaceuticals USA, Inc.
  			</td>
  			<td>
  				650 East Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				332210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lumasiran
  			</td>
  			<td>
  				Oxlumo™
  			</td>
  			<td>
  				02/08/2016
  			</td>
  			<td>
  				Treatment of primary hyperoxaluria type 1
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
	  			</td>
				
	  			<td>
					
						11/23/2020
					
	  			</td>

	  			<td>

					
					11/23/2027
					
					
	  			</td>

				<td>
					treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
				</td>
			
  			<td>
  				Alnylam Pharmaceuticals, Inc.
  			</td>
  			<td>
  				300 Third Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				505315
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Anthrax Vaccine Adsorbed
  			</td>
  			<td>
  				BioThrax
  			</td>
  			<td>
  				04/11/2014
  			</td>
  			<td>
  				For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.
	  			</td>
				
	  			<td>
					
						11/23/2015
					
	  			</td>

	  			<td>

					
					11/23/2022
					
					
	  			</td>

				<td>
					For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.
				</td>
			
  			<td>
  				Emergent BioDefense Operations Lansing LLC
  			</td>
  			<td>
  				300 Proessional Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20879
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				424914
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sirolimus protein-bound particles for injectable suspension (albumin-bound)
  			</td>
  			<td>
  				Fyarro
  			</td>
  			<td>
  				12/21/2017
  			</td>
  			<td>
  				Treatment of perivascular epithelioid cell tumors (PEComa)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)
	  			</td>
				
	  			<td>
					
						11/22/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Aadi Bioscience, Inc.
  			</td>
  			<td>
  				17383 Sunset Blvd, A250
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Pacific Palisades
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90272
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				616217
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				riluzole oral film
  			</td>
  			<td>
  				EXSERVAN
  			</td>
  			<td>
  				01/23/2018
  			</td>
  			<td>
  				Treatment of amyotrophic lateral sclerosis (ALS)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				EXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
	  			</td>
				
	  			<td>
					
						11/22/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Aquestive Therapeutics
  			</td>
  			<td>
  				30 Technology Drive South
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Warren
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07059
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				563216
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sorafenib
  			</td>
  			<td>
  				Nexavar
  			</td>
  			<td>
  				12/12/2011
  			</td>
  			<td>
  				Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.  
	  			</td>
				
	  			<td>
					
						11/22/2013
					
	  			</td>

	  			<td>

					
					11/22/2020
					
					
	  			</td>

				<td>
					Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.  
				</td>
			
  			<td>
  				Bayer HealthCare Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 Bayer Blvd.
  			</td>
  			<td>
  				PO Box 915
  			</td>
  			<td>
  				Whippany
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07981
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				320310
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Nitazoxanide
  			</td>
  			<td>
  				Alinia
  			</td>
  			<td>
  				12/12/1996
  			</td>
  			<td>
  				Treatment of cryptosporidiosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia
	  			</td>
				
	  			<td>
					
						11/22/2002
					
	  			</td>

	  			<td>

					
					11/22/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Romark Laboratories, L.C.
  			</td>
  			<td>
  				6200 Courtney Campbell Causeway
  			</td>
  			<td>
  				Suite 880
  			</td>
  			<td>
  				Tampa
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33607
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				091895
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nitazoxanide
  			</td>
  			<td>
  				Alinia
  			</td>
  			<td>
  				02/14/2002
  			</td>
  			<td>
  				Treatment of intestinal giardiasis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia
	  			</td>
				
	  			<td>
					
						11/22/2002
					
	  			</td>

	  			<td>

					
					11/22/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Romark Laboratories, L.C.
  			</td>
  			<td>
  				6200 Courtney Campbell Causeway
  			</td>
  			<td>
  				Suite 880
  			</td>
  			<td>
  				Tampa
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33607
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				150401
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tretinoin
  			</td>
  			<td>
  				Vesanoid
  			</td>
  			<td>
  				10/24/1990
  			</td>
  			<td>
  				Treatment of acute promyelocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.
	  			</td>
				
	  			<td>
					
						11/22/1995
					
	  			</td>

	  			<td>

					
					11/22/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				050990
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Metronidazole (topical)
  			</td>
  			<td>
  				Metrogel
  			</td>
  			<td>
  				10/22/1987
  			</td>
  			<td>
  				Treatment of acne rosacea.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						11/22/1988
					
	  			</td>

	  			<td>

					
					11/22/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Galderma Laboratories, Inc.
  			</td>
  			<td>
  				P.O. Box 331329
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Fort Worth
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				76163
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				021687
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				acalabrutinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				05/13/2015
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia (CLL).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
	  			</td>
				
	  			<td>
					
						11/21/2019
					
	  			</td>

	  			<td>

					
					11/21/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
				</td>
			
  			<td>
  				Acerta Pharma, LLC (a member of the AstraZeneca Group)
  			</td>
  			<td>
  				121 Oyster Point Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				477415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Glasdegib
  			</td>
  			<td>
  				DAURISMO
  			</td>
  			<td>
  				06/28/2017
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia (AML)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
	  			</td>
				
	  			<td>
					
						11/21/2018
					
	  			</td>

	  			<td>

					
					11/21/2025
					
					
	  			</td>

				<td>
					DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				445 Eastern Point Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Groton
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06340
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				585517
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				venetoclax
  			</td>
  			<td>
  				VENCLEXTA
  			</td>
  			<td>
  				02/04/2016
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
	  			</td>
				
	  			<td>
					
						11/21/2018
					
	  			</td>

	  			<td>

					
					11/21/2025
					
					
	  			</td>

				<td>
					VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
				</td>
			
  			<td>
  				AbbVie Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				Dept PA72, Bldg. AP30-4
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				506815
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab
  			</td>
  			<td>
  				Darzalex
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  					DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
	  			</td>
				
	  			<td>
					
						11/21/2016
					
	  			</td>

	  			<td>

					
					11/21/2023
					
					
	  			</td>

				<td>
					DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. 
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				PO Box 300
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cinacalcet
  			</td>
  			<td>
  				Sensipar
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.  
	  			</td>
				
	  			<td>
					
						11/21/2014
					
	  			</td>

	  			<td>

					
					11/21/2021
					
					
	  			</td>

				<td>
					Treatment of less severe hypercalcemia (serum calcium >11.2 mg/dl and <= 12.5 mg/dl) in adult patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.  
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				Bldg 17, 1A-4-4, Mail Stop 17-1-B
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				165102
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Interferon alfa-2a (recombinant)
  			</td>
  			<td>
  				Roferon-A
  			</td>
  			<td>
  				12/14/1987
  			</td>
  			<td>
  				Treatment of AIDS related Kaposi's sarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						11/21/1988
					
	  			</td>

	  			<td>

					
					11/21/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				025987
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Interferon alfa-2b (recombinant)
  			</td>
  			<td>
  				Intron A
  			</td>
  			<td>
  				06/24/1987
  			</td>
  			<td>
  				Treatment of AIDS-related Kaposi's sarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of selected patients with AIDS-related Kaposi's sarcoma.
	  			</td>
				
	  			<td>
					
						11/21/1988
					
	  			</td>

	  			<td>

					
					11/21/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Schering Corporation
  			</td>
  			<td>
  				2000 Galloping Hill Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kenilworth
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07033
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				019187
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lonafarnib
  			</td>
  			<td>
  				ZOKINVY
  			</td>
  			<td>
  				04/18/2011
  			</td>
  			<td>
  				Treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations
	  			</td>
				
	  			<td>
					
						11/20/2020
					
	  			</td>

	  			<td>

					
					11/20/2027
					
					
	  			</td>

				<td>
					in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations
				</td>
			
  			<td>
  				Eiger BioPharmaceuticals, Inc.
  			</td>
  			<td>
  				2155 Park Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94306
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				333411
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				givosiran
  			</td>
  			<td>
  				GIVLAARI
  			</td>
  			<td>
  				08/29/2016
  			</td>
  			<td>
  				Treatment of acute hepatic porphyria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).
	  			</td>
				
	  			<td>
					
						11/20/2019
					
	  			</td>

	  			<td>

					
					11/20/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of adults with acute hepatic porphyria (AHP).
				</td>
			
  			<td>
  				Alnylam Pharmaceuticals, Inc.
  			</td>
  			<td>
  				101 Main Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				535516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Emapalumab-lzsg
  			</td>
  			<td>
  				GAMIFANT™
  			</td>
  			<td>
  				03/26/2010
  			</td>
  			<td>
  				Treatment of hemophagocytic lymphohistiocytosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
	  			</td>
				
	  			<td>
					
						11/20/2018
					
	  			</td>

	  			<td>

					
					11/20/2025
					
					
	  			</td>

				<td>
					GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
				</td>
			
  			<td>
  				Swedish Orphan Biovitrum AB
  			</td>
  			<td>
  				SE-112
  			</td>
  			<td>
  				75 Stockholm
  			</td>
  			<td>
  				Stockholm
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				302910
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ixazomib citrate
  			</td>
  			<td>
  				Ninlaro
  			</td>
  			<td>
  				02/18/2011
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use in combination with lenalidomide and dexamethasone for the treatment of  patients with multiple myeloma who have received at least one prior therapy
	  			</td>
				
	  			<td>
					
						11/20/2015
					
	  			</td>

	  			<td>

					
					11/20/2022
					
					
	  			</td>

				<td>
					Use in combination with lenalidomide and dexamethasone for the treatment of  patients with multiple myeloma who have received at least one prior therapy
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				330510
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eltrombopag 
  			</td>
  			<td>
  				Promacta
  			</td>
  			<td>
  				05/05/2008
  			</td>
  			<td>
  				Treatment of idiopathic thrombocytopenia purpura
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
	  			</td>
				
	  			<td>
					
						11/20/2008
					
	  			</td>

	  			<td>

					
					11/20/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				251907
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				 bosentan
  			</td>
  			<td>
  				Tracleer
  			</td>
  			<td>
  				10/06/2000
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension.
	  			</td>
				
	  			<td>
					
						11/20/2001
					
	  			</td>

	  			<td>

					
					11/20/2008
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Actelion Pharmaceuticals Ltd
  			</td>
  			<td>
  				1840 Gateway Drive
  			</td>
  			<td>
  				Suite 300
  			</td>
  			<td>
  				Cherry Hill
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08002
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				134200
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vosoritide
  			</td>
  			<td>
  				Voxzogo
  			</td>
  			<td>
  				01/17/2013
  			</td>
  			<td>
  				Treatment of achondroplasia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
	  			</td>
				
	  			<td>
					
						11/19/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				BioMarin Pharmaceutical, Inc.
  			</td>
  			<td>
  				105 Digital Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				386012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Erwinia L-asparaginase
  			</td>
  			<td>
  				Erwinase
  			</td>
  			<td>
  				07/30/1986
  			</td>
  			<td>
  				Treatment of acute lymphocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved/Withdrawn
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
	  			</td>
				
	  			<td>
					
						11/18/2011
					
	  			</td>

	  			<td>

					
					11/18/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Jazz Pharmaceuticals, Inc.
  			</td>
  			<td>
  				3180 Porter Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94304
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				015186
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sodium oxybate
  			</td>
  			<td>
  				 Xyrem
  			</td>
  			<td>
  				11/07/1994
  			</td>
  			<td>
  				Treatment of narcolepsy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of excessive daytime sleepiness in patients with narcolepsy
	  			</td>
				
	  			<td>
					
						11/18/2005
					
	  			</td>

	  			<td>

					
					11/18/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Jazz Pharmaceuticals Ireland Limited
  			</td>
  			<td>
  				5th Floor Waterloo Exchange
  			</td>
  			<td>
  				Waterloo Road
  			</td>
  			<td>
  				Dublin 4
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D04 E5W7
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				085894
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pulmonary surfactant replacement, porcine
  			</td>
  			<td>
  				Curosurf
  			</td>
  			<td>
  				08/02/1993
  			</td>
  			<td>
  				For the treatment and prevention of respiratory distress syndrome in premature infants.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment (rescue) of respiratory distress syndrome in premature infants.
	  			</td>
				
	  			<td>
					
						11/18/1999
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiesi USA, Inc.
  			</td>
  			<td>
  				175 Regency Woods Place
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27518
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				071192
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Melphalan
  			</td>
  			<td>
  				Alkeran For Injection
  			</td>
  			<td>
  				02/24/1992
  			</td>
  			<td>
  				Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.
	  			</td>
				
	  			<td>
					
						11/18/1992
					
	  			</td>

	  			<td>

					
					11/18/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Inc.
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				060991
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin for injection
  			</td>
  			<td>
  				Nutropin
  			</td>
  			<td>
  				08/04/1989
  			</td>
  			<td>
  				Treatment of growth retardation associated with chronic renal failure.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of children with growth failure associated with chronic renal insufficency.
	  			</td>
				
	  			<td>
					
						11/17/1993
					
	  			</td>

	  			<td>

					
					11/17/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				460 Point San Bruno Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				034989
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eltrombopag
  			</td>
  			<td>
  				Promacta
  			</td>
  			<td>
  				11/08/2013
  			</td>
  			<td>
  				Treatment of aplastic anemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.
	  			</td>
				
	  			<td>
					
						11/16/2018
					
	  			</td>

	  			<td>

					
					11/16/2025
					
					
	  			</td>

				<td>
					PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				410213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brentuximab  vedotin
  			</td>
  			<td>
  				Adcetris
  			</td>
  			<td>
  				10/23/2008
  			</td>
  			<td>
  				Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone
	  			</td>
				
	  			<td>
					
						11/16/2018
					
	  			</td>

	  			<td>

					
					11/16/2025
					
					
	  			</td>

				<td>
					ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823 30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				268908
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				obinutuzumab
  			</td>
  			<td>
  				GAZYVA
  			</td>
  			<td>
  				04/15/2015
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma
	  			</td>
				
	  			<td>
					
						11/16/2017
					
	  			</td>

	  			<td>

					
					11/16/2024
					
					
	  			</td>

				<td>
					In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.
				</td>
			
  			<td>
  				Genentech Inc., a member of the Roche Group
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				473415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				emicizumab-kxwh
  			</td>
  			<td>
  				Hemlibra
  			</td>
  			<td>
  				01/10/2014
  			</td>
  			<td>
  				Treatment of hemophilia A
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors
	  			</td>
				
	  			<td>
					
						11/16/2017
					
	  			</td>

	  			<td>

					
					11/16/2024
					
					
	  			</td>

				<td>
					Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors
				</td>
			
  			<td>
  				Genentech
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS 355e
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				416913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab
  			</td>
  			<td>
  				Darzalex
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent
	  			</td>
				
	  			<td>
					
						11/16/2015
					
	  			</td>

	  			<td>

					
					11/16/2022
					
					
	  			</td>

				<td>
					For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				PO Box 300
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ruxolitinib phosphate
  			</td>
  			<td>
  				Jakafi
  			</td>
  			<td>
  				09/05/2008
  			</td>
  			<td>
  				Treatment of myelofibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis
	  			</td>
				
	  			<td>
					
						11/16/2011
					
	  			</td>

	  			<td>

					
					11/16/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Incyte Corporation
  			</td>
  			<td>
  				1801 Augustine Cut-Off
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				265308
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				capsaicin 
  			</td>
  			<td>
  				Qutenza
  			</td>
  			<td>
  				05/22/2009
  			</td>
  			<td>
  				Management of neuropathic pain in patients with postherpetic neuralgia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of neuropathic pain associated with postherpetic neuralgia
	  			</td>
				
	  			<td>
					
						11/16/2009
					
	  			</td>

	  			<td>

					
					11/16/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Averitas Pharma, Inc.
  			</td>
  			<td>
  				360 Mount Kemble Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Morristown
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07960
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				269508
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sorafenib
  			</td>
  			<td>
  				Nexavar
  			</td>
  			<td>
  				04/20/2006
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of unresectable hepatocellular carcinoma
	  			</td>
				
	  			<td>
					
						11/16/2007
					
	  			</td>

	  			<td>

					
					11/16/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bayer Pharmaceuticals Corporation
  			</td>
  			<td>
  				400 Morgan Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				West Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06516
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				220206
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				crizanlizumab
  			</td>
  			<td>
  				ADAKVEO
  			</td>
  			<td>
  				07/22/2008
  			</td>
  			<td>
  				Treatment of sickle cell disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ADAKVEO® is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
	  			</td>
				
	  			<td>
					
						11/15/2019
					
	  			</td>

	  			<td>

					
					11/15/2026
					
					
	  			</td>

				<td>
					Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Building 337 B11.3D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936-
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				259708
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vestronidase alfa-vjbk
  			</td>
  			<td>
  				Mepsevii
  			</td>
  			<td>
  				02/16/2012
  			</td>
  			<td>
  				Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).
	  			</td>
				
	  			<td>
					
						11/15/2017
					
	  			</td>

	  			<td>

					
					11/15/2024
					
					
	  			</td>

				<td>
					Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).
				</td>
			
  			<td>
  				Ultragenyx Pharmaceutical, Inc.
  			</td>
  			<td>
  				60 Leveroni Court
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				359811
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				zanubrutinib
  			</td>
  			<td>
  				BRUKINSA
  			</td>
  			<td>
  				06/23/2016
  			</td>
  			<td>
  				Treatment of mantle cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
	  			</td>
				
	  			<td>
					
						11/14/2019
					
	  			</td>

	  			<td>

					
					11/14/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
				</td>
			
  			<td>
  				BeiGene USA, Inc.
  			</td>
  			<td>
  				2955 Campus Drive
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				San Mateo
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94403
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				527416
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				11/23/2010
  			</td>
  			<td>
  				Treatment of fallopian tube carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.
	  			</td>
				
	  			<td>
					
						11/14/2014
					
	  			</td>

	  			<td>

					
					11/14/2021
					
					
	  			</td>

				<td>
					In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				318010
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				11/02/2010
  			</td>
  			<td>
  				Treatment of primary peritoneal carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens
	  			</td>
				
	  			<td>
					
						11/14/2014
					
	  			</td>

	  			<td>

					
					11/14/2021
					
					
	  			</td>

				<td>
					In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				317810
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				02/09/2006
  			</td>
  			<td>
  				Therapeutic treatment of patients with ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens
	  			</td>
				
	  			<td>
					
						11/14/2014
					
	  			</td>

	  			<td>

					
					11/14/2021
					
					
	  			</td>

				<td>
					In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				216405
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rufinamide
  			</td>
  			<td>
  				Banzel
  			</td>
  			<td>
  				10/08/2004
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut Syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.
	  			</td>
				
	  			<td>
					
						11/14/2008
					
	  			</td>

	  			<td>

					
					11/14/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eisai, Inc.
  			</td>
  			<td>
  				300 Tice Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Woodcliff Lake
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07677
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				193504
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pegfilgrastim
  			</td>
  			<td>
  				Neulasta
  			</td>
  			<td>
  				11/20/2013
  			</td>
  			<td>
  				Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)
	  			</td>
				
	  			<td>
					
						11/13/2015
					
	  			</td>

	  			<td>

					
					11/13/2022
					
					
	  			</td>

				<td>
					To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				M/S 17-1-C
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				413013
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				osimertinib
  			</td>
  			<td>
  				Tagrisso
  			</td>
  			<td>
  				09/04/2014
  			</td>
  			<td>
  				Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy
	  			</td>
				
	  			<td>
					
						11/13/2015
					
	  			</td>

	  			<td>

					
					11/13/2022
					
					
	  			</td>

				<td>
					For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				445214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				12/03/2012
  			</td>
  			<td>
  				Treatment of mantle cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy 
	  			</td>
				
	  			<td>
					
						11/13/2013
					
	  			</td>

	  			<td>

					
					11/13/2020
					
					
	  			</td>

				<td>
					Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy 
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				383112
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Mitoxantrone
  			</td>
  			<td>
  				Novantrone
  			</td>
  			<td>
  				08/21/1996
  			</td>
  			<td>
  				Treatment of hormone refractory prostate cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.
	  			</td>
				
	  			<td>
					
						11/13/1996
					
	  			</td>

	  			<td>

					
					11/13/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Serono
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				096696
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ropeginterferon alfa-2b-njft
  			</td>
  			<td>
  				Besremi
  			</td>
  			<td>
  				04/02/2012
  			</td>
  			<td>
  				Treatment of polycythemia vera
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with polycythemia vera
	  			</td>
				
	  			<td>
					
						11/12/2021
					
	  			</td>

	  			<td>

					
					11/12/2028
					
					
	  			</td>

				<td>
					Treatment of adults with polycythemia vera
				</td>
			
  			<td>
  				PharmaEssentia
  			</td>
  			<td>
  				13F, No. 3, YuanQu St.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Taipei
  			</td>
  			<td>
  				Taiwan
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Taiwan
  			</td>
			<td>
  				367012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cobimetinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				01/31/2014
  			</td>
  			<td>
  				Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. Limitations of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.
	  			</td>
				
	  			<td>
					
						11/10/2015
					
	  			</td>

	  			<td>

					
					11/10/2022
					
					
	  			</td>

				<td>
					For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way, MS 241A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				419513
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				06/12/2017
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma (HCC)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
	  			</td>
				
	  			<td>
					
						11/09/2018
					
	  			</td>

	  			<td>

					
					11/09/2025
					
					
	  			</td>

				<td>
					KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib
				</td>
			
  			<td>
  				Merck, Sharp & Dohme Corp
  			</td>
  			<td>
  				1 Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				576917
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Brentuximab vedotin
  			</td>
  			<td>
  				Adcetris
  			</td>
  			<td>
  				09/07/2016
  			</td>
  			<td>
  				Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy
	  			</td>
				
	  			<td>
					
						11/09/2017
					
	  			</td>

	  			<td>

					
					11/09/2024
					
					
	  			</td>

				<td>
					For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823 30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				536516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brentuximab vedotin
  			</td>
  			<td>
  				Adcetris
  			</td>
  			<td>
  				11/19/2012
  			</td>
  			<td>
  				Treatment of mycosis fungoides
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy
	  			</td>
				
	  			<td>
					
						11/09/2017
					
	  			</td>

	  			<td>

					
					11/09/2024
					
					
	  			</td>

				<td>
					Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823 30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				362611
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dasatinib
  			</td>
  			<td>
  				Sprycel
  			</td>
  			<td>
  				11/28/2005
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
	  			</td>
				
	  			<td>
					
						11/09/2017
					
	  			</td>

	  			<td>

					
					11/09/2024
					
					
	  			</td>

				<td>
					Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				3401 Princeton Pike, B-3043C
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lawrence Township
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08648
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				212405
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Luspatercept-aamt
  			</td>
  			<td>
  				REBLOZYL
  			</td>
  			<td>
  				03/11/2013
  			</td>
  			<td>
  				Treatment of B-thalassemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
	  			</td>
				
	  			<td>
					
						11/08/2019
					
	  			</td>

	  			<td>

					
					11/08/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				389813
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				letermovir
  			</td>
  			<td>
  				PREVYMIS
  			</td>
  			<td>
  				12/12/2011
  			</td>
  			<td>
  				Prevention of human cytomegalovirus viremia and disease in at risk populations
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). 
	  			</td>
				
	  			<td>
					
						11/08/2017
					
	  			</td>

	  			<td>

					
					11/08/2024
					
					
	  			</td>

				<td>
					Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). 
				</td>
			
  			<td>
  				Merck Sharpe & Dhome Corporation
  			</td>
  			<td>
  				P. O. Box 1000, UG2D-68
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				340211
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Trientine HCl
  			</td>
  			<td>
  				Syprine
  			</td>
  			<td>
  				12/24/1984
  			</td>
  			<td>
  				Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						11/08/1985
					
	  			</td>

	  			<td>

					
					11/08/1992
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Merck Sharp & Dohme Research
  			</td>
  			<td>
  				Division Of Merck And Company
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				West Point
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19486
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				004884
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				elotuzumab
  			</td>
  			<td>
  				Empliciti
  			</td>
  			<td>
  				09/01/2011
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
	  			</td>
				
	  			<td>
					
						11/06/2018
					
	  			</td>

	  			<td>

					
					11/06/2025
					
					
	  			</td>

				<td>
					Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Empliciti’s previously approved indication for multiple myeloma.
				</td>
			
  			<td>
  				Bristol-Myers Squibb Co.
  			</td>
  			<td>
  				P.O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				348411
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				alectinib
  			</td>
  			<td>
  				Alecensa
  			</td>
  			<td>
  				01/27/2015
  			</td>
  			<td>
  				Treatment of ALK-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						11/06/2017
					
	  			</td>

	  			<td>

					
					11/06/2024
					
					
	  			</td>

				<td>
					Treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small-cell lung cancer (NSCLC) as detected by an FDA-approved test, excluding patients who have progressed on or are intolerant to crizotinib.
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)
  			</td>
  			<td>
  				1 DNA Way, MS #355E
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				462814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vemurafenib
  			</td>
  			<td>
  				Zelboraf
  			</td>
  			<td>
  				08/02/2016
  			</td>
  			<td>
  				Treatment of Erdheim-Chester Disease 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation
	  			</td>
				
	  			<td>
					
						11/06/2017
					
	  			</td>

	  			<td>

					
					11/06/2024
					
					
	  			</td>

				<td>
					Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				529616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ramucirumab
  			</td>
  			<td>
  				CYRAMZA
  			</td>
  			<td>
  				02/16/2012
  			</td>
  			<td>
  				Treatment of gastric cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.  
	  			</td>
				
	  			<td>
					
						11/05/2014
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				33 ImClone Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Branchburg
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08876
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				359711
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				romidepsin
  			</td>
  			<td>
  				Istodax
  			</td>
  			<td>
  				09/30/2004
  			</td>
  			<td>
  				Treatment of non-Hodgkin T-cell lymphomas
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
	  			</td>
				
	  			<td>
					
						11/05/2009
					
	  			</td>

	  			<td>

					
					11/05/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				One Broadway
  			</td>
  			<td>
  				14th Floor
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				193404
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Lorlatinib
  			</td>
  			<td>
  				LORBRENA
  			</td>
  			<td>
  				06/23/2015
  			</td>
  			<td>
  				Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.
	  			</td>
				
	  			<td>
					
						11/02/2018
					
	  			</td>

	  			<td>

					
					11/02/2025
					
					
	  			</td>

				<td>
					LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				235 East 42nd Street (M/S 219/9/30)
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				481015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Deferasirox
  			</td>
  			<td>
  				Exjade; Jadenu Sprinkles
  			</td>
  			<td>
  				11/21/2002
  			</td>
  			<td>
  				Treatment of chronic iron overload in patients with transfusion-dependent anemias
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older
	  			</td>
				
	  			<td>
					
						11/02/2005
					
	  			</td>

	  			<td>

					
					11/02/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Hampshire
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				161002
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				obinutuzumab
  			</td>
  			<td>
  				GAZYVA
  			</td>
  			<td>
  				02/17/2012
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).
	  			</td>
				
	  			<td>
					
						11/01/2013
					
	  			</td>

	  			<td>

					
					11/01/2020
					
					
	  			</td>

				<td>
					Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.
				</td>
			
  			<td>
  				Genentech Inc., a member of the Roche Group
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				359911
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin  
  			</td>
  			<td>
  				Humatrope
  			</td>
  			<td>
  				12/15/2005
  			</td>
  			<td>
  				Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed
	  			</td>
				
	  			<td>
					
						11/01/2006
					
	  			</td>

	  			<td>

					
					11/01/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				211205
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Synthetic porcine secretin
  			</td>
  			<td>
  				Secreflo
  			</td>
  			<td>
  				06/18/1999
  			</td>
  			<td>
  				For use in the evaluation of exocrine pancreas function.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in secretin stimulation testing for: Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangio-pancreatography (ERCP)
	  			</td>
				
	  			<td>
					
						11/01/2002
					
	  			</td>

	  			<td>

					
					11/01/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ChiRhoClin, Inc.
  			</td>
  			<td>
  				15500 Gallaudet Ave.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Silver Spring
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20905
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				120298
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				acalabrutinib
  			</td>
  			<td>
  				CALQUENCE
  			</td>
  			<td>
  				09/21/2015
  			</td>
  			<td>
  				Treatment of mantle cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
	  			</td>
				
	  			<td>
					
						10/31/2017
					
	  			</td>

	  			<td>

					
					10/31/2024
					
					
	  			</td>

				<td>
					treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
				</td>
			
  			<td>
  				Acerta Pharma, LLC (a member of the AstraZeneca Group)
  			</td>
  			<td>
  				121 Oyster Point Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				488915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bendamustine hydrochloride
  			</td>
  			<td>
  				Treanda
  			</td>
  			<td>
  				11/26/2013
  			</td>
  			<td>
  				Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. 
	  			</td>
				
	  			<td>
					
						10/31/2008
					
	  			</td>

	  			<td>

					
					10/31/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cephalon, Inc.
  			</td>
  			<td>
  				A wholly owned subsidiary of Teva Pharmaceuticals
  			</td>
  			<td>
  				PO Box 4011
  			</td>
  			<td>
  				Frazer
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				253107
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin
  			</td>
  			<td>
  				Genotropin
  			</td>
  			<td>
  				09/06/1994
  			</td>
  			<td>
  				Treatment of adults with growth hormone deficiency.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/31/1997
					
	  			</td>

	  			<td>

					
					10/31/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia & Upjohn
  			</td>
  			<td>
  				7000 Portage Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kalamazoo
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				49001
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				083594
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Calcitonin-human for injection
  			</td>
  			<td>
  				Cibacalcin
  			</td>
  			<td>
  				01/20/1987
  			</td>
  			<td>
  				Treatment of symptomatic Paget's disease (osteitis deformans).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/31/1986
					
	  			</td>

	  			<td>

					
					10/31/1993
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceutical Corporation
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				013186
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Monooctanoin
  			</td>
  			<td>
  				Moctanin
  			</td>
  			<td>
  				05/30/1984
  			</td>
  			<td>
  				For dissolution of cholesterol gallstones retained in the common bile duct.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/31/1985
					
	  			</td>

	  			<td>

					
					10/31/1992
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ethitek Pharmaceuticals, Inc.
  			</td>
  			<td>
  				7855 Gross Point Road, Unit L
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Skokie
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60077
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				002484
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				MANNITOL
  			</td>
  			<td>
  				 Bronchitol® 
  			</td>
  			<td>
  				02/11/2005
  			</td>
  			<td>
  				For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test.
	  			</td>
				
	  			<td>
					
						10/30/2020
					
	  			</td>

	  			<td>

					
					10/30/2027
					
					
	  			</td>

				<td>
					as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis and who have passed the Bronchitol Tolerance Test
				</td>
			
  			<td>
  				Chiesi Farmaceutici S.p.A (Chiesi USA, Inc.)
  			</td>
  			<td>
  				175 Regency Woods Place 
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27518
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				198704
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sotalol HCl
  			</td>
  			<td>
  				Betapace
  			</td>
  			<td>
  				09/23/1988
  			</td>
  			<td>
  				1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of life-threatening ventricular tachyarrhythmias
	  			</td>
				
	  			<td>
					
						10/30/1992
					
	  			</td>

	  			<td>

					
					10/30/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Berlex Laboratories, Inc.
  			</td>
  			<td>
  				300 Fairfield Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wayne
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07470
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				030088
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				asciminib
  			</td>
  			<td>
  				Scemblix
  			</td>
  			<td>
  				02/27/2017
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation
	  			</td>
				
	  			<td>
					
						10/29/2021
					
	  			</td>

	  			<td>

					
					10/29/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation
				</td>
			
  			<td>
  				Novartis Pharmaceutical Corporation
  			</td>
  			<td>
  				One Health Plaza 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				556416
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				asciminib
  			</td>
  			<td>
  				Scemblix
  			</td>
  			<td>
  				02/27/2017
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)
	  			</td>
				
	  			<td>
					
						10/29/2021
					
	  			</td>

	  			<td>

					
					10/29/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)
				</td>
			
  			<td>
  				Novartis Pharmaceutical Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				556416
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				everolimus
  			</td>
  			<td>
  				Afinitor 
  			</td>
  			<td>
  				06/08/2009
  			</td>
  			<td>
  				 Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection
	  			</td>
				
	  			<td>
					
						10/29/2010
					
	  			</td>

	  			<td>

					
					10/29/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza, 315/5450A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				283609
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nilotinib; nilotinib; nilotinib
  			</td>
  			<td>
  				Tasigna; Tasigna; Tasigna 
  			</td>
  			<td>
  				04/27/2006
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia  (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.
	  			</td>
				
	  			<td>
					
						10/29/2007
					
	  			</td>

	  			<td>

					
					10/29/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				220806
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ipilimumab
  			</td>
  			<td>
  				Yervoy
  			</td>
  			<td>
  				06/03/2004
  			</td>
  			<td>
  				Treatment of high risk Stage II, Stage III, and Stage IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.
	  			</td>
				
	  			<td>
					
						10/28/2015
					
	  			</td>

	  			<td>

					
					10/28/2022
					
					
	  			</td>

				<td>
					For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177703
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nelarabine
  			</td>
  			<td>
  				Arranon
  			</td>
  			<td>
  				08/10/2004
  			</td>
  			<td>
  				Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens
	  			</td>
				
	  			<td>
					
						10/28/2005
					
	  			</td>

	  			<td>

					
					10/28/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				184404
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				talimogene laherparepvec
  			</td>
  			<td>
  				IMLYGIC
  			</td>
  			<td>
  				03/14/2011
  			</td>
  			<td>
  				Treatment of stage IIb-stage IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
	  			</td>
				
	  			<td>
					
						10/27/2015
					
	  			</td>

	  			<td>

					
					10/27/2022
					
					
	  			</td>

				<td>
					Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
				</td>
			
  			<td>
  				BioVex, Inc. (subsidiary of Amgen)
  			</td>
  			<td>
  				Amgen
  			</td>
  			<td>
  				Mail Stop 17-2-B
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				334011
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sodium oxybate
  			</td>
  			<td>
  				 Xyrem
  			</td>
  			<td>
  				11/07/1994
  			</td>
  			<td>
  				Treatment of narcolepsy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
	  			</td>
				
	  			<td>
					
						10/26/2018
					
	  			</td>

	  			<td>

					
					10/26/2025
					
					
	  			</td>

				<td>
					Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in pediatric patients 7 years of age and older with narcolepsy.
				</td>
			
  			<td>
  				Jazz Pharmaceuticals Ireland Limited
  			</td>
  			<td>
  				5th Floor Waterloo Exchange
  			</td>
  			<td>
  				Waterloo Road
  			</td>
  			<td>
  				Dublin 4
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D04 E5W7
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				085894
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				omacetaxine mepesuccinate
  			</td>
  			<td>
  				Synribo
  			</td>
  			<td>
  				03/10/2006
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)
	  			</td>
				
	  			<td>
					
						10/26/2012
					
	  			</td>

	  			<td>

					
					10/26/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				IVAX International GmbH
  			</td>
  			<td>
  				Alpenstrasse 2
  			</td>
  			<td>
  				8640 Rapperswil
  			</td>
  			<td>
  				Frazer
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				218205
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ofatumumab
  			</td>
  			<td>
  				ARZERRA
  			</td>
  			<td>
  				03/10/2009
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine
	  			</td>
				
	  			<td>
					
						10/26/2009
					
	  			</td>

	  			<td>

					
					10/26/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				275809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Betaine
  			</td>
  			<td>
  				Cystadane
  			</td>
  			<td>
  				05/16/1994
  			</td>
  			<td>
  				Treatment of homocystinuria.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of homocystinuria to decrease elevated homocysteine blood levels.
	  			</td>
				
	  			<td>
					
						10/25/1996
					
	  			</td>

	  			<td>

					
					10/25/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Orphan Europe SARL
  			</td>
  			<td>
  				70 Avenue du Général de Gaulle
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Puteaux
  			</td>
  			<td>
  				Île-de-France
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				081794
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				niraparib
  			</td>
  			<td>
  				Zejula
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ZEJULA® is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either, (1) a deleterious or suspected deleterious BRCA mutation, or (2) genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy
	  			</td>
				
	  			<td>
					
						10/23/2019
					
	  			</td>

	  			<td>

					
					10/23/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy.
				</td>
			
  			<td>
  				GlaxoSmithKline, LLC.
  			</td>
  			<td>
  				1000 Winter St.
  			</td>
  			<td>
  				Suite 3300
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				306510
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eculizumab
  			</td>
  			<td>
  				Soliris
  			</td>
  			<td>
  				06/12/2014
  			</td>
  			<td>
  				Treatment of Myasthenia Gravis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive
	  			</td>
				
	  			<td>
					
						10/23/2017
					
	  			</td>

	  			<td>

					
					10/23/2024
					
					
	  			</td>

				<td>
					for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				121 Seaport Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				434214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trabectedin
  			</td>
  			<td>
  				Yondelis
  			</td>
  			<td>
  				09/30/2004
  			</td>
  			<td>
  				Treatment of soft tissue sarcoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen
	  			</td>
				
	  			<td>
					
						10/23/2015
					
	  			</td>

	  			<td>

					
					10/23/2022
					
					
	  			</td>

				<td>
					For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen
				</td>
			
  			<td>
  				Janssen Research & Development, LLC
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				193604
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Asfotase alfa
  			</td>
  			<td>
  				Strensiq
  			</td>
  			<td>
  				09/12/2008
  			</td>
  			<td>
  				Treatment of hypophosphatasia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)
	  			</td>
				
	  			<td>
					
						10/23/2015
					
	  			</td>

	  			<td>

					
					10/23/2022
					
					
	  			</td>

				<td>
					For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 College St.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06510
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				266608
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				antihemophilic factor (recombinant), porcine sequence
  			</td>
  			<td>
  				OBIZUR
  			</td>
  			<td>
  				03/16/2004
  			</td>
  			<td>
  				Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of bleeding episodes in adults with acquired hemophilia A.  
	  			</td>
				
	  			<td>
					
						10/23/2014
					
	  			</td>

	  			<td>

					
					10/23/2021
					
					
	  			</td>

				<td>
					Treatment of bleeding episodes in adults with acquired hemophilia A.  
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				181403
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Botulism immune globulin
  			</td>
  			<td>
  				BabyBIG 
  			</td>
  			<td>
  				01/31/1989
  			</td>
  			<td>
  				Treatment of infant botulism.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum.
	  			</td>
				
	  			<td>
					
						10/23/2003
					
	  			</td>

	  			<td>

					
					10/23/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				California Department of Health Services
  			</td>
  			<td>
  				2151 Berkeley Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Berkeley
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94704
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				034488
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				irinotecan liposome injection
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				07/21/2011
  			</td>
  			<td>
  				Treatment of pancreatic cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy
	  			</td>
				
	  			<td>
					
						10/22/2015
					
	  			</td>

	  			<td>

					
					10/22/2022
					
					
	  			</td>

				<td>
					For use in combination with 5-fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy
				</td>
			
  			<td>
  				Ipsen Bioscience,Inc.
  			</td>
  			<td>
  				650 East Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				344311
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				elexacaftor/tezacaftor/ivacaftor
  			</td>
  			<td>
  				TRIKAFTA
  			</td>
  			<td>
  				08/29/2018
  			</td>
  			<td>
  				Treatment of Cystic Fibrosis 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
	  			</td>
				
	  			<td>
					
						10/21/2019
					
	  			</td>

	  			<td>

					
					10/21/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				647618
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				clobazam
  			</td>
  			<td>
  				Onfi
  			</td>
  			<td>
  				12/18/2007
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut Syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older
	  			</td>
				
	  			<td>
					
						10/21/2011
					
	  			</td>

	  			<td>

					
					10/21/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Lundbeck, Inc.
  			</td>
  			<td>
  				Four Parkway North
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				248307
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Exemestane
  			</td>
  			<td>
  				Aromasin
  			</td>
  			<td>
  				09/19/1991
  			</td>
  			<td>
  				Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
	  			</td>
				
	  			<td>
					
						10/21/1999
					
	  			</td>

	  			<td>

					
					10/21/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia & Upjohn
  			</td>
  			<td>
  				7000 Portage Road
  			</td>
  			<td>
  				Mail Stop:  0636-298-113
  			</td>
  			<td>
  				Kalamazoo
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				49001
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				060191
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor X (human)
  			</td>
  			<td>
  				COAGADEX
  			</td>
  			<td>
  				11/08/2007
  			</td>
  			<td>
  				Treatment of hereditary factor X deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency
	  			</td>
				
	  			<td>
					
						10/20/2015
					
	  			</td>

	  			<td>

					
					10/20/2022
					
					
	  			</td>

				<td>
					Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency
				</td>
			
  			<td>
  				Bio Products Laboratory Limited
  			</td>
  			<td>
  				Dagger Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Elstree
  			</td>
  			<td>
  				Hertfordshire
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				246907
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trastuzumab
  			</td>
  			<td>
  				Herceptin
  			</td>
  			<td>
  				10/13/2009
  			</td>
  			<td>
  				Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease
	  			</td>
				
	  			<td>
					
						10/20/2010
					
	  			</td>

	  			<td>

					
					10/20/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				292409
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaratumab
  			</td>
  			<td>
  				Lartruvo
  			</td>
  			<td>
  				10/09/2014
  			</td>
  			<td>
  				Treatment of soft tissue sarcoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. (Indication withdrawn)
	  			</td>
				
	  			<td>
					
						10/19/2016
					
	  			</td>

	  			<td>

					
					02/25/2020
					
					
	  			</td>

				<td>
					In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. (Indication withdrawn)
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center, Drop Code 2543
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				448414
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mebendazole
  			</td>
  			<td>
  				VERMOX 500 mg chewable tablets
  			</td>
  			<td>
  				09/03/2014
  			</td>
  			<td>
  				Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm) 
	  			</td>
				
	  			<td>
					
						10/19/2016
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Janssen Pharmaceutical Research & Development, LLC
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397013
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Imatinib mesylate
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				10/05/2005
  			</td>
  			<td>
  				Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements
	  			</td>
				
	  			<td>
					
						10/19/2006
					
	  			</td>

	  			<td>

					
					10/19/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				209105
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Imatinib mesylate
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				09/09/2005
  			</td>
  			<td>
  				Treatment of systemic mastocytosis without the D816V c-kit mutation
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown
	  			</td>
				
	  			<td>
					
						10/19/2006
					
	  			</td>

	  			<td>

					
					10/19/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				209205
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Imatinib mesylate
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				08/25/2005
  			</td>
  			<td>
  				Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÿ}ÿ± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRÿ}ÿ± fusion kinase negative or unknown
	  			</td>
				
	  			<td>
					
						10/19/2006
					
	  			</td>

	  			<td>

					
					10/19/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				209005
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				imatinib
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				10/11/2005
  			</td>
  			<td>
  				Treatment of Philadelphia-positive acute lymphoblastic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)
	  			</td>
				
	  			<td>
					
						10/19/2006
					
	  			</td>

	  			<td>

					
					10/19/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				208905
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				imatinib mesylate
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				12/19/2005
  			</td>
  			<td>
  				Treatment of dermatofibrosarcoma protuberans
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)
	  			</td>
				
	  			<td>
					
						10/19/2006
					
	  			</td>

	  			<td>

					
					10/19/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				208805
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Interferon alfa-2a
  			</td>
  			<td>
  				Roferon A
  			</td>
  			<td>
  				06/06/1989
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic myelogenous leukemia.
	  			</td>
				
	  			<td>
					
						10/19/1995
					
	  			</td>

	  			<td>

					
					10/19/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				036989
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				treprostinil
  			</td>
  			<td>
  				Remodulin;Orenitram
  			</td>
  			<td>
  				06/04/1997
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.
	  			</td>
				
	  			<td>
					
						10/18/2019
					
	  			</td>

	  			<td>

					
					10/18/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression.
				</td>
			
  			<td>
  				United Therapeutics Corp.
  			</td>
  			<td>
  				55 T.W. Alexander Dr.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				105197
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				axicabtagene ciloleucel
  			</td>
  			<td>
  				Yescarta
  			</td>
  			<td>
  				04/20/2016
  			</td>
  			<td>
  				Treatment of primary mediastinal B-cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
	  			</td>
				
	  			<td>
					
						10/18/2017
					
	  			</td>

	  			<td>

					
					10/18/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma
				</td>
			
  			<td>
  				Kite Pharma, Inc.
  			</td>
  			<td>
  				2225 Colorado Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				axicabtagene ciloleucel
  			</td>
  			<td>
  				Yescarta
  			</td>
  			<td>
  				04/25/2016
  			</td>
  			<td>
  				Treatment of follicular lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
	  			</td>
				
	  			<td>
					
						10/18/2017
					
	  			</td>

	  			<td>

					
					10/18/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma
				</td>
			
  			<td>
  				Kite Pharma, Inc.
  			</td>
  			<td>
  				2225 Colorado Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515615
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				axicabtagene ciloleucel
  			</td>
  			<td>
  				Yescarta
  			</td>
  			<td>
  				03/27/2014
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
	  			</td>
				
	  			<td>
					
						10/18/2017
					
	  			</td>

	  			<td>

					
					10/18/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma
				</td>
			
  			<td>
  				Kite Pharma, Inc.
  			</td>
  			<td>
  				2225 Colorado Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				423914
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				paricalcitol
  			</td>
  			<td>
  				Zemplar
  			</td>
  			<td>
  				10/27/2015
  			</td>
  			<td>
  				Treatment of pediatric hyperparathyroidism
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4  and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis 
	  			</td>
				
	  			<td>
					
						10/18/2016
					
	  			</td>

	  			<td>

					
					10/18/2023
					
					
	  			</td>

				<td>
					Indicated in pediatric patients ages 10 -16 years for treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4  and pediatric patients ages 10-16 years for treatment of secondary hyperparathyroidism associated with CKD Stage 5. 
				</td>
			
  			<td>
  				Abbvie, inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				492815
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				macitentan
  			</td>
  			<td>
  				Opsumit
  			</td>
  			<td>
  				09/03/2009
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression.  Disease progression included:  death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment).  Opsumit also reduced hospitalization for PAH.  
	  			</td>
				
	  			<td>
					
						10/18/2013
					
	  			</td>

	  			<td>

					
					10/18/2020
					
					
	  			</td>

				<td>
					Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression.  Disease progression included:  death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment).  Opsumit also reduced hospitalization for PAH.  
				</td>
			
  			<td>
  				Actelion Pharmaceuticals Ltd
  			</td>
  			<td>
  				Gewerbestrasse 16
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Allschwil
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				282209
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Amphotericin B lipid complex
  			</td>
  			<td>
  				Abelcet
  			</td>
  			<td>
  				12/05/1991
  			</td>
  			<td>
  				Treatment of invasive fungal infections.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.
	  			</td>
				
	  			<td>
					
						10/18/1996
					
	  			</td>

	  			<td>

					
					10/18/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Liposome Company, Inc.
  			</td>
  			<td>
  				One Research Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				057891
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				romiplostim
  			</td>
  			<td>
  				Nplate
  			</td>
  			<td>
  				03/27/2003
  			</td>
  			<td>
  				Treatment of immune thrombocytopenic purpura
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
	  			</td>
				
	  			<td>
					
						10/17/2019
					
	  			</td>

	  			<td>

					
					10/17/2026
					
					
	  			</td>

				<td>
					For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				Mail Stop: 27-2-D
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				165402
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatrem for injection
  			</td>
  			<td>
  				Protropin
  			</td>
  			<td>
  				12/09/1985
  			</td>
  			<td>
  				1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/17/1985
					
	  			</td>

	  			<td>

					
					10/17/1992
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				460 Point San Bruno Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				010785
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin
  			</td>
  			<td>
  				Nutropin
  			</td>
  			<td>
  				03/06/1987
  			</td>
  			<td>
  				For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/17/1985
					
	  			</td>

	  			<td>

					
					10/17/1992
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				460 Point San Bruno Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				012586
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				HUMIRA
  			</td>
  			<td>
  				05/13/2015
  			</td>
  			<td>
  				Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
	  			</td>
				
	  			<td>
					
						10/16/2018
					
	  			</td>

	  			<td>

					
					10/16/2025
					
					
	  			</td>

				<td>
					Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				446414
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				idarucizumab
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				05/28/2015
  			</td>
  			<td>
  				To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding
	  			</td>
				
	  			<td>
					
						10/16/2015
					
	  			</td>

	  			<td>

					
					10/16/2022
					
					
	  			</td>

				<td>
					For use in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding
				</td>
			
  			<td>
  				Boehringer Ingelheim Pharmaceuticals, Inc.
  			</td>
  			<td>
  				PO Box 368
  			</td>
  			<td>
  				900 Ridgebury Road
  			</td>
  			<td>
  				Ridgefield
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06877
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				445714
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pentamidine isethionate
  			</td>
  			<td>
  				Pentam 300
  			</td>
  			<td>
  				02/28/1984
  			</td>
  			<td>
  				Treatment of Pneumocystis carinii pneumonia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/16/1984
					
	  			</td>

	  			<td>

					
					10/16/1991
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fujisawa USA, Inc.
  			</td>
  			<td>
  				3 Parkway North Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				001083
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pirfenidone
  			</td>
  			<td>
  				ESBRIET
  			</td>
  			<td>
  				03/05/2004
  			</td>
  			<td>
  				Treatment of idiopathic pulmonary fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of idiopathic pulmonary fibrosis
	  			</td>
				
	  			<td>
					
						10/15/2014
					
	  			</td>

	  			<td>

					
					10/15/2021
					
					
	  			</td>

				<td>
					Treatment of idiopathic pulmonary fibrosis
				</td>
			
  			<td>
  				Genentech
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177903
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nintedanib
  			</td>
  			<td>
  				OFEV
  			</td>
  			<td>
  				06/29/2011
  			</td>
  			<td>
  				Treatment of patients with idiopathic pulmonary fibrosis. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of idiopathic pulmonary fibrosis
	  			</td>
				
	  			<td>
					
						10/15/2014
					
	  			</td>

	  			<td>

					
					10/15/2021
					
					
	  			</td>

				<td>
					Treatment of idiopathic pulmonary fibrosis
				</td>
			
  			<td>
  				Boehringer Ingelheim Pharmaceuticals, Inc.
  			</td>
  			<td>
  				900 Ridgebury Road
  			</td>
  			<td>
  				P. O. Box 368
  			</td>
  			<td>
  				Ridgefield
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06877
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				344511
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				repository corticotropin or adrenocorticotropic hormone
  			</td>
  			<td>
  				H.P. Acthar Gel
  			</td>
  			<td>
  				05/21/2003
  			</td>
  			<td>
  				Treatment of infantile spasms
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To treat infantile spasms
	  			</td>
				
	  			<td>
					
						10/15/2010
					
	  			</td>

	  			<td>

					
					10/15/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Questcor Pharmaceuticals,  Inc.
  			</td>
  			<td>
  				26118 Research Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Hayward
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94545
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				168103
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				atoltivimab, maftivimab, and odesivimab-ebgn
  			</td>
  			<td>
  				INMAZEB™
  			</td>
  			<td>
  				07/14/2016
  			</td>
  			<td>
  				Treatment of ebola virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection
	  			</td>
				
	  			<td>
					
						10/14/2020
					
	  			</td>

	  			<td>

					
					10/14/2027
					
					
	  			</td>

				<td>
					treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection
				</td>
			
  			<td>
  				Regeneron Pharmaceuticals, Inc.
  			</td>
  			<td>
  				777 Old Saw Mill River Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tarrytown
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10591
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				536316
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deferiprone
  			</td>
  			<td>
  				Ferriprox
  			</td>
  			<td>
  				12/12/2001
  			</td>
  			<td>
  				Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate
	  			</td>
				
	  			<td>
					
						10/14/2011
					
	  			</td>

	  			<td>

					
					10/14/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiesi USA, Inc.
  			</td>
  			<td>
  				175 Regency Woods Place
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27518
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				150701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pitolisant
  			</td>
  			<td>
  				WAKIX®
  			</td>
  			<td>
  				05/17/2010
  			</td>
  			<td>
  				Treatment of narcolepsy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy
	  			</td>
				
	  			<td>
					
						10/13/2020
					
	  			</td>

	  			<td>

					
					10/13/2027
					
					
	  			</td>

				<td>
					treatment of cataplexy in adult patients with narcolepsy
				</td>
			
  			<td>
  				Harmony Biosciences, LLC
  			</td>
  			<td>
  				630 W Germantown Pike
  			</td>
  			<td>
  				Suite 215
  			</td>
  			<td>
  				 Plymouth Meeting
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19462
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				307210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation Factor VIIa (Recombinant)
  			</td>
  			<td>
  				NovoSeven
  			</td>
  			<td>
  				07/16/2004
  			</td>
  			<td>
  				Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia
	  			</td>
				
	  			<td>
					
						10/13/2006
					
	  			</td>

	  			<td>

					
					10/13/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk, Inc.
  			</td>
  			<td>
  				100 Overlook Center
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				186204
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor VIIa (recombinant)
  			</td>
  			<td>
  				NovoSeven
  			</td>
  			<td>
  				07/21/2004
  			</td>
  			<td>
  				Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia
	  			</td>
				
	  			<td>
					
						10/13/2006
					
	  			</td>

	  			<td>

					
					10/13/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk, Inc.
  			</td>
  			<td>
  				100 Overlook Center
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				190104
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Mitoxantrone
  			</td>
  			<td>
  				Novantrone
  			</td>
  			<td>
  				08/13/1999
  			</td>
  			<td>
  				Treatment of progressive-relapsing multiple sclerosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).
	  			</td>
				
	  			<td>
					
						10/13/2000
					
	  			</td>

	  			<td>

					
					10/13/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				128499
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Mitoxantrone
  			</td>
  			<td>
  				Novantrone
  			</td>
  			<td>
  				08/13/1999
  			</td>
  			<td>
  				Treatment of secondary-progressive multiple sclerosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).
	  			</td>
				
	  			<td>
					
						10/13/2000
					
	  			</td>

	  			<td>

					
					10/13/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Serono, Inc.
  			</td>
  			<td>
  				One Technoloogy Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				125199
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pentostatin for injection
  			</td>
  			<td>
  				Nipent
  			</td>
  			<td>
  				09/10/1987
  			</td>
  			<td>
  				Treatment of hairy cell leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.
	  			</td>
				
	  			<td>
					
						10/11/1991
					
	  			</td>

	  			<td>

					
					10/11/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				SuperGen, Inc.
  			</td>
  			<td>
  				4140 Dublin Blvd.
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Dublin
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94568
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				021287
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				C1 esterase inhibitor (human); C1 esterase inhibitor (human)
  			</td>
  			<td>
  				Cinryze(r); Cinryze(r)
  			</td>
  			<td>
  				07/16/2004
  			</td>
  			<td>
  				Treatment of angioedema 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)
	  			</td>
				
	  			<td>
					
						10/10/2008
					
	  			</td>

	  			<td>

					
					10/10/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				185804
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Gonadorelin acetate
  			</td>
  			<td>
  				Lutrepulse
  			</td>
  			<td>
  				04/22/1987
  			</td>
  			<td>
  				For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/10/1989
					
	  			</td>

	  			<td>

					
					10/10/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ferring Laboratories, Inc.
  			</td>
  			<td>
  				400 Rella Boulevard, Suite 201
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Suffern
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				017086
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				RAVULIZUMAB
  			</td>
  			<td>
  				Ultomiris
  			</td>
  			<td>
  				01/04/2017
  			</td>
  			<td>
  				Treatment of paroxysmal nocturnal hemoglobinuria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
	  			</td>
				
	  			<td>
					
						10/09/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alexion Pharmaceuticals Inc.
  			</td>
  			<td>
  				121 SEAPORT BLVD 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				BOSTON
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				513015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				allogeneic processed thymus tissue-agdc
  			</td>
  			<td>
  				Rethymic
  			</td>
  			<td>
  				08/15/2003
  			</td>
  			<td>
  				Treatment of congenital athymia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				immune reconstitution in pediatric patients with congenital athymia
	  			</td>
				
	  			<td>
					
						10/08/2021
					
	  			</td>

	  			<td>

					
					10/08/2028
					
					
	  			</td>

				<td>
					immune reconstitution in pediatric patients with congenital athymia
				</td>
			
  			<td>
  				Enzyvant Therapeutics GmbH
  			</td>
  			<td>
  				Viaduktstrasse 8
  			</td>
  			<td>
  				CH-4051 
  			</td>
  			<td>
  				Basel
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				172603
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				afamelanotide
  			</td>
  			<td>
  				SCENESSE®
  			</td>
  			<td>
  				07/17/2008
  			</td>
  			<td>
  				Treatment of erythropoietic porphyrias
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SCENESSE® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)
	  			</td>
				
	  			<td>
					
						10/08/2019
					
	  			</td>

	  			<td>

					
					10/08/2026
					
					
	  			</td>

				<td>
					Indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
				</td>
			
  			<td>
  				Clinuvel Inc.
  			</td>
  			<td>
  				P. O. Box 94026
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Menlo Park
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94026
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				263208
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bortezomib
  			</td>
  			<td>
  				Velcade
  			</td>
  			<td>
  				05/30/2012
  			</td>
  			<td>
  				Treatment of mantle cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with mantle cell lymphoma.
	  			</td>
				
	  			<td>
					
						10/08/2014
					
	  			</td>

	  			<td>

					
					10/08/2021
					
					
	  			</td>

				<td>
					Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy
				</td>
			
  			<td>
  				Millennium Pharmaceuticals, Inc.
  			</td>
  			<td>
  				40 Landsdowne Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				226106
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				riociguat
  			</td>
  			<td>
  				Adempas
  			</td>
  			<td>
  				09/19/2013
  			</td>
  			<td>
  				Treatment of chronic thromboembolic pulmonary hypertension 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class
	  			</td>
				
	  			<td>
					
						10/08/2013
					
	  			</td>

	  			<td>

					
					10/08/2020
					
					
	  			</td>

				<td>
					Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class
				</td>
			
  			<td>
  				Bayer HealthCare Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 Bayer Blvd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whippany
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07981
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				406913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				riociguat
  			</td>
  			<td>
  				Adempas
  			</td>
  			<td>
  				09/19/2013
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.   
	  			</td>
				
	  			<td>
					
						10/08/2013
					
	  			</td>

	  			<td>

					
					10/08/2020
					
					
	  			</td>

				<td>
					Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.   
				</td>
			
  			<td>
  				Bayer HealthCare Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 Bayer Blvd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whippany
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07981
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				392113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				C1-esterase-inhibitor, human, pasteurized
  			</td>
  			<td>
  				HAEGARDA
  			</td>
  			<td>
  				10/16/1992
  			</td>
  			<td>
  				Prevention and/or treatment of acute attacks of hereditary angioedema.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute attacks of hereditary angioedema. 
	  			</td>
				
	  			<td>
					
						10/08/2009
					
	  			</td>

	  			<td>

					
					10/08/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CSL Behring LLC
  			</td>
  			<td>
  				1020 First Ave.
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				067592
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Recombinant human luteinizing hormone
  			</td>
  			<td>
  				Luveris
  			</td>
  			<td>
  				10/07/1994
  			</td>
  			<td>
  				For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less than) 1.2 IU/L).
	  			</td>
				
	  			<td>
					
						10/08/2004
					
	  			</td>

	  			<td>

					
					10/08/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				EMD Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				080292
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				buprenorphine in combination with naloxone
  			</td>
  			<td>
  				Suboxone
  			</td>
  			<td>
  				10/27/1994
  			</td>
  			<td>
  				Treatment of opiate addiction in opiate users
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of opioid dependence in patients 16 years of age or older
	  			</td>
				
	  			<td>
					
						10/08/2002
					
	  			</td>

	  			<td>

					
					10/08/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Indivior, Inc.
  			</td>
  			<td>
  				10710 Midlothian Turnpike
  			</td>
  			<td>
  				Suite 430
  			</td>
  			<td>
  				Richmond
  			</td>
  			<td>
  				Virginia
  			</td>
  			<td>
  				23235
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				079093
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin (rDNA origin)
  			</td>
  			<td>
  				Saizen
  			</td>
  			<td>
  				03/06/1987
  			</td>
  			<td>
  				Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.  
	  			</td>
				
	  			<td>
					
						10/08/1996
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				EMD Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				015486
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				avacopan
  			</td>
  			<td>
  				Tavneos
  			</td>
  			<td>
  				06/02/2014
  			</td>
  			<td>
  				Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids
	  			</td>
				
	  			<td>
					
						10/07/2021
					
	  			</td>

	  			<td>

					
					10/07/2028
					
					
	  			</td>

				<td>
					As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) 
				</td>
			
  			<td>
  				ChemoCentryx, Inc.
  			</td>
  			<td>
  				835 Industrial Road, Suite 600
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Carlos
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94070
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				432014
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bictegravir, emtricitabine, and tenofovir alafenamide
  			</td>
  			<td>
  				Biktarvy
  			</td>
  			<td>
  				05/17/2017
  			</td>
  			<td>
  				Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy
	  			</td>
				
	  			<td>
					
						10/07/2021
					
	  			</td>

	  			<td>

					
					10/07/2028
					
					
	  			</td>

				<td>
					As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing 14 kg to less than 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				559316
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				intravenous carbamazepine
  			</td>
  			<td>
  				CARNEXIV
  			</td>
  			<td>
  				06/27/2013
  			</td>
  			<td>
  				Treatment of epilepsy patients who cannot take anything by mouth (NPO)  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures
	  			</td>
				
	  			<td>
					
						10/07/2016
					
	  			</td>

	  			<td>

					
					10/07/2023
					
					
	  			</td>

				<td>
					Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures
				</td>
			
  			<td>
  				Lundbeck LLC
  			</td>
  			<td>
  				3530 Toringdon Way, Suite 200
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Charlotte
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				28277
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				265508
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vorinostat
  			</td>
  			<td>
  				Zolinza
  			</td>
  			<td>
  				03/16/2004
  			</td>
  			<td>
  				Treatment of T-cell non-Hodgkin's lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.
	  			</td>
				
	  			<td>
					
						10/06/2006
					
	  			</td>

	  			<td>

					
					10/06/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Merck & Co., Inc.
  			</td>
  			<td>
  				P. O. Box 2000, RY 32-605
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rahway
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07065
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				174203
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				coagulation factor IX (recombinant)
  			</td>
  			<td>
  				BeneFIX
  			</td>
  			<td>
  				10/03/1994
  			</td>
  			<td>
  				Treatment of hemophilia B
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease)
	  			</td>
				
	  			<td>
					
						10/05/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
  			</td>
  			<td>
  				235 E. 42nd St 219/9/1
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				082294
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Inotersen
  			</td>
  			<td>
  				TEGSEDI™
  			</td>
  			<td>
  				07/24/2012
  			</td>
  			<td>
  				Treatment of transthyretin amyloidosis (ATTR amyloidosis)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TEGSEDI™ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
	  			</td>
				
	  			<td>
					
						10/05/2018
					
	  			</td>

	  			<td>

					
					10/05/2025
					
					
	  			</td>

				<td>
					TEGSEDI™ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
				</td>
			
  			<td>
  				Akcea Therapeutics, Inc.
  			</td>
  			<td>
  				22 Boston Wharf Road
  			</td>
  			<td>
  				9th Floor
  			</td>
  			<td>
  				Boston 
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				374512
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				elapegademase-lvlr
  			</td>
  			<td>
  				Revcovi
  			</td>
  			<td>
  				03/19/2015
  			</td>
  			<td>
  				Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID).
	  			</td>
				
	  			<td>
					
						10/05/2018
					
	  			</td>

	  			<td>

					
					10/05/2025
					
					
	  			</td>

				<td>
					treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
				</td>
			
  			<td>
  				Chiesi USA Inc.
  			</td>
  			<td>
  				175 Regency Woods Place
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27518
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				467514
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				emicizumab-kxwh
  			</td>
  			<td>
  				Hemlibra
  			</td>
  			<td>
  				01/10/2014
  			</td>
  			<td>
  				Treatment of hemophilia A
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
	  			</td>
				
	  			<td>
					
						10/04/2018
					
	  			</td>

	  			<td>

					
					10/04/2025
					
					
	  			</td>

				<td>
					HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.
				</td>
			
  			<td>
  				Genentech
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS 355e
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				416913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dexamethasone
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				03/26/2018
  			</td>
  			<td>
  				Treatment of multiple myeloma (MM)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma
	  			</td>
				
	  			<td>
					
						10/03/2019
					
	  			</td>

	  			<td>

					
					10/03/2026
					
					
	  			</td>

				<td>
					Indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM).
				</td>
			
  			<td>
  				Dexcel Pharma Technologies Ltd
  			</td>
  			<td>
  				Dexcel Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Or Akiva
  			</td>
  			<td>
  				Haifa District
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Israel
  			</td>
			<td>
  				626318
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cobicistat
  			</td>
  			<td>
  				Tybost®
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg coadminstered with atazanavir or weighing at least 40 kg coadministered with darunavir.
	  			</td>
				
	  			<td>
					
						10/03/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				577917
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cromolyn sodium 4% ophthalmic solution
  			</td>
  			<td>
  				Opticrom 4% ophthalmic solution
  			</td>
  			<td>
  				07/24/1985
  			</td>
  			<td>
  				Treatment of vernal keratoconjunctivitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/03/1984
					
	  			</td>

	  			<td>

					
					10/03/1991
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fisons Corporation
  			</td>
  			<td>
  				755 Jefferson Rd.
  			</td>
  			<td>
  				P.O. Box 1710
  			</td>
  			<td>
  				Rochester
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				14603
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				008285
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab and ipilimumab
  			</td>
  			<td>
  				OPDIVO® and YERVOY®
  			</td>
  			<td>
  				08/16/2017
  			</td>
  			<td>
  				Treatment of mesothelioma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
	  			</td>
				
	  			<td>
					
						10/02/2020
					
	  			</td>

	  			<td>

					
					10/02/2027
					
					
	  			</td>

				<td>
					OPDIVO (nivolumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				595917
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab and ipilimumab
  			</td>
  			<td>
  				OPDIVO® and YERVOY®
  			</td>
  			<td>
  				08/16/2017
  			</td>
  			<td>
  				Treatment of mesothelioma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				YERVOY® (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.
	  			</td>
				
	  			<td>
					
						10/02/2020
					
	  			</td>

	  			<td>

					
					10/02/2027
					
					
	  			</td>

				<td>
					YERVOY® (ipilimumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				595917
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ascorbic acid
  			</td>
  			<td>
  				Ascor
  			</td>
  			<td>
  				08/31/2007
  			</td>
  			<td>
  				Treatment of scurvy 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated
	  			</td>
				
	  			<td>
					
						10/02/2017
					
	  			</td>

	  			<td>

					
					10/02/2024
					
					
	  			</td>

				<td>
					for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated
				</td>
			
  			<td>
  				McGuff Pharmaceuticals Inc.
  			</td>
  			<td>
  				2921 W. MacArthur Blvd.
  			</td>
  			<td>
  				Suite 141
  			</td>
  			<td>
  				Santa Ana
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92704
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				243707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cysteamine hydrochloride
  			</td>
  			<td>
  				Cystaran
  			</td>
  			<td>
  				08/19/1997
  			</td>
  			<td>
  				Treatment of corneal cystine crystal accumulation in cystinosis patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of corneal cystine crystal accumulation in patients with cystinosis
	  			</td>
				
	  			<td>
					
						10/02/2012
					
	  			</td>

	  			<td>

					
					10/02/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Leadiant Biosciences, Inc.
  			</td>
  			<td>
  				9841 Washingtonian Blvd
  			</td>
  			<td>
  				Suite 500
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20878
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				105997
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				iron(III)-hexacyanoferrate(II)
  			</td>
  			<td>
  				Radiogardase
  			</td>
  			<td>
  				05/01/2003
  			</td>
  			<td>
  				Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination
	  			</td>
				
	  			<td>
					
						10/02/2003
					
	  			</td>

	  			<td>

					
					10/02/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG
  			</td>
  			<td>
  				Goerzallee 253
  			</td>
  			<td>
  				D-14167  
  			</td>
  			<td>
  				Berlin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Germany
  			</td>
			<td>
  				169203
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antivenin, crotalidae polyvalent immune Fab (ovine)
  			</td>
  			<td>
  				CroFab
  			</td>
  			<td>
  				01/12/1994
  			</td>
  			<td>
  				Treatment of envenomations inflicted by North American crotalid snakes.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of minimal and moderate North American Crotalidae envenomation
	  			</td>
				
	  			<td>
					
						10/02/2000
					
	  			</td>

	  			<td>

					
					10/02/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Protherics, Inc.
  			</td>
  			<td>
  				1207 17th Ave. S., Suite 103
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nashville
  			</td>
  			<td>
  				Tennessee
  			</td>
  			<td>
  				37212
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				078993
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Clonidine
  			</td>
  			<td>
  				Duraclon
  			</td>
  			<td>
  				01/24/1989
  			</td>
  			<td>
  				For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.
	  			</td>
				
	  			<td>
					
						10/02/1996
					
	  			</td>

	  			<td>

					
					10/02/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Roxane Laboratories, Inc.
  			</td>
  			<td>
  				PO Box 16532
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Columbus
  			</td>
  			<td>
  				Ohio
  			</td>
  			<td>
  				43216
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				034388
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Citric acid, glucono-delta-lactone and magnesium carbonate
  			</td>
  			<td>
  				Renacidin Irrigation
  			</td>
  			<td>
  				08/28/1989
  			</td>
  			<td>
  				Treatment of renal and bladder calculi of the apatite or struvite variety.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						10/02/1990
					
	  			</td>

	  			<td>

					
					10/02/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				United-Guardian, Inc.
  			</td>
  			<td>
  				P.O. Box 2500
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Smithtown
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				11787
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				040189
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brexucabtagene autoleucel
  			</td>
  			<td>
  				Tecartus
  			</td>
  			<td>
  				04/20/2016
  			</td>
  			<td>
  				Treatment of acute lymphoblastic leukemia (ALL)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL)
	  			</td>
				
	  			<td>
					
						10/01/2021
					
	  			</td>

	  			<td>

					
					10/01/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL)
				</td>
			
  			<td>
  				Kite Pharma, Inc.
  			</td>
  			<td>
  				2225 Colorado Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515815
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Combination of nivolumab and ipilimumab
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				10/09/2014
  			</td>
  			<td>
  				Treatment of Stage IIb to Stage IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma
	  			</td>
				
	  			<td>
					
						09/30/2015
					
	  			</td>

	  			<td>

					
					09/30/2022
					
					
	  			</td>

				<td>
					Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				5 Research Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wallingford
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06492
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				445014
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				Humira
  			</td>
  			<td>
  				03/21/2005
  			</td>
  			<td>
  				Treatment of juvenile rheumatoid arthritis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. 
	  			</td>
				
	  			<td>
					
						09/30/2014
					
	  			</td>

	  			<td>

					
					09/30/2021
					
					
	  			</td>

				<td>
					Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age. 
				</td>
			
  			<td>
  				AbbVie Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				Bldg. AP-30
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				200905
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				maralixibat
  			</td>
  			<td>
  				 Livmarli
  			</td>
  			<td>
  				09/04/2013
  			</td>
  			<td>
  				Treatment of alagille syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older
	  			</td>
				
	  			<td>
					
						09/29/2021
					
	  			</td>

	  			<td>

					
					09/29/2028
					
					
	  			</td>

				<td>
					Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older
				</td>
			
  			<td>
  				Mirum Pharmaceuticals, Inc. 
  			</td>
  			<td>
  				950 Tower Lane
  			</td>
  			<td>
  				Suite 1050
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				401513
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Hydrocortisone
  			</td>
  			<td>
  				ALKINDI® SPRINKLE
  			</td>
  			<td>
  				05/13/2015
  			</td>
  			<td>
  				Treatment of pediatric adrenal insufficiency (0 through 16 years of age).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ALKINDI® SPRINKLE is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency
	  			</td>
				
	  			<td>
					
						09/29/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eton Pharmaceuticals, Inc.
  			</td>
  			<td>
  				21925 West Field Parkway, Suite 235
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deer Park
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60010
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				441614
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				golimumab
  			</td>
  			<td>
  				SIMPONI ARIA®
  			</td>
  			<td>
  				04/02/2015
  			</td>
  			<td>
  				Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						09/29/2020
					
	  			</td>

	  			<td>

					
					09/29/2027
					
					
	  			</td>

				<td>
					treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age
				</td>
			
  			<td>
  				Janssen Research & Development, LLC
  			</td>
  			<td>
  				1400 McKean Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Spring House
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19477
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				325610
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cannabidiol
  			</td>
  			<td>
  				Epidiolex
  			</td>
  			<td>
  				02/27/2014
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.
	  			</td>
				
	  			<td>
					
						09/28/2018
					
	  			</td>

	  			<td>

					
					09/28/2025
					
					
	  			</td>

				<td>
					EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
				</td>
			
  			<td>
  				GW Research Ltd.
  			</td>
  			<td>
  				Sovereign House
  			</td>
  			<td>
  				Histon
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				421213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cannabidiol
  			</td>
  			<td>
  				Epidiolex
  			</td>
  			<td>
  				11/14/2013
  			</td>
  			<td>
  				Treatment of Dravet syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.
	  			</td>
				
	  			<td>
					
						09/28/2018
					
	  			</td>

	  			<td>

					
					09/28/2025
					
					
	  			</td>

				<td>
					EPIDIOLEX is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older.
				</td>
			
  			<td>
  				GW Research Ltd.
  			</td>
  			<td>
  				Sovereign House
  			</td>
  			<td>
  				Histon
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				409313
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				Humira
  			</td>
  			<td>
  				05/13/2014
  			</td>
  			<td>
  				Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						09/28/2018
					
	  			</td>

	  			<td>

					
					09/28/2025
					
					
	  			</td>

				<td>
					Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				318510
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				liposomal amikacin
  			</td>
  			<td>
  				Arikayce
  			</td>
  			<td>
  				03/25/2013
  			</td>
  			<td>
  				Treatment of infections caused by non-tuberculous mycobacteria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy    
	  			</td>
				
	  			<td>
					
						09/28/2018
					
	  			</td>

	  			<td>

					
					09/28/2025
					
					
	  			</td>

				<td>
					Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy 
				</td>
			
  			<td>
  				Insmed Incorporated
  			</td>
  			<td>
  				10 Finderne Avenue
  			</td>
  			<td>
  				Building 10
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				342011
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				emtricitabine and tenofovir alafenamide combination
  			</td>
  			<td>
  				DESCOVY(R)
  			</td>
  			<td>
  				06/06/2017
  			</td>
  			<td>
  				Treatment of HIV-1 infection in pediatric patients under 12 years of age
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 25 kg and less than 35 kg.
	  			</td>
				
	  			<td>
					
						09/28/2017
					
	  			</td>

	  			<td>

					
					09/28/2024
					
					
	  			</td>

				<td>
					• In combination with other antiretroviral agents, for the treatment of HIV-1 infection in pediatric patients under 12 years of age weighing at least 35kg; and • In combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients under 12 years of age weighing at least 25kg and less than 35kg
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				569716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lumacaftor/ivacaftor
  			</td>
  			<td>
  				Orkambi
  			</td>
  			<td>
  				06/30/2014
  			</td>
  			<td>
  				Treatment of cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene
	  			</td>
				
	  			<td>
					
						09/28/2016
					
	  			</td>

	  			<td>

					
					09/28/2023
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis (CF) in patients age 6-11 years old who are homozygous for the F508del mutation in the CFTR gene
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				434814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				burosumab-twza
  			</td>
  			<td>
  				Crysvita
  			</td>
  			<td>
  				12/14/2009
  			</td>
  			<td>
  				Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
	  			</td>
				
	  			<td>
					
						09/27/2019
					
	  			</td>

	  			<td>

					
					09/27/2026
					
					
	  			</td>

				<td>
					For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age
				</td>
			
  			<td>
  				Kyowa Kirin, Inc.
  			</td>
  			<td>
  				135 US Highway 202/206
  			</td>
  			<td>
  				Suite 6
  			</td>
  			<td>
  				Bedminster
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07921
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				296109
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab
  			</td>
  			<td>
  				Rituxan
  			</td>
  			<td>
  				02/14/2006
  			</td>
  			<td>
  				Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
	  			</td>
				
	  			<td>
					
						09/27/2019
					
	  			</td>

	  			<td>

					
					09/27/2026
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				216305
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dacomitinib
  			</td>
  			<td>
  				VIZIMPRO
  			</td>
  			<td>
  				03/03/2015
  			</td>
  			<td>
  				Treatment of non-small cell lung cancer  with EGFR, HER2, HER4, or DDR2 mutations.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R  
	  			</td>
				
	  			<td>
					
						09/27/2018
					
	  			</td>

	  			<td>

					
					09/27/2025
					
					
	  			</td>

				<td>
					For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R  
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				235 East 42nd Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				435114
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Buffered intrathecal electrolyte/dextrose injection
  			</td>
  			<td>
  				Elliotts B Solution
  			</td>
  			<td>
  				08/24/1994
  			</td>
  			<td>
  				For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.
	  			</td>
				
	  			<td>
					
						09/27/1996
					
	  			</td>

	  			<td>

					
					09/27/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Lukare Medical, LLC
  			</td>
  			<td>
  				4 Julia Court
  			</td>
  			<td>
  				P. O. Box 782
  			</td>
  			<td>
  				Scotch Plains
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07076
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				083994
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Idarubicin HCl for injection
  			</td>
  			<td>
  				Idamycin
  			</td>
  			<td>
  				07/25/1988
  			</td>
  			<td>
  				Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						09/27/1990
					
	  			</td>

	  			<td>

					
					09/27/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Adria Laboratories, Inc.
  			</td>
  			<td>
  				P.O. Box 16529
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Columbus
  			</td>
  			<td>
  				Ohio
  			</td>
  			<td>
  				43216
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				029388
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab
  			</td>
  			<td>
  				Darzalex
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients 
	  			</td>
				
	  			<td>
					
						09/26/2019
					
	  			</td>

	  			<td>

					
					09/26/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				PO Box 300
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sermorelin acetate
  			</td>
  			<td>
  				Geref
  			</td>
  			<td>
  				09/14/1988
  			</td>
  			<td>
  				Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						09/26/1997
					
	  			</td>

	  			<td>

					
					09/26/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				EMD Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				024687
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pentosan polysulfate sodium
  			</td>
  			<td>
  				Elmiron
  			</td>
  			<td>
  				08/07/1985
  			</td>
  			<td>
  				Treatment of interstitial cystitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Relief of bladder pain or discomfort associated with interstitial cystitis.
	  			</td>
				
	  			<td>
					
						09/26/1996
					
	  			</td>

	  			<td>

					
					09/26/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alza Corporation
  			</td>
  			<td>
  				950 Page Mill Rd.
  			</td>
  			<td>
  				PO Box 10950
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94303
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				001784
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mepolizumab
  			</td>
  			<td>
  				NUCALA®
  			</td>
  			<td>
  				05/28/2004
  			</td>
  			<td>
  				For treatment of hypereosinophilic syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause
	  			</td>
				
	  			<td>
					
						09/25/2020
					
	  			</td>

	  			<td>

					
					09/25/2027
					
					
	  			</td>

				<td>
					treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause
				</td>
			
  			<td>
  				GlaxoSmithKline LLC
  			</td>
  			<td>
  				1250 S. Collegeville Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Collegeville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19426
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				182103
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Arsenic trioxide
  			</td>
  			<td>
  				Trisenox
  			</td>
  			<td>
  				03/03/1998
  			</td>
  			<td>
  				Treatment of acute promyelocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression.
	  			</td>
				
	  			<td>
					
						09/25/2000
					
	  			</td>

	  			<td>

					
					09/25/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Teva Branded Pharmaceutical Products R&D, Inc.
  			</td>
  			<td>
  				41 Moores Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Frazer
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				109697
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Valrubicin
  			</td>
  			<td>
  				Valstar
  			</td>
  			<td>
  				05/23/1994
  			</td>
  			<td>
  				Treatment of carcinoma in situ of the urinary bladder.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
	  			</td>
				
	  			<td>
					
						09/25/1998
					
	  			</td>

	  			<td>

					
					09/25/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Anthra Pharmaceuticals, Inc.
  			</td>
  			<td>
  				103 Carnegie Center, Suite 102
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				082194
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				evolocumab
  			</td>
  			<td>
  				Repatha
  			</td>
  			<td>
  				09/12/2013
  			</td>
  			<td>
  				Treatment of homozygous familial hypercholesterolemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C
	  			</td>
				
	  			<td>
					
						09/24/2021
					
	  			</td>

	  			<td>

					
					09/24/2028
					
					
	  			</td>

				<td>
					to reduce LDL-C in pediatric patients aged 10 to less than 13 years with homozygous familial hypercholesterolemia (HoFH) 
				</td>
			
  			<td>
  				Amgen Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				M/S 17 2 B
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				404113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				KALYDECO® 
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
	  			</td>
				
	  			<td>
					
						09/24/2020
					
	  			</td>

	  			<td>

					
					09/24/2027
					
					
	  			</td>

				<td>
					treatment of cystic fibrosis (CF) in patients age 4 months to less than 6 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				C1 Esterase Inhibitor Subcutaneous [Human]
  			</td>
  			<td>
  				HAEGARDA®
  			</td>
  			<td>
  				10/16/1992
  			</td>
  			<td>
  				Prevention and/or treatment of acute attacks of hereditary angioedema.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older
	  			</td>
				
	  			<td>
					
						09/24/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CSL Behring LLC
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				067592
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				duvelisib
  			</td>
  			<td>
  				COPIKTRA
  			</td>
  			<td>
  				04/15/2013
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies
	  			</td>
				
	  			<td>
					
						09/24/2018
					
	  			</td>

	  			<td>

					
					09/24/2025
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies
				</td>
			
  			<td>
  				Secura Bio, Inc.
  			</td>
  			<td>
  				1995 Village Center Cir.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Las Vegas
  			</td>
  			<td>
  				Nevada
  			</td>
  			<td>
  				89134-6360
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				394413
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				duvelisib
  			</td>
  			<td>
  				COPIKTRA
  			</td>
  			<td>
  				08/01/2013
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies
	  			</td>
				
	  			<td>
					
						09/24/2018
					
	  			</td>

	  			<td>

					
					09/24/2025
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies
				</td>
			
  			<td>
  				Secura Bio, Inc.
  			</td>
  			<td>
  				1995 Village Center Cir.
  			</td>
  			<td>
  				Suite 128
  			</td>
  			<td>
  				Las Vegas
  			</td>
  			<td>
  				Nevada
  			</td>
  			<td>
  				89134-6360
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				399913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dexamethasone intravitreal implant
  			</td>
  			<td>
  				Ozurdex
  			</td>
  			<td>
  				09/11/1998
  			</td>
  			<td>
  				Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For treatment of non-infectious uveitis affecting the posterior segment of the eye
	  			</td>
				
	  			<td>
					
						09/24/2010
					
	  			</td>

	  			<td>

					
					09/24/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Allergan
  			</td>
  			<td>
  				2525 Dupont Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92623
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				115298
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pralatrexate
  			</td>
  			<td>
  				Folotyn
  			</td>
  			<td>
  				07/20/2006
  			</td>
  			<td>
  				Treatment of T-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with relapsed or refractory peripheral T-cell lymphoma
	  			</td>
				
	  			<td>
					
						09/24/2009
					
	  			</td>

	  			<td>

					
					09/24/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Acrotech Biopharma LLC
  			</td>
  			<td>
  				279 Princeton Hightstown Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Windsor
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				225306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nilotinib
  			</td>
  			<td>
  				Tasigna 
  			</td>
  			<td>
  				04/27/2006
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy
	  			</td>
				
	  			<td>
					
						09/23/2021
					
	  			</td>

	  			<td>

					
					09/23/2028
					
					
	  			</td>

				<td>
					Treatment of pediatric patients greater than or equal to 1 year of age with accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				220806
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				canakinumab
  			</td>
  			<td>
  				ILARIS
  			</td>
  			<td>
  				12/05/2013
  			</td>
  			<td>
  				Treatment of familial mediterranean fever 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients
	  			</td>
				
	  			<td>
					
						09/23/2016
					
	  			</td>

	  			<td>

					
					09/23/2023
					
					
	  			</td>

				<td>
					Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				412813
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				canakinumab
  			</td>
  			<td>
  				ILARIS
  			</td>
  			<td>
  				12/05/2013
  			</td>
  			<td>
  				Treatment of hyperimmunoglobulinemia D and periodic fever syndrome 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients
	  			</td>
				
	  			<td>
					
						09/23/2016
					
	  			</td>

	  			<td>

					
					09/23/2023
					
					
	  			</td>

				<td>
					Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				412913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				canakinumab
  			</td>
  			<td>
  				Ilaris
  			</td>
  			<td>
  				09/04/2012
  			</td>
  			<td>
  				Treatment of TNF-receptor associated periodic syndrome (TRAPS)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
	  			</td>
				
	  			<td>
					
						09/23/2016
					
	  			</td>

	  			<td>

					
					09/23/2023
					
					
	  			</td>

				<td>
					Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				376912
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				HUMIRA
  			</td>
  			<td>
  				10/19/2006
  			</td>
  			<td>
  				Treatment of pediatric Crohn's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate. 
	  			</td>
				
	  			<td>
					
						09/23/2014
					
	  			</td>

	  			<td>

					
					09/23/2021
					
					
	  			</td>

				<td>
					Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate. 
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 N. Waukegan Road
  			</td>
  			<td>
  				Bldg AP30, Dept. PA77
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				230306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eculizumab
  			</td>
  			<td>
  				Soliris
  			</td>
  			<td>
  				04/29/2009
  			</td>
  			<td>
  				Treatment of atypical hemolytic uremic syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the treatment of atypical Hemolytic Uremic Syndrome (aHUS) 
	  			</td>
				
	  			<td>
					
						09/23/2011
					
	  			</td>

	  			<td>

					
					09/23/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				121 Seaport Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				279509
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				infliximab
  			</td>
  			<td>
  				Remicade
  			</td>
  			<td>
  				11/12/2003
  			</td>
  			<td>
  				Treatment of pediatric (0 to 16 years of age) ulcerative colitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
	  			</td>
				
	  			<td>
					
						09/23/2011
					
	  			</td>

	  			<td>

					
					09/23/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				200 Great Valley Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Malvern
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				175903
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				polifeprosan 20 with carmustine
  			</td>
  			<td>
  				Gliadel
  			</td>
  			<td>
  				12/13/1989
  			</td>
  			<td>
  				Treatment of malignant glioma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated
	  			</td>
				
	  			<td>
					
						09/23/1996
					
	  			</td>

	  			<td>

					
					09/23/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Guilford Pharmaceuticals, Inc.
  			</td>
  			<td>
  				6611 Tributary Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Baltimore
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				21224
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				037089
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Lodoxamide tromethamine
  			</td>
  			<td>
  				Alomide Ophthalmic Solution
  			</td>
  			<td>
  				10/16/1991
  			</td>
  			<td>
  				Treatment of vernal keratoconjunctivitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis.
	  			</td>
				
	  			<td>
					
						09/23/1993
					
	  			</td>

	  			<td>

					
					09/23/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alcon Laboratories, Inc.
  			</td>
  			<td>
  				6201 South Freeway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Fort Worth
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				76134
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				059791
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ruxolitinib
  			</td>
  			<td>
  				Jakafi
  			</td>
  			<td>
  				11/03/2016
  			</td>
  			<td>
  				Treatment of graft versus host disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older
	  			</td>
				
	  			<td>
					
						09/22/2021
					
	  			</td>

	  			<td>

					
					09/22/2028
					
					
	  			</td>

				<td>
					Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older
				</td>
			
  			<td>
  				Incyte Corporation
  			</td>
  			<td>
  				1801 Augustine Cut-Off
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				542716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				OPDIVO
  			</td>
  			<td>
  				09/02/2015
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn)
	  			</td>
				
	  			<td>
					
						09/22/2017
					
	  			</td>

	  			<td>

					
					07/23/2021
					
					
	  			</td>

				<td>
					Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn)
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				489915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				06/16/2015
  			</td>
  			<td>
  				Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.
	  			</td>
				
	  			<td>
					
						09/22/2017
					
	  			</td>

	  			<td>

					
					09/22/2024
					
					
	  			</td>

				<td>
					Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop
				</td>
			
  			<td>
  				Merck Research Laboratories
  			</td>
  			<td>
  				351 North Sumneytown Pike
  			</td>
  			<td>
  				UG2D-44
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				481715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor X (human)
  			</td>
  			<td>
  				COAGADEX
  			</td>
  			<td>
  				11/08/2007
  			</td>
  			<td>
  				Treatment of hereditary factor X deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				COAGADEX is indicated in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild and moderate hereditary Factor X deficiency. 
	  			</td>
				
	  			<td>
					
						09/21/2018
					
	  			</td>

	  			<td>

					
					09/21/2025
					
					
	  			</td>

				<td>
					Coagadex is indicated for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hereditary Factor X deficiency; on-demand treatment and control of bleeding episodes in children under the age of 12 years with hereditary Factor X deficiency; perioperative management of bleeding in children under the age of 12 years with mild hereditary factor X deficiency; perioperative management of bleeding in adults and children with moderate hereditary Factor X deficiency
				</td>
			
  			<td>
  				Bio Products Laboratory Limited
  			</td>
  			<td>
  				Dagger Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Elstree
  			</td>
  			<td>
  				Hertfordshire
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				246907
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Caffeine
  			</td>
  			<td>
  				Cafcit
  			</td>
  			<td>
  				09/20/1988
  			</td>
  			<td>
  				Treatment of apnea of prematurity.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.  
	  			</td>
				
	  			<td>
					
						09/21/1999
					
	  			</td>

	  			<td>

					
					09/21/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				O.P.R. Development, L.P.
  			</td>
  			<td>
  				1501 Wakarusa Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lawrence
  			</td>
  			<td>
  				Kansas
  			</td>
  			<td>
  				66047
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				031288
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Epoprostenol
  			</td>
  			<td>
  				Flolan
  			</td>
  			<td>
  				09/25/1985
  			</td>
  			<td>
  				Treatment of primary pulmonary hypertension.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.
	  			</td>
				
	  			<td>
					
						09/20/1995
					
	  			</td>

	  			<td>

					
					09/20/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Inc.
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				008785
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eteplirsen
  			</td>
  			<td>
  				Exondys 51 
  			</td>
  			<td>
  				10/23/2007
  			</td>
  			<td>
  				Treatment of Duchenne Muscular Dystrophy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping
	  			</td>
				
	  			<td>
					
						09/19/2016
					
	  			</td>

	  			<td>

					
					09/19/2023
					
					
	  			</td>

				<td>
					Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping
				</td>
			
  			<td>
  				Sarepta Therapeutics, Inc.
  			</td>
  			<td>
  				215 First Street
  			</td>
  			<td>
  				Suite 415
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				248407
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Iobenguane I 123
  			</td>
  			<td>
  				Adreview
  			</td>
  			<td>
  				12/01/2006
  			</td>
  			<td>
  				For the diagnosis of neuroblastomas
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests
	  			</td>
				
	  			<td>
					
						09/19/2008
					
	  			</td>

	  			<td>

					
					09/19/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				GE Healthcare, Inc.
  			</td>
  			<td>
  				101 Carnegie Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				226406
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Iobenguane I 123
  			</td>
  			<td>
  				AdreView
  			</td>
  			<td>
  				12/01/2006
  			</td>
  			<td>
  				For the diagnosis of pheochromocytomas
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests
	  			</td>
				
	  			<td>
					
						09/19/2008
					
	  			</td>

	  			<td>

					
					09/19/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				GE Healthcare, Inc.
  			</td>
  			<td>
  				101 Carnegie Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				226506
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				baclofen
  			</td>
  			<td>
  				OZOBAX
  			</td>
  			<td>
  				12/16/1991
  			</td>
  			<td>
  				Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. OZOBAX may also be of some value in patients with spinal cord injuries and other spinal cord diseases.
	  			</td>
				
	  			<td>
					
						09/18/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Metacel Pharmaceuticals, LLC
  			</td>
  			<td>
  				244 E Washington Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Athens
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30601
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				064091
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Urofollitropin
  			</td>
  			<td>
  				Metrodin
  			</td>
  			<td>
  				11/25/1987
  			</td>
  			<td>
  				For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						09/18/1986
					
	  			</td>

	  			<td>

					
					09/18/1993
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				EMD Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				014086
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cabozantinib
  			</td>
  			<td>
  				Cabometyx
  			</td>
  			<td>
  				11/29/2010
  			</td>
  			<td>
  				Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible
	  			</td>
				
	  			<td>
					
						09/17/2021
					
	  			</td>

	  			<td>

					
					09/17/2028
					
					
	  			</td>

				<td>
					Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible
				</td>
			
  			<td>
  				Exelixis, Inc.
  			</td>
  			<td>
  				1851 Harbor Bay Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Alameda
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94502
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				297109
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mobocertinib
  			</td>
  			<td>
  				Exkivity
  			</td>
  			<td>
  				12/17/2019
  			</td>
  			<td>
  				Treatment of non-small cell lung cancer with genetic alterations in EGFR including EGFR mutations and/or EGFR gene amplifications, HER2 mutations, or BRAF G466V mutations
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
	  			</td>
				
	  			<td>
					
						09/15/2021
					
	  			</td>

	  			<td>

					
					09/15/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				653018
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lanreotide acetate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				09/08/2011
  			</td>
  			<td>
  				Treatment of carcinoid syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy
	  			</td>
				
	  			<td>
					
						09/15/2017
					
	  			</td>

	  			<td>

					
					09/15/2024
					
					
	  			</td>

				<td>
					treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy
				</td>
			
  			<td>
  				Ipsen Biopharmaceuticals, Inc.
  			</td>
  			<td>
  				106 Allen Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Basking Ridge
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07920
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				347111
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ganciclovir
  			</td>
  			<td>
  				Zirgan
  			</td>
  			<td>
  				03/22/2007
  			</td>
  			<td>
  				Treatment of acute herpetic keratitis (dendritic and geographic ulcers)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute herpetic keratitis (dendritic ulcers)
	  			</td>
				
	  			<td>
					
						09/15/2009
					
	  			</td>

	  			<td>

					
					09/15/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Sirion Therapeutics, Inc.
  			</td>
  			<td>
  				9314 East Broadway Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tampa
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33619
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				237607
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Epirubicin
  			</td>
  			<td>
  				Ellence
  			</td>
  			<td>
  				09/14/1999
  			</td>
  			<td>
  				Treatment of breast cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
	  			</td>
				
	  			<td>
					
						09/15/1999
					
	  			</td>

	  			<td>

					
					09/15/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia & Upjohn Company
  			</td>
  			<td>
  				0634-298-113
  			</td>
  			<td>
  				7000 Portage Rd.
  			</td>
  			<td>
  				Kalamazoo
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				49001
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				121498
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sargramostim
  			</td>
  			<td>
  				Leukine
  			</td>
  			<td>
  				03/06/1995
  			</td>
  			<td>
  				To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.
	  			</td>
				
	  			<td>
					
						09/15/1995
					
	  			</td>

	  			<td>

					
					09/15/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Immunex Corporation
  			</td>
  			<td>
  				51 University Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				081494
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				zanubrutinib
  			</td>
  			<td>
  				Brukinsa
  			</td>
  			<td>
  				08/24/2020
  			</td>
  			<td>
  				Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen

	  			</td>
				
	  			<td>
					
						09/14/2021
					
	  			</td>

	  			<td>

					
					09/14/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen

				</td>
			
  			<td>
  				BeiGene USA, Inc.
  			</td>
  			<td>
  				2955 Campus Drive
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				San Mateo
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94403
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				756920
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				zanubrutinib
  			</td>
  			<td>
  				Brukinsa
  			</td>
  			<td>
  				08/24/2020
  			</td>
  			<td>
  				Treatment of nodal marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen
	  			</td>
				
	  			<td>
					
						09/14/2021
					
	  			</td>

	  			<td>

					
					09/14/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen
				</td>
			
  			<td>
  				BeiGene USA, Inc.
  			</td>
  			<td>
  				2955 Campus Drive
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				San Mateo
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94403
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				757120
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				zanubrutinib
  			</td>
  			<td>
  				Brukinsa
  			</td>
  			<td>
  				08/24/2020
  			</td>
  			<td>
  				Treatment of splenic marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen

	  			</td>
				
	  			<td>
					
						09/14/2021
					
	  			</td>

	  			<td>

					
					09/14/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen

				</td>
			
  			<td>
  				BeiGene USA, Inc.
  			</td>
  			<td>
  				2955 Campus Drive
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				San Mateo
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94403
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				757020
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				midazolam 
  			</td>
  			<td>
  				SEIZALAM
  			</td>
  			<td>
  				02/04/2016
  			</td>
  			<td>
  				Treatment of status epilepticus
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SEIZALAM is indicated for the treatment of status epilepticus in adults.
	  			</td>
				
	  			<td>
					
						09/14/2018
					
	  			</td>

	  			<td>

					
					09/14/2025
					
					
	  			</td>

				<td>
					SEIZALAM is indicated for the treatment of status epilepticus in adults.
				</td>
			
  			<td>
  				Meridian Medical Technologies
  			</td>
  			<td>
  				6350 Stevens Forest Road
  			</td>
  			<td>
  				Suite 301
  			</td>
  			<td>
  				Columbia
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				21046
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				508215
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				copanlisib
  			</td>
  			<td>
  				ALIQOPA
  			</td>
  			<td>
  				02/05/2015
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
	  			</td>
				
	  			<td>
					
						09/14/2017
					
	  			</td>

	  			<td>

					
					09/14/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
				</td>
			
  			<td>
  				Bayer US LLC
  			</td>
  			<td>
  				100 Bayer Boulevard
  			</td>
  			<td>
  				P. O. Box 915
  			</td>
  			<td>
  				Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07981
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				463314
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pegloticase
  			</td>
  			<td>
  				Krystexxa
  			</td>
  			<td>
  				02/21/2001
  			</td>
  			<td>
  				To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic gout in adult patients refractory to conventional treatment
	  			</td>
				
	  			<td>
					
						09/14/2010
					
	  			</td>

	  			<td>

					
					09/14/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Horizon Therapeutics Ireland DAC
  			</td>
  			<td>
  				70 St. Stephen’s Green
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dublin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				2 D02 E2X4
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				135600
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				moxetumomab pasudotox-tdfk
  			</td>
  			<td>
  				LUMOXITI
  			</td>
  			<td>
  				11/15/2007
  			</td>
  			<td>
  				Treatment of hairy cell leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
	  			</td>
				
	  			<td>
					
						09/13/2018
					
	  			</td>

	  			<td>

					
					09/13/2025
					
					
	  			</td>

				<td>
					LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike PO Box 8355
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803-8355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				248707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				raloxifene 
  			</td>
  			<td>
  				Evista
  			</td>
  			<td>
  				07/14/2005
  			</td>
  			<td>
  				Reduction of the risk of breast cancer in  postmenopausal women
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer
	  			</td>
				
	  			<td>
					
						09/13/2007
					
	  			</td>

	  			<td>

					
					09/13/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center
  			</td>
  			<td>
  				Drop Code 1853
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				197504
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				coagulation factor IX (recombinant)
  			</td>
  			<td>
  				RIXUBIS
  			</td>
  			<td>
  				10/31/2012
  			</td>
  			<td>
  				Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adults and children with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis
	  			</td>
				
	  			<td>
					
						09/12/2014
					
	  			</td>

	  			<td>

					
					09/12/2021
					
					
	  			</td>

				<td>
					Children with hemophilia B for routine prophylaxis.
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				300 Massachusetts Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				377412
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Immune Globulin (Human)
  			</td>
  			<td>
  				Gamunex-C
  			</td>
  			<td>
  				07/27/2004
  			</td>
  			<td>
  				Treatment of chronic inflammatory demyelinating polyneuropathy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse
	  			</td>
				
	  			<td>
					
						09/12/2008
					
	  			</td>

	  			<td>

					
					09/12/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Grifols Therapeutics, Inc.
  			</td>
  			<td>
  				8368 US 70 Busines Hwy West
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Clayton
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				185604
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Megestrol acetate
  			</td>
  			<td>
  				Megace
  			</td>
  			<td>
  				04/13/1988
  			</td>
  			<td>
  				Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome.
	  			</td>
				
	  			<td>
					
						09/10/1993
					
	  			</td>

	  			<td>

					
					09/10/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Pharmaceutical Research Institute
  			</td>
  			<td>
  				2400 West Lloyd Expressway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Evansville
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				47721
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				026187
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				HUMIRA
  			</td>
  			<td>
  				05/13/2015
  			</td>
  			<td>
  				Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of moderate to severe hidradenitis suppurativa
	  			</td>
				
	  			<td>
					
						09/09/2015
					
	  			</td>

	  			<td>

					
					09/09/2022
					
					
	  			</td>

				<td>
					Treatment of moderate to severe hidradenitis suppurativa
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				446414
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				multi-vitamin infusion without vitamin K
  			</td>
  			<td>
  				M.V.I.-12
  			</td>
  			<td>
  				03/08/2004
  			</td>
  			<td>
  				 Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of vitamin deficiency and thrombormbolic complications in people receiving home parenteral nutrition who also receive warfarin-type anticoagulant therapy
	  			</td>
				
	  			<td>
					
						09/09/2004
					
	  			</td>

	  			<td>

					
					09/09/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mayne Pharma (USA) Inc.
  			</td>
  			<td>
  				Mack-Cali Centre II
  			</td>
  			<td>
  				Second Floor
  			</td>
  			<td>
  				Paramus
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07652
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				182003
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nintedanib
  			</td>
  			<td>
  				OFEV
  			</td>
  			<td>
  				07/06/2016
  			</td>
  			<td>
  				Treatment of systemic sclerosis (including the associated interstitial lung disease).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				 OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).
	  			</td>
				
	  			<td>
					
						09/06/2019
					
	  			</td>

	  			<td>

					
					09/06/2026
					
					
	  			</td>

				<td>
					Indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
				</td>
			
  			<td>
  				Boehringer Ingelheim Pharmaceuticals, Inc.
  			</td>
  			<td>
  				900 Ridgebury Road
  			</td>
  			<td>
  				P. O. Box 368
  			</td>
  			<td>
  				Ridgefield
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06877
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				528516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				paclitaxel protein-bound particles 
  			</td>
  			<td>
  				Abraxane
  			</td>
  			<td>
  				09/03/2009
  			</td>
  			<td>
  				Treatment of pancreatic cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
	  			</td>
				
	  			<td>
					
						09/06/2013
					
	  			</td>

	  			<td>

					
					09/06/2020
					
					
	  			</td>

				<td>
					Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
				</td>
			
  			<td>
  				Abraxis BioScience, LLC
  			</td>
  			<td>
  				9225 Indian Creek Parkway, Suite 900
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Overland Park
  			</td>
  			<td>
  				Kansas
  			</td>
  			<td>
  				66210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				291009
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dexrazoxane
  			</td>
  			<td>
  				Totect(r)
  			</td>
  			<td>
  				03/25/2004
  			</td>
  			<td>
  				Treatment of anthracycline extravasation during chemotherapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of extravasation resulting from IV anthracycline chemotherapy
	  			</td>
				
	  			<td>
					
						09/06/2007
					
	  			</td>

	  			<td>

					
					09/06/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Clinigen, Inc.
  			</td>
  			<td>
  				790 Township Line Road
  			</td>
  			<td>
  				Suite 120
  			</td>
  			<td>
  				Yardley
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19067
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				181103
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Midodrine HCl
  			</td>
  			<td>
  				Amatine
  			</td>
  			<td>
  				06/21/1985
  			</td>
  			<td>
  				Treatment of patients with symptomatic orthostatic hypotension.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of symptomatic orthostatic hypotension.
	  			</td>
				
	  			<td>
					
						09/06/1996
					
	  			</td>

	  			<td>

					
					09/06/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				007585
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				riluzole oral suspension
  			</td>
  			<td>
  				Tiglutik
  			</td>
  			<td>
  				09/15/2016
  			</td>
  			<td>
  				Treatment of amyotrophic lateral sclerosis (ALS).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
	  			</td>
				
	  			<td>
					
						09/05/2018
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Italfarmaco SpA
  			</td>
  			<td>
  				54 Via dei Lavoratori
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cinisello Balsamo
  			</td>
  			<td>
  				Lombardia
  			</td>
  			<td>
  				20092
  			</td>
  			<td>
  				Italy
  			</td>
			<td>
  				508715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				 bosentan
  			</td>
  			<td>
  				Tracleer
  			</td>
  			<td>
  				10/06/2000
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability
	  			</td>
				
	  			<td>
					
						09/05/2017
					
	  			</td>

	  			<td>

					
					09/05/2024
					
					
	  			</td>

				<td>
					Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability
				</td>
			
  			<td>
  				Actelion Pharmaceuticals Ltd
  			</td>
  			<td>
  				1840 Gateway Drive
  			</td>
  			<td>
  				Suite 300
  			</td>
  			<td>
  				Cherry Hill
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08002
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				134200
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pralsetinib
  			</td>
  			<td>
  				GAVRETO™
  			</td>
  			<td>
  				04/11/2018
  			</td>
  			<td>
  				Treatment of rearranged during transfection (RET)-rearranged non-small cell lung cancer (NSCLC), JAK1/2-positive NSCLC, or TRKC-positive NSCLC.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
	  			</td>
				
	  			<td>
					
						09/04/2020
					
	  			</td>

	  			<td>

					
					09/04/2027
					
					
	  			</td>

				<td>
					treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080-4990
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				634318
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				uridine triacetate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				08/09/2013
  			</td>
  			<td>
  				Treatment of hereditary orotic aciduria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of hereditary orotic aciduria
	  			</td>
				
	  			<td>
					
						09/04/2015
					
	  			</td>

	  			<td>

					
					09/04/2022
					
					
	  			</td>

				<td>
					Treatment of hereditary orotic aciduria
				</td>
			
  			<td>
  				Wellstat Therapeutics, Inc.
  			</td>
  			<td>
  				14200 Shady Grove Road
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Rockville
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20850
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				401013
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				KEYTRUDA
  			</td>
  			<td>
  				11/19/2012
  			</td>
  			<td>
  				Treatment of Stage IIB through IV malignant melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.  
	  			</td>
				
	  			<td>
					
						09/04/2014
					
	  			</td>

	  			<td>

					
					09/04/2021
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Merck, Sharp & Dohme Corp.
  			</td>
  			<td>
  				351 North Sumneytown Pike 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				381012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bosutinib
  			</td>
  			<td>
  				Bosulif
  			</td>
  			<td>
  				02/24/2009
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy
	  			</td>
				
	  			<td>
					
						09/04/2012
					
	  			</td>

	  			<td>

					
					09/04/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pfizer Inc.
  			</td>
  			<td>
  				445 Eastern Point Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Groton
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06340
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				274808
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				copper Cu 64 dotatate
  			</td>
  			<td>
  				Detectnet
  			</td>
  			<td>
  				05/18/2016
  			</td>
  			<td>
  				Diagnostic for the management of neuroendocrine tumors.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients
	  			</td>
				
	  			<td>
					
						09/03/2020
					
	  			</td>

	  			<td>

					
					09/03/2027
					
					
	  			</td>

				<td>
					indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients
				</td>
			
  			<td>
  				RadioMedix Inc.
  			</td>
  			<td>
  				9701 Richmond Avenue, Suite 222
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Houston
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				77042
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				520716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Azacitidine
  			</td>
  			<td>
  				ONUREG
  			</td>
  			<td>
  				06/18/2008
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy
	  			</td>
				
	  			<td>
					
						09/01/2020
					
	  			</td>

	  			<td>

					
					09/01/2027
					
					
	  			</td>

				<td>
					ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy
				</td>
			
  			<td>
  				Bristol-Myers Squibb
  			</td>
  			<td>
  				86 Morris Ave
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				257008
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Gemtuzumab ozogamicin
  			</td>
  			<td>
  				Mylotarg
  			</td>
  			<td>
  				11/24/1999
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older
	  			</td>
				
	  			<td>
					
						09/01/2017
					
	  			</td>

	  			<td>

					
					09/01/2024
					
					
	  			</td>

				<td>
					Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals, Inc., a Pfizer Company
  			</td>
  			<td>
  				10646 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				127899
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				zanubrutinib
  			</td>
  			<td>
  				Brukinsa
  			</td>
  			<td>
  				06/29/2016
  			</td>
  			<td>
  				Treatment of Waldenstrom's macroglobulinemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Waldenstrom¿s macroglobulinemia (WM)
	  			</td>
				
	  			<td>
					
						08/31/2021
					
	  			</td>

	  			<td>

					
					08/31/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with Waldenstrom¿s macroglobulinemia (WM)
				</td>
			
  			<td>
  				BeiGene USA, Inc.
  			</td>
  			<td>
  				2955 Campus Drive
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				San Mateo
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94403
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				527616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Leucovorin
  			</td>
  			<td>
  				Leucovorin calcium
  			</td>
  			<td>
  				08/17/1988
  			</td>
  			<td>
  				For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						08/31/1988
					
	  			</td>

	  			<td>

					
					08/31/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Immunex Corporation
  			</td>
  			<td>
  				51 University Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				030588
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19
  			</td>
  			<td>
  				Kymriah (tisagenlecleucel)
  			</td>
  			<td>
  				01/31/2014
  			</td>
  			<td>
  				For the treatment of Acute Lymphoblastic Leukemia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
	  			</td>
				
	  			<td>
					
						08/30/2017
					
	  			</td>

	  			<td>

					
					08/30/2024
					
					
	  			</td>

				<td>
					Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza,
  			</td>
  			<td>
  				Bldg 315 - Room 3650B
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				415113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tocilizumab
  			</td>
  			<td>
  				Actemra
  			</td>
  			<td>
  				08/01/2017
  			</td>
  			<td>
  				Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						08/30/2017
					
	  			</td>

	  			<td>

					
					08/30/2024
					
					
	  			</td>

				<td>
					Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older
				</td>
			
  			<td>
  				Genentech Inc., a member of the Roche Group
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS #355e
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				589317
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				blinatumomab
  			</td>
  			<td>
  				Blincyto
  			</td>
  			<td>
  				05/16/2008
  			</td>
  			<td>
  				Treatment of acute lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
	  			</td>
				
	  			<td>
					
						08/30/2016
					
	  			</td>

	  			<td>

					
					08/30/2023
					
					
	  			</td>

				<td>
					treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients weighing less than 45 kg
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Dr.
  			</td>
  			<td>
  				Mail Stop 17-2-A
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				255707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ofatumumab
  			</td>
  			<td>
  				ARZERRA
  			</td>
  			<td>
  				03/10/2009
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).  
	  			</td>
				
	  			<td>
					
						08/30/2016
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				275809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Lanreotide
  			</td>
  			<td>
  				Somatuline Depot
  			</td>
  			<td>
  				09/11/2000
  			</td>
  			<td>
  				Treatment for acromegly
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy
	  			</td>
				
	  			<td>
					
						08/30/2007
					
	  			</td>

	  			<td>

					
					08/30/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				IPSEN, Inc.
  			</td>
  			<td>
  				27 Maple Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Milford
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				01757
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				136300
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Mecasermin
  			</td>
  			<td>
  				Increlex
  			</td>
  			<td>
  				12/12/1995
  			</td>
  			<td>
  				Treatment of growth hormone insensitivity syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.  
	  			</td>
				
	  			<td>
					
						08/30/2005
					
	  			</td>

	  			<td>

					
					08/30/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ipsen Biopharmaceuticals, Inc.
  			</td>
  			<td>
  				106 Allen Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Basking Ridge
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07920
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				093695
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Potassium citrate
  			</td>
  			<td>
  				Urocit-K
  			</td>
  			<td>
  				11/01/1984
  			</td>
  			<td>
  				Prevention of uric acid nephrolithiasis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						08/30/1985
					
	  			</td>

	  			<td>

					
					08/30/1992
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				University of Texas Health Science Center at Dallas
  			</td>
  			<td>
  				5323 Harry Hines Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dallas
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				75235
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				002784
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				benznidazole
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				04/14/2014
  			</td>
  			<td>
  				Treatment of Chagas disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.
	  			</td>
				
	  			<td>
					
						08/29/2017
					
	  			</td>

	  			<td>

					
					08/29/2024
					
					
	  			</td>

				<td>
					Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.
				</td>
			
  			<td>
  				Chemo Research, S.L.
  			</td>
  			<td>
  				 Edificio Nectar
  			</td>
  			<td>
  				c/Quintanapalla, 2, 3 planta
  			</td>
  			<td>
  				Madrid
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Spain
  			</td>
			<td>
  				425214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ledipasvir/sofosbuvir
  			</td>
  			<td>
  				Harvoni
  			</td>
  			<td>
  				10/12/2016
  			</td>
  			<td>
  				Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin
	  			</td>
				
	  			<td>
					
						08/28/2019
					
	  			</td>

	  			<td>

					
					08/28/2026
					
					
	  			</td>

				<td>
					For treatment of pediatric patients between 3 years of age and 12 years of age or weighing 35 kg with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; (2) treatment of pediatric patients 3 years of age and older with chronic HCV genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin; and (3) treatment of pediatric patients 3 years of age and older with chronic HCV genotype 1 or 4 infection who are 
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				535916
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sofosbuvir
  			</td>
  			<td>
  				Sovaldi
  			</td>
  			<td>
  				10/25/2016
  			</td>
  			<td>
  				Treatment of pediatric chronic hepatitis C virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
	  			</td>
				
	  			<td>
					
						08/28/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				541716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ledipasvir/sofosbuvir
  			</td>
  			<td>
  				Harvoni
  			</td>
  			<td>
  				10/12/2016
  			</td>
  			<td>
  				Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin
	  			</td>
				
	  			<td>
					
						08/28/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				535916
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sofosbuvir
  			</td>
  			<td>
  				Sovaldi
  			</td>
  			<td>
  				10/25/2016
  			</td>
  			<td>
  				Treatment of pediatric chronic hepatitis C virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
	  			</td>
				
	  			<td>
					
						08/28/2019
					
	  			</td>

	  			<td>

					
					08/28/2026
					
					
	  			</td>

				<td>
					For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				541716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Topiramate
  			</td>
  			<td>
  				Topamax
  			</td>
  			<td>
  				11/25/1992
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.
	  			</td>
				
	  			<td>
					
						08/28/2001
					
	  			</td>

	  			<td>

					
					08/28/2008
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Johnson & Johnson Pharmaceutical R & D, LLC
  			</td>
  			<td>
  				Route 202, P.O. Box 300
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				070792
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				evolocumab
  			</td>
  			<td>
  				Repatha
  			</td>
  			<td>
  				09/12/2013
  			</td>
  			<td>
  				Treatment of homozygous familial hypercholesterolemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C. 
	  			</td>
				
	  			<td>
					
						08/27/2015
					
	  			</td>

	  			<td>

					
					08/27/2022
					
					
	  			</td>

				<td>
					As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C. 
				</td>
			
  			<td>
  				Amgen Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				M/S 17 2 B
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				404113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eltrombopag
  			</td>
  			<td>
  				Promacta
  			</td>
  			<td>
  				11/08/2013
  			</td>
  			<td>
  				Treatment of aplastic anemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.  
	  			</td>
				
	  			<td>
					
						08/26/2014
					
	  			</td>

	  			<td>

					
					08/26/2021
					
					
	  			</td>

				<td>
					Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				410213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				crizotinib
  			</td>
  			<td>
  				Xalkori
  			</td>
  			<td>
  				09/13/2010
  			</td>
  			<td>
  				Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapprovedtest
	  			</td>
				
	  			<td>
					
						08/26/2011
					
	  			</td>

	  			<td>

					
					08/26/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				10646 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				310610
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lonapegsomatropin-tcgd
  			</td>
  			<td>
  				Skytrofa
  			</td>
  			<td>
  				04/13/2020
  			</td>
  			<td>
  				Treatment of growth hormone deficiency 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH)
	  			</td>
				
	  			<td>
					
						08/25/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ascendis Pharma Endocrinology Division A/S
  			</td>
  			<td>
  				12 Tuborg Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Hellerup
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Denmark
  			</td>
			<td>
  				654718
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivosidenib
  			</td>
  			<td>
  				Tibsovo
  			</td>
  			<td>
  				04/26/2017
  			</td>
  			<td>
  				Treatment of cholangiocarcinoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						08/25/2021
					
	  			</td>

	  			<td>

					
					08/25/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
				</td>
			
  			<td>
  				Servier Pharmaceuticals LLC
  			</td>
  			<td>
  				200 Pier Four Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				562216
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				icatibant
  			</td>
  			<td>
  				Firazyr
  			</td>
  			<td>
  				11/25/2003
  			</td>
  			<td>
  				Treatment of angioedema
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older
	  			</td>
				
	  			<td>
					
						08/25/2011
					
	  			</td>

	  			<td>

					
					08/25/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				176203
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Amantadine hydrochloride
  			</td>
  			<td>
  				Gocovri
  			</td>
  			<td>
  				04/09/2015
  			</td>
  			<td>
  				Treatment of levodopa-induced dyskinesia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications
	  			</td>
				
	  			<td>
					
						08/24/2017
					
	  			</td>

	  			<td>

					
					08/24/2024
					
					
	  			</td>

				<td>
					treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications
				</td>
			
  			<td>
  				Adamas Pharmaceuticals, Inc.
  			</td>
  			<td>
  				1900  Powell Street
  			</td>
  			<td>
  				Suite 750
  			</td>
  			<td>
  				Emeryville
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94608
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				413213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				infliximab
  			</td>
  			<td>
  				Remicade
  			</td>
  			<td>
  				11/14/1995
  			</td>
  			<td>
  				Treatment of Crohn's disease 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).  
	  			</td>
				
	  			<td>
					
						08/24/1998
					
	  			</td>

	  			<td>

					
					08/24/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Centocor, Inc.
  			</td>
  			<td>
  				200 Great Valley Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Malvern
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				092495
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Lamotrigine
  			</td>
  			<td>
  				Lamictal
  			</td>
  			<td>
  				08/23/1995
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.
	  			</td>
				
	  			<td>
					
						08/24/1998
					
	  			</td>

	  			<td>

					
					08/24/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Research and Development
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				P.O. Box 13398
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				091695
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lanadelumab-flyo
  			</td>
  			<td>
  				Takhzyro
  			</td>
  			<td>
  				11/26/2013
  			</td>
  			<td>
  				Treatment of angioedema 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older
	  			</td>
				
	  			<td>
					
						08/23/2018
					
	  			</td>

	  			<td>

					
					08/23/2025
					
					
	  			</td>

				<td>
					Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older
				</td>
			
  			<td>
  				Takeda Pharmaceuticals USA, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				meclorethamine
  			</td>
  			<td>
  				Valchlor
  			</td>
  			<td>
  				08/17/2004
  			</td>
  			<td>
  				Treatment of mycosis fungoides
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.  
	  			</td>
				
	  			<td>
					
						08/23/2013
					
	  			</td>

	  			<td>

					
					08/23/2020
					
					
	  			</td>

				<td>
					Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.  
				</td>
			
  			<td>
  				Helsinn Birex Pharmaceuticals Ltd.
  			</td>
  			<td>
  				Damastown
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Mulhuddart
  			</td>
  			<td>
  				County Dublin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				188404
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin for injection
  			</td>
  			<td>
  				Serostim
  			</td>
  			<td>
  				11/15/1991
  			</td>
  			<td>
  				Treatment of AIDS-associated catabolism/weight loss.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of AIDS wasting or cachexia.
	  			</td>
				
	  			<td>
					
						08/23/1996
					
	  			</td>

	  			<td>

					
					08/23/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				EMD Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				060491
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cobicistat
  			</td>
  			<td>
  				Tybost®
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg
	  			</td>
				
	  			<td>
					
						08/22/2019
					
	  			</td>

	  			<td>

					
					08/22/2026
					
					
	  			</td>

				<td>
					Indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg.
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				577917
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cenegermin-bkbj
  			</td>
  			<td>
  				Oxervate
  			</td>
  			<td>
  				06/23/2014
  			</td>
  			<td>
  				Treatment of neurotrophic keratitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of neurotrophic keratitis
	  			</td>
				
	  			<td>
					
						08/22/2018
					
	  			</td>

	  			<td>

					
					08/22/2025
					
					
	  			</td>

				<td>
					Treatment of neurotrophic keratitis
				</td>
			
  			<td>
  				Dompe S.p.A.
  			</td>
  			<td>
  				Via S. Martino 12-12/A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Milan
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Italy
  			</td>
			<td>
  				436214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				romiplostim
  			</td>
  			<td>
  				Nplate
  			</td>
  			<td>
  				03/27/2003
  			</td>
  			<td>
  				Treatment of immune thrombocytopenic purpura
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
	  			</td>
				
	  			<td>
					
						08/22/2008
					
	  			</td>

	  			<td>

					
					08/22/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				Mail Stop: 27-2-D
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				165402
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Gallium-68 (DOTA0-Phel-Tyr3)octreotide
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				10/25/2013
  			</td>
  			<td>
  				The management of neuroendocrine tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
	  			</td>
				
	  			<td>
					
						08/21/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					Exclusivity waived by sponsor
				</td>
			
  			<td>
  				University of Iowa Hospital & Clinics
  			</td>
  			<td>
  				Department of Radiology/PET Imaging Center
  			</td>
  			<td>
  				200 Hawkins Drive
  			</td>
  			<td>
  				Iowa City
  			</td>
  			<td>
  				Iowa
  			</td>
  			<td>
  				52242
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				409513
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vigabatrin
  			</td>
  			<td>
  				Sabril
  			</td>
  			<td>
  				06/12/2000
  			</td>
  			<td>
  				Treatment of infantile spasms.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For infantile spasms (IS) - 1 month to 2 years of age.
	  			</td>
				
	  			<td>
					
						08/21/2009
					
	  			</td>

	  			<td>

					
					08/21/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				H. Lundbeck A/S
  			</td>
  			<td>
  				Four Parkway North
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				135100
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				carfilzomib
  			</td>
  			<td>
  				Kyprolis
  			</td>
  			<td>
  				01/18/2008
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone.
	  			</td>
				
	  			<td>
					
						08/20/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					  
				</td>
			
  			<td>
  				Onyx Therapeutics, Inc.
  			</td>
  			<td>
  				249 East Grand Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				252507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab
  			</td>
  			<td>
  				Darzalex
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy
	  			</td>
				
	  			<td>
					
						08/20/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				PO Box 300
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				stiripentol
  			</td>
  			<td>
  				Diacomit
  			</td>
  			<td>
  				10/30/2008
  			</td>
  			<td>
  				Treatment of Dravet syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.
	  			</td>
				
	  			<td>
					
						08/20/2018
					
	  			</td>

	  			<td>

					
					08/20/2025
					
					
	  			</td>

				<td>
					DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.
				</td>
			
  			<td>
  				Biocodex
  			</td>
  			<td>
  				7, avenue Gallieni
  			</td>
  			<td>
  				94250 
  			</td>
  			<td>
  				Gentilly
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				266108
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Zoledronate
  			</td>
  			<td>
  				Zometa, Zabel
  			</td>
  			<td>
  				08/18/2000
  			</td>
  			<td>
  				Treatment of tumor induced hypercalcemia.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of hypercalcemia of malignancy.
	  			</td>
				
	  			<td>
					
						08/20/2001
					
	  			</td>

	  			<td>

					
					08/20/2008
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				130899
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor IX
  			</td>
  			<td>
  				Mononine
  			</td>
  			<td>
  				06/27/1989
  			</td>
  			<td>
  				Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.
	  			</td>
				
	  			<td>
					
						08/20/1992
					
	  			</td>

	  			<td>

					
					08/20/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Armour Pharmaceutical Company
  			</td>
  			<td>
  				500 Arcola Road, P.O. Box 1200
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Collegeville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19426
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				036189
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eliglustat
  			</td>
  			<td>
  				CERDELGA
  			</td>
  			<td>
  				09/17/2008
  			</td>
  			<td>
  				Treatment of Type I Gaucher disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.  
	  			</td>
				
	  			<td>
					
						08/19/2014
					
	  			</td>

	  			<td>

					
					08/19/2021
					
					
	  			</td>

				<td>
					Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.  
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				500 Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				265408
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brentuximab  vedotin
  			</td>
  			<td>
  				Adcetris
  			</td>
  			<td>
  				10/23/2008
  			</td>
  			<td>
  				Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen
	  			</td>
				
	  			<td>
					
						08/19/2011
					
	  			</td>

	  			<td>

					
					08/19/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823 30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				268908
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brentuximab vedotin
  			</td>
  			<td>
  				Adcetris
  			</td>
  			<td>
  				01/30/2007
  			</td>
  			<td>
  				Treatment of Hodgkin's lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates
	  			</td>
				
	  			<td>
					
						08/19/2011
					
	  			</td>

	  			<td>

					
					08/19/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823 30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				235606
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				Lynparza
  			</td>
  			<td>
  				10/16/2013
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
	  			</td>
				
	  			<td>
					
						08/17/2017
					
	  			</td>

	  			<td>

					
					08/17/2024
					
					
	  			</td>

				<td>
					Maintenance treatment of adult patients with recurrent epithelial ovarian cancer, who are in a complete or partial response to platinum-based chemotherapy.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				409213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				 Lynparza 
  			</td>
  			<td>
  				05/15/2018
  			</td>
  			<td>
  				Treatment of primary peritoneal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. 
	  			</td>
				
	  			<td>
					
						08/17/2017
					
	  			</td>

	  			<td>

					
					08/17/2024
					
					
	  			</td>

				<td>
					Maintenance treatment of adult patients with recurrent primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				419013
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				inotuzumab ozogamicin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				03/25/2013
  			</td>
  			<td>
  				Treatment of B-cell acute lymphoblastic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
	  			</td>
				
	  			<td>
					
						08/17/2017
					
	  			</td>

	  			<td>

					
					08/17/2024
					
					
	  			</td>

				<td>
					Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				10646 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				391413
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				 Lynparza 
  			</td>
  			<td>
  				05/15/2018
  			</td>
  			<td>
  				Treatment of Fallopian Tube Cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. 
	  			</td>
				
	  			<td>
					
						08/17/2017
					
	  			</td>

	  			<td>

					
					08/17/2024
					
					
	  			</td>

				<td>
					Maintenance treatment of adult patients with recurrent fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				417613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brentuximab vedotin
  			</td>
  			<td>
  				Adcetris
  			</td>
  			<td>
  				01/30/2007
  			</td>
  			<td>
  				Treatment of Hodgkin's lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
	  			</td>
				
	  			<td>
					
						08/17/2015
					
	  			</td>

	  			<td>

					
					08/17/2022
					
					
	  			</td>

				<td>
					Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823 30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				235606
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vemurafenib
  			</td>
  			<td>
  				Zelboraf
  			</td>
  			<td>
  				12/20/2010
  			</td>
  			<td>
  				Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						08/17/2011
					
	  			</td>

	  			<td>

					
					08/17/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				325310
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Fedratinib
  			</td>
  			<td>
  				INREBIC
  			</td>
  			<td>
  				05/18/2009
  			</td>
  			<td>
  				Treatment of secondary and primary myelofibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
	  			</td>
				
	  			<td>
					
						08/16/2019
					
	  			</td>

	  			<td>

					
					08/16/2026
					
					
	  			</td>

				<td>
					For the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
				</td>
			
  			<td>
  				Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				279409
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				OPDIVO
  			</td>
  			<td>
  				09/15/2015
  			</td>
  			<td>
  				Treatment of small cell lung cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn)
	  			</td>
				
	  			<td>
					
						08/16/2018
					
	  			</td>

	  			<td>

					
					12/29/2020
					
					
	  			</td>

				<td>
					For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn)
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				5 Research Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wallingford
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06492
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				491415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				entrectinib
  			</td>
  			<td>
  				ROZLYTREK
  			</td>
  			<td>
  				07/05/2017
  			</td>
  			<td>
  				Treatment of NTRK fusion-positive solid tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy
	  			</td>
				
	  			<td>
					
						08/15/2019
					
	  			</td>

	  			<td>

					
					08/15/2026
					
					
	  			</td>

				<td>
					For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS#241A
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				587117
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				entrectinib
  			</td>
  			<td>
  				ROZLYTREK
  			</td>
  			<td>
  				02/03/2015
  			</td>
  			<td>
  				Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
	  			</td>
				
	  			<td>
					
						08/15/2019
					
	  			</td>

	  			<td>

					
					08/15/2026
					
					
	  			</td>

				<td>
					For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS#241A
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				462914
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenvatinib
  			</td>
  			<td>
  				LENVIMA
  			</td>
  			<td>
  				03/27/2014
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
	  			</td>
				
	  			<td>
					
						08/15/2018
					
	  			</td>

	  			<td>

					
					08/15/2025
					
					
	  			</td>

				<td>
					 LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) 
				</td>
			
  			<td>
  				Eisai Inc.
  			</td>
  			<td>
  				200 Metro Blvd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110-6102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				423714
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data. 
	  			</td>
				
	  			<td>
					
						08/15/2018
					
	  			</td>

	  			<td>

					
					08/15/2025
					
					
	  			</td>

				<td>
					For the treatment of cystic fibrosis (CF) in patients age 12 months to less than 2 years who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tetrabenazine
  			</td>
  			<td>
  				Xenazine
  			</td>
  			<td>
  				12/11/1997
  			</td>
  			<td>
  				Treatment of Huntington's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chorea associated with Huntington's disease
	  			</td>
				
	  			<td>
					
						08/15/2008
					
	  			</td>

	  			<td>

					
					08/15/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Prestwick Pharmaceuticals, Inc
  			</td>
  			<td>
  				1825 K Street NW
  			</td>
  			<td>
  				Suite 1475
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				District of Columbia
  			</td>
  			<td>
  				20006
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				108897
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cysteamine
  			</td>
  			<td>
  				Cystagon
  			</td>
  			<td>
  				01/25/1991
  			</td>
  			<td>
  				Treatment of nephropathic cystinosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of nephropathic cystinosis in adults and children.
	  			</td>
				
	  			<td>
					
						08/15/1994
					
	  			</td>

	  			<td>

					
					08/15/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mylan Laboratories, Inc.
  			</td>
  			<td>
  				781 Chestnut Ridge Road
  			</td>
  			<td>
  				P.O. Box 4310
  			</td>
  			<td>
  				Morgantown
  			</td>
  			<td>
  				West Virginia
  			</td>
  			<td>
  				26504
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				055690
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				satralizumab-mwge
  			</td>
  			<td>
  				ENSPRYNG™
  			</td>
  			<td>
  				06/30/2014
  			</td>
  			<td>
  				Treatment of  neuromyelitis optica and neuromyelitis optica spectrum disorder
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive
	  			</td>
				
	  			<td>
					
						08/14/2020
					
	  			</td>

	  			<td>

					
					08/14/2027
					
					
	  			</td>

				<td>
					treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive
				</td>
			
  			<td>
  				GENENTECH, INC.
  			</td>
  			<td>
  				1 DNA WAY 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				SOUTH SAN FRANCISCO
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				436114
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pretomanid
  			</td>
  			<td>
  				Pretomanid
  			</td>
  			<td>
  				07/05/2007
  			</td>
  			<td>
  				Treatment of tuberculosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Pretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
	  			</td>
				
	  			<td>
					
						08/14/2019
					
	  			</td>

	  			<td>

					
					08/14/2026
					
					
	  			</td>

				<td>
					As part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
				</td>
			
  			<td>
  				Global Alliance for TB Drug Development
  			</td>
  			<td>
  				40 Wall Street
  			</td>
  			<td>
  				24th Floor
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10005
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				243107
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pitolisant
  			</td>
  			<td>
  				WAKIX
  			</td>
  			<td>
  				05/17/2010
  			</td>
  			<td>
  				Treatment of narcolepsy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy
	  			</td>
				
	  			<td>
					
						08/14/2019
					
	  			</td>

	  			<td>

					
					08/14/2026
					
					
	  			</td>

				<td>
					For the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy
				</td>
			
  			<td>
  				Harmony Biosciences, LLC
  			</td>
  			<td>
  				630 W Germantown Pike
  			</td>
  			<td>
  				Suite 215
  			</td>
  			<td>
  				 Plymouth Meeting
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19462
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				307210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cysteamine enteric coated
  			</td>
  			<td>
  				PROCYSBI
  			</td>
  			<td>
  				10/24/2006
  			</td>
  			<td>
  				Treatment of cystinosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				PROCYSBI is indicated for the treatment of nephropathic cystinosis in adult and pediatric patients 2 years of age and older.
	  			</td>
				
	  			<td>
					
						08/14/2015
					
	  			</td>

	  			<td>

					
					08/14/2022
					
					
	  			</td>

				<td>
					Treatment of nephropathic cystinosis in pediatric patients 2 years of age to less than 6 years of age.
				</td>
			
  			<td>
  				Horizon Therapeutics USA, Inc.
  			</td>
  			<td>
  				150 S. Saunders Road
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Lake Forest
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60045
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				231006
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				belzutifan
  			</td>
  			<td>
  				Welireg
  			</td>
  			<td>
  				06/24/2020
  			</td>
  			<td>
  				Treatment of von Hippel-Lindau disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery
	  			</td>
				
	  			<td>
					
						08/13/2021
					
	  			</td>

	  			<td>

					
					08/13/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery
				</td>
			
  			<td>
  				Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  			</td>
  			<td>
  				One Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				745820
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Technetium Tc99m sulfur colloid injection, lyophilized 
  			</td>
  			<td>
  				Technetium Tc99m Sulfur Colloi
  			</td>
  			<td>
  				03/17/2009
  			</td>
  			<td>
  				For localization of sentinel lymph nodes in patients with melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter
	  			</td>
				
	  			<td>
					
						08/13/2012
					
	  			</td>

	  			<td>

					
					08/13/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmalucence, Inc.
  			</td>
  			<td>
  				10 DeAngelo Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bedford
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				01730
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				271608
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				calcium, magnesium, potassium, and sodium oxybates
  			</td>
  			<td>
  				Xywav
  			</td>
  			<td>
  				07/31/2019
  			</td>
  			<td>
  				Treatment of idiopathic hypersomnia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of idiopathic hypersomnia (IH) in adults
	  			</td>
				
	  			<td>
					
						08/12/2021
					
	  			</td>

	  			<td>

					
					08/12/2028
					
					
	  			</td>

				<td>
					Treatment of idiopathic hypersomnia (IH) in adults
				</td>
			
  			<td>
  				Jazz Pharmaceuticals Ireland Limited
  			</td>
  			<td>
  				5th Floor Waterloo Exchange
  			</td>
  			<td>
  				Waterloo Road
  			</td>
  			<td>
  				Dublin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				694619
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				viltolarsen
  			</td>
  			<td>
  				VILTEPSO
  			</td>
  			<td>
  				01/12/2017
  			</td>
  			<td>
  				Treatment of Duchenne Muscular Dystrophy 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
	  			</td>
				
	  			<td>
					
						08/12/2020
					
	  			</td>

	  			<td>

					
					08/12/2027
					
					
	  			</td>

				<td>
					VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
				</td>
			
  			<td>
  				NS Pharma, Inc.
  			</td>
  			<td>
  				140 East Ridgewood Avenue, Suite 280S
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Paramus
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07652
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				565616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor VIIa (recombinant)
  			</td>
  			<td>
  				NovoSeven
  			</td>
  			<td>
  				06/18/2004
  			</td>
  			<td>
  				Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
	  			</td>
				
	  			<td>
					
						08/12/2005
					
	  			</td>

	  			<td>

					
					08/12/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk, Inc.
  			</td>
  			<td>
  				100 Overlook Center
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				186104
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				quinine Sulfate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				06/03/2004
  			</td>
  			<td>
  				Treatment of malaria 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of uncomplicated Plasmodium falciparum malaria
	  			</td>
				
	  			<td>
					
						08/12/2005
					
	  			</td>

	  			<td>

					
					08/12/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AR Holding Company, Inc.
  			</td>
  			<td>
  				1100 Orthodox Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Philadelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19124
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				185004
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				meloxicam
  			</td>
  			<td>
  				Mobic
  			</td>
  			<td>
  				11/22/2002
  			</td>
  			<td>
  				Treatment of juvenile rheumatoid arthritis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older
	  			</td>
				
	  			<td>
					
						08/11/2005
					
	  			</td>

	  			<td>

					
					08/11/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Boehringer Ingelheim Pharmaceuticals, Inc.
  			</td>
  			<td>
  				900 Ridgebury Road
  			</td>
  			<td>
  				P. O. Box 368
  			</td>
  			<td>
  				Ridgefield
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06877
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				160602
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Diethylenetriaminepentaacetic acid (DTPA)
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				04/28/2004
  			</td>
  			<td>
  				Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of internal contamination with plutonium, americium or curium
	  			</td>
				
	  			<td>
					
						08/11/2004
					
	  			</td>

	  			<td>

					
					08/11/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hameln Pharmaceuticals gmbh
  			</td>
  			<td>
  				Langes Feld 13
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Hameln
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Germany
  			</td>
			<td>
  				186804
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				temozolomide
  			</td>
  			<td>
  				Temodar
  			</td>
  			<td>
  				10/05/1998
  			</td>
  			<td>
  				Treatment of recurrent malignant glioma.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine
	  			</td>
				
	  			<td>
					
						08/11/1999
					
	  			</td>

	  			<td>

					
					08/11/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Schering-Plough Research Institute
  			</td>
  			<td>
  				2000 Galloping Hill Rd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kenilworth
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07033
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				116798
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Liposomal amphotericin B
  			</td>
  			<td>
  				AmBisome
  			</td>
  			<td>
  				12/10/1996
  			</td>
  			<td>
  				Treatment of cryptococcal meningitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of disseminated cryptococcosis including meningitis.
	  			</td>
				
	  			<td>
					
						08/11/1997
					
	  			</td>

	  			<td>

					
					08/11/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fujisawa USA, Inc.
  			</td>
  			<td>
  				3 Parkway North Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				099496
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Liposomal amphotericin B
  			</td>
  			<td>
  				AmBisome
  			</td>
  			<td>
  				12/06/1996
  			</td>
  			<td>
  				Treatment of visceral leishmaniasis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of visceral leishmaniasis.
	  			</td>
				
	  			<td>
					
						08/11/1997
					
	  			</td>

	  			<td>

					
					08/11/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fujisawa USA, Inc.
  			</td>
  			<td>
  				3 Parkway North Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				099596
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tiopronin
  			</td>
  			<td>
  				Thiola
  			</td>
  			<td>
  				01/17/1986
  			</td>
  			<td>
  				Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification or who have adverse reactions to d-penicillamine.
	  			</td>
				
	  			<td>
					
						08/11/1988
					
	  			</td>

	  			<td>

					
					08/11/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mission Pharmacal Company
  			</td>
  			<td>
  				P.O. Box 786099
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Antonio
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				78278
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				012386
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				migalastat hydrochloride
  			</td>
  			<td>
  				GALAFOLD
  			</td>
  			<td>
  				02/25/2004
  			</td>
  			<td>
  				Treatment of Fabry Disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GALAFOLD™ is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
	  			</td>
				
	  			<td>
					
						08/10/2018
					
	  			</td>

	  			<td>

					
					08/10/2025
					
					
	  			</td>

				<td>
					GALAFOLD™ is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
				</td>
			
  			<td>
  				Amicus Therapeutics, Inc.
  			</td>
  			<td>
  				1 Cedarbrook Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cranbury
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08512
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				180003
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				patisiran
  			</td>
  			<td>
  				ONPATTRO
  			</td>
  			<td>
  				06/14/2012
  			</td>
  			<td>
  				Treatment of transthyretin-mediated amyloidosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
	  			</td>
				
	  			<td>
					
						08/10/2018
					
	  			</td>

	  			<td>

					
					08/10/2025
					
					
	  			</td>

				<td>
					ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
				</td>
			
  			<td>
  				Alnylam Pharmaceuticals, Inc.
  			</td>
  			<td>
  				300 Third Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				371112
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bedaquiline
  			</td>
  			<td>
  				SIRTURO
  			</td>
  			<td>
  				01/10/2005
  			</td>
  			<td>
  				Treatment of active tuberculosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.
	  			</td>
				
	  			<td>
					
						08/09/2019
					
	  			</td>

	  			<td>

					
					08/09/2026
					
					
	  			</td>

				<td>
					As part of combination therapy in the treatment of pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB)
				</td>
			
  			<td>
  				Janssen Research & Development, LLC
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				199304
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vinCRIStine sulfate LIPOSOME injection
  			</td>
  			<td>
  				Marqibo
  			</td>
  			<td>
  				01/08/2007
  			</td>
  			<td>
  				Treatment of acute lymphoblastic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.  
	  			</td>
				
	  			<td>
					
						08/09/2012
					
	  			</td>

	  			<td>

					
					08/09/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Acrotech Biopharma LLC
  			</td>
  			<td>
  				279 Princeton Hightstown Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Windsor
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				234406
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mogamulizumab
  			</td>
  			<td>
  				POTELIGEO
  			</td>
  			<td>
  				11/02/2010
  			</td>
  			<td>
  				Treatment of patients with cutaneous T-cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
	  			</td>
				
	  			<td>
					
						08/08/2018
					
	  			</td>

	  			<td>

					
					08/08/2025
					
					
	  			</td>

				<td>
					POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
				</td>
			
  			<td>
  				Kyowa Kirin Pharmaceutical Development Inc.
  			</td>
  			<td>
  				212 Carnegie  Center # 101
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				322010
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				risdiplam
  			</td>
  			<td>
  				EVRYSDI
  			</td>
  			<td>
  				01/04/2017
  			</td>
  			<td>
  				Treatment of spinal muscular atrophy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older
	  			</td>
				
	  			<td>
					
						08/07/2020
					
	  			</td>

	  			<td>

					
					08/07/2027
					
					
	  			</td>

				<td>
					treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.
				</td>
			
  			<td>
  				Genentech, Inc., a Member of the Roche Group
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080-4990
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				548116
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lumacaftor/ivacaftor
  			</td>
  			<td>
  				Orkambi
  			</td>
  			<td>
  				06/30/2014
  			</td>
  			<td>
  				Treatment of cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.
	  			</td>
				
	  			<td>
					
						08/07/2018
					
	  			</td>

	  			<td>

					
					08/07/2025
					
					
	  			</td>

				<td>
					ORKAMBI (lumacaftor/ivacaftor) oral granules indicated for the treatment of cystic fibrosis (CF) in patients age 2 through 5 years old who are homozygous for the F508del mutation in the CFTR gene.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				434814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dichlorphenamide
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				09/02/2010
  			</td>
  			<td>
  				Treatment of primary periodic paralyses
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants
	  			</td>
				
	  			<td>
					
						08/07/2015
					
	  			</td>

	  			<td>

					
					08/07/2022
					
					
	  			</td>

				<td>
					Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants
				</td>
			
  			<td>
  				Xeris Pharmaceuticals, Inc.
  			</td>
  			<td>
  				180 N La Salle Street, Suite 1600
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60601
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				314210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Potassium citrate
  			</td>
  			<td>
  				Urocit-K
  			</td>
  			<td>
  				11/01/1984
  			</td>
  			<td>
  				1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of recurring calcium conating stines associated with a deficiency in the urine.
	  			</td>
				
	  			<td>
					
						08/07/1985
					
	  			</td>

	  			<td>

					
					08/07/1992
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				University of Texas Health Science Center at Dallas
  			</td>
  			<td>
  				5323 Harry Hines Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dallas
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				75235
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				009685
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				avalglucosidase alfa-ngpt
  			</td>
  			<td>
  				Nexviazyme
  			</td>
  			<td>
  				11/19/2013
  			</td>
  			<td>
  				Treatment of Pompe Disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)
	  			</td>
				
	  			<td>
					
						08/06/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation, a Sanofi Company
  			</td>
  			<td>
  				50 Binney Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				411913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nifurtimox
  			</td>
  			<td>
  				LAMPIT
  			</td>
  			<td>
  				08/05/2010
  			</td>
  			<td>
  				Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi
	  			</td>
				
	  			<td>
					
						08/06/2020
					
	  			</td>

	  			<td>

					
					08/06/2027
					
					
	  			</td>

				<td>
					indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi
				</td>
			
  			<td>
  				Bayer HealthCare Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 BAYER BLVD 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				WHIPPANY
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07981
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				310110
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sodium sulfate, potassium sulfate, and magnesium sulfate
  			</td>
  			<td>
  				SUPREP Bowel Prep Kit
  			</td>
  			<td>
  				10/31/2012
  			</td>
  			<td>
  				For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older
	  			</td>
				
	  			<td>
					
						08/05/2020
					
	  			</td>

	  			<td>

					
					08/05/2027
					
					
	  			</td>

				<td>
					for cleansing of the colon as a preparation for colonoscopy in pediatric patients 12 years of age and older.
				</td>
			
  			<td>
  				Braintree Laboratories, Inc.
  			</td>
  			<td>
  				60 Columbian Street West
  			</td>
  			<td>
  				PO Box 850929
  			</td>
  			<td>
  				Braintree
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02185
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				379212
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				belantamab mafodotin-blmf 
  			</td>
  			<td>
  				BLENREP
  			</td>
  			<td>
  				06/22/2017
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
	  			</td>
				
	  			<td>
					
						08/05/2020
					
	  			</td>

	  			<td>

					
					08/05/2027
					
					
	  			</td>

				<td>
					for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
				</td>
			
  			<td>
  				GlaxoSmithKline Intellectual Property Development Ltd.
  			</td>
  			<td>
  				980 GREAT WEST ROAD 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				BRENTFORD
  			</td>
  			<td>
  				MIDDLESEX
  			</td>
  			<td>
  				TW89GS
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				590517
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Fosphenytoin
  			</td>
  			<td>
  				Cerebyx
  			</td>
  			<td>
  				06/04/1991
  			</td>
  			<td>
  				For the acute treatment of patients with status epilepticus of the grand mal type.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the control of generalized convulsive status epilepticus.
	  			</td>
				
	  			<td>
					
						08/05/1996
					
	  			</td>

	  			<td>

					
					08/05/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Warner-Lambert Company
  			</td>
  			<td>
  				2800 Plymouth Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ann Arbor
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				48106
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				055790
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Centruroides immune F(ab)2
  			</td>
  			<td>
  				Anascorp
  			</td>
  			<td>
  				06/12/2000
  			</td>
  			<td>
  				Treatment of scorpion envenomations requiring medical attention.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of clinical signs of scorpion envenomation
	  			</td>
				
	  			<td>
					
						08/04/2011
					
	  			</td>

	  			<td>

					
					08/04/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Rare Disease Therapeutics, Inc.
  			</td>
  			<td>
  				12975 Brookprinter Drive
  			</td>
  			<td>
  				Suite 170
  			</td>
  			<td>
  				Poway
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				135900
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Paclitaxel
  			</td>
  			<td>
  				Taxol
  			</td>
  			<td>
  				03/25/1997
  			</td>
  			<td>
  				Treatment of AIDS-related Kaposi's sarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the second line treatment of AIDS-related Kaposi's sarcoma.
	  			</td>
				
	  			<td>
					
						08/04/1997
					
	  			</td>

	  			<td>

					
					08/04/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Pharmaceutical Research Institute
  			</td>
  			<td>
  				5 Research Parkway
  			</td>
  			<td>
  				P.O. Box 5100
  			</td>
  			<td>
  				Wallingford
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06492
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				103497
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection
  			</td>
  			<td>
  				VYXEOS ; Vyxeos ; Vyxeos 
  			</td>
  			<td>
  				08/22/2008
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
	  			</td>
				
	  			<td>
					
						08/03/2017
					
	  			</td>

	  			<td>

					
					08/03/2024
					
					
	  			</td>

				<td>
					Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
				</td>
			
  			<td>
  				Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)
  			</td>
  			<td>
  				3170 Porter Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94304
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				265808
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Amiodarone HCl
  			</td>
  			<td>
  				Cordarone
  			</td>
  			<td>
  				03/16/1994
  			</td>
  			<td>
  				For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.
	  			</td>
				
	  			<td>
					
						08/03/1995
					
	  			</td>

	  			<td>

					
					08/03/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wyeth-Ayerst Laboratories
  			</td>
  			<td>
  				P.O. Box 8299
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Philadelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				077293
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pexidartinib
  			</td>
  			<td>
  				TURALIO
  			</td>
  			<td>
  				02/14/2014
  			</td>
  			<td>
  				Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
	  			</td>
				
	  			<td>
					
						08/02/2019
					
	  			</td>

	  			<td>

					
					08/02/2026
					
					
	  			</td>

				<td>
					For the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
				</td>
			
  			<td>
  				Daiichi Sankyo, Inc.
  			</td>
  			<td>
  				211 Mount Airy Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Basking Ridge
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07920
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				419913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				06/23/2016
  			</td>
  			<td>
  				Treatment of chronic Graft versus Host disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
	  			</td>
				
	  			<td>
					
						08/02/2017
					
	  			</td>

	  			<td>

					
					08/02/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 East Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				525616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Colfosceril palmitate, cetyl alcohol, tyloxapol
  			</td>
  			<td>
  				Exosurf Neonatal for Intratracheal Suspension
  			</td>
  			<td>
  				10/20/1989
  			</td>
  			<td>
  				1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages
	  			</td>
				
	  			<td>
					
						08/02/1990
					
	  			</td>

	  			<td>

					
					08/02/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Inc.
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				014886
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				enasidenib
  			</td>
  			<td>
  				Idhifa
  			</td>
  			<td>
  				06/12/2014
  			</td>
  			<td>
  				Treatment of acute myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						08/01/2017
					
	  			</td>

	  			<td>

					
					08/01/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				9225 Indian Creek Parkway
  			</td>
  			<td>
  				Suite 900
  			</td>
  			<td>
  				Overland Park
  			</td>
  			<td>
  				Kansas
  			</td>
  			<td>
  				66210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				434514
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Recombinant human acid alpha-glucosidase; alglucosidase alfa
  			</td>
  			<td>
  				1. Myozyme 2. Lumizyme
  			</td>
  			<td>
  				08/19/1997
  			</td>
  			<td>
  				Treatment of glycogen storage disease type II.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)).  
	  			</td>
				
	  			<td>
					
						08/01/2014
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				500 Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				106597
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				porfimer
  			</td>
  			<td>
  				Photofrin
  			</td>
  			<td>
  				10/19/2001
  			</td>
  			<td>
  				For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the ablation  of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy
	  			</td>
				
	  			<td>
					
						08/01/2003
					
	  			</td>

	  			<td>

					
					08/01/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Axcan Scandipharm Inc.
  			</td>
  			<td>
  				22 Inverness Parkway
  			</td>
  			<td>
  				Suite 310
  			</td>
  			<td>
  				Birmingham
  			</td>
  			<td>
  				Alabama
  			</td>
  			<td>
  				35242
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				146601
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cannabidiol
  			</td>
  			<td>
  				EPIDIOLEX
  			</td>
  			<td>
  				02/27/2014
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age and older.
	  			</td>
				
	  			<td>
					
						07/31/2020
					
	  			</td>

	  			<td>

					
					07/31/2027
					
					
	  			</td>

				<td>
					treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients between 1 and 2 years of age
				</td>
			
  			<td>
  				GW Research Ltd.
  			</td>
  			<td>
  				Sovereign House
  			</td>
  			<td>
  				Histon
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				421213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cannabidiol
  			</td>
  			<td>
  				EPIDIOLEX
  			</td>
  			<td>
  				11/14/2013
  			</td>
  			<td>
  				Treatment of Dravet syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.
	  			</td>
				
	  			<td>
					
						07/31/2020
					
	  			</td>

	  			<td>

					
					07/31/2027
					
					
	  			</td>

				<td>
					treatment of seizures associated with Dravet syndrome (DS) in patients between 1 and 2 years of age
				</td>
			
  			<td>
  				GW Research Ltd.
  			</td>
  			<td>
  				Sovereign House
  			</td>
  			<td>
  				Histon
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				409313
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cannabidiol
  			</td>
  			<td>
  				Epidiolex
  			</td>
  			<td>
  				04/19/2016
  			</td>
  			<td>
  				Treatment of tuberous sclerosis complex.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older
	  			</td>
				
	  			<td>
					
						07/31/2020
					
	  			</td>

	  			<td>

					
					07/31/2027
					
					
	  			</td>

				<td>
					 treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older
				</td>
			
  			<td>
  				GW Research Ltd.
  			</td>
  			<td>
  				Sovereign House
  			</td>
  			<td>
  				Histon
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				510716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tafasitamab
  			</td>
  			<td>
  				MONJUVI
  			</td>
  			<td>
  				12/01/2014
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				MONJUVI® is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)
	  			</td>
				
	  			<td>
					
						07/31/2020
					
	  			</td>

	  			<td>

					
					07/31/2027
					
					
	  			</td>

				<td>
					indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)
				</td>
			
  			<td>
  				MorphoSys AG
  			</td>
  			<td>
  				Semmelweisstrasse 7
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Plannegg
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Germany
  			</td>
			<td>
  				456014
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.
	  			</td>
				
	  			<td>
					
						07/31/2017
					
	  			</td>

	  			<td>

					
					07/31/2024
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: 711+3A  G, E831X, 2789+5G  A, 3272-26A  G, and 3849+10kbC  T.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				11/06/2003
  			</td>
  			<td>
  				Treatment of renal cell carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of renal cell carcinoma in combination with interferon alfa
	  			</td>
				
	  			<td>
					
						07/31/2009
					
	  			</td>

	  			<td>

					
					07/31/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				172903
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				miglustat
  			</td>
  			<td>
  				Zavesca
  			</td>
  			<td>
  				05/29/1998
  			</td>
  			<td>
  				Treatment of Gaucher disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access). 
	  			</td>
				
	  			<td>
					
						07/31/2003
					
	  			</td>

	  			<td>

					
					07/31/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				IC-MedTech Corporation
  			</td>
  			<td>
  				9902 Indian Creek Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				112598
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				atezolizumab 
  			</td>
  			<td>
  				TECENTRIQ®
  			</td>
  			<td>
  				02/13/2017
  			</td>
  			<td>
  				Treatment of Stage llb, llc, lll and IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
	  			</td>
				
	  			<td>
					
						07/30/2020
					
	  			</td>

	  			<td>

					
					07/30/2027
					
					
	  			</td>

				<td>
					indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS 35-5E
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				550616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of esophageal carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.
	  			</td>
				
	  			<td>
					
						07/30/2019
					
	  			</td>

	  			<td>

					
					07/30/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.
				</td>
			
  			<td>
  				Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.
  			</td>
  			<td>
  				1 Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				578717
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Iobenguane I 131
  			</td>
  			<td>
  				Azedra Ultratrace
  			</td>
  			<td>
  				01/18/2006
  			</td>
  			<td>
  				Treatment of neuroendocrine tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.
	  			</td>
				
	  			<td>
					
						07/30/2018
					
	  			</td>

	  			<td>

					
					07/30/2025
					
					
	  			</td>

				<td>
					AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.
				</td>
			
  			<td>
  				Progenics Pharmaceuticals, Inc.
  			</td>
  			<td>
  				One World Trade Center.
  			</td>
  			<td>
  				47th Floor, Suite J
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10007
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				216205
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				treprostinil (inhalational)
  			</td>
  			<td>
  				Tyvaso
  			</td>
  			<td>
  				06/17/2010
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance
	  			</td>
				
	  			<td>
					
						07/30/2009
					
	  			</td>

	  			<td>

					
					07/30/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				United Therapeutics Corporation
  			</td>
  			<td>
  				PO Box 14186
  			</td>
  			<td>
  				55 TW Alexander Drive
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				189104
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selexipag
  			</td>
  			<td>
  				Uptravi
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH
	  			</td>
				
	  			<td>
					
						07/29/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Actelion Pharmaceuticals Ltd
  			</td>
  			<td>
  				Gewerbestrasse 16
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Allschwil   
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				304810
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Botulinum toxin type A
  			</td>
  			<td>
  				Dysport
  			</td>
  			<td>
  				10/20/1999
  			</td>
  			<td>
  				Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of lower limb spasticity in pediatric patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						07/29/2016
					
	  			</td>

	  			<td>

					
					07/29/2023
					
					
	  			</td>

				<td>
					Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older
				</td>
			
  			<td>
  				Ipsen Biopharmaceuticals, Inc.
  			</td>
  			<td>
  				650 East Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				128299
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				coccidioidin SD Skin Test Antigen
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				12/19/2007
  			</td>
  			<td>
  				For the diagnosis of Coccidioidomycosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the detection of delayed type hypersensitivity to C. immitis in individuals, 18-64 years of age, with a history of pulmonary coccidioidomy-cosis
	  			</td>
				
	  			<td>
					
						07/29/2011
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Allermed Labortories, Inc.
  			</td>
  			<td>
  				7203 Convoy Court
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92111
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				246007
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				colchicine
  			</td>
  			<td>
  				Colcrys
  			</td>
  			<td>
  				09/25/2007
  			</td>
  			<td>
  				Treatment of familial Mediterranean fever
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of familial Mediterranean fever
	  			</td>
				
	  			<td>
					
						07/29/2009
					
	  			</td>

	  			<td>

					
					07/29/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AR Holding Company, Inc.
  			</td>
  			<td>
  				1100 Orthodox Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Philadelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19124
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				245807
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ribavirin
  			</td>
  			<td>
  				REBETOL
  			</td>
  			<td>
  				04/04/2003
  			</td>
  			<td>
  				Treatment of chronic hepatitis C in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.
	  			</td>
				
	  			<td>
					
						07/29/2003
					
	  			</td>

	  			<td>

					
					07/29/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Schering Corporation
  			</td>
  			<td>
  				2000 Galloping Hill Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kenilworth
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07033
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				162402
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Diazepam viscous solution for rectal administration
  			</td>
  			<td>
  				Diastat
  			</td>
  			<td>
  				02/25/1992
  			</td>
  			<td>
  				For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						07/29/1997
					
	  			</td>

	  			<td>

					
					07/29/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Valeant Pharmaceuticals
  			</td>
  			<td>
  				3300 Hyland Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Costa Mesa
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92626
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				061591
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sulfadiazine
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				03/14/1994
  			</td>
  			<td>
  				For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Toxoplasmosis, as adjunctive with pyrimethamine
	  			</td>
				
	  			<td>
					
						07/29/1994
					
	  			</td>

	  			<td>

					
					07/29/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eon Labs Manufacturing, Inc.
  			</td>
  			<td>
  				227-15 North Conduit Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Laurelton
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				11413
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				078093
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Felbamate
  			</td>
  			<td>
  				Felbatol
  			</td>
  			<td>
  				01/24/1989
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children.
	  			</td>
				
	  			<td>
					
						07/29/1993
					
	  			</td>

	  			<td>

					
					07/29/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wallace Laboratories
  			</td>
  			<td>
  				301B College Road East
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				033488
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				04/06/2012
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia (CLL)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion
	  			</td>
				
	  			<td>
					
						07/28/2014
					
	  			</td>

	  			<td>

					
					07/28/2021
					
					
	  			</td>

				<td>
					Treatment of chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				368012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				glycopyrrolate 
  			</td>
  			<td>
  				Cuvposa
  			</td>
  			<td>
  				06/09/2006
  			</td>
  			<td>
  				Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy)
	  			</td>
				
	  			<td>
					
						07/28/2010
					
	  			</td>

	  			<td>

					
					07/28/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Shionogi, Inc.
  			</td>
  			<td>
  				300 Campus Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Florham
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07932
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				204105
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				chenodiol
  			</td>
  			<td>
  				Chenix
  			</td>
  			<td>
  				09/21/1984
  			</td>
  			<td>
  				For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						07/28/1983
					
	  			</td>

	  			<td>

					
					07/28/1990
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Solvay
  			</td>
  			<td>
  				901 Sawyer Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Marietta
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				003384
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fish oil triglycerides
  			</td>
  			<td>
  				Omegaven
  			</td>
  			<td>
  				02/27/2008
  			</td>
  			<td>
  				Treatment of parenteral nutrition-associated liver disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)
	  			</td>
				
	  			<td>
					
						07/27/2018
					
	  			</td>

	  			<td>

					
					07/27/2025
					
					
	  			</td>

				<td>
					Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)
				</td>
			
  			<td>
  				Fresenius Kabi USA, LLC
  			</td>
  			<td>
  				3 Corporate Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lake Zurich
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60047
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				251507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bicarbonate infusate
  			</td>
  			<td>
  				Normocarb HF
  			</td>
  			<td>
  				08/09/2005
  			</td>
  			<td>
  				Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children
	  			</td>
				
	  			<td>
					
						07/26/2006
					
	  			</td>

	  			<td>

					
					07/26/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Dialysis Solutions, Inc.
  			</td>
  			<td>
  				14 Emmett Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitby
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				198904
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				somatropin [rDNA]
  			</td>
  			<td>
  				Genotropin
  			</td>
  			<td>
  				12/27/2000
  			</td>
  			<td>
  				Treatment of growth failure in children who were born small for gestational age.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For long-term treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by two years of age.
	  			</td>
				
	  			<td>
					
						07/25/2001
					
	  			</td>

	  			<td>

					
					07/25/2008
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia and Upjohn Company
  			</td>
  			<td>
  				7000 Portage Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kalamazoo
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				49001
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				135400
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brexucabtagene autoleucel
  			</td>
  			<td>
  				TECARTUS™
  			</td>
  			<td>
  				04/28/2016
  			</td>
  			<td>
  				Treatment of mantle cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TECARTUS™ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
	  			</td>
				
	  			<td>
					
						07/24/2020
					
	  			</td>

	  			<td>

					
					07/24/2027
					
					
	  			</td>

				<td>
					TECARTUS™ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
				</td>
			
  			<td>
  				Kite Pharma, Inc.
  			</td>
  			<td>
  				199 E Blaine St
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				idursulfase
  			</td>
  			<td>
  				Elaprase
  			</td>
  			<td>
  				11/28/2001
  			</td>
  			<td>
  				Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II).  Idursulfase has been shown to improve walking capacity in these patients
	  			</td>
				
	  			<td>
					
						07/24/2006
					
	  			</td>

	  			<td>

					
					07/24/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Pharmaceuticals U.S.A., Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				147301
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Halofantrine
  			</td>
  			<td>
  				Halfan
  			</td>
  			<td>
  				11/04/1991
  			</td>
  			<td>
  				Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.
	  			</td>
				
	  			<td>
					
						07/24/1992
					
	  			</td>

	  			<td>

					
					07/24/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				SmithKline Beecham Pharmaceuticals
  			</td>
  			<td>
  				One Franklin Plaza
  			</td>
  			<td>
  				P.O. Box 7929
  			</td>
  			<td>
  				Philadelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				061791
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				idelalisib
  			</td>
  			<td>
  				Zydelig
  			</td>
  			<td>
  				10/15/2013
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.       
	  			</td>
				
	  			<td>
					
						07/23/2014
					
	  			</td>

	  			<td>

					
					07/23/2021
					
					
	  			</td>

				<td>
					(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.  
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				199 E. Blaine St
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				405913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				idelalisib
  			</td>
  			<td>
  				Zydelig
  			</td>
  			<td>
  				09/26/2013
  			</td>
  			<td>
  				Treatment of follicular lymphoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies.
	  			</td>
				
	  			<td>
					
						07/23/2014
					
	  			</td>

	  			<td>

					
					07/23/2021
					
					
	  			</td>

				<td>
					Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.  
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				199 E. Blaine St
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				405813
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Interferon beta-1b
  			</td>
  			<td>
  				Betaseron
  			</td>
  			<td>
  				11/17/1988
  			</td>
  			<td>
  				Treatment of multiple sclerosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.
	  			</td>
				
	  			<td>
					
						07/23/1993
					
	  			</td>

	  			<td>

					
					07/23/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiron Corp. & Berlex Laboratories
  			</td>
  			<td>
  				4560 Horton Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Emeryville
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94608
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				031888
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dantrolene sodium suspension for injection
  			</td>
  			<td>
  				RYANODEX
  			</td>
  			<td>
  				08/16/2013
  			</td>
  			<td>
  				Treatment of malignant hyperthermia syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
	  			</td>
				
	  			<td>
					
						07/22/2014
					
	  			</td>

	  			<td>

					
					07/22/2021
					
					
	  			</td>

				<td>
					Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
				</td>
			
  			<td>
  				Eagle Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Tice Blvd
  			</td>
  			<td>
  				Suite 315
  			</td>
  			<td>
  				Woodcliff Lake
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07677
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				179703
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				calcium, magnesium, potassium, and sodium oxybates
  			</td>
  			<td>
  				Xywav
  			</td>
  			<td>
  				11/07/1994
  			</td>
  			<td>
  				Treatment of narcolepsy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
	  			</td>
				
	  			<td>
					
						07/21/2020
					
	  			</td>

	  			<td>

					
					07/21/2027
					
					
	  			</td>

				<td>
					XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
				</td>
			
  			<td>
  				Jazz Pharmaceuticals 
  			</td>
  			<td>
  				5th Floor Waterloo Exchange
  			</td>
  			<td>
  				Waterloo Road
  			</td>
  			<td>
  				Dublin 4
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D04 E5W7
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				085894
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ipilimumab
  			</td>
  			<td>
  				Yervoy
  			</td>
  			<td>
  				06/03/2004
  			</td>
  			<td>
  				Treatment of high risk Stage II, Stage III, and Stage IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older)
	  			</td>
				
	  			<td>
					
						07/21/2017
					
	  			</td>

	  			<td>

					
					07/21/2024
					
					
	  			</td>

				<td>
					treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177703
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				odevixibat
  			</td>
  			<td>
  				Bylvay
  			</td>
  			<td>
  				10/31/2012
  			</td>
  			<td>
  				Treatment of progressive familial intrahepatic cholestasis 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump protein (BSEP-3)
	  			</td>
				
	  			<td>
					
						07/20/2021
					
	  			</td>

	  			<td>

					
					07/20/2028
					
					
	  			</td>

				<td>
					Treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump protein (BSEP-3)
				</td>
			
  			<td>
  				Albireo AB c/o Albireo Pharma, Inc. 
  			</td>
  			<td>
  				10 Post Office Square
  			</td>
  			<td>
  				Suite 1000
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02109
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				370912
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivosidenib
  			</td>
  			<td>
  				TIBSOVO
  			</td>
  			<td>
  				06/09/2015
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia (AML)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						07/20/2018
					
	  			</td>

	  			<td>

					
					07/20/2025
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test
				</td>
			
  			<td>
  				Servier Pharmaceuticals LLC
  			</td>
  			<td>
  				200 Pier Four Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				481515
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tafenoquine
  			</td>
  			<td>
  				Krintafel
  			</td>
  			<td>
  				01/15/2013
  			</td>
  			<td>
  				Treatment of malaria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
	  			</td>
				
	  			<td>
					
						07/20/2018
					
	  			</td>

	  			<td>

					
					07/20/2025
					
					
	  			</td>

				<td>
					KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
				</td>
			
  			<td>
  				GlaxoSmithKline Intellectual Property Development Ltd. England
  			</td>
  			<td>
  				980 Great West Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Brentford, Middlesex
  			</td>
  			<td>
  				England
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				385812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				carfilzomib
  			</td>
  			<td>
  				Kyprolis
  			</td>
  			<td>
  				01/18/2008
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  
	  			</td>
				
	  			<td>
					
						07/20/2012
					
	  			</td>

	  			<td>

					
					07/20/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Onyx Therapeutics, Inc.
  			</td>
  			<td>
  				249 East Grand Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				252507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Hemin
  			</td>
  			<td>
  				Panhematin
  			</td>
  			<td>
  				03/16/1984
  			</td>
  			<td>
  				Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						07/20/1983
					
	  			</td>

	  			<td>

					
					07/20/1990
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Abbott Laboratories
  			</td>
  			<td>
  				Diagnostics Division
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Abbott Park
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				000683
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				apremilast
  			</td>
  			<td>
  				OTEZLA®
  			</td>
  			<td>
  				01/17/2013
  			</td>
  			<td>
  				Treatment of Behcet's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				OTEZLA is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
	  			</td>
				
	  			<td>
					
						07/19/2019
					
	  			</td>

	  			<td>

					
					07/19/2026
					
					
	  			</td>

				<td>
					For the treatment of adult patients with oral ulcers associated with Behçet’s disease
				</td>
			
  			<td>
  				Amgen Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				Mailstop: 27-2-D
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				384812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Morphine sulfate concentrate (preservative free)
  			</td>
  			<td>
  				Infumorph
  			</td>
  			<td>
  				07/12/1990
  			</td>
  			<td>
  				For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For intrathecal or epidural infusion in the treatment of tractable chronic pain. It was developed for use in continuous microinfusion devices and may require dilution before use as directed.
	  			</td>
				
	  			<td>
					
						07/19/1991
					
	  			</td>

	  			<td>

					
					07/19/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Elkins-Sinn, Inc.
  			</td>
  			<td>
  				2 Esterbrook Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cherry Hill
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08003
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				018587
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sodium oxybate
  			</td>
  			<td>
  				 Xyrem
  			</td>
  			<td>
  				11/07/1994
  			</td>
  			<td>
  				Treatment of narcolepsy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cataplexy associated with narcolepsy
	  			</td>
				
	  			<td>
					
						07/17/2002
					
	  			</td>

	  			<td>

					
					07/17/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Jazz Pharmaceuticals Ireland Limited
  			</td>
  			<td>
  				5th Floor Waterloo Exchange
  			</td>
  			<td>
  				Waterloo Road
  			</td>
  			<td>
  				Dublin 4
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D04 E5W7
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				085894
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tacrolimus
  			</td>
  			<td>
  				Prograf
  			</td>
  			<td>
  				09/12/2019
  			</td>
  			<td>
  				Prevention of rejection in lung transplantation 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic kidney transplant, liver transplant, heart transplant, or lung transplant in combination with other immunosuppressants
	  			</td>
				
	  			<td>
					
						07/16/2021
					
	  			</td>

	  			<td>

					
					07/16/2028
					
					
	  			</td>

				<td>
					Prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic lung transplant 
				</td>
			
  			<td>
  				Astellas Pharma Global Development, Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				701319
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fexinidazole
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				04/04/2016
  			</td>
  			<td>
  				Treatment of human African trypanosomiasis (HAT) or sleeping sickness
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of use: Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/?L) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there 
	  			</td>
				
	  			<td>
					
						07/16/2021
					
	  			</td>

	  			<td>

					
					07/16/2028
					
					
	  			</td>

				<td>
					Treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of use: Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/?L) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there 
				</td>
			
  			<td>
  				Sanofi US Services Inc., A SANOFI COMPANY
  			</td>
  			<td>
  				55 Corporate Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807-5925
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				513915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				belumosudil
  			</td>
  			<td>
  				Rezurock
  			</td>
  			<td>
  				10/05/2017
  			</td>
  			<td>
  				Treatment of graft versus host disease (GVHD)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy
	  			</td>
				
	  			<td>
					
						07/16/2021
					
	  			</td>

	  			<td>

					
					07/16/2028
					
					
	  			</td>

				<td>
					Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy
				</td>
			
  			<td>
  				Kadmon Pharmaceuticals, LLC
  			</td>
  			<td>
  				55 Cambridge Parkway, Suite 300E
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				606717
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				C1-esterase inhibitor (recombinant)
  			</td>
  			<td>
  				RUCONEST
  			</td>
  			<td>
  				02/23/1999
  			</td>
  			<td>
  				Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.  
	  			</td>
				
	  			<td>
					
						07/16/2014
					
	  			</td>

	  			<td>

					
					07/16/2021
					
					
	  			</td>

				<td>
					Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.  
				</td>
			
  			<td>
  				Pharming Group N.V.
  			</td>
  			<td>
  				P. O. Box 451  Darwinweg 24
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Leiden
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Netherlands
  			</td>
			<td>
  				123599
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Thalidomide
  			</td>
  			<td>
  				Thalomid
  			</td>
  			<td>
  				07/26/1995
  			</td>
  			<td>
  				Treatment of erythema nodosum leprosum.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.
	  			</td>
				
	  			<td>
					
						07/16/1998
					
	  			</td>

	  			<td>

					
					07/16/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				090795
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Immune Globulin Intravenous (Human)
  			</td>
  			<td>
  				Octagam 10%
  			</td>
  			<td>
  				04/19/2017
  			</td>
  			<td>
  				Treatment of dermatomyositis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of dermatomyositis in adults
	  			</td>
				
	  			<td>
					
						07/15/2021
					
	  			</td>

	  			<td>

					
					07/15/2028
					
					
	  			</td>

				<td>
					Treatment of dermatomyositis in adults
				</td>
			
  			<td>
  				OCTAPHARMA USA, Inc.
  			</td>
  			<td>
  				117 West Century Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Paramus
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07652
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				564716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation
  			</td>
  			<td>
  				Photrexa Viscous
  			</td>
  			<td>
  				12/02/2011
  			</td>
  			<td>
  				Treatment of corneal ectasia following refractive surgery
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of corneal ectasia following refractive surgery
	  			</td>
				
	  			<td>
					
						07/15/2016
					
	  			</td>

	  			<td>

					
					07/15/2023
					
					
	  			</td>

				<td>
					Treatment of corneal ectasia following refractive surgery
				</td>
			
  			<td>
  				Avedro, Inc.
  			</td>
  			<td>
  				230 Third Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				352511
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Teniposide
  			</td>
  			<td>
  				Vumon for injection
  			</td>
  			<td>
  				11/01/1984
  			</td>
  			<td>
  				Treatment of refractory childhood acute lymphocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.
	  			</td>
				
	  			<td>
					
						07/14/1992
					
	  			</td>

	  			<td>

					
					07/14/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Pharmaceutical Research Institute
  			</td>
  			<td>
  				5 Research Parkway
  			</td>
  			<td>
  				P.O. Box 5100
  			</td>
  			<td>
  				Wallingford
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06492
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				000883
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tecovirimat
  			</td>
  			<td>
  				TPOXX
  			</td>
  			<td>
  				12/27/2006
  			</td>
  			<td>
  				Treatment of smallpox
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TPOXX® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
	  			</td>
				
	  			<td>
					
						07/13/2018
					
	  			</td>

	  			<td>

					
					07/13/2025
					
					
	  			</td>

				<td>
					TPOXX® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
				</td>
			
  			<td>
  				SIGA Technologies, Inc.
  			</td>
  			<td>
  				4575 SW Research Way
  			</td>
  			<td>
  				Suite 230
  			</td>
  			<td>
  				Corvallis
  			</td>
  			<td>
  				Oregon
  			</td>
  			<td>
  				97333
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				229806
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				gefitinib
  			</td>
  			<td>
  				Iressa
  			</td>
  			<td>
  				08/26/2014
  			</td>
  			<td>
  				Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						07/13/2015
					
	  			</td>

	  			<td>

					
					07/13/2022
					
					
	  			</td>

				<td>
					For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				443014
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				afatinib
  			</td>
  			<td>
  				Gilotrif 
  			</td>
  			<td>
  				12/03/2012
  			</td>
  			<td>
  				Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						07/12/2013
					
	  			</td>

	  			<td>

					
					07/12/2020
					
					
	  			</td>

				<td>
					First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Boehringer Ingelheim Pharmaceuticals, Inc.
  			</td>
  			<td>
  				900 Ridgebury Road
  			</td>
  			<td>
  				P. O. Box 368
  			</td>
  			<td>
  				Ridgefield
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06877
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				375712
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rasburicase
  			</td>
  			<td>
  				Elitek
  			</td>
  			<td>
  				10/11/2000
  			</td>
  			<td>
  				Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
	  			</td>
				
	  			<td>
					
						07/12/2002
					
	  			</td>

	  			<td>

					
					07/12/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Sanofi-Synthelabo Research
  			</td>
  			<td>
  				9 Great Valley Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Malvern
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				131499
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				blinatumomab
  			</td>
  			<td>
  				Blincyto
  			</td>
  			<td>
  				05/16/2008
  			</td>
  			<td>
  				Treatment of acute lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children
	  			</td>
				
	  			<td>
					
						07/11/2017
					
	  			</td>

	  			<td>

					
					07/11/2024
					
					
	  			</td>

				<td>
					treatment of Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Dr.
  			</td>
  			<td>
  				Mail Stop 17-2-A
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				255707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor VIIa (recombinant)
  			</td>
  			<td>
  				NovoSeven
  			</td>
  			<td>
  				09/10/2004
  			</td>
  			<td>
  				Prevention of bleeding episodes in patients with congenital Factor VII deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency
	  			</td>
				
	  			<td>
					
						07/11/2005
					
	  			</td>

	  			<td>

					
					07/11/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk, Inc.
  			</td>
  			<td>
  				100 Overlook Center
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				189904
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor VIIa (recombinant)
  			</td>
  			<td>
  				NovoSeven
  			</td>
  			<td>
  				09/10/2004
  			</td>
  			<td>
  				Treatment of bleeding episodes in patients with congenital factor VII deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of bleeding episodes in patients with Factor VII Deficiency
	  			</td>
				
	  			<td>
					
						07/11/2005
					
	  			</td>

	  			<td>

					
					07/11/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk, Inc.
  			</td>
  			<td>
  				100 Overlook Center
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				185904
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tacrolimus
  			</td>
  			<td>
  				Envarsus XR
  			</td>
  			<td>
  				12/20/2013
  			</td>
  			<td>
  				Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants
	  			</td>
				
	  			<td>
					
						07/10/2015
					
	  			</td>

	  			<td>

					
					07/10/2022
					
					
	  			</td>

				<td>
					Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants
				</td>
			
  			<td>
  				Veloxis Pharmaceuticals, Inc.
  			</td>
  			<td>
  				1001 Winstead Drive
  			</td>
  			<td>
  				Suite 310
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27513
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				407113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Levomethadyl acetate hydrochloride
  			</td>
  			<td>
  				Orlaam
  			</td>
  			<td>
  				01/24/1985
  			</td>
  			<td>
  				Treatment of heroin addicts suitable for maintenance on opiate agonists.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the management of opiate dependence.
	  			</td>
				
	  			<td>
					
						07/09/1993
					
	  			</td>

	  			<td>

					
					07/09/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Biodevelopment Corporation
  			</td>
  			<td>
  				8180 Greensboro Drive, Suite 1000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				McLean
  			</td>
  			<td>
  				Virginia
  			</td>
  			<td>
  				22102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				004784
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cedazuridine and decitabine
  			</td>
  			<td>
  				Inqovi
  			</td>
  			<td>
  				08/21/2019
  			</td>
  			<td>
  				Treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
	  			</td>
				
	  			<td>
					
						07/07/2020
					
	  			</td>

	  			<td>

					
					07/07/2027
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
				</td>
			
  			<td>
  				Astex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				4420 Rosewood Drive
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Pleasanton
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94588
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				697019
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				L-glutamine
  			</td>
  			<td>
  				Endari 
  			</td>
  			<td>
  				08/01/2001
  			</td>
  			<td>
  				Treatment of sickle cell disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. 
	  			</td>
				
	  			<td>
					
						07/07/2017
					
	  			</td>

	  			<td>

					
					07/07/2024
					
					
	  			</td>

				<td>
					To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. 
				</td>
			
  			<td>
  				Emmaus Medical, Inc.
  			</td>
  			<td>
  				21250 Hawthorne Blvd., Suite 800
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Torrance
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90503
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				145901
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selinexor
  			</td>
  			<td>
  				XPOVIO
  			</td>
  			<td>
  				01/05/2015
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
	  			</td>
				
	  			<td>
					
						07/03/2019
					
	  			</td>

	  			<td>

					
					07/03/2026
					
					
	  			</td>

				<td>
					Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
				</td>
			
  			<td>
  				Karyopharm Therapeutics, Inc.
  			</td>
  			<td>
  				85 Wells Avenue, Suite 210
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Newton
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02459
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				459014
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Belinostat
  			</td>
  			<td>
  				Beleodaq
  			</td>
  			<td>
  				09/03/2009
  			</td>
  			<td>
  				Treatment of peripheral T-cell lymphoma (PTCL). 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with relapsed or refractory peripheral T-cell lymphoma   
	  			</td>
				
	  			<td>
					
						07/03/2014
					
	  			</td>

	  			<td>

					
					07/03/2021
					
					
	  			</td>

				<td>
					Treatment of patients with relapsed or refractory peripheral T-cell lymphoma   
				</td>
			
  			<td>
  				Acrotech Biopharma LLC
  			</td>
  			<td>
  				279 Princeton Hightstown Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Windsor
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				289309
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lumacaftor/ivacaftor
  			</td>
  			<td>
  				Orkambi
  			</td>
  			<td>
  				06/30/2014
  			</td>
  			<td>
  				Treatment of cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene
	  			</td>
				
	  			<td>
					
						07/02/2015
					
	  			</td>

	  			<td>

					
					07/02/2022
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				434814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				coagulation factor VIIa (recombinant)
  			</td>
  			<td>
  				NovoSeven RT
  			</td>
  			<td>
  				06/18/2004
  			</td>
  			<td>
  				Treatment of bleeding episodes in Glanzmann's thrombasthenia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.  
	  			</td>
				
	  			<td>
					
						07/02/2014
					
	  			</td>

	  			<td>

					
					07/02/2021
					
					
	  			</td>

				<td>
					Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.  
				</td>
			
  			<td>
  				Novo Nordisk Inc.
  			</td>
  			<td>
  				800 Scudders Mill Rd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Plainsboro
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08536
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				186004
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sotalol (IV)
  			</td>
  			<td>
  				So-Aqueous
  			</td>
  			<td>
  				07/25/2008
  			</td>
  			<td>
  				For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation /flutter, and for treatment of documented life-threatening ventricular arrhythmias]
	  			</td>
				
	  			<td>
					
						07/02/2009
					
	  			</td>

	  			<td>

					
					07/02/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AltaThera Pharmaceuticals LLC
  			</td>
  			<td>
  				311 South Wacker Drive
  			</td>
  			<td>
  				Suite 2275A
  			</td>
  			<td>
  				Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60606
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				247707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Beractant
  			</td>
  			<td>
  				Survanta intratracheal suspension
  			</td>
  			<td>
  				02/05/1986
  			</td>
  			<td>
  				Treatment of neonatal respiratory distress syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency
	  			</td>
				
	  			<td>
					
						07/02/1991
					
	  			</td>

	  			<td>

					
					07/02/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ross Laboratories
  			</td>
  			<td>
  				625 Cleveland Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Columbus
  			</td>
  			<td>
  				Ohio
  			</td>
  			<td>
  				43215
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				010885
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				calfactant
  			</td>
  			<td>
  				Infasurf
  			</td>
  			<td>
  				06/07/1985
  			</td>
  			<td>
  				Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.
	  			</td>
				
	  			<td>
					
						07/01/1998
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ONY Biotech Inc.
  			</td>
  			<td>
  				1576 Sweet Home Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Amherst
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				14228
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				006285
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Beractant
  			</td>
  			<td>
  				Survanta intratracheal suspension
  			</td>
  			<td>
  				02/05/1986
  			</td>
  			<td>
  				Treatment of neonatal respiratory distress syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of ("rescue") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation
	  			</td>
				
	  			<td>
					
						07/01/1991
					
	  			</td>

	  			<td>

					
					07/01/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ross Laboratories
  			</td>
  			<td>
  				625 Cleveland Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Columbus
  			</td>
  			<td>
  				Ohio
  			</td>
  			<td>
  				43215
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				010885
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				asparaginase erwinia chrysanthemi (recombinant)-rywn
  			</td>
  			<td>
  				Rylaze
  			</td>
  			<td>
  				06/22/2021
  			</td>
  			<td>
  				Treatment of Acute lymphoblastic leukemia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
	  			</td>
				
	  			<td>
					
						06/30/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Jazz Pharmaceuticals Ireland Limited
  			</td>
  			<td>
  				Waterloo Exchange, Waterloo Road
  			</td>
  			<td>
  				Fifth floor
  			</td>
  			<td>
  				Dublin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D04 E5W7
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				773420
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				triheptanoin
  			</td>
  			<td>
  				Dojolvi
  			</td>
  			<td>
  				04/15/2015
  			</td>
  			<td>
  				Treatment of fatty acid oxidation disorders
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
	  			</td>
				
	  			<td>
					
						06/30/2020
					
	  			</td>

	  			<td>

					
					06/30/2027
					
					
	  			</td>

				<td>
					Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
				</td>
			
  			<td>
  				Ultragenyx Pharmaceutical, Inc.
  			</td>
  			<td>
  				60 Leveroni Court
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				474015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				Humira
  			</td>
  			<td>
  				05/13/2014
  			</td>
  			<td>
  				Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients
	  			</td>
				
	  			<td>
					
						06/30/2016
					
	  			</td>

	  			<td>

					
					06/30/2023
					
					
	  			</td>

				<td>
					Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				318510
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Aminosalicylic acid
  			</td>
  			<td>
  				Paser Granules
  			</td>
  			<td>
  				02/19/1992
  			</td>
  			<td>
  				Treatment of tuberculosis infections
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of tuberculosis
	  			</td>
				
	  			<td>
					
						06/30/1994
					
	  			</td>

	  			<td>

					
					06/30/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Jacobus Pharmaceutical Company
  			</td>
  			<td>
  				37 Cleveland Lane
  			</td>
  			<td>
  				P.O. Box 5290
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				065792
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pasireotide
  			</td>
  			<td>
  				Signifor
  			</td>
  			<td>
  				07/24/2009
  			</td>
  			<td>
  				Treatment of Cushing's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SIGNIFOR® LAR is indicated for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
	  			</td>
				
	  			<td>
					
						06/29/2018
					
	  			</td>

	  			<td>

					
					06/29/2025
					
					
	  			</td>

				<td>
					Indicated for treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Bldg 104, 3K28
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				288709
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				triptorelin pamoate
  			</td>
  			<td>
  				Triptodur
  			</td>
  			<td>
  				08/20/2012
  			</td>
  			<td>
  				Treatment of central precocious puberty
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients 2 years of age and older with central precocious puberty
	  			</td>
				
	  			<td>
					
						06/29/2017
					
	  			</td>

	  			<td>

					
					06/29/2024
					
					
	  			</td>

				<td>
					Treatment of pediatric patients 2 years of age and older with central precocious puberty
				</td>
			
  			<td>
  				Arbor Pharmaceuticals, LLC
  			</td>
  			<td>
  				6 Concourse Parkway
  			</td>
  			<td>
  				Suite 1800
  			</td>
  			<td>
  				Atlanta
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30328
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				376012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid 
  			</td>
  			<td>
  				09/20/2001
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy
	  			</td>
				
	  			<td>
					
						06/29/2006
					
	  			</td>

	  			<td>

					
					06/29/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				147701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tiopronin
  			</td>
  			<td>
  				Thiola
  			</td>
  			<td>
  				01/17/1986
  			</td>
  			<td>
  				Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.
	  			</td>
				
	  			<td>
					
						06/28/2019
					
	  			</td>

	  			<td>

					
					06/28/2026
					
					
	  			</td>

				<td>
					Indicated in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in pediatric patients between 20 kg and 9 years of age with severe homozygous cystinuria, who are not responsive to these measures alone
				</td>
			
  			<td>
  				Mission Pharmacal Company
  			</td>
  			<td>
  				P.O. Box 786099
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Antonio
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				78278
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				012386
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tiopronin
  			</td>
  			<td>
  				Thiola
  			</td>
  			<td>
  				01/17/1986
  			</td>
  			<td>
  				Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.
	  			</td>
				
	  			<td>
					
						06/28/2019
					
	  			</td>

	  			<td>

					
					06/28/2026
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mission Pharmacal Company
  			</td>
  			<td>
  				P.O. Box 786099
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Antonio
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				78278
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				012386
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Dasatinib
  			</td>
  			<td>
  				Sprycel
  			</td>
  			<td>
  				11/18/2005
  			</td>
  			<td>
  				Treatment of Philadelphia-positive acute lymphoblastic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy
	  			</td>
				
	  			<td>
					
						06/28/2006
					
	  			</td>

	  			<td>

					
					06/28/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O Box 5326
  			</td>
  			<td>
  				Mailstop C 4065
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08542
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				214605
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dasatinib
  			</td>
  			<td>
  				Sprycel
  			</td>
  			<td>
  				11/28/2005
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
	  			</td>
				
	  			<td>
					
						06/28/2006
					
	  			</td>

	  			<td>

					
					06/28/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				3401 Princeton Pike, B-3043C
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lawrence Township
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08648
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				212405
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Doxorubicin liposome
  			</td>
  			<td>
  				Doxil
  			</td>
  			<td>
  				11/04/1998
  			</td>
  			<td>
  				Treatment of ovarian cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens.  Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment.  
	  			</td>
				
	  			<td>
					
						06/28/1999
					
	  			</td>

	  			<td>

					
					06/28/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alza Corporation
  			</td>
  			<td>
  				1550 Plymouth St.
  			</td>
  			<td>
  				PO Box 7210
  			</td>
  			<td>
  				Mountain View
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94039
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				117398
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab
  			</td>
  			<td>
  				Darzalex
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
	  			</td>
				
	  			<td>
					
						06/27/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				PO Box 300
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eculizumab
  			</td>
  			<td>
  				Soliris
  			</td>
  			<td>
  				06/24/2013
  			</td>
  			<td>
  				Treatment of neuromyelitis optica
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
	  			</td>
				
	  			<td>
					
						06/27/2019
					
	  			</td>

	  			<td>

					
					06/27/2026
					
					
	  			</td>

				<td>
					For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				121 Seaport Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				398713
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				encorafenib + binimetinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				11/19/2013
  			</td>
  			<td>
  				Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				BRAFTOVI™ is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						06/27/2018
					
	  			</td>

	  			<td>

					
					06/27/2025
					
					
	  			</td>

				<td>
					BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Array BioPharma, Inc.
  			</td>
  			<td>
  				100 Cambridgepark Drive
  			</td>
  			<td>
  				Suite 505
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02140
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				411613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				encorafenib + binimetinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				11/19/2013
  			</td>
  			<td>
  				Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				MEKTOVI® is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						06/27/2018
					
	  			</td>

	  			<td>

					
					06/27/2025
					
					
	  			</td>

				<td>
					BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Array BioPharma, Inc.
  			</td>
  			<td>
  				100 Cambridgepark Drive
  			</td>
  			<td>
  				Suite 505
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02140
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				411613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tositumomab and iodine I 131 tositumomab
  			</td>
  			<td>
  				Bexxar
  			</td>
  			<td>
  				05/16/1994
  			</td>
  			<td>
  				Treatment of non-Hodgkin's B-cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy
	  			</td>
				
	  			<td>
					
						06/27/2003
					
	  			</td>

	  			<td>

					
					06/27/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				GlaxoSmithKline LLC
  			</td>
  			<td>
  				Corporation Service Company
  			</td>
  			<td>
  				2711 Centerville Road, Suite 400
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19808
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				079493
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation Factor IX (recombinant)
  			</td>
  			<td>
  				BeneFix
  			</td>
  			<td>
  				10/03/1994
  			</td>
  			<td>
  				Treatment of hemophilia B.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Routine prophylaxis to reduce the frequency of bleeding episodes in patients 16 years of age and older with hemophilia B (congenital factor IX deficiency or Christmas disease).
	  			</td>
				
	  			<td>
					
						06/26/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
  			</td>
  			<td>
  				35 E. 42nd St 219/9/1
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				082294
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				octreotide (oral)
  			</td>
  			<td>
  				MYCAPSSA (formerly Octreolin)
  			</td>
  			<td>
  				06/17/2010
  			</td>
  			<td>
  				For the oral treatment of acromegaly
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
	  			</td>
				
	  			<td>
					
						06/26/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amryt Pharmaceutical DAC
  			</td>
  			<td>
  				45 Mespil Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dublin 4
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D04 W2F1
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				309310
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mesalamine; 5-aminosalicylic acid
  			</td>
  			<td>
  				Lialda
  			</td>
  			<td>
  				02/27/2008
  			</td>
  			<td>
  				Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lialda (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.
	  			</td>
				
	  			<td>
					
						06/26/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				253607
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				avatrombopag maleate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				09/01/2011
  			</td>
  			<td>
  				Treatment of idiopathic thrombocytopenic purpura 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment
	  			</td>
				
	  			<td>
					
						06/26/2019
					
	  			</td>

	  			<td>

					
					06/26/2026
					
					
	  			</td>

				<td>
					For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment
				</td>
			
  			<td>
  				Sobi, Inc. 
  			</td>
  			<td>
  				240 Leigh Farm Road
  			</td>
  			<td>
  				Suite 245
  			</td>
  			<td>
  				Durham
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27707
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				325110
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				coagulation factor IX (recombinant)
  			</td>
  			<td>
  				RIXUBIS
  			</td>
  			<td>
  				10/31/2012
  			</td>
  			<td>
  				Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
	  			</td>
				
	  			<td>
					
						06/26/2013
					
	  			</td>

	  			<td>

					
					06/26/2020
					
					
	  			</td>

				<td>
					Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.  
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				300 Massachusetts Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				377412
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fenfluramine HCI
  			</td>
  			<td>
  				Fintepla
  			</td>
  			<td>
  				12/20/2013
  			</td>
  			<td>
  				For the Treatment of Dravet Syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Fintepla (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.
	  			</td>
				
	  			<td>
					
						06/25/2020
					
	  			</td>

	  			<td>

					
					06/25/2027
					
					
	  			</td>

				<td>
					For the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.
				</td>
			
  			<td>
  				Zogenix, Inc.
  			</td>
  			<td>
  				5959 Horton Street
  			</td>
  			<td>
  				Suite 500
  			</td>
  			<td>
  				Emeryville
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94608
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				414613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				baclofen
  			</td>
  			<td>
  				Lioresal Intrathecal
  			</td>
  			<td>
  				11/10/1987
  			</td>
  			<td>
  				Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.
	  			</td>
				
	  			<td>
					
						06/25/1992
					
	  			</td>

	  			<td>

					
					06/25/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Medtronic, Inc.
  			</td>
  			<td>
  				800 53rd Avenue N.E.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Minneapolis
  			</td>
  			<td>
  				Minnesota
  			</td>
  			<td>
  				55432
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				023987
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Amifostine
  			</td>
  			<td>
  				Ethyol
  			</td>
  			<td>
  				05/12/1998
  			</td>
  			<td>
  				Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. 
	  			</td>
				
	  			<td>
					
						06/24/1999
					
	  			</td>

	  			<td>

					
					06/24/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Medimmune Oncology, Inc.
  			</td>
  			<td>
  				One Tower Bridge
  			</td>
  			<td>
  				100 Front Street, Suite 400
  			</td>
  			<td>
  				West Conshohocken
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19428
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				111698
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cyclosporine
  			</td>
  			<td>
  				Verkazia
  			</td>
  			<td>
  				05/04/2007
  			</td>
  			<td>
  				Treatment of vernal keratoconjunctivitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of vernal keratoconjunctivitis (VKC) in children and adults
	  			</td>
				
	  			<td>
					
						06/23/2021
					
	  			</td>

	  			<td>

					
					06/23/2028
					
					
	  			</td>

				<td>
					Treatment of vernal keratoconjunctivitis (VKC) in children and adults
				</td>
			
  			<td>
  				Santen SAS
  			</td>
  			<td>
  				Batiment Genavenir IV
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				F-91058-Evry cedex
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				239907
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ganciclovir sodium
  			</td>
  			<td>
  				Cytovene
  			</td>
  			<td>
  				10/31/1985
  			</td>
  			<td>
  				Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.
  			</td>
  			<td>
  				Designated/Approved/Withdrawn
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						06/23/1989
					
	  			</td>

	  			<td>

					
					06/23/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Syntex (USA), Inc.
  			</td>
  			<td>
  				3401 Hillview Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94304
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				007985
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selinexor
  			</td>
  			<td>
  				Xpovio
  			</td>
  			<td>
  				05/14/2014
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
	  			</td>
				
	  			<td>
					
						06/22/2020
					
	  			</td>

	  			<td>

					
					06/22/2027
					
					
	  			</td>

				<td>
					For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy
				</td>
			
  			<td>
  				Karyopharm Therapeutics, Inc.
  			</td>
  			<td>
  				2 Mercer Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Natick
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				01760
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				436414
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab and recombinant human hyaluronidase
  			</td>
  			<td>
  				Rituxan SC
  			</td>
  			<td>
  				09/07/2016
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
	  			</td>
				
	  			<td>
					
						06/22/2017
					
	  			</td>

	  			<td>

					
					06/22/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				546516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dabrafenib and trametinib
  			</td>
  			<td>
  				Mekinist
  			</td>
  			<td>
  				10/29/2015
  			</td>
  			<td>
  				Treatment of patients with BRAF mutation positive non-small cell lung cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						06/22/2017
					
	  			</td>

	  			<td>

					
					06/22/2024
					
					
	  			</td>

				<td>
					Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test; AND Tafinlar in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				495915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab and recombinant human hyaluronidase
  			</td>
  			<td>
  				Rituxan SC
  			</td>
  			<td>
  				08/22/2016
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia (CLL)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide
	  			</td>
				
	  			<td>
					
						06/22/2017
					
	  			</td>

	  			<td>

					
					06/22/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				545616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				C1-esterase-inhibitor, human, pasteurized
  			</td>
  			<td>
  				HAEGARDA
  			</td>
  			<td>
  				10/16/1992
  			</td>
  			<td>
  				Prevention and/or treatment of acute attacks of hereditary angioedema.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.
	  			</td>
				
	  			<td>
					
						06/22/2017
					
	  			</td>

	  			<td>

					
					06/22/2024
					
					
	  			</td>

				<td>
					For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.
				</td>
			
  			<td>
  				CSL Behring LLC
  			</td>
  			<td>
  				1020 First Ave.
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				067592
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab and recombinant human hyaluronidase 
  			</td>
  			<td>
  				Rituxan SC
  			</td>
  			<td>
  				08/22/2016
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				 Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy; and non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
	  			</td>
				
	  			<td>
					
						06/22/2017
					
	  			</td>

	  			<td>

					
					06/22/2024
					
					
	  			</td>

				<td>
					 Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therap; and non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				529816
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				immune globulin infusion (human)
  			</td>
  			<td>
  				Gammagard Liquid
  			</td>
  			<td>
  				07/20/2006
  			</td>
  			<td>
  				Treatment of multifocal motor neuropathy 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).  
	  			</td>
				
	  			<td>
					
						06/22/2012
					
	  			</td>

	  			<td>

					
					06/22/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				One Baxter Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Westlake Village
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91362
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				224906
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Rifapentine
  			</td>
  			<td>
  				Priftin
  			</td>
  			<td>
  				06/09/1995
  			</td>
  			<td>
  				Treatment of pulmonary tuberculosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						06/22/1998
					
	  			</td>

	  			<td>

					
					06/22/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoechst Marion Roussel
  			</td>
  			<td>
  				P.O. Box 9627
  			</td>
  			<td>
  				Mail Station:  H3-M2516
  			</td>
  			<td>
  				Kansas City
  			</td>
  			<td>
  				Missouri
  			</td>
  			<td>
  				64134
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				089495
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tezacaftor and Ivacaftor combination therapy
  			</td>
  			<td>
  				SYMDEKO
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of cystic fibrosis (CF)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SYMDEKO® is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
	  			</td>
				
	  			<td>
					
						06/21/2019
					
	  			</td>

	  			<td>

					
					06/21/2026
					
					
	  			</td>

				<td>
					For the treatment of patients with cystic fibrosis (CF) age 6 years to less than 12 years who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				577517
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dehydrated alcohol 
  			</td>
  			<td>
  				Ablysinol
  			</td>
  			<td>
  				09/11/2013
  			</td>
  			<td>
  				Treatment of hypertrophic obstructive cardiomyopathy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.
	  			</td>
				
	  			<td>
					
						06/21/2018
					
	  			</td>

	  			<td>

					
					06/21/2025
					
					
	  			</td>

				<td>
					ABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.
				</td>
			
  			<td>
  				Belcher Pharmaceuticals, LLC
  			</td>
  			<td>
  				6911 Bryan Dairy Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Largo
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33777
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				402513
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				botulinum toxin type A
  			</td>
  			<td>
  				Botox
  			</td>
  			<td>
  				12/06/1991
  			</td>
  			<td>
  				Treatment of dynamic muscle contracture in pediatric cerebral palsy patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.
	  			</td>
				
	  			<td>
					
						06/20/2019
					
	  			</td>

	  			<td>

					
					06/20/2026
					
					
	  			</td>

				<td>
					For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age
				</td>
			
  			<td>
  				Allergan, Inc.
  			</td>
  			<td>
  				2525 Dupont Drive
  			</td>
  			<td>
  				T1-2A
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92623
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				056591
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				C1 esterase inhibitor (human); C1 esterase inhibitor (human)
  			</td>
  			<td>
  				Cinryze(r); Cinryze(r)
  			</td>
  			<td>
  				07/16/2004
  			</td>
  			<td>
  				Treatment of angioedema 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).
	  			</td>
				
	  			<td>
					
						06/20/2018
					
	  			</td>

	  			<td>

					
					06/20/2025
					
					
	  			</td>

				<td>
					CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				185804
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bortezomib
  			</td>
  			<td>
  				Velcade
  			</td>
  			<td>
  				01/15/2003
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				First-line therapy of multiple myeloma.
	  			</td>
				
	  			<td>
					
						06/20/2008
					
	  			</td>

	  			<td>

					
					06/20/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Millennium Pharmaceuticals, Inc.
  			</td>
  			<td>
  				40 Landsdowne Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				163002
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin [rDNA]
  			</td>
  			<td>
  				Genotropin
  			</td>
  			<td>
  				07/06/1999
  			</td>
  			<td>
  				Treatment of short stature in patients with Prader-Willi syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS).
	  			</td>
				
	  			<td>
					
						06/20/2000
					
	  			</td>

	  			<td>

					
					06/20/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia & Upjohn
  			</td>
  			<td>
  				7000 Portage Rd.
  			</td>
  			<td>
  				0633-298-113
  			</td>
  			<td>
  				Kalamazoo
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				49001
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				124799
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin (rDNA origin) injection
  			</td>
  			<td>
  				Norditropin
  			</td>
  			<td>
  				07/10/1987
  			</td>
  			<td>
  				1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term treatment of children who have growth failure due to inadequate secretion of endogenous growth hormone.
	  			</td>
				
	  			<td>
					
						06/20/2000
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk Pharmaceuticals
  			</td>
  			<td>
  				100 Overlook Center
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				013386
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Zalcitabine
  			</td>
  			<td>
  				Hivid
  			</td>
  			<td>
  				06/28/1988
  			</td>
  			<td>
  				Treatment of AIDS.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.
	  			</td>
				
	  			<td>
					
						06/19/1992
					
	  			</td>

	  			<td>

					
					06/19/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				028388
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				burosumab-twza
  			</td>
  			<td>
  				Crysvita
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of tumor-induced osteomalacia (TIO) syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
	  			</td>
				
	  			<td>
					
						06/18/2020
					
	  			</td>

	  			<td>

					
					06/18/2027
					
					
	  			</td>

				<td>
					For the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older
				</td>
			
  			<td>
  				Kyowa Kirin, Inc.
  			</td>
  			<td>
  				135 US Highway 202 206
  			</td>
  			<td>
  				Suite 6
  			</td>
  			<td>
  				Bedminster Township
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07921
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				576217
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tazemetostat
  			</td>
  			<td>
  				Tazverik
  			</td>
  			<td>
  				11/14/2017
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TAZVERIK (tazemetostat) is indicated for: the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies; and the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options.
	  			</td>
				
	  			<td>
					
						06/18/2020
					
	  			</td>

	  			<td>

					
					06/18/2027
					
					
	  			</td>

				<td>
					For the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for the treatment of adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options
				</td>
			
  			<td>
  				Epizyme, Inc.
  			</td>
  			<td>
  				400 Technology Square
  			</td>
  			<td>
  				4th Floor
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				607017
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bictegravir/emtricitabine/tenofovir alafenamide
  			</td>
  			<td>
  				BIKTARVY
  			</td>
  			<td>
  				05/17/2017
  			</td>
  			<td>
  				Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				BIKTARVY® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components o
	  			</td>
				
	  			<td>
					
						06/18/2019
					
	  			</td>

	  			<td>

					
					06/18/2026
					
					
	  			</td>

				<td>
					As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components of
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				559316
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				posaconazole
  			</td>
  			<td>
  				Noxafil
  			</td>
  			<td>
  				10/04/2016
  			</td>
  			<td>
  				Treatment of invasive aspergillosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older
	  			</td>
				
	  			<td>
					
						06/17/2021
					
	  			</td>

	  			<td>

					
					06/17/2028
					
					
	  			</td>

				<td>
					Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older
				</td>
			
  			<td>
  				Merck, Sharp & Dohme Corp.
  			</td>
  			<td>
  				1 Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				539016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Solriamfetol
  			</td>
  			<td>
  				Sunosi
  			</td>
  			<td>
  				08/20/2012
  			</td>
  			<td>
  				Treatment of narcolepsy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy
	  			</td>
				
	  			<td>
					
						06/17/2019
					
	  			</td>

	  			<td>

					
					06/17/2026
					
					
	  			</td>

				<td>
					To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy
				</td>
			
  			<td>
  				Axsome Malta, Ltd.
  			</td>
  			<td>
  				78 Mill Street, Zone 5, Central Business District
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Qormi
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				CBD 5090
  			</td>
  			<td>
  				Malta
  			</td>
			<td>
  				375112
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				10/03/2017
  			</td>
  			<td>
  				Treatment of Small Cell Lung Cancer 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn)
	  			</td>
				
	  			<td>
					
						06/17/2019
					
	  			</td>

	  			<td>

					
					03/30/2021
					
					
	  			</td>

				<td>
					Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn)
				</td>
			
  			<td>
  				Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.
  			</td>
  			<td>
  				1 Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				605417
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				canakinumab
  			</td>
  			<td>
  				Ilaris
  			</td>
  			<td>
  				12/18/2007
  			</td>
  			<td>
  				Treatment of cryopyrin-associated periodic syndromes
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.
	  			</td>
				
	  			<td>
					
						06/17/2009
					
	  			</td>

	  			<td>

					
					06/17/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				250507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				avapritinib
  			</td>
  			<td>
  				Ayvakit
  			</td>
  			<td>
  				01/21/2016
  			</td>
  			<td>
  				Treatment of mastocytosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

	  			</td>
				
	  			<td>
					
						06/16/2021
					
	  			</td>

	  			<td>

					
					06/16/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

				</td>
			
  			<td>
  				Blueprint Medicines Corporation
  			</td>
  			<td>
  				45 Sidney Street, Suite 200
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				506515
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				canakinumab
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				07/31/2017
  			</td>
  			<td>
  				Treatment of adult-onset Still's Disease 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ILARIS is indicated for the treatment of active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
	  			</td>
				
	  			<td>
					
						06/16/2020
					
	  			</td>

	  			<td>

					
					06/16/2027
					
					
	  			</td>

				<td>
					For the treatment of active adult-onset Still’s Disease (AOSD).
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				591317
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Gemtuzumab ozogamicin
  			</td>
  			<td>
  				Mylotarg
  			</td>
  			<td>
  				11/24/1999
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Mylotarg™ is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.
	  			</td>
				
	  			<td>
					
						06/16/2020
					
	  			</td>

	  			<td>

					
					06/16/2027
					
					
	  			</td>

				<td>
					For the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in pediatric patients 1 month and older
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals, Inc., a Pfizer Company
  			</td>
  			<td>
  				10646 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				127899
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab
  			</td>
  			<td>
  				Darzalex
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received 
	  			</td>
				
	  			<td>
					
						06/16/2017
					
	  			</td>

	  			<td>

					
					06/16/2024
					
					
	  			</td>

				<td>
					In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				PO Box 300
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				romidepsin
  			</td>
  			<td>
  				Istodax
  			</td>
  			<td>
  				09/30/2004
  			</td>
  			<td>
  				Treatment of non-Hodgkin T-cell lymphomas
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy
	  			</td>
				
	  			<td>
					
						06/16/2011
					
	  			</td>

	  			<td>

					
					06/16/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				One Broadway
  			</td>
  			<td>
  				14th Floor
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				193404
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat
  			</td>
  			<td>
  				StrataGraft
  			</td>
  			<td>
  				05/21/2012
  			</td>
  			<td>
  				Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns)
	  			</td>
				
	  			<td>
					
						06/15/2021
					
	  			</td>

	  			<td>

					
					06/15/2028
					
					
	  			</td>

				<td>
					Treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns)
				</td>
			
  			<td>
  				Stratatech Corporation, a Mallinckrodt company
  			</td>
  			<td>
  				505 S. Rosa Road
  			</td>
  			<td>
  				Suite 169
  			</td>
  			<td>
  				Madison
  			</td>
  			<td>
  				Wisconsin
  			</td>
  			<td>
  				53719
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				365312
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lurbinectedin 
  			</td>
  			<td>
  				Zepzelca
  			</td>
  			<td>
  				08/01/2018
  			</td>
  			<td>
  				Treatment of small cell lung cancer (SCLC)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.
	  			</td>
				
	  			<td>
					
						06/15/2020
					
	  			</td>

	  			<td>

					
					06/15/2027
					
					
	  			</td>

				<td>
					For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
				</td>
			
  			<td>
  				Jazz Pharmaceuticals Ireland Limited
  			</td>
  			<td>
  				5th Floor Waterloo Exchange
  			</td>
  			<td>
  				Waterloo Road
  			</td>
  			<td>
  				Dublin 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				646018
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				belatacept
  			</td>
  			<td>
  				Nulojix
  			</td>
  			<td>
  				02/20/2008
  			</td>
  			<td>
  				Prophylaxis of organ rejection in renal allograft recipients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of organ rejection in adult patients receiving kidney transplants
	  			</td>
				
	  			<td>
					
						06/15/2011
					
	  			</td>

	  			<td>

					
					06/15/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				253907
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ambrisentan
  			</td>
  			<td>
  				Letairis
  			</td>
  			<td>
  				07/16/2004
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening
	  			</td>
				
	  			<td>
					
						06/15/2007
					
	  			</td>

	  			<td>

					
					06/15/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Gilead Colorado
  			</td>
  			<td>
  				7575 West 103rd Avenue
  			</td>
  			<td>
  				Suite 102
  			</td>
  			<td>
  				Westminister
  			</td>
  			<td>
  				Colorado
  			</td>
  			<td>
  				80021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				183604
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Filgrastim
  			</td>
  			<td>
  				Neupogen
  			</td>
  			<td>
  				10/01/1990
  			</td>
  			<td>
  				Treatment of neutropenia associated with bone marrow transplants.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT.
	  			</td>
				
	  			<td>
					
						06/15/1994
					
	  			</td>

	  			<td>

					
					06/15/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				1840 Dehavilland Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				050090
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pentamidine isethionate
  			</td>
  			<td>
  				Nebupent
  			</td>
  			<td>
  				01/12/1988
  			</td>
  			<td>
  				Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						06/15/1989
					
	  			</td>

	  			<td>

					
					06/15/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fujisawa USA, Inc.
  			</td>
  			<td>
  				3 Parkway North Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				025887
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				11/23/2010
  			</td>
  			<td>
  				Treatment of fallopian tube carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei
	  			</td>
				
	  			<td>
					
						06/13/2018
					
	  			</td>

	  			<td>

					
					06/13/2025
					
					
	  			</td>

				<td>
					In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				318010
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				01/14/2016
  			</td>
  			<td>
  				Treatment of primary mediastinal B cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy
	  			</td>
				
	  			<td>
					
						06/13/2018
					
	  			</td>

	  			<td>

					
					06/13/2025
					
					
	  			</td>

				<td>
					KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy
				</td>
			
  			<td>
  				Merck, Sharp & Dohme Corp.
  			</td>
  			<td>
  				One Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				495415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				02/09/2006
  			</td>
  			<td>
  				Therapeutic treatment of patients with ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei
	  			</td>
				
	  			<td>
					
						06/13/2018
					
	  			</td>

	  			<td>

					
					06/13/2025
					
					
	  			</td>

				<td>
					In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				216405
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				moxidectin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				09/29/2010
  			</td>
  			<td>
  				Treatment of onchocerciasis volvulus in children and adults
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
	  			</td>
				
	  			<td>
					
						06/13/2018
					
	  			</td>

	  			<td>

					
					06/13/2025
					
					
	  			</td>

				<td>
					Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older
				</td>
			
  			<td>
  				Medicines Development Limited
  			</td>
  			<td>
  				Level 1, 18 Kevanagh Street
  			</td>
  			<td>
  				Southbank VIC  3006
  			</td>
  			<td>
  				Melbourne
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Australia
  			</td>
			<td>
  				316510
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				11/02/2010
  			</td>
  			<td>
  				Treatment of primary peritoneal carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei
	  			</td>
				
	  			<td>
					
						06/13/2018
					
	  			</td>

	  			<td>

					
					06/13/2025
					
					
	  			</td>

				<td>
					In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				317810
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				technetium Tc 99m tilmanocept 
  			</td>
  			<td>
  				LYMPHOSEEK
  			</td>
  			<td>
  				09/17/2014
  			</td>
  			<td>
  				Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
	  			</td>
				
	  			<td>
					
						06/13/2014
					
	  			</td>

	  			<td>

					
					06/13/2021
					
					
	  			</td>

				<td>
					Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
				</td>
			
  			<td>
  				Cardinal Health 414, LLC
  			</td>
  			<td>
  				7200 Cardinal Pl
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dublin
  			</td>
  			<td>
  				Ohio
  			</td>
  			<td>
  				43017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				427814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				denosumab
  			</td>
  			<td>
  				Xgeva
  			</td>
  			<td>
  				12/20/2010
  			</td>
  			<td>
  				Treatment of patients with giant cell tumor of bone
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.  
	  			</td>
				
	  			<td>
					
						06/13/2013
					
	  			</td>

	  			<td>

					
					06/13/2020
					
					
	  			</td>

				<td>
					Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.  
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				324110
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				difluprednate
  			</td>
  			<td>
  				Durezol
  			</td>
  			<td>
  				09/30/2008
  			</td>
  			<td>
  				Treatment of endogenous and traumatic anterior uveitis and panuveitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of endogenous anterior uveitis
	  			</td>
				
	  			<td>
					
						06/13/2012
					
	  			</td>

	  			<td>

					
					06/13/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alcon Pharmaceuticals. Ltd.
  			</td>
  			<td>
  				Route Des Arsenaux 41
  			</td>
  			<td>
  				 (P.O. Box 61)
  			</td>
  			<td>
  				Fribourg
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				265608
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				inebilizumab
  			</td>
  			<td>
  				Uplizna
  			</td>
  			<td>
  				02/10/2016
  			</td>
  			<td>
  				Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
	  			</td>
				
	  			<td>
					
						06/11/2020
					
	  			</td>

	  			<td>

					
					06/11/2027
					
					
	  			</td>

				<td>
					Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
				</td>
			
  			<td>
  				Horizon Therapeutics Ireland DAC
  			</td>
  			<td>
  				70St. Stephen’s Green
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dublin 2
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				D02 E2X4
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				490415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Albendazole
  			</td>
  			<td>
  				Albenza
  			</td>
  			<td>
  				01/18/1996
  			</td>
  			<td>
  				Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocys
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.
	  			</td>
				
	  			<td>
					
						06/11/1996
					
	  			</td>

	  			<td>

					
					06/11/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Impax Laboratories, LLC
  			</td>
  			<td>
  				400 Crossing Boulevard
  			</td>
  			<td>
  				Third Floor
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				094295
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Albendazole
  			</td>
  			<td>
  				Albenza
  			</td>
  			<td>
  				01/17/1996
  			</td>
  			<td>
  				Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
	  			</td>
				
	  			<td>
					
						06/11/1996
					
	  			</td>

	  			<td>

					
					06/11/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Impax Laboratories, LLC
  			</td>
  			<td>
  				400 Crossing Boulevard
  			</td>
  			<td>
  				Third Floor
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				094195
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sofosbuvir and velpatasvir
  			</td>
  			<td>
  				Epclusa
  			</td>
  			<td>
  				02/22/2017
  			</td>
  			<td>
  				Treatment of pediatric patients with chronic hepatitis C virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin
	  			</td>
				
	  			<td>
					
						06/10/2021
					
	  			</td>

	  			<td>

					
					06/10/2028
					
					
	  			</td>

				<td>
					treatment of pediatric patients 3 years of age to less than 6 years of age weighing less than 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for use in combination with ribavirin
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				554816
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				glecaprevir and pibrentasvir
  			</td>
  			<td>
  				Mavyret
  			</td>
  			<td>
  				01/09/2017
  			</td>
  			<td>
  				Treatment of pediatric patients with chronic hepatitis C virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both
	  			</td>
				
	  			<td>
					
						06/10/2021
					
	  			</td>

	  			<td>

					
					06/10/2028
					
					
	  			</td>

				<td>
					treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but n
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60044
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				550516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				OPDIVO
  			</td>
  			<td>
  				08/22/2016
  			</td>
  			<td>
  				Treatment of esophageal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
	  			</td>
				
	  			<td>
					
						06/10/2020
					
	  			</td>

	  			<td>

					
					06/10/2027
					
					
	  			</td>

				<td>
					For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				531016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				polatuzumab vedotin-piiq
  			</td>
  			<td>
  				POLIVY
  			</td>
  			<td>
  				12/12/2016
  			</td>
  			<td>
  				Treatment of diffuse  large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
	  			</td>
				
	  			<td>
					
						06/10/2019
					
	  			</td>

	  			<td>

					
					06/10/2026
					
					
	  			</td>

				<td>
					In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS# 451A
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				547416
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Glutamine
  			</td>
  			<td>
  				NutreStore
  			</td>
  			<td>
  				03/06/1995
  			</td>
  			<td>
  				For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication.
	  			</td>
				
	  			<td>
					
						06/10/2004
					
	  			</td>

	  			<td>

					
					06/10/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Emmaus Medical, Inc.
  			</td>
  			<td>
  				20725 S. Western Avenue
  			</td>
  			<td>
  				Suite 136
  			</td>
  			<td>
  				Torrence
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90501
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				085794
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				elexacaftor, tezacaftor, and ivacaftor; ivacaftor
  			</td>
  			<td>
  				Trikafta
  			</td>
  			<td>
  				08/29/2018
  			</td>
  			<td>
  				Treatment of cystic fibrosis 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data
	  			</td>
				
	  			<td>
					
						06/08/2021
					
	  			</td>

	  			<td>

					
					06/08/2028
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis (CF) in patients aged 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				647618
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				venetoclax
  			</td>
  			<td>
  				VENCLEXTA
  			</td>
  			<td>
  				09/20/2012
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				VENCLEXTA® (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
	  			</td>
				
	  			<td>
					
						06/08/2018
					
	  			</td>

	  			<td>

					
					06/08/2025
					
					
	  			</td>

				<td>
					For treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), without 17p deletion, who have received at least one prior therapy.
				</td>
			
  			<td>
  				AbbVie, Inc
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				Dept. PA72, Bldg. AP30
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				375612
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ravulizumab-cwvz
  			</td>
  			<td>
  				Ultomiris
  			</td>
  			<td>
  				01/04/2017
  			</td>
  			<td>
  				Treatment of paroxysmal nocturnal hemoglobinuria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) 
	  			</td>
				
	  			<td>
					
						06/07/2021
					
	  			</td>

	  			<td>

					
					06/07/2028
					
					
	  			</td>

				<td>
					Treatment of pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) 
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 College Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New Haven
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06510
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				513015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deflazacort
  			</td>
  			<td>
  				Emflaza
  			</td>
  			<td>
  				08/16/2013
  			</td>
  			<td>
  				Treatment of Duchenne muscular dystrophy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
	  			</td>
				
	  			<td>
					
						06/07/2019
					
	  			</td>

	  			<td>

					
					06/07/2026
					
					
	  			</td>

				<td>
					For the treatment of Duchene muscular dystrophy in patients 2 years of age to less than 5 years of age
				</td>
			
  			<td>
  				PTC Therapeutics, Inc.
  			</td>
  			<td>
  				100 Corporate Court
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South Plainfield
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				403413
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab
  			</td>
  			<td>
  				Rituxan(r); MabThera(r)
  			</td>
  			<td>
  				02/23/2015
  			</td>
  			<td>
  				Treatment of pemphigus vulgaris.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris. 
	  			</td>
				
	  			<td>
					
						06/07/2018
					
	  			</td>

	  			<td>

					
					06/07/2025
					
					
	  			</td>

				<td>
					RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris. 
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				465014
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ritonavir powder for oral suspension
  			</td>
  			<td>
  				Norvir Powder for Oral Suspension
  			</td>
  			<td>
  				01/11/2017
  			</td>
  			<td>
  				Use with other antiretroviral agents for the treatment of pediatric HIV-1 infection
  			</td>
  			<td>
  				Designated/Approved/Withdrawn
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Used in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection
	  			</td>
				
	  			<td>
					
						06/07/2017
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AbbVie Inc.
  			</td>
  			<td>
  				Regulatory Affairs
  			</td>
  			<td>
  				1 Waukegan Road
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60044
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				549816
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mepolizumab
  			</td>
  			<td>
  				NUCALA
  			</td>
  			<td>
  				07/14/2011
  			</td>
  			<td>
  				Treatment of Churg-Strauss Syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
	  			</td>
				
	  			<td>
					
						06/06/2019
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				GlaxoSmithKline LLC
  			</td>
  			<td>
  				Corporation Service Company
  			</td>
  			<td>
  				1250 S. Collegeville Rd.
  			</td>
  			<td>
  				Collegeville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19426
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				345111
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				5-aminolevulinic acid
  			</td>
  			<td>
  				Gleolan
  			</td>
  			<td>
  				01/15/2013
  			</td>
  			<td>
  				Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery
	  			</td>
				
	  			<td>
					
						06/06/2017
					
	  			</td>

	  			<td>

					
					06/06/2024
					
					
	  			</td>

				<td>
					Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery
				</td>
			
  			<td>
  				NX Development Corporation
  			</td>
  			<td>
  				1827 South Bayshore Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Miami
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33133
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				387312
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				antihemophilic factor (recombinant), Fc fusion protein 
  			</td>
  			<td>
  				Eloctate
  			</td>
  			<td>
  				11/23/2010
  			</td>
  			<td>
  				Treatment of hemophilia A
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.              
	  			</td>
				
	  			<td>
					
						06/06/2014
					
	  			</td>

	  			<td>

					
					06/06/2021
					
					
	  			</td>

				<td>
					Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. 
				</td>
			
  			<td>
  				Bioverativ Therapeutics, Inc.
  			</td>
  			<td>
  				225 2nd Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				321610
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				gabapentin enacarbil
  			</td>
  			<td>
  				Horizant
  			</td>
  			<td>
  				06/07/2011
  			</td>
  			<td>
  				Treatment of postherpetic neuralgia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of postherpetic neuralgia in adults.
	  			</td>
				
	  			<td>
					
						06/06/2012
					
	  			</td>

	  			<td>

					
					06/06/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Arbor Pharmaceuticals, LLC
  			</td>
  			<td>
  				6 Concourse Parkway
  			</td>
  			<td>
  				Suite 1800
  			</td>
  			<td>
  				Atlanta
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30328
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				330710
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid
  			</td>
  			<td>
  				04/27/2009
  			</td>
  			<td>
  				Treatment of mantle cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
	  			</td>
				
	  			<td>
					
						06/05/2013
					
	  			</td>

	  			<td>

					
					06/05/2020
					
					
	  			</td>

				<td>
					Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				278809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Mafenide acetate solution
  			</td>
  			<td>
  				Sulfamylon solution
  			</td>
  			<td>
  				07/18/1990
  			</td>
  			<td>
  				For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						06/05/1998
					
	  			</td>

	  			<td>

					
					06/05/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mylan Laboratories, Inc.
  			</td>
  			<td>
  				781 Chestnut Ridge Road
  			</td>
  			<td>
  				P.O. Box 4310
  			</td>
  			<td>
  				Morgantown
  			</td>
  			<td>
  				West Virginia
  			</td>
  			<td>
  				26504
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				047890
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Selegiline HCl
  			</td>
  			<td>
  				Eldepryl
  			</td>
  			<td>
  				11/07/1984
  			</td>
  			<td>
  				As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						06/05/1989
					
	  			</td>

	  			<td>

					
					06/05/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Somerset Pharmaceuticals, Inc.
  			</td>
  			<td>
  				400 Morris Ave., Suite 7s
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Denville
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07834
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				000583
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brincidofovir
  			</td>
  			<td>
  				Tembexa
  			</td>
  			<td>
  				06/05/2018
  			</td>
  			<td>
  				Treatment of smallpox 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates
	  			</td>
				
	  			<td>
					
						06/04/2021
					
	  			</td>

	  			<td>

					
					06/04/2028
					
					
	  			</td>

				<td>
					Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates
				</td>
			
  			<td>
  				Chimerix, Inc.
  			</td>
  			<td>
  				2505 Meridian Parkway
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Durham
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27713
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				640518
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				plasminogen, human-tvmh
  			</td>
  			<td>
  				Ryplazim
  			</td>
  			<td>
  				03/05/2013
  			</td>
  			<td>
  				Treatment of hypoplasminogenemia, or type I plasminogen deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).
	  			</td>
				
	  			<td>
					
						06/04/2021
					
	  			</td>

	  			<td>

					
					06/04/2028
					
					
	  			</td>

				<td>
					Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia)
				</td>
			
  			<td>
  				ProMetic BioTherapeutics, Inc.
  			</td>
  			<td>
  				1330 Piccard Drive
  			</td>
  			<td>
  				Suite 201
  			</td>
  			<td>
  				Rockville
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20850
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				389112
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ganaxolone
  			</td>
  			<td>
  				Ztalmy
  			</td>
  			<td>
  				06/28/2017
  			</td>
  			<td>
  				Treatment of cyclin-dependent kinase-like 5 (CDKL5) gene-related early-onset infantile epileptic encephalopathy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						06/01/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Marinus Pharmaceuticals
  			</td>
  			<td>
  				170 North Radnor Chester Road
  			</td>
  			<td>
  				Suite 250
  			</td>
  			<td>
  				Radnor
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19087
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				578017
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide
  			</td>
  			<td>
  				NETSPOT 
  			</td>
  			<td>
  				12/31/2013
  			</td>
  			<td>
  				Diagnostic for the clinical management of neuroendocrine tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
	  			</td>
				
	  			<td>
					
						06/01/2016
					
	  			</td>

	  			<td>

					
					06/01/2023
					
					
	  			</td>

				<td>
					A radioactive diagnostic agent indicated for use with with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
				</td>
			
  			<td>
  				Advanced Accelerator Applications, USA
  			</td>
  			<td>
  				57 East Willow Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Millburn
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07041
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				413613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Epoetin alfa
  			</td>
  			<td>
  				Epogen
  			</td>
  			<td>
  				04/10/1986
  			</td>
  			<td>
  				Treatment of anemia associated with end stage renal disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients  not on dialysis
	  			</td>
				
	  			<td>
					
						06/01/1989
					
	  			</td>

	  			<td>

					
					06/01/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				1840 Dehavilland Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				012486
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin
  			</td>
  			<td>
  				Norditropin
  			</td>
  			<td>
  				08/09/2006
  			</td>
  			<td>
  				Treatment of short stature in patients with Noonan syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of short stature in patients with Noonan syndrome
	  			</td>
				
	  			<td>
					
						05/31/2007
					
	  			</td>

	  			<td>

					
					05/31/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk Inc.
  			</td>
  			<td>
  				100 College Road West
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				226606
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				N-acetylgalactosamine-4-sulfatase, recombinant human
  			</td>
  			<td>
  				Naglazyme
  			</td>
  			<td>
  				02/17/1999
  			</td>
  			<td>
  				Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For patients with mucopolysaccharidosis VI.  Galsulfase has been shown to improve walking and stair-climbing capacity.
	  			</td>
				
	  			<td>
					
						05/31/2005
					
	  			</td>

	  			<td>

					
					05/31/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				BioMarin Pharmaceutical, Inc.
  			</td>
  			<td>
  				105 Digital Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				119898
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Rifampin, isoniazid, pyrazinamide
  			</td>
  			<td>
  				Rifater
  			</td>
  			<td>
  				09/12/1985
  			</td>
  			<td>
  				For the short-course treatment of tuberculosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Short-course treatment of tuberculosis.
	  			</td>
				
	  			<td>
					
						05/31/1994
					
	  			</td>

	  			<td>

					
					05/31/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoechst Marion Roussel
  			</td>
  			<td>
  				P.O. Box 9627
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kansas City
  			</td>
  			<td>
  				Missouri
  			</td>
  			<td>
  				64134
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				006585
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Temsirolimus
  			</td>
  			<td>
  				Torisel
  			</td>
  			<td>
  				12/16/2004
  			</td>
  			<td>
  				Treatment of renal cell carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of advanced renal cell carcinoma
	  			</td>
				
	  			<td>
					
						05/30/2007
					
	  			</td>

	  			<td>

					
					05/30/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals, Inc.
  			</td>
  			<td>
  				P. O. Box 8299
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Phildelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				196404
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				atezolizumab + bevacizumab
  			</td>
  			<td>
  				Tecentriq and Avastin
  			</td>
  			<td>
  				01/08/2018
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma (HCC)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				AVASTIN, in combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
	  			</td>
				
	  			<td>
					
						05/29/2020
					
	  			</td>

	  			<td>

					
					05/29/2027
					
					
	  			</td>

				<td>
					AVASTIN for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS 451A
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				619317
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				atezolizumab + bevacizumab
  			</td>
  			<td>
  				Tecentriq and Avastin
  			</td>
  			<td>
  				01/08/2018
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma (HCC)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TECENTRIQ, in combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
	  			</td>
				
	  			<td>
					
						05/29/2020
					
	  			</td>

	  			<td>

					
					05/29/2027
					
					
	  			</td>

				<td>
					TECENTRIQ for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				MS 451A
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				619317
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dabrafenib
  			</td>
  			<td>
  				TAFINLAR
  			</td>
  			<td>
  				01/12/2011
  			</td>
  			<td>
  				Treatment BRAF V600 mutation positive Stage IIB through IV melanoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.  
	  			</td>
				
	  			<td>
					
						05/29/2013
					
	  			</td>

	  			<td>

					
					05/29/2020
					
					
	  			</td>

				<td>
					Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.  
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				329610
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trametinib
  			</td>
  			<td>
  				MEKINIST
  			</td>
  			<td>
  				12/20/2010
  			</td>
  			<td>
  				Treatment of Stage IIb through Stage IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.  
	  			</td>
				
	  			<td>
					
						05/29/2013
					
	  			</td>

	  			<td>

					
					05/29/2020
					
					
	  			</td>

				<td>
					Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.  
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				325410
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Toremifene
  			</td>
  			<td>
  				Fareston
  			</td>
  			<td>
  				09/19/1991
  			</td>
  			<td>
  				Hormonal therapy of metastatic carcinoma of the breast.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.
	  			</td>
				
	  			<td>
					
						05/29/1997
					
	  			</td>

	  			<td>

					
					05/29/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Orion Corporation
  			</td>
  			<td>
  				Orionintie 1
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Espoo
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Finland
  			</td>
			<td>
  				060291
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sotorasib
  			</td>
  			<td>
  				Lumakras
  			</td>
  			<td>
  				05/01/2019
  			</td>
  			<td>
  				Treatment of KRAS p.G12C-positive non-small cell lung cancer 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
	  			</td>
				
	  			<td>
					
						05/28/2021
					
	  			</td>

	  			<td>

					
					05/28/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
				</td>
			
  			<td>
  				Amgen Inc.
  			</td>
  			<td>
  				1 Amgen Center Drive
  			</td>
  			<td>
  				Mail Stop 27-3-A
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				653818
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				infigratinib
  			</td>
  			<td>
  				Truseltiq
  			</td>
  			<td>
  				09/11/2019
  			</td>
  			<td>
  				Treatment of cholangiocarcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						05/28/2021
					
	  			</td>

	  			<td>

					
					05/28/2028
					
					
	  			</td>

				<td>
					Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
				</td>
			
  			<td>
  				QED Therapeutics, Inc.
  			</td>
  			<td>
  				8000 Marina Boulevard
  			</td>
  			<td>
  				Suite 400
  			</td>
  			<td>
  				Brisbane
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94005
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				707019
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid
  			</td>
  			<td>
  				04/29/2015
  			</td>
  			<td>
  				Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
	  			</td>
				
	  			<td>
					
						05/28/2019
					
	  			</td>

	  			<td>

					
					05/28/2026
					
					
	  			</td>

				<td>
					In combination with a rituximab product for the treatment of adult patients with previously treated extranodal marginal zone lymphoma
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				476115
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid
  			</td>
  			<td>
  				01/04/2017
  			</td>
  			<td>
  				Treatment of nodal marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
	  			</td>
				
	  			<td>
					
						05/28/2019
					
	  			</td>

	  			<td>

					
					05/28/2026
					
					
	  			</td>

				<td>
					In combination with a rituximab product for the treatment of adult patients with previously treated nodal marginal zone lymphoma
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				476015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid
  			</td>
  			<td>
  				09/17/2013
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).
	  			</td>
				
	  			<td>
					
						05/28/2019
					
	  			</td>

	  			<td>

					
					05/28/2026
					
					
	  			</td>

				<td>
					In combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma (FL).
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				390813
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid
  			</td>
  			<td>
  				01/04/2017
  			</td>
  			<td>
  				Treatment of splenic marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
	  			</td>
				
	  			<td>
					
						05/28/2019
					
	  			</td>

	  			<td>

					
					05/28/2026
					
					
	  			</td>

				<td>
					In combination with a rituximab product for the treatment of adult patients with previously treated splenic marginal zone lymphoma
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				475915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sirolimus
  			</td>
  			<td>
  				Rapamune
  			</td>
  			<td>
  				10/31/2012
  			</td>
  			<td>
  				Treatment of lymphangioleiomyomatosis 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment  of lymphangioleiomyomatosis (LAM)
	  			</td>
				
	  			<td>
					
						05/28/2015
					
	  			</td>

	  			<td>

					
					05/28/2022
					
					
	  			</td>

				<td>
					Treatment  of lymphangioleiomyomatosis (LAM)
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				500 Arcola Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Collegeville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19426
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				379312
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				08/22/2016
  			</td>
  			<td>
  				Treatment of esophageal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)
	  			</td>
				
	  			<td>
					
						05/27/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				531016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				08/22/2016
  			</td>
  			<td>
  				Treatment of esophageal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma
	  			</td>
				
	  			<td>
					
						05/27/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				531016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tisagenlecleucel
  			</td>
  			<td>
  				Kymriah
  			</td>
  			<td>
  				09/16/2020
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy
	  			</td>
				
	  			<td>
					
						05/27/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				765120
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				risdiplam
  			</td>
  			<td>
  				Evrysdi
  			</td>
  			<td>
  				01/04/2017
  			</td>
  			<td>
  				Treatment of spinal muscular atrophy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of spinal muscular atrophy (SMA) in pediatric and adult patients
	  			</td>
				
	  			<td>
					
						05/27/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				c/o Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				548116
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bedaquiline
  			</td>
  			<td>
  				SIRTURO
  			</td>
  			<td>
  				01/10/2005
  			</td>
  			<td>
  				Treatment of active tuberculosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.
	  			</td>
				
	  			<td>
					
						05/27/2020
					
	  			</td>

	  			<td>

					
					05/27/2027
					
					
	  			</td>

				<td>
					As part of combination therapy in the treatment of pediatric patients 5 years and older to less than 12 years of age and weighing at least 15 kg with pulmonary multi-drug resistant tuberculosis (MDR-TB)
				</td>
			
  			<td>
  				Janssen Research & Development, LLC
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				199304
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				obeticholic acid
  			</td>
  			<td>
  				OCALIVA
  			</td>
  			<td>
  				04/09/2008
  			</td>
  			<td>
  				Treatment of primary biliary cirrhosis  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA
	  			</td>
				
	  			<td>
					
						05/27/2016
					
	  			</td>

	  			<td>

					
					05/27/2023
					
					
	  			</td>

				<td>
					Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA
				</td>
			
  			<td>
  				Intercept Pharmaceuticals, Inc.
  			</td>
  			<td>
  				4760 Eastgate Mall 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92122
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				253207
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rosuvastatin 
  			</td>
  			<td>
  				Crestor
  			</td>
  			<td>
  				02/14/2014
  			</td>
  			<td>
  				For the treatment of pediatric homozygous familial hypercholesterolemia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).
	  			</td>
				
	  			<td>
					
						05/27/2016
					
	  			</td>

	  			<td>

					
					05/27/2023
					
					
	  			</td>

				<td>
					An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).
				</td>
			
  			<td>
  				iPR Pharmaceuticals, Inc.
  			</td>
  			<td>
  				1 MedImmune Way 
  			</td>
  			<td>
  				 
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20878
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				420513
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				etanercept
  			</td>
  			<td>
  				Enbrel
  			</td>
  			<td>
  				10/27/1998
  			</td>
  			<td>
  				Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older
	  			</td>
				
	  			<td>
					
						05/27/1999
					
	  			</td>

	  			<td>

					
					05/27/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Immunex Corporation
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				116198
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				artesunate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				03/28/2006
  			</td>
  			<td>
  				Immediate treatment of malaria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.     
	  			</td>
				
	  			<td>
					
						05/26/2020
					
	  			</td>

	  			<td>

					
					05/26/2027
					
					
	  			</td>

				<td>
					For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.
				</td>
			
  			<td>
  				Amivas Inc.
  			</td>
  			<td>
  				100 Tuscanney Drive, Suite B2
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Frederick
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				21702
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				221206
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ceritinib
  			</td>
  			<td>
  				ZYKADIA
  			</td>
  			<td>
  				09/27/2013
  			</td>
  			<td>
  				Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						05/26/2017
					
	  			</td>

	  			<td>

					
					05/26/2024
					
					
	  			</td>

				<td>
					Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				405213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Dexrazoxane
  			</td>
  			<td>
  				Zinecard
  			</td>
  			<td>
  				12/17/1991
  			</td>
  			<td>
  				For the prevention of cardiomyopathy associated with doxorubicin administration.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.
	  			</td>
				
	  			<td>
					
						05/26/1995
					
	  			</td>

	  			<td>

					
					05/26/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pharmacia & Upjohn
  			</td>
  			<td>
  				7000 Portage Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kalamazoo
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				49001
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				063291
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivosidenib
  			</td>
  			<td>
  				Tibsovo
  			</td>
  			<td>
  				06/09/2015
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia (AML)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
	  			</td>
				
	  			<td>
					
						05/25/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Servier Pharmaceuticals LLC
  			</td>
  			<td>
  				200 Pier Four Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				481515
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ipilimumab
  			</td>
  			<td>
  				Yervoy
  			</td>
  			<td>
  				06/03/2004
  			</td>
  			<td>
  				Treatment of high risk Stage II, Stage III, and Stage IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult patients
	  			</td>
				
	  			<td>
					
						05/25/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177703
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Thalidomide
  			</td>
  			<td>
  				thalomid
  			</td>
  			<td>
  				10/14/1998
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with newly diagnosed multiple myeloma
	  			</td>
				
	  			<td>
					
						05/25/2006
					
	  			</td>

	  			<td>

					
					05/25/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				P.O. Box 4914
  			</td>
  			<td>
  				7 Powder Horn Srive
  			</td>
  			<td>
  				Warren
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07059
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				115598
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Rifampin
  			</td>
  			<td>
  				Rifadin I.V.
  			</td>
  			<td>
  				12/09/1985
  			</td>
  			<td>
  				For antituberculosis treatment where use of the oral form of the drug is not feasible.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						05/25/1989
					
	  			</td>

	  			<td>

					
					05/25/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoechst Marion Roussel
  			</td>
  			<td>
  				P.O. Box 9627
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kansas City
  			</td>
  			<td>
  				Missouri
  			</td>
  			<td>
  				64134
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				007685
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ruxolitinib
  			</td>
  			<td>
  				JAKAFI
  			</td>
  			<td>
  				11/03/2016
  			</td>
  			<td>
  				Treatment of graft versus host disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.
	  			</td>
				
	  			<td>
					
						05/24/2019
					
	  			</td>

	  			<td>

					
					05/24/2026
					
					
	  			</td>

				<td>
					Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.
				</td>
			
  			<td>
  				Incyte Corporation
  			</td>
  			<td>
  				1801 Augustine Cut-Off
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				542716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				onasemnogene abeparvovec
  			</td>
  			<td>
  				ZOLGENSMA
  			</td>
  			<td>
  				09/30/2014
  			</td>
  			<td>
  				Treatment of spinal muscular atrophy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
	  			</td>
				
	  			<td>
					
						05/24/2019
					
	  			</td>

	  			<td>

					
					05/24/2026
					
					
	  			</td>

				<td>
					Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
				</td>
			
  			<td>
  				AveXis, Inc.
  			</td>
  			<td>
  				2275 Half Day Road
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Bannockburn
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				444714
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tacrolimus
  			</td>
  			<td>
  				Prograf
  			</td>
  			<td>
  				10/04/2016
  			</td>
  			<td>
  				Prevention of rejection in kidney, liver or heart transplant in pediatric patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.
	  			</td>
				
	  			<td>
					
						05/24/2018
					
	  			</td>

	  			<td>

					
					05/24/2025
					
					
	  			</td>

				<td>
					For the prophylaxis of organ rejection in pediatric patients receiving allogeneic kidney transplant and heart transplant, in combination with other immunosuppressants.
				</td>
			
  			<td>
  				Astellas Pharma Global Development, Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				534516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tacrolimus
  			</td>
  			<td>
  				Prograf
  			</td>
  			<td>
  				10/04/2016
  			</td>
  			<td>
  				Prevention of rejection in kidney, liver or heart transplant in pediatric patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.
	  			</td>
				
	  			<td>
					
						05/24/2018
					
	  			</td>

	  			<td>

					
					05/24/2025
					
					
	  			</td>

				<td>
					For the prophylaxis of organ rejection in pediatric patients receiving allogeneic kidney transplant and heart transplant, in combination with other immunosuppressants.
				</td>
			
  			<td>
  				Astellas Pharma Global Development, Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				534516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tacrolimus
  			</td>
  			<td>
  				Prograf
  			</td>
  			<td>
  				10/04/2016
  			</td>
  			<td>
  				Prevention of rejection in kidney, liver or heart transplant in pediatric patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.
	  			</td>
				
	  			<td>
					
						05/24/2018
					
	  			</td>

	  			<td>

					
					05/24/2025
					
					
	  			</td>

				<td>
					For the prophylaxis of organ rejection in pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants.
				</td>
			
  			<td>
  				Astellas Pharma Global Development, Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				534516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pegvaliase-pqpz
  			</td>
  			<td>
  				PALYNZIQ
  			</td>
  			<td>
  				03/08/1995
  			</td>
  			<td>
  				Treatment of hyperphenylalaninemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management
	  			</td>
				
	  			<td>
					
						05/24/2018
					
	  			</td>

	  			<td>

					
					05/24/2025
					
					
	  			</td>

				<td>
					Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management
				</td>
			
  			<td>
  				BioMarin Pharmaceutical Inc.
  			</td>
  			<td>
  				105 Digital Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				088195
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Recombinant human acid alpha-glucosidase; alglucosidase alfa
  			</td>
  			<td>
  				1. Myozyme 2. Lumizyme
  			</td>
  			<td>
  				08/19/1997
  			</td>
  			<td>
  				Treatment of glycogen storage disease type II.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of Lumizyme (alglucosidase alfa) have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age
	  			</td>
				
	  			<td>
					
						05/24/2010
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				500 Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				106597
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Follitropin alfa, recombinant
  			</td>
  			<td>
  				Gonal-F
  			</td>
  			<td>
  				12/21/1998
  			</td>
  			<td>
  				For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.  AMENDED indication 6/27/00:  For the induction of spermatogenesis in men with pr
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.
	  			</td>
				
	  			<td>
					
						05/24/2000
					
	  			</td>

	  			<td>

					
					05/24/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				EMD Serono, Inc.
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				119398
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				treprostinil
  			</td>
  			<td>
  				Tyvaso DPI
  			</td>
  			<td>
  				06/17/2010
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability
	  			</td>
				
	  			<td>
					
						05/23/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				United Therapeutics Corporation
  			</td>
  			<td>
  				PO Box 14186
  			</td>
  			<td>
  				55 TW Alexander Drive
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				189104
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Corticorelin ovine triflutate
  			</td>
  			<td>
  				Acthrel
  			</td>
  			<td>
  				11/24/1989
  			</td>
  			<td>
  				For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
	  			</td>
				
	  			<td>
					
						05/23/1996
					
	  			</td>

	  			<td>

					
					05/23/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ferring Laboratories, Inc.
  			</td>
  			<td>
  				400 Rella Boulevard, Suite 201
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Suffern
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				035089
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Imiglucerase
  			</td>
  			<td>
  				Cerezyme
  			</td>
  			<td>
  				11/05/1991
  			</td>
  			<td>
  				Replacement therapy in patients with types I, II, and III Gaucher's disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Enzyme replacement therapy in patients with type I Gaucher's disease.
	  			</td>
				
	  			<td>
					
						05/23/1994
					
	  			</td>

	  			<td>

					
					05/23/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				One Kendall Square
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				062491
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brigatinib; brigatinib
  			</td>
  			<td>
  				Alunbrig; Alunbrig
  			</td>
  			<td>
  				04/28/2016
  			</td>
  			<td>
  				Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ALUNBRIG (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						05/22/2020
					
	  			</td>

	  			<td>

					
					05/22/2027
					
					
	  			</td>

				<td>
					For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, not including patients who have progressed on or are intolerant to crizotinib.
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				505415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tadalafil
  			</td>
  			<td>
  				Adcirca
  			</td>
  			<td>
  				12/18/2006
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability
	  			</td>
				
	  			<td>
					
						05/22/2009
					
	  			</td>

	  			<td>

					
					05/22/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228206
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ofloxacin
  			</td>
  			<td>
  				Ocuflox Ophthalmic Solution
  			</td>
  			<td>
  				04/18/1991
  			</td>
  			<td>
  				Treatment of bacterial corneal ulcers.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of bacterial corneal ulcers.
	  			</td>
				
	  			<td>
					
						05/22/1996
					
	  			</td>

	  			<td>

					
					05/22/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Allergan, Inc.
  			</td>
  			<td>
  				2525 Dupont Drive
  			</td>
  			<td>
  				P.O. Box 19534
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92713
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				056791
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				treprostinil
  			</td>
  			<td>
  				Remodulin;Orenitram
  			</td>
  			<td>
  				06/04/1997
  			</td>
  			<td>
  				Treatment of pulmonary arterial hypertension.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pulmonary arterial hypertension.
	  			</td>
				
	  			<td>
					
						05/21/2002
					
	  			</td>

	  			<td>

					
					05/21/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				United Therapeutics Corp.
  			</td>
  			<td>
  				55 T.W. Alexander Dr.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				105197
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				azacitidine
  			</td>
  			<td>
  				Vidaza
  			</td>
  			<td>
  				07/28/2021
  			</td>
  			<td>
  				Treatment of Juvenile myelomonocytic leukemia  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients aged one month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML)
	  			</td>
				
	  			<td>
					
						05/20/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Ave
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				829021
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dupilumab
  			</td>
  			<td>
  				Dupixent
  			</td>
  			<td>
  				09/05/2017
  			</td>
  			<td>
  				Treatment of eosinophilic esophagitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)
	  			</td>
				
	  			<td>
					
						05/20/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Regeneron Pharmaceuticals, Inc.
  			</td>
  			<td>
  				777 Old Saw Mill River Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tarrytown
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10591
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				599317
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				12/20/2016
  			</td>
  			<td>
  				Treatment of gastric cancer and gastro-esophageal junction cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)
	  			</td>
				
	  			<td>
					
						05/20/2021
					
	  			</td>

	  			<td>

					
					05/20/2028
					
					
	  			</td>

				<td>
					adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				545016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				08/22/2016
  			</td>
  			<td>
  				Treatment of esophageal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)
	  			</td>
				
	  			<td>
					
						05/20/2021
					
	  			</td>

	  			<td>

					
					05/20/2028
					
					
	  			</td>

				<td>
					adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				531016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deferiprone
  			</td>
  			<td>
  				Ferriprox
  			</td>
  			<td>
  				12/12/2001
  			</td>
  			<td>
  				Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Ferriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
	  			</td>
				
	  			<td>
					
						05/19/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiesi USA, Inc.
  			</td>
  			<td>
  				175 Regency Woods Place
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27518
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				150701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Infliximab
  			</td>
  			<td>
  				Remicade
  			</td>
  			<td>
  				11/12/2003
  			</td>
  			<td>
  				Treatment of pediatric (0 to 16 years of age) Crohn's Disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy
	  			</td>
				
	  			<td>
					
						05/19/2006
					
	  			</td>

	  			<td>

					
					05/19/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Centocor, Inc.
  			</td>
  			<td>
  				200 Great Valley Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Malvern
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				175803
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				azacitidine
  			</td>
  			<td>
  				Vidaza
  			</td>
  			<td>
  				12/03/2001
  			</td>
  			<td>
  				Treatament of myelodysplastic syndromes
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with the following myelodysplastic syndrome subtypes:  refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia
	  			</td>
				
	  			<td>
					
						05/19/2004
					
	  			</td>

	  			<td>

					
					05/19/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				150101
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pentastarch
  			</td>
  			<td>
  				Pentaspan
  			</td>
  			<td>
  				08/28/1985
  			</td>
  			<td>
  				As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						05/19/1987
					
	  			</td>

	  			<td>

					
					05/19/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				DuPont Pharmaceuticals
  			</td>
  			<td>
  				E.I. Du Pont De Nemours & Co.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19880
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				008085
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tecovirimat
  			</td>
  			<td>
  				TPOXX
  			</td>
  			<td>
  				12/27/2006
  			</td>
  			<td>
  				Treatment of smallpox
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 3 kg
	  			</td>
				
	  			<td>
					
						05/18/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				SIGA Technologies, Inc.
  			</td>
  			<td>
  				4575 SW Research Way
  			</td>
  			<td>
  				Suite 230
  			</td>
  			<td>
  				Corvallis
  			</td>
  			<td>
  				Oregon
  			</td>
  			<td>
  				97333
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				229806
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Deferasirox
  			</td>
  			<td>
  				Exjade; Jadenu Sprinkles
  			</td>
  			<td>
  				11/21/2002
  			</td>
  			<td>
  				Treatment of chronic iron overload in patients with transfusion-dependent anemias
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						05/18/2017
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Hampshire
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				161002
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deferasirox
  			</td>
  			<td>
  				Exjade; Jadenu Sprinkles
  			</td>
  			<td>
  				02/24/2015
  			</td>
  			<td>
  				Treatment of chronic iron overload in alpha-thalassemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.
	  			</td>
				
	  			<td>
					
						05/18/2017
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				354411
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				midazolam
  			</td>
  			<td>
  				NAYZILAM
  			</td>
  			<td>
  				10/20/2009
  			</td>
  			<td>
  				Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
	  			</td>
				
	  			<td>
					
						05/17/2019
					
	  			</td>

	  			<td>

					
					05/17/2026
					
					
	  			</td>

				<td>
					NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.
				</td>
			
  			<td>
  				UCB, Inc.
  			</td>
  			<td>
  				1950 Lake Park Drive
  			</td>
  			<td>
  				Building 2100
  			</td>
  			<td>
  				Smyrna
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				277809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.
	  			</td>
				
	  			<td>
					
						05/17/2017
					
	  			</td>

	  			<td>

					
					05/17/2024
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, and D1270N.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				OPDIVO 
  			</td>
  			<td>
  				08/07/2014
  			</td>
  			<td>
  				Treatment of Hodgkin lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin
	  			</td>
				
	  			<td>
					
						05/17/2016
					
	  			</td>

	  			<td>

					
					05/17/2023
					
					
	  			</td>

				<td>
					Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				Route 206 & Province Line Road 
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				442614
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Japanese encephalitis vaccine, inactivated, adsorbed
  			</td>
  			<td>
  				IXIARO
  			</td>
  			<td>
  				09/25/2012
  			</td>
  			<td>
  				Prevention of Japanese encephalitis virus in pediatric patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.
	  			</td>
				
	  			<td>
					
						05/17/2013
					
	  			</td>

	  			<td>

					
					05/17/2020
					
					
	  			</td>

				<td>
					To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus.  
				</td>
			
  			<td>
  				Intercell AG
  			</td>
  			<td>
  				Campus Vienna Biocenter 3
  			</td>
  			<td>
  				A-1030
  			</td>
  			<td>
  				Vienna
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Austria
  			</td>
			<td>
  				376112
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				doxorubicin HCL liposome injection
  			</td>
  			<td>
  				Doxil
  			</td>
  			<td>
  				12/29/2004
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior therapy.
	  			</td>
				
	  			<td>
					
						05/17/2007
					
	  			</td>

	  			<td>

					
					05/17/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Johnson & Johnson Pharmaceutical Research & Dev.
  			</td>
  			<td>
  				920 US Highway 202, P. O. Box 300
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				191704
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tinidazole
  			</td>
  			<td>
  				Tindamax
  			</td>
  			<td>
  				04/18/2002
  			</td>
  			<td>
  				Treatment of giardiasis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age
	  			</td>
				
	  			<td>
					
						05/17/2004
					
	  			</td>

	  			<td>

					
					05/17/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Presutti Laboratories, Inc.
  			</td>
  			<td>
  				1607 N. Douglas Ave.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Arlington Heights
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60004
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				155402
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tinidazole
  			</td>
  			<td>
  				Tindamax
  			</td>
  			<td>
  				08/20/2003
  			</td>
  			<td>
  				Treatment of amebiasis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age.  It is not indicated for the treatment of asymptomatic cyst passage.
	  			</td>
				
	  			<td>
					
						05/17/2004
					
	  			</td>

	  			<td>

					
					05/17/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Presutti Laboratories, Inc.
  			</td>
  			<td>
  				1607 N. Douglas Ave.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Arlington Heights
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60004
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				173603
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Gemtuzumab ozogamicin
  			</td>
  			<td>
  				Mylotarg
  			</td>
  			<td>
  				11/24/1999
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy
	  			</td>
				
	  			<td>
					
						05/17/2000
					
	  			</td>

	  			<td>

					
					05/17/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals, Inc., a Pfizer Company
  			</td>
  			<td>
  				10646 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				127899
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Allopurinol sodium
  			</td>
  			<td>
  				Aloprim for Injection
  			</td>
  			<td>
  				10/16/1992
  			</td>
  			<td>
  				Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.
	  			</td>
				
	  			<td>
					
						05/17/1996
					
	  			</td>

	  			<td>

					
					05/17/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Catalytica Pharmaceuticals, Inc
  			</td>
  			<td>
  				PO Box 1887
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Greenville
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27835
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				068392
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Interferon beta-1a
  			</td>
  			<td>
  				Avonex
  			</td>
  			<td>
  				12/16/1991
  			</td>
  			<td>
  				Treatment of multiple sclerosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.
	  			</td>
				
	  			<td>
					
						05/17/1996
					
	  			</td>

	  			<td>

					
					05/17/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Biogen, Inc.
  			</td>
  			<td>
  				14 Cambridge Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				062791
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				teduglutide [rDNA origin]; teduglutide [rDNA origin]
  			</td>
  			<td>
  				GATTEX; GATTEX
  			</td>
  			<td>
  				06/29/2000
  			</td>
  			<td>
  				Treatment of short bowel syndrome.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GATTEX® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
	  			</td>
				
	  			<td>
					
						05/16/2019
					
	  			</td>

	  			<td>

					
					05/16/2026
					
					
	  			</td>

				<td>
					Treatment of pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
				</td>
			
  			<td>
  				Takeda Pharmaceuticals U.S.A., Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				126999
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ripretinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				10/02/2014
  			</td>
  			<td>
  				Treatment of gastrointestinal stromal tumors (GIST)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				QINLOCK (ripretinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
	  			</td>
				
	  			<td>
					
						05/15/2020
					
	  			</td>

	  			<td>

					
					05/15/2027
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
				</td>
			
  			<td>
  				Deciphera Pharmaceuticals, LLC
  			</td>
  			<td>
  				200 Smith Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				447414
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				venetoclax
  			</td>
  			<td>
  				VENCLEXTA
  			</td>
  			<td>
  				09/20/2012
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
	  			</td>
				
	  			<td>
					
						05/15/2019
					
	  			</td>

	  			<td>

					
					05/15/2026
					
					
	  			</td>

				<td>
					Treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
				</td>
			
  			<td>
  				AbbVie, Inc
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				Dept. PA72, Bldg. AP30
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				375612
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pegcetacoplan
  			</td>
  			<td>
  				Empaveli
  			</td>
  			<td>
  				04/20/2014
  			</td>
  			<td>
  				Treatment of paroxysmal nocturnal hemoglobinuria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
	  			</td>
				
	  			<td>
					
						05/14/2021
					
	  			</td>

	  			<td>

					
					05/14/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
				</td>
			
  			<td>
  				Apellis Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 Fifth Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				427614
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pomalidomide
  			</td>
  			<td>
  				POMALYST®
  			</td>
  			<td>
  				04/04/2018
  			</td>
  			<td>
  				Treatment of Kaposi sarcoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.
	  			</td>
				
	  			<td>
					
						05/14/2020
					
	  			</td>

	  			<td>

					
					05/14/2027
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				635818
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bortezomib
  			</td>
  			<td>
  				Velcade
  			</td>
  			<td>
  				01/15/2003
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy
	  			</td>
				
	  			<td>
					
						05/13/2003
					
	  			</td>

	  			<td>

					
					05/13/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Millennium Pharmaceuticals, Inc.
  			</td>
  			<td>
  				40 Landsdowne Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				163002
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				edaravone
  			</td>
  			<td>
  				Radicava ORS
  			</td>
  			<td>
  				05/12/2015
  			</td>
  			<td>
  				Treatment of amyotrophic lateral sclerosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of amyotrophic lateral sclerosis (ALS)
	  			</td>
				
	  			<td>
					
						05/12/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mitsubishi Tanabe Pharma Corporation
  			</td>
  			<td>
  				17-10, Nihonbashi-Koamicho
  			</td>
  			<td>
  				Chuo-ku, 
  			</td>
  			<td>
  				Tokyo 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Japan
  			</td>
			<td>
  				478215
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Basiliximab
  			</td>
  			<td>
  				Simulect
  			</td>
  			<td>
  				12/12/1997
  			</td>
  			<td>
  				Prophylaxis of solid organ rejection.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.
	  			</td>
				
	  			<td>
					
						05/12/1998
					
	  			</td>

	  			<td>

					
					05/12/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				109197
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tocilizumab
  			</td>
  			<td>
  				Actemra
  			</td>
  			<td>
  				07/31/2012
  			</td>
  			<td>
  				Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						05/11/2018
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				367812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ramucirumab
  			</td>
  			<td>
  				CYRAMZA
  			</td>
  			<td>
  				11/04/2011
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.
	  			</td>
				
	  			<td>
					
						05/10/2019
					
	  			</td>

	  			<td>

					
					05/10/2026
					
					
	  			</td>

				<td>
					CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				353911
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nimodipine
  			</td>
  			<td>
  				NYMALIZE
  			</td>
  			<td>
  				09/16/2011
  			</td>
  			<td>
  				Treatment of subarachnoid hemorrhage.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
	  			</td>
				
	  			<td>
					
						05/10/2013
					
	  			</td>

	  			<td>

					
					05/10/2020
					
					
	  			</td>

				<td>
					Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).
				</td>
			
  			<td>
  				Arbor Pharmaceuticals, Inc.
  			</td>
  			<td>
  				6 Concourse Parkway
  			</td>
  			<td>
  				Suite 1800
  			</td>
  			<td>
  				Atlanta
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30328
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				338611
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Imatinib
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				01/31/2001
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy
	  			</td>
				
	  			<td>
					
						05/10/2001
					
	  			</td>

	  			<td>

					
					05/10/2008
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				59 Route 10
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				140100
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				canakinumab
  			</td>
  			<td>
  				ILARIS
  			</td>
  			<td>
  				09/30/2008
  			</td>
  			<td>
  				Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.  
	  			</td>
				
	  			<td>
					
						05/09/2013
					
	  			</td>

	  			<td>

					
					05/09/2020
					
					
	  			</td>

				<td>
					Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.  
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Bldg 135-566G
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				260408
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				 Lynparza 
  			</td>
  			<td>
  				05/15/2018
  			</td>
  			<td>
  				Treatment of Fallopian Tube Cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:  a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD
	  			</td>
				
	  			<td>
					
						05/08/2020
					
	  			</td>

	  			<td>

					
					05/08/2027
					
					
	  			</td>

				<td>
					LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				417613
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				 Lynparza 
  			</td>
  			<td>
  				05/15/2018
  			</td>
  			<td>
  				Treatment of primary peritoneal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA
	  			</td>
				
	  			<td>
					
						05/08/2020
					
	  			</td>

	  			<td>

					
					05/08/2027
					
					
	  			</td>

				<td>
					LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				419013
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selpercatinib
  			</td>
  			<td>
  				RETEVMO
  			</td>
  			<td>
  				11/21/2019
  			</td>
  			<td>
  				Treatment of RET fusion-positive or RET mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				RETEVMO is indicated for the treatment of: • Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; • Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
	  			</td>
				
	  			<td>
					
						05/08/2020
					
	  			</td>

	  			<td>

					
					05/08/2027
					
					
	  			</td>

				<td>
					For the treatment of: adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and, adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
				</td>
			
  			<td>
  				Loxo Oncolocy at Lilly
  			</td>
  			<td>
  				701 Gateway Boulevard, Suite 420
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				653118
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selpercatinib
  			</td>
  			<td>
  				RETEVMO
  			</td>
  			<td>
  				10/30/2019
  			</td>
  			<td>
  				Treatment of RET-fusion-positive non-small cell lung cancer 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				RETEVMO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
	  			</td>
				
	  			<td>
					
						05/08/2020
					
	  			</td>

	  			<td>

					
					05/08/2027
					
					
	  			</td>

				<td>
					For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
				</td>
			
  			<td>
  				Loxo Oncolocy at Lilly
  			</td>
  			<td>
  				701 Gateway Boulevard, Suite 420
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				675218
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				olaparib
  			</td>
  			<td>
  				Lynparza
  			</td>
  			<td>
  				10/16/2013
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:  a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FD
	  			</td>
				
	  			<td>
					
						05/08/2020
					
	  			</td>

	  			<td>

					
					05/08/2027
					
					
	  			</td>

				<td>
					LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				409213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab
  			</td>
  			<td>
  				Darzalex
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh
	  			</td>
				
	  			<td>
					
						05/07/2018
					
	  			</td>

	  			<td>

					
					05/07/2025
					
					
	  			</td>

				<td>
					In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
				</td>
			
  			<td>
  				Janssen Biotech, Inc.
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				PO Box 300
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				397113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				alemtuzumab
  			</td>
  			<td>
  				Campath
  			</td>
  			<td>
  				10/20/1997
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.
	  			</td>
				
	  			<td>
					
						05/07/2001
					
	  			</td>

	  			<td>

					
					05/07/2008
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				4545 Horizon Hill Blvd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Antonio
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				78229
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				107197
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				capmatinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				03/15/2019
  			</td>
  			<td>
  				Treatment of non-small cell lung cancer with MET genomic tumor aberrations
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Tabrecta (capmatinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						05/06/2020
					
	  			</td>

	  			<td>

					
					05/06/2027
					
					
	  			</td>

				<td>
					For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				644518
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				IMBRUVICA
  			</td>
  			<td>
  				05/30/2013
  			</td>
  			<td>
  				Treatment of small lymphocytic lymphoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with 17p deletion.     
	  			</td>
				
	  			<td>
					
						05/06/2016
					
	  			</td>

	  			<td>

					
					05/06/2023
					
					
	  			</td>

				<td>
					For treatment of patients with small lymphocytic lymphoma (SLL) 
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				395513
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antivenin crotaline (pit-viper) equine immune F(ab)2)
  			</td>
  			<td>
  				Anavip
  			</td>
  			<td>
  				01/29/2004
  			</td>
  			<td>
  				Treatment of envenomation by Crotaline snakes
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of adult and pediatric patients with North American rattlesnake envenomation
	  			</td>
				
	  			<td>
					
						05/06/2015
					
	  			</td>

	  			<td>

					
					05/06/2022
					
					
	  			</td>

				<td>
					Management of adult and pediatric patients with North American rattlesnake envenomation
				</td>
			
  			<td>
  				Rare Disease Therapeutics, Inc.
  			</td>
  			<td>
  				12975 Brookprinter Place
  			</td>
  			<td>
  				Suite 170
  			</td>
  			<td>
  				Poway
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177503
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				06/16/2015
  			</td>
  			<td>
  				Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
	  			</td>
				
	  			<td>
					
						05/05/2021
					
	  			</td>

	  			<td>

					
					05/05/2028
					
					
	  			</td>

				<td>
					for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, excluding patients covered by Keytruda's previous indication for gastric or GEJ adenocarcinoma approved on September 22, 2017
				</td>
			
  			<td>
  				Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc.
  			</td>
  			<td>
  				351 North Sumneytown Pike
  			</td>
  			<td>
  				UG2D-44
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				481715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				edaravone
  			</td>
  			<td>
  				Radicava
  			</td>
  			<td>
  				05/12/2015
  			</td>
  			<td>
  				Treatment of amyotrophic lateral sclerosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of amyotrophic lateral sclerosis (ALS)
	  			</td>
				
	  			<td>
					
						05/05/2017
					
	  			</td>

	  			<td>

					
					05/05/2024
					
					
	  			</td>

				<td>
					Treatment of amyotrophic lateral sclerosis (ALS)
				</td>
			
  			<td>
  				Mitsubishi Tanabe Pharma Corporation
  			</td>
  			<td>
  				17-10, Nihonbashi-Koamicho
  			</td>
  			<td>
  				Chuo-ku, 
  			</td>
  			<td>
  				Tokyo 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Japan
  			</td>
			<td>
  				478215
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				everolimus
  			</td>
  			<td>
  				Afinitor
  			</td>
  			<td>
  				02/14/2008
  			</td>
  			<td>
  				Treatment of neuroendocrine tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.
	  			</td>
				
	  			<td>
					
						05/05/2011
					
	  			</td>

	  			<td>

					
					05/05/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza, 315/5450A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				254107
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bevacizumab
  			</td>
  			<td>
  				Avastin
  			</td>
  			<td>
  				05/26/2006
  			</td>
  			<td>
  				Treatment of malignant glioma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of glioblastoma with progressive disease following prior therapy
	  			</td>
				
	  			<td>
					
						05/05/2009
					
	  			</td>

	  			<td>

					
					05/05/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way, MS 241B
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				222906
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Aldesleukin
  			</td>
  			<td>
  				Proleukin
  			</td>
  			<td>
  				09/14/1988
  			</td>
  			<td>
  				Treatment of metastatic renal cell carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults (>18 years old) with metastatic renal cell carcinoma.
	  			</td>
				
	  			<td>
					
						05/05/1992
					
	  			</td>

	  			<td>

					
					05/05/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiron Corporation
  			</td>
  			<td>
  				4560 Horton Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Emeryville
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94608
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				029088
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dabrafenib and trametinib
  			</td>
  			<td>
  				Tafinlar(r) Capsules a nd Mekinist(r) Tablets
  			</td>
  			<td>
  				09/01/2016
  			</td>
  			<td>
  				Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
	  			</td>
				
	  			<td>
					
						05/04/2018
					
	  			</td>

	  			<td>

					
					05/04/2025
					
					
	  			</td>

				<td>
					MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				1 Health Plaza
  			</td>
  			<td>
  				Building 337
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				521616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dabrafenib and trametinib
  			</td>
  			<td>
  				Tafinlar(r) Capsules a nd Mekinist(r) Tablets
  			</td>
  			<td>
  				09/01/2016
  			</td>
  			<td>
  				Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
	  			</td>
				
	  			<td>
					
						05/04/2018
					
	  			</td>

	  			<td>

					
					05/04/2025
					
					
	  			</td>

				<td>
					MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				1 Health Plaza
  			</td>
  			<td>
  				Building 337
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				521616
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tafamidis meglumine
  			</td>
  			<td>
  				VYNDAQEL; VYNDAMAX
  			</td>
  			<td>
  				02/17/2012
  			</td>
  			<td>
  				Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.   
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
	  			</td>
				
	  			<td>
					
						05/03/2019
					
	  			</td>

	  			<td>

					
					05/03/2026
					
					
	  			</td>

				<td>
					VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
				</td>
			
  			<td>
  				FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.
  			</td>
  			<td>
  				445 Eastern Point Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Groton
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06340
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				363312
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor Xa (recombinant), inactivated-zhzo
  			</td>
  			<td>
  				ANDEXXA
  			</td>
  			<td>
  				02/23/2015
  			</td>
  			<td>
  				For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding
	  			</td>
				
	  			<td>
					
						05/03/2018
					
	  			</td>

	  			<td>

					
					05/03/2025
					
					
	  			</td>

				<td>
					Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				121 Seaport Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				437414
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Histrelin 
  			</td>
  			<td>
  				Supprelin LA
  			</td>
  			<td>
  				11/18/2005
  			</td>
  			<td>
  				Treatment of central precocious puberty
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of central precocious puberty
	  			</td>
				
	  			<td>
					
						05/03/2007
					
	  			</td>

	  			<td>

					
					05/03/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Endo Pharmaceuticals Solutions, Inc.
  			</td>
  			<td>
  				100 Endo Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Chadds Ford
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19317
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				212605
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mefloquine HCL
  			</td>
  			<td>
  				Lariam
  			</td>
  			<td>
  				04/13/1988
  			</td>
  			<td>
  				For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs
	  			</td>
				
	  			<td>
					
						05/03/1989
					
	  			</td>

	  			<td>

					
					05/03/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				026287
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivosidenib
  			</td>
  			<td>
  				TIBSOVO
  			</td>
  			<td>
  				06/09/2015
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia (AML)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
	  			</td>
				
	  			<td>
					
						05/02/2019
					
	  			</td>

	  			<td>

					
					05/02/2026
					
					
	  			</td>

				<td>
					TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
				</td>
			
  			<td>
  				Servier Pharmaceuticals LLC
  			</td>
  			<td>
  				200 Pier Four Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				481515
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				decitabine
  			</td>
  			<td>
  				Dacogen
  			</td>
  			<td>
  				03/08/1999
  			</td>
  			<td>
  				Treatment of myelodysplastic syndromes.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
	  			</td>
				
	  			<td>
					
						05/02/2006
					
	  			</td>

	  			<td>

					
					05/02/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Otsuka Pharmaceutical Development
  			</td>
  			<td>
  				and Commercialization, Inc.
  			</td>
  			<td>
  				508 Carnegie Center Drive
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				122298
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Vaccinia Immune Globulin (Human) Intravenous
  			</td>
  			<td>
  				CNJ-016
  			</td>
  			<td>
  				06/18/2004
  			</td>
  			<td>
  				Treatment of complications of vaccinia vaccination
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination: Eczema vaccinatum Progressive vaccinia Severe generalized vaccinia Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions Aberrant infections induced by vaccinia virus that include its accidental implan
	  			</td>
				
	  			<td>
					
						05/02/2005
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cangene Corporation
  			</td>
  			<td>
  				104 Chancellor Matheson Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Winnipeg 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				179303
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mefloquine HCL
  			</td>
  			<td>
  				Lariam
  			</td>
  			<td>
  				04/13/1988
  			</td>
  			<td>
  				For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax
	  			</td>
				
	  			<td>
					
						05/02/1989
					
	  			</td>

	  			<td>

					
					05/02/1996
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoffmann-La Roche, Inc.
  			</td>
  			<td>
  				340 Kingsland Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				026287
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tisagenlecleucel-T
  			</td>
  			<td>
  				Kymriah
  			</td>
  			<td>
  				02/03/2015
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma
	  			</td>
				
	  			<td>
					
						05/01/2018
					
	  			</td>

	  			<td>

					
					05/01/2025
					
					
	  			</td>

				<td>
					For treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma after two or more lines of systemic therapy. 
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza,
  			</td>
  			<td>
  				Bldg 315 - Room 3650B
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				463114
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sterile talc
  			</td>
  			<td>
  				Steritalc
  			</td>
  			<td>
  				12/08/1997
  			</td>
  			<td>
  				Treatment of malignant pleural effusion
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion.
	  			</td>
				
	  			<td>
					
						05/01/2017
					
	  			</td>

	  			<td>

					
					05/01/2024
					
					
	  			</td>

				<td>
					To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. 
				</td>
			
  			<td>
  				Novatech SA
  			</td>
  			<td>
  				Z.I. Athelia III
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				La Ciotat 
  			</td>
  			<td>
  				CEDEX
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				106797
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sterile talc
  			</td>
  			<td>
  				Steritalc
  			</td>
  			<td>
  				12/08/1997
  			</td>
  			<td>
  				Treatment of pneumothorax
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Steritalc is indicated in adults to decrease the recurrence of pneumothorax.
	  			</td>
				
	  			<td>
					
						05/01/2017
					
	  			</td>

	  			<td>

					
					05/01/2024
					
					
	  			</td>

				<td>
					To decrease the recurrence of pneumothorax in adults. 
				</td>
			
  			<td>
  				Novatech SA
  			</td>
  			<td>
  				Z.I. Athelia III
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				La Ciotat 
  			</td>
  			<td>
  				CEDEX
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				109297
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Taliglucerase alfa
  			</td>
  			<td>
  				ELELYSO for injection
  			</td>
  			<td>
  				09/03/2009
  			</td>
  			<td>
  				Treatment of Gaucher's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease
	  			</td>
				
	  			<td>
					
						05/01/2012
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				235 East 42nd Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				191004
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deferiprone
  			</td>
  			<td>
  				Ferriprox
  			</td>
  			<td>
  				12/12/2001
  			</td>
  			<td>
  				Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with sickle cell disease or other anemias
	  			</td>
				
	  			<td>
					
						04/30/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiesi USA, Inc.
  			</td>
  			<td>
  				175 Regency Woods Place
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27518
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				150701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deferiprone
  			</td>
  			<td>
  				Ferriprox
  			</td>
  			<td>
  				12/12/2001
  			</td>
  			<td>
  				Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with sickle cell disease or other anemias
	  			</td>
				
	  			<td>
					
						04/30/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiesi USA, Inc.
  			</td>
  			<td>
  				175 Regency Woods Place
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Cary
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27518
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				150701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				glecaprevir and pibrentasvir
  			</td>
  			<td>
  				MAVYRET
  			</td>
  			<td>
  				01/09/2017
  			</td>
  			<td>
  				Treatment of pediatric patients with chronic hepatitis C virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/
	  			</td>
				
	  			<td>
					
						04/30/2019
					
	  			</td>

	  			<td>

					
					04/30/2026
					
					
	  			</td>

				<td>
					For the treatment of pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and also for the treatment of pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60044
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				550516
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trametinib and dabrafenib
  			</td>
  			<td>
  				MEKINIST and TAFINLAR
  			</td>
  			<td>
  				09/20/2012
  			</td>
  			<td>
  				Treatment of Stage IIb through IV melanoma. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection
	  			</td>
				
	  			<td>
					
						04/30/2018
					
	  			</td>

	  			<td>

					
					04/30/2025
					
					
	  			</td>

				<td>
					MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Office 337 A13.5B
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				376812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trametinib and dabrafenib
  			</td>
  			<td>
  				MEKINIST and TAFINLAR
  			</td>
  			<td>
  				09/20/2012
  			</td>
  			<td>
  				Treatment of Stage IIb through IV melanoma. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection
	  			</td>
				
	  			<td>
					
						04/30/2018
					
	  			</td>

	  			<td>

					
					04/30/2025
					
					
	  			</td>

				<td>
					MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Office 337 A13.5B
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				376812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cysteamine enteric coated
  			</td>
  			<td>
  				PROCYSBI
  			</td>
  			<td>
  				10/24/2006
  			</td>
  			<td>
  				Treatment of cystinosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				PROCYSBI is indicated for the management of nephropathic cystinosis in adults and children ages 6 years and older.
	  			</td>
				
	  			<td>
					
						04/30/2013
					
	  			</td>

	  			<td>

					
					04/30/2020
					
					
	  			</td>

				<td>
					Management of nephropathic cystinosis in adults and children ages 6 years and older.
				</td>
			
  			<td>
  				Horizon Therapeutics USA, Inc.
  			</td>
  			<td>
  				150 S. Saunders Road
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Lake Forest
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60045
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				231006
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				laronidase
  			</td>
  			<td>
  				Aldurazyme
  			</td>
  			<td>
  				09/24/1997
  			</td>
  			<td>
  				Treatment of patients with mucopolysaccharidosis-I.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms
	  			</td>
				
	  			<td>
					
						04/30/2003
					
	  			</td>

	  			<td>

					
					04/30/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				BioMarin Pharmaceutical, Inc.
  			</td>
  			<td>
  				105 Digital Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				106097
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sodium phenylbutyrate
  			</td>
  			<td>
  				Buphenyl
  			</td>
  			<td>
  				11/22/1993
  			</td>
  			<td>
  				Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.
	  			</td>
				
	  			<td>
					
						04/30/1996
					
	  			</td>

	  			<td>

					
					04/30/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Medicis Pharmaceutical Corp.
  			</td>
  			<td>
  				8125 N. Hayden Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Scottsdale
  			</td>
  			<td>
  				Alaska
  			</td>
  			<td>
  				85258
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				077893
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				niraparib
  			</td>
  			<td>
  				Zejula
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
	  			</td>
				
	  			<td>
					
						04/29/2020
					
	  			</td>

	  			<td>

					
					04/29/2027
					
					
	  			</td>

				<td>
					Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
				</td>
			
  			<td>
  				GlaxoSmithKline, LLC.
  			</td>
  			<td>
  				1000 Winter St.
  			</td>
  			<td>
  				Suite 3300
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				306510
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
	  			</td>
				
	  			<td>
					
						04/29/2019
					
	  			</td>

	  			<td>

					
					04/29/2026
					
					
	  			</td>

				<td>
					For the treatment of cystic fibrosis (CF) in patients age 6 months to less than 12 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ceritinib
  			</td>
  			<td>
  				ZYKADIA
  			</td>
  			<td>
  				09/27/2013
  			</td>
  			<td>
  				Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
	  			</td>
				
	  			<td>
					
						04/29/2014
					
	  			</td>

	  			<td>

					
					04/29/2021
					
					
	  			</td>

				<td>
					Treatment of patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				405213
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tocilizumab
  			</td>
  			<td>
  				Actemra
  			</td>
  			<td>
  				07/31/2012
  			</td>
  			<td>
  				Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						04/29/2013
					
	  			</td>

	  			<td>

					
					04/29/2020
					
					
	  			</td>

				<td>
					Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				367812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				prothrombin complex concentrate (human)
  			</td>
  			<td>
  				Kcentra
  			</td>
  			<td>
  				12/27/2012
  			</td>
  			<td>
  				Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.  
	  			</td>
				
	  			<td>
					
						04/29/2013
					
	  			</td>

	  			<td>

					
					04/29/2020
					
					
	  			</td>

				<td>
					Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.  
				</td>
			
  			<td>
  				CSL Behring
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				305310
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				levoleucovorin
  			</td>
  			<td>
  				Fusilev
  			</td>
  			<td>
  				12/18/1990
  			</td>
  			<td>
  				For use in combination chemotherapy with the approved agent 5-fluorouracil in the  palliative treatment of metastatic adenocarcinoma of the colon and rectum
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer
	  			</td>
				
	  			<td>
					
						04/29/2011
					
	  			</td>

	  			<td>

					
					04/29/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Acrotech Biopharma LLC
  			</td>
  			<td>
  				279 Princeton Hightstown Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Windsor
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				048590
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mavacamten
  			</td>
  			<td>
  				Camzyos
  			</td>
  			<td>
  				04/27/2016
  			</td>
  			<td>
  				Treatment of symptomatic hypertrophic cardiomyopathy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with symptomatic New York Heart
Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms
	  			</td>
				
	  			<td>
					
						04/28/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				MyoKardia, Inc. (A Wholly-Owned Subsidiary of Bristol Myers Squibb)
  			</td>
  			<td>
  				1000 Sierra Point Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Brisbane
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94005
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trientine tetrahydrochloride
  			</td>
  			<td>
  				Cuvrior
  			</td>
  			<td>
  				03/10/2016
  			</td>
  			<td>
  				Treatment of Wilson's disease excluding patients intolerant to penicillamine
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with stable Wilson¿s disease who are de-coppered and tolerant to penicillamine
	  			</td>
				
	  			<td>
					
						04/28/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Orphalan
  			</td>
  			<td>
  				226 boulevard Voltaire
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Paris
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				75011
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				492915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				midostaurin
  			</td>
  			<td>
  				Rydapt
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of mastocytosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)
	  			</td>
				
	  			<td>
					
						04/28/2017
					
	  			</td>

	  			<td>

					
					04/28/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza, 105/3W038
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				306410
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brigatinib; brigatinib
  			</td>
  			<td>
  				Alunbrig; Alunbrig
  			</td>
  			<td>
  				04/28/2016
  			</td>
  			<td>
  				Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib
	  			</td>
				
	  			<td>
					
						04/28/2017
					
	  			</td>

	  			<td>

					
					04/28/2024
					
					
	  			</td>

				<td>
					Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				505415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				glycerol phenylbutyrate
  			</td>
  			<td>
  				RAVICTI
  			</td>
  			<td>
  				04/27/2009
  			</td>
  			<td>
  				Maintenance treatment of patients with deficiencies in enzymes of the urea cycle 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use as a nitrogen-binding agent for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
	  			</td>
				
	  			<td>
					
						04/28/2017
					
	  			</td>

	  			<td>

					
					04/28/2024
					
					
	  			</td>

				<td>
					For use as a nitrogen-binding agent for chronic management of pediatric patients > or =2 months and <2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
				</td>
			
  			<td>
  				Horizon Pharma USA, INc.
  			</td>
  			<td>
  				150 South Saunders Road
  			</td>
  			<td>
  				Suite 400
  			</td>
  			<td>
  				Lake Forest
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60045
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				203505
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				midostaurin
  			</td>
  			<td>
  				Rydapt
  			</td>
  			<td>
  				07/07/2009
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
	  			</td>
				
	  			<td>
					
						04/28/2017
					
	  			</td>

	  			<td>

					
					04/28/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza, 105/3W038
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				285909
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mercaptopurine oral solution
  			</td>
  			<td>
  				Purixan
  			</td>
  			<td>
  				08/20/2012
  			</td>
  			<td>
  				Treatment of acute lymphoblastic leukemia in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen.
	  			</td>
				
	  			<td>
					
						04/28/2014
					
	  			</td>

	  			<td>

					
					04/28/2021
					
					
	  			</td>

				<td>
					Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen (in pediatric patients).
				</td>
			
  			<td>
  				Nova Laboratories Limited
  			</td>
  			<td>
  				Martin House
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Leicester 
  			</td>
  			<td>
  				Wigston
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				373512
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Recombinant human acid alpha-glucosidase; alglucosidase alfa
  			</td>
  			<td>
  				1. Myozyme 2. Lumizyme
  			</td>
  			<td>
  				08/19/1997
  			</td>
  			<td>
  				Treatment of glycogen storage disease type II.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Myozyme for use in patients with Pompe disease (GAA deficiency).  Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphaglucosidase in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy.
	  			</td>
				
	  			<td>
					
						04/28/2006
					
	  			</td>

	  			<td>

					
					04/28/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				500 Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				106597
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ravulizumab-cwvz
  			</td>
  			<td>
  				Ultomiris
  			</td>
  			<td>
  				06/12/2014
  			</td>
  			<td>
  				Treatment of myasthenia gravis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive
	  			</td>
				
	  			<td>
					
						04/27/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				121 Seaport Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				434214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cerliponase alfa
  			</td>
  			<td>
  				Brineura
  			</td>
  			<td>
  				04/01/2013
  			</td>
  			<td>
  				Treatment of neuronal ceroid lipofuscinosis type 2 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.  
	  			</td>
				
	  			<td>
					
						04/27/2017
					
	  			</td>

	  			<td>

					
					04/27/2024
					
					
	  			</td>

				<td>
					To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.  
				</td>
			
  			<td>
  				BioMarin Pharmaceutical, Inc.
  			</td>
  			<td>
  				105 Digital Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				391913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				regorafenib
  			</td>
  			<td>
  				Stivarga
  			</td>
  			<td>
  				06/04/2015
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				 Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.
	  			</td>
				
	  			<td>
					
						04/27/2017
					
	  			</td>

	  			<td>

					
					04/27/2024
					
					
	  			</td>

				<td>
					 Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.
				</td>
			
  			<td>
  				Bayer HealthCare Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 Bayer Blvd
  			</td>
  			<td>
  				P. O. Box 915
  			</td>
  			<td>
  				Whippany
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07981
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				478015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				everolimus
  			</td>
  			<td>
  				Afinitor 
  			</td>
  			<td>
  				06/08/2009
  			</td>
  			<td>
  				 Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery. 
	  			</td>
				
	  			<td>
					
						04/26/2012
					
	  			</td>

	  			<td>

					
					04/26/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza, 315/5450A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				283609
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pazopanib
  			</td>
  			<td>
  				Votrient
  			</td>
  			<td>
  				10/20/2009
  			</td>
  			<td>
  				Treatment of soft tissue sarcomas
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Advanced soft tissue sarcoma (STS) who have received prior chemotherapy
	  			</td>
				
	  			<td>
					
						04/26/2012
					
	  			</td>

	  			<td>

					
					04/26/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp
  			</td>
  			<td>
  				1 Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				293809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				methotrexate oral solution
  			</td>
  			<td>
  				Xatmep 
  			</td>
  			<td>
  				08/27/2015
  			</td>
  			<td>
  				Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
	  			</td>
				
	  			<td>
					
						04/25/2017
					
	  			</td>

	  			<td>

					
					04/25/2024
					
					
	  			</td>

				<td>
					Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant or of had an inadequate response to first-line therapy.
				</td>
			
  			<td>
  				Silvergate Pharmaeuticals, Inc.
  			</td>
  			<td>
  				6251 Greenwood Plaza Blvd
  			</td>
  			<td>
  				Suite 101
  			</td>
  			<td>
  				Greenwood Village
  			</td>
  			<td>
  				Colorado
  			</td>
  			<td>
  				80111
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				479515
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				OPDIVO 
  			</td>
  			<td>
  				08/07/2014
  			</td>
  			<td>
  				Treatment of Hodgkin lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT.
	  			</td>
				
	  			<td>
					
						04/25/2017
					
	  			</td>

	  			<td>

					
					04/25/2024
					
					
	  			</td>

				<td>
					Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				Route 206 & Province Line Road 
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				442614
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				methotrexate oral solution
  			</td>
  			<td>
  				Xatmep
  			</td>
  			<td>
  				05/28/2015
  			</td>
  			<td>
  				Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen
	  			</td>
				
	  			<td>
					
						04/25/2017
					
	  			</td>

	  			<td>

					
					04/25/2024
					
					
	  			</td>

				<td>
					Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen
				</td>
			
  			<td>
  				Silvergate Pharmaceuticals, Inc.
  			</td>
  			<td>
  				6251 Greenwood Plaza Blvd.
  			</td>
  			<td>
  				Suite 101
  			</td>
  			<td>
  				Greenwood Village
  			</td>
  			<td>
  				Colorado
  			</td>
  			<td>
  				80111
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				479615
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ceramide trihexosidase/alpha-galactosidase A
  			</td>
  			<td>
  				Fabrazyme
  			</td>
  			<td>
  				01/19/1988
  			</td>
  			<td>
  				Treatment of Fabry's disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types
	  			</td>
				
	  			<td>
					
						04/24/2003
					
	  			</td>

	  			<td>

					
					04/24/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				One Kendall Square
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				015286
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				loncastuximab tesirine-lpyl
  			</td>
  			<td>
  				Zynlonta
  			</td>
  			<td>
  				06/08/2017
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma
	  			</td>
				
	  			<td>
					
						04/23/2021
					
	  			</td>

	  			<td>

					
					04/23/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
				</td>
			
  			<td>
  				ADC Therapeutics SA
  			</td>
  			<td>
  				Route de la Corniche, 3B 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Epalinges
  			</td>
  			<td>
  				Vaud
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				572716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tolvaptan
  			</td>
  			<td>
  				Jynarque
  			</td>
  			<td>
  				04/06/2012
  			</td>
  			<td>
  				Treatment of autosomal dominant polycystic kidney disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
	  			</td>
				
	  			<td>
					
						04/23/2018
					
	  			</td>

	  			<td>

					
					04/23/2025
					
					
	  			</td>

				<td>
					JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
				</td>
			
  			<td>
  				Otsuka Pharmaceutical Company, Ltd.
  			</td>
  			<td>
  				2-9, Kanda-Tsukasamachi
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tokyo
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Japan
  			</td>
			<td>
  				347311
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				siltuximab
  			</td>
  			<td>
  				SYLVANT
  			</td>
  			<td>
  				05/26/2006
  			</td>
  			<td>
  				Treatment of Castleman's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
	  			</td>
				
	  			<td>
					
						04/23/2014
					
	  			</td>

	  			<td>

					
					04/23/2021
					
					
	  			</td>

				<td>
					Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
				</td>
			
  			<td>
  				EUSA Pharma (UK) Ltd.
  			</td>
  			<td>
  				Breakspear Park
  			</td>
  			<td>
  				Breakspear Way
  			</td>
  			<td>
  				Hertfordshire
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				200605
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivabradine
  			</td>
  			<td>
  				CORLANOR
  			</td>
  			<td>
  				03/23/2016
  			</td>
  			<td>
  				Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.
	  			</td>
				
	  			<td>
					
						04/22/2019
					
	  			</td>

	  			<td>

					
					04/22/2026
					
					
	  			</td>

				<td>
					Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.
				</td>
			
  			<td>
  				Amgen, Inc.,
  			</td>
  			<td>
  				1 Amgen Center Drive
  			</td>
  			<td>
  				Mail Stop 27-2-D
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				511915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Nitisinone
  			</td>
  			<td>
  				Orfadin
  			</td>
  			<td>
  				05/16/1995
  			</td>
  			<td>
  				Treatment of tyrosinemia type 1.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.
	  			</td>
				
	  			<td>
					
						04/22/2016
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Swedish Orphan Biovitrum AB 
  			</td>
  			<td>
  				SE-112
  			</td>
  			<td>
  				75 Stockholm
  			</td>
  			<td>
  				Stockholm
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				089095
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Digoxin immune FAB (Ovine)
  			</td>
  			<td>
  				Digibind
  			</td>
  			<td>
  				11/01/1984
  			</td>
  			<td>
  				Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						04/22/1986
					
	  			</td>

	  			<td>

					
					04/22/1993
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Inc.
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				002584
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ramucirumab
  			</td>
  			<td>
  				CYRAMZA
  			</td>
  			<td>
  				02/16/2012
  			</td>
  			<td>
  				Treatment of gastric cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.    
	  			</td>
				
	  			<td>
					
						04/21/2014
					
	  			</td>

	  			<td>

					
					04/21/2021
					
					
	  			</td>

				<td>
					Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				33 ImClone Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Branchburg
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08876
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				359711
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Etidronate disodium
  			</td>
  			<td>
  				Didronel
  			</td>
  			<td>
  				03/21/1986
  			</td>
  			<td>
  				Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						04/21/1987
					
	  			</td>

	  			<td>

					
					04/21/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				MGI Pharma, Inc.
  			</td>
  			<td>
  				5775 West Old Shakoppe Rd.
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Bloomington
  			</td>
  			<td>
  				Minnesota
  			</td>
  			<td>
  				55437
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				012185
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Apomorphine HCl
  			</td>
  			<td>
  				Apokyn
  			</td>
  			<td>
  				04/22/1993
  			</td>
  			<td>
  				Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose-wearing-off" and unpredictable :on/off" episodes) associated with advanced Parkinson's disease
	  			</td>
				
	  			<td>
					
						04/20/2004
					
	  			</td>

	  			<td>

					
					04/20/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc.
  			</td>
  			<td>
  				9715 Key West Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockville
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20850
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				057591
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab
  			</td>
  			<td>
  				Rituxan
  			</td>
  			<td>
  				02/14/2006
  			</td>
  			<td>
  				Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).  )
	  			</td>
				
	  			<td>
					
						04/19/2011
					
	  			</td>

	  			<td>

					
					04/19/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				216305
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				osimertinib
  			</td>
  			<td>
  				Tagrisso
  			</td>
  			<td>
  				09/04/2014
  			</td>
  			<td>
  				Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TAGRISSO® is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						04/18/2018
					
	  			</td>

	  			<td>

					
					04/18/2025
					
					
	  			</td>

				<td>
					TAGRISSO® is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				P. O. Box 8355
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				445214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Fludarabine phosphate
  			</td>
  			<td>
  				Fludara
  			</td>
  			<td>
  				04/18/1989
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						04/18/1991
					
	  			</td>

	  			<td>

					
					04/18/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Berlex Laboratories, Inc.
  			</td>
  			<td>
  				15049 San Pablo Avenue, P.O. Box 4099
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Richmond
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94804
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				027688
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pemigatinib
  			</td>
  			<td>
  				PEMAZYRE
  			</td>
  			<td>
  				03/12/2018
  			</td>
  			<td>
  				Treatment of cholangiocarcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test
	  			</td>
				
	  			<td>
					
						04/17/2020
					
	  			</td>

	  			<td>

					
					04/17/2027
					
					
	  			</td>

				<td>
					For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Incyte Corporation
  			</td>
  			<td>
  				1801 Augustine Cut-Off
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				624117
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tucatinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				06/05/2017
  			</td>
  			<td>
  				Treatment of breast cancer patients with brain metastases.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
	  			</td>
				
	  			<td>
					
						04/17/2020
					
	  			</td>

	  			<td>

					
					04/17/2027
					
					
	  			</td>

				<td>
					For use in combination with trastuzumab and capecitabine for treatment of adult patients with metastatic HER2-positive breast cancer and brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823  30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				570716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fostamatinib disodium hexahydrate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				08/25/2015
  			</td>
  			<td>
  				Treatment of immune thrombocytopenic purpura
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
	  			</td>
				
	  			<td>
					
						04/17/2018
					
	  			</td>

	  			<td>

					
					04/17/2025
					
					
	  			</td>

				<td>
					TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
				</td>
			
  			<td>
  				Rigel Pharmaceuticals, Inc.
  			</td>
  			<td>
  				1180 Veterans Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				487715
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				burosumab-twza
  			</td>
  			<td>
  				Crysvita
  			</td>
  			<td>
  				12/14/2009
  			</td>
  			<td>
  				Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older
	  			</td>
				
	  			<td>
					
						04/17/2018
					
	  			</td>

	  			<td>

					
					04/17/2025
					
					
	  			</td>

				<td>
					CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older
				</td>
			
  			<td>
  				Kyowa Kirin, Inc.
  			</td>
  			<td>
  				135 US Highway 202/206
  			</td>
  			<td>
  				Suite 6
  			</td>
  			<td>
  				Bedminster
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07921
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				296109
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ofatumumab
  			</td>
  			<td>
  				ARZERRA
  			</td>
  			<td>
  				03/10/2009
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
	  			</td>
				
	  			<td>
					
						04/17/2014
					
	  			</td>

	  			<td>

					
					04/17/2021
					
					
	  			</td>

				<td>
					Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				275809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				08/22/2016
  			</td>
  			<td>
  				Treatment of esophageal cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
	  			</td>
				
	  			<td>
					
						04/16/2021
					
	  			</td>

	  			<td>

					
					04/16/2028
					
					
	  			</td>

				<td>
					treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				531016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				Opdivo
  			</td>
  			<td>
  				12/20/2016
  			</td>
  			<td>
  				Treatment of gastric cancer and gastro-esophageal junction cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
	  			</td>
				
	  			<td>
					
						04/16/2021
					
	  			</td>

	  			<td>

					
					04/16/2028
					
					
	  			</td>

				<td>
					treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				545016
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Leuprolide acetate
  			</td>
  			<td>
  				Lupron Injection
  			</td>
  			<td>
  				07/25/1988
  			</td>
  			<td>
  				Treatment of central precocious puberty
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of children with central precocious puberty
	  			</td>
				
	  			<td>
					
						04/16/1993
					
	  			</td>

	  			<td>

					
					04/16/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AbbVie Endocrine Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				028688
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mitomycin 
  			</td>
  			<td>
  				Jelmyto
  			</td>
  			<td>
  				09/08/2014
  			</td>
  			<td>
  				Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				JELMYTO™ is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC)
	  			</td>
				
	  			<td>
					
						04/15/2020
					
	  			</td>

	  			<td>

					
					04/15/2027
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).
				</td>
			
  			<td>
  				UroGen Pharma, Ltd.
  			</td>
  			<td>
  				9 Ha'Ta'asiya St., POB 2397
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ra'anana
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Israel
  			</td>
			<td>
  				445114
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				afatinib
  			</td>
  			<td>
  				Gilotrif
  			</td>
  			<td>
  				08/03/2015
  			</td>
  			<td>
  				Treatment of non-small cell lung cancer with squamous histology.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy
	  			</td>
				
	  			<td>
					
						04/15/2016
					
	  			</td>

	  			<td>

					
					04/15/2023
					
					
	  			</td>

				<td>
					Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy
				</td>
			
  			<td>
  				Boehringer Ingelheim Pharmaceuticals, Inc.
  			</td>
  			<td>
  				900 Ridgebury Road
  			</td>
  			<td>
  				P. O. Box 368
  			</td>
  			<td>
  				Ridgefield
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06877
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				484115
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				riboflavin ophthalmic solution & ultraviolet A 
  			</td>
  			<td>
  				Photrexa Viscous
  			</td>
  			<td>
  				09/02/2011
  			</td>
  			<td>
  				Treatment of keratoconus
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for use in corneal collagen crosslinking in combination with the KXL™ System for the treatment of progressive keratoconus
	  			</td>
				
	  			<td>
					
						04/15/2016
					
	  			</td>

	  			<td>

					
					04/15/2023
					
					
	  			</td>

				<td>
					Treatment of progressive keratoconus
				</td>
			
  			<td>
  				Avedro, Inc.
  			</td>
  			<td>
  				230 Third Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				344911
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				epoprostenol
  			</td>
  			<td>
  				Flolan
  			</td>
  			<td>
  				03/22/1999
  			</td>
  			<td>
  				Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.
	  			</td>
				
	  			<td>
					
						04/14/2000
					
	  			</td>

	  			<td>

					
					04/14/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				GlaxoSmithKline
  			</td>
  			<td>
  				2301 Renaissance Blvd
  			</td>
  			<td>
  				P. O. Box 61540
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				121698
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				recombinant von Willebrand factor (rhVWF)
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				11/23/2010
  			</td>
  			<td>
  				Treatment of von Willebrand disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding
	  			</td>
				
	  			<td>
					
						04/13/2018
					
	  			</td>

	  			<td>

					
					04/13/2025
					
					
	  			</td>

				<td>
					Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				650 E. Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				322210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ibuprofen lysine
  			</td>
  			<td>
  				NeoProfen
  			</td>
  			<td>
  				10/29/1996
  			</td>
  			<td>
  				Treatment of patent ductus arteriosus
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is  ineffective
	  			</td>
				
	  			<td>
					
						04/13/2006
					
	  			</td>

	  			<td>

					
					04/13/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Lundbeck, Inc.
  			</td>
  			<td>
  				Four Parkway North
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				101496
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				venetoclax
  			</td>
  			<td>
  				VENCLEXTA
  			</td>
  			<td>
  				09/20/2012
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy
	  			</td>
				
	  			<td>
					
						04/11/2016
					
	  			</td>

	  			<td>

					
					04/11/2023
					
					
	  			</td>

				<td>
					Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy
				</td>
			
  			<td>
  				AbbVie, Inc
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				Dept. PA72, Bldg. AP30
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				375612
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				selumetinib
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				02/14/2018
  			</td>
  			<td>
  				Treatment of Neurofibromatosis Type 1
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)
	  			</td>
				
	  			<td>
					
						04/10/2020
					
	  			</td>

	  			<td>

					
					04/10/2027
					
					
	  			</td>

				<td>
					Indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				624017
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				everolimus
  			</td>
  			<td>
  				Afinitor 
  			</td>
  			<td>
  				06/08/2009
  			</td>
  			<td>
  				 Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. 
	  			</td>
				
	  			<td>
					
						04/10/2018
					
	  			</td>

	  			<td>

					
					04/10/2025
					
					
	  			</td>

				<td>
					For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. 
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza, 315/5450A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				283609
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Levocarnitine
  			</td>
  			<td>
  				Carnitor
  			</td>
  			<td>
  				02/28/1984
  			</td>
  			<td>
  				Treatment of genetic carnitine deficiency.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						04/10/1986
					
	  			</td>

	  			<td>

					
					04/10/1993
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Leadiant Biosciences, Inc.
  			</td>
  			<td>
  				9841 Washingtonian Blvd
  			</td>
  			<td>
  				Suite 500
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20878
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				001384
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Synthetic human secretin
  			</td>
  			<td>
  				Chirostim
  			</td>
  			<td>
  				06/16/1999
  			</td>
  			<td>
  				For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography
	  			</td>
				
	  			<td>
					
						04/09/2004
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ChiRhoClin, Inc.
  			</td>
  			<td>
  				15500 Gallaudet Ave.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Silver Spring
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20905
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				120798
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Sacrosidase
  			</td>
  			<td>
  				Sucraid
  			</td>
  			<td>
  				12/10/1993
  			</td>
  			<td>
  				Treatment of congenital sucrase-isomaltase deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.
	  			</td>
				
	  			<td>
					
						04/09/1998
					
	  			</td>

	  			<td>

					
					04/09/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				QOL Medical, LLC
  			</td>
  			<td>
  				4445 North Highway A1A, 241
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Vero Beach
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				32963
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				078693
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				methylene blue0.5%
  			</td>
  			<td>
  				ProvayBlue
  			</td>
  			<td>
  				12/18/2012
  			</td>
  			<td>
  				Treatment of hereditary and acquired methemoglobinemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For treatment of pediatric and adult patients with acquired methemoglobinemia.
	  			</td>
				
	  			<td>
					
						04/08/2016
					
	  			</td>

	  			<td>

					
					04/08/2023
					
					
	  			</td>

				<td>
					For treatment of pediatric and adult patients with acquired methemoglobinemia.
				</td>
			
  			<td>
  				Provepharm SAS
  			</td>
  			<td>
  				Technopote de Chateau-Combert
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Marseille
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				385512
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Fluocinolone
  			</td>
  			<td>
  				Retisert
  			</td>
  			<td>
  				07/31/2000
  			</td>
  			<td>
  				Treatment uveitis involving the posterior segment of the eye.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
	  			</td>
				
	  			<td>
					
						04/08/2005
					
	  			</td>

	  			<td>

					
					04/08/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bausch & Lomb Pharmaceuticals, Inc.
  			</td>
  			<td>
  				8500 Hidden River Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tampa
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				33637
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				132800
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Daunorubicin citrate liposome injection
  			</td>
  			<td>
  				DaunoXome
  			</td>
  			<td>
  				05/14/1993
  			</td>
  			<td>
  				Treatment of patients with advanced HIV-associated Kaposi's sarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma. 
	  			</td>
				
	  			<td>
					
						04/08/1996
					
	  			</td>

	  			<td>

					
					04/08/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				NeXstar Pharmaceuticals, Inc.
  			</td>
  			<td>
  				650 Cliffside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Dimas
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91773
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				073693
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ledipasvir/sofosbuvir
  			</td>
  			<td>
  				Harvoni
  			</td>
  			<td>
  				10/12/2016
  			</td>
  			<td>
  				Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
	  			</td>
				
	  			<td>
					
						04/07/2017
					
	  			</td>

	  			<td>

					
					04/07/2024
					
					
	  			</td>

				<td>
					Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				535916
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sofosbuvir
  			</td>
  			<td>
  				Sovaldi
  			</td>
  			<td>
  				10/25/2016
  			</td>
  			<td>
  				Treatment of pediatric chronic hepatitis C virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
	  			</td>
				
	  			<td>
					
						04/07/2017
					
	  			</td>

	  			<td>

					
					04/07/2024
					
					
	  			</td>

				<td>
					Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				541716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				artemether/lumefantrine
  			</td>
  			<td>
  				Coartem
  			</td>
  			<td>
  				08/31/2007
  			</td>
  			<td>
  				For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum
	  			</td>
				
	  			<td>
					
						04/07/2009
					
	  			</td>

	  			<td>

					
					04/07/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals
  			</td>
  			<td>
  				Bldg 405/4051
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				245507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Methotrexate sodium
  			</td>
  			<td>
  				Methotrexate
  			</td>
  			<td>
  				10/21/1985
  			</td>
  			<td>
  				Treatment of osteogenic sarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.
	  			</td>
				
	  			<td>
					
						04/07/1988
					
	  			</td>

	  			<td>

					
					04/07/1995
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Lederle Laboratories
  			</td>
  			<td>
  				Division of American Cyanamid Company
  			</td>
  			<td>
  				401 N. Middletown Road
  			</td>
  			<td>
  				Pearl River
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10965
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				009985
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rucaparib
  			</td>
  			<td>
  				Rubraca
  			</td>
  			<td>
  				07/31/2012
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. 
	  			</td>
				
	  			<td>
					
						04/06/2018
					
	  			</td>

	  			<td>

					
					04/06/2025
					
					
	  			</td>

				<td>
					For the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy. 
				</td>
			
  			<td>
  				Clovis Oncology, Inc.
  			</td>
  			<td>
  				5500 Flatiron Parkway
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Boulder
  			</td>
  			<td>
  				Colorado
  			</td>
  			<td>
  				80301
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				374712
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				vandetanib
  			</td>
  			<td>
  				CAPRELSA(r)
  			</td>
  			<td>
  				10/21/2005
  			</td>
  			<td>
  				Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease
	  			</td>
				
	  			<td>
					
						04/06/2011
					
	  			</td>

	  			<td>

					
					04/06/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				500 Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				211005
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				hepatitis B immune globulin (human)
  			</td>
  			<td>
  				HepaGam B
  			</td>
  			<td>
  				03/24/2008
  			</td>
  			<td>
  				Prevention of hepatitis B recurrence following orthotopic liver transplant
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients
	  			</td>
				
	  			<td>
					
						04/06/2007
					
	  			</td>

	  			<td>

					
					04/06/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cangene Corporation
  			</td>
  			<td>
  				155 Innovation Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Winnipeg
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				228506
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				alpelisib
  			</td>
  			<td>
  				Vijoice
  			</td>
  			<td>
  				11/18/2019
  			</td>
  			<td>
  				Treatment of PIK3CA-related overgrowth spectrum 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy
	  			</td>
				
	  			<td>
					
						04/05/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				710819
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Alglucerase injection
  			</td>
  			<td>
  				Ceredase
  			</td>
  			<td>
  				03/11/1985
  			</td>
  			<td>
  				For replacement therapy in patients with Gaucher's disease type I.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a) moderate-to-severe anemia; b) thrombocytopenia with bleeding tendency; c) bone disease; d) significant hepatomegaly or splenomegaly.
	  			</td>
				
	  			<td>
					
						04/05/1991
					
	  			</td>

	  			<td>

					
					04/05/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				One Kendall Square
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				005585
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ethiodized oil injection
  			</td>
  			<td>
  				Lipiodol
  			</td>
  			<td>
  				09/26/2013
  			</td>
  			<td>
  				Management of patients with known hepatocellular carcinoma (HCC)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)
	  			</td>
				
	  			<td>
					
						04/04/2014
					
	  			</td>

	  			<td>

					
					04/04/2021
					
					
	  			</td>

				<td>
					Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)
				</td>
			
  			<td>
  				Guerbet LLC
  			</td>
  			<td>
  				120 West 7th St., Suite 108
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bloomington
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				47404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				400113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Synthetic porcine secretin
  			</td>
  			<td>
  				Secreflo
  			</td>
  			<td>
  				06/18/1999
  			</td>
  			<td>
  				For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma
	  			</td>
				
	  			<td>
					
						04/04/2002
					
	  			</td>

	  			<td>

					
					04/04/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ChiRhoClin, Inc.
  			</td>
  			<td>
  				15500 Gallaudet Ave.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Silver Spring
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20905
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				120498
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Synthetic porcine secretin
  			</td>
  			<td>
  				Secreflo
  			</td>
  			<td>
  				03/07/2000
  			</td>
  			<td>
  				For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use in secretin stimulation testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction
	  			</td>
				
	  			<td>
					
						04/04/2002
					
	  			</td>

	  			<td>

					
					04/04/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ChiRhoClin, Inc.
  			</td>
  			<td>
  				15500 Gallaudet Ave.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Silver Spring
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20905
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				130299
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Luspatercept
  			</td>
  			<td>
  				REBLOZYL
  			</td>
  			<td>
  				03/18/2013
  			</td>
  			<td>
  				Treatment of myelodysplastic syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
	  			</td>
				
	  			<td>
					
						04/03/2020
					
	  			</td>

	  			<td>

					
					04/03/2027
					
					
	  			</td>

				<td>
					For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS)
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				387112
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				d6-tetrabenazine, deutetrabenazine
  			</td>
  			<td>
  				Austedo
  			</td>
  			<td>
  				11/05/2014
  			</td>
  			<td>
  				Treatment of Huntington's Disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chorea associated with Huntington’s disease
	  			</td>
				
	  			<td>
					
						04/03/2017
					
	  			</td>

	  			<td>

					
					04/03/2024
					
					
	  			</td>

				<td>
					Treatment of chorea associated with Huntington’s disease
				</td>
			
  			<td>
  				Teva Branded Pharmaceutical Products R&D, Inc.
  			</td>
  			<td>
  				3333 N. Torrey Pines Court
  			</td>
  			<td>
  				Suite 400
  			</td>
  			<td>
  				La Jolla
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92037
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				383212
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Filgrastim
  			</td>
  			<td>
  				Neupogen
  			</td>
  			<td>
  				11/07/1996
  			</td>
  			<td>
  				Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.
	  			</td>
				
	  			<td>
					
						04/02/1998
					
	  			</td>

	  			<td>

					
					04/02/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Dr.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				101096
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				axicabtagene ciloleucel
  			</td>
  			<td>
  				Yescarta
  			</td>
  			<td>
  				04/25/2016
  			</td>
  			<td>
  				Treatment of follicular lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
	  			</td>
				
	  			<td>
					
						04/01/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Kite Pharma Inc.
  			</td>
  			<td>
  				2400 Broadway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515615
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				axicabtagene ciloleucel
  			</td>
  			<td>
  				Yescarta
  			</td>
  			<td>
  				04/20/2016
  			</td>
  			<td>
  				Treatment of primary mediastinal B-cell lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
	  			</td>
				
	  			<td>
					
						04/01/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Kite Pharma, Inc.
  			</td>
  			<td>
  				2225 Colorado Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				axicabtagene ciloleucel
  			</td>
  			<td>
  				Yescarta
  			</td>
  			<td>
  				03/27/2014
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
	  			</td>
				
	  			<td>
					
						04/01/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Kite Pharma, Inc.
  			</td>
  			<td>
  				2225 Colorado Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				423914
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				alirocumab
  			</td>
  			<td>
  				Praluent
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of homozygous familial hypercholesterolemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				as an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C 
	  			</td>
				
	  			<td>
					
						04/01/2021
					
	  			</td>

	  			<td>

					
					04/01/2028
					
					
	  			</td>

				<td>
					as an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C 
				</td>
			
  			<td>
  				Regeneron Pharmaceuticals, Inc.
  			</td>
  			<td>
  				777 Old Saw Mill River Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tarrytown
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10591
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				580617
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Crotalidae Immune F(ab')2 (Equine)
  			</td>
  			<td>
  				Anavip
  			</td>
  			<td>
  				01/29/2004
  			</td>
  			<td>
  				Treatment of envenomation by Crotaline snakes
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the management of adult and pediatric patients with North American Pit Viper envenomation
	  			</td>
				
	  			<td>
					
						04/01/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Rare Disease Therapeutics, Inc.
  			</td>
  			<td>
  				2550 Meridian Blvd.
  			</td>
  			<td>
  				Suite 150
  			</td>
  			<td>
  				Franklin
  			</td>
  			<td>
  				Tennessee
  			</td>
  			<td>
  				37067
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177503
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cytarabine liposomal
  			</td>
  			<td>
  				DepoCyt
  			</td>
  			<td>
  				06/02/1993
  			</td>
  			<td>
  				Treatment of neoplastic meningitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Intrathecal treatment of lymphomatous meningitis.
	  			</td>
				
	  			<td>
					
						04/01/1999
					
	  			</td>

	  			<td>

					
					04/01/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Pacira Pharmaceuticals, Inc.
  			</td>
  			<td>
  				10450 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				073393
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized
  			</td>
  			<td>
  				Humate-P
  			</td>
  			<td>
  				10/16/1992
  			</td>
  			<td>
  				Treatment of patients with von Willebrand's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				(1) In adult patients for treatment and prevention of bleeding in hemophilia A (classic hemophilia) and (2) in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate.
	  			</td>
				
	  			<td>
					
						04/01/1999
					
	  			</td>

	  			<td>

					
					04/01/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CSL Behring
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King Of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				067992
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				isatuximab-irfc
  			</td>
  			<td>
  				Sarclisa
  			</td>
  			<td>
  				05/22/2014
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy
	  			</td>
				
	  			<td>
					
						03/31/2021
					
	  			</td>

	  			<td>

					
					03/31/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 prior line of therapy, and for treatment of adult patients with relapsed or refractory multiple myeloma who have received 2 to 3 prior therapies excluding patients covered by the indication approved on March 2, 2020
				</td>
			
  			<td>
  				Sanofi U.S. Services, Inc.
  			</td>
  			<td>
  				50 Binney St.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				431914
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection
  			</td>
  			<td>
  				VYXEOS ; Vyxeos ; Vyxeos 
  			</td>
  			<td>
  				08/22/2008
  			</td>
  			<td>
  				Treatment of acute myeloid leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients ages 1 year and older
	  			</td>
				
	  			<td>
					
						03/30/2021
					
	  			</td>

	  			<td>

					
					03/30/2028
					
					
	  			</td>

				<td>
					treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients ages 1 year and older
				</td>
			
  			<td>
  				Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)
  			</td>
  			<td>
  				3170 Porter Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94304
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				265808
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				defibrotide
  			</td>
  			<td>
  				Defitelio
  			</td>
  			<td>
  				05/21/2003
  			</td>
  			<td>
  				For the treatment of hepatic veno-occlusive disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).
	  			</td>
				
	  			<td>
					
						03/30/2016
					
	  			</td>

	  			<td>

					
					03/30/2023
					
					
	  			</td>

				<td>
					For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).
				</td>
			
  			<td>
  				Jazz Pharmaceuticals, Inc.
  			</td>
  			<td>
  				3180 Porter Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94304
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				168803
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				filgrastim
  			</td>
  			<td>
  				Neupogen
  			</td>
  			<td>
  				11/20/2013
  			</td>
  			<td>
  				Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome). 
	  			</td>
				
	  			<td>
					
						03/30/2015
					
	  			</td>

	  			<td>

					
					03/30/2022
					
					
	  			</td>

				<td>
					To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome). 
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				M/S 17-1-C
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				413113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Protein C concentrate
  			</td>
  			<td>
  				Ceprotin
  			</td>
  			<td>
  				06/23/1992
  			</td>
  			<td>
  				For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention and treatment of venous thrombosis and purpura fulminans
	  			</td>
				
	  			<td>
					
						03/30/2007
					
	  			</td>

	  			<td>

					
					03/30/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				One Baxter Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				West Lake Village
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91362
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				065392
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				acyclovir 
  			</td>
  			<td>
  				Avaclyr
  			</td>
  			<td>
  				12/13/2010
  			</td>
  			<td>
  				Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.
	  			</td>
				
	  			<td>
					
						03/29/2019
					
	  			</td>

	  			<td>

					
					03/29/2026
					
					
	  			</td>

				<td>
					AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.
				</td>
			
  			<td>
  				Fera Pharmaceuticals
  			</td>
  			<td>
  				134 Birch Hill Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Locust Valley
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				11560
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				325010
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sargramostim
  			</td>
  			<td>
  				Leukine
  			</td>
  			<td>
  				11/09/2016
  			</td>
  			<td>
  				Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				LEUKINE® is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
	  			</td>
				
	  			<td>
					
						03/29/2018
					
	  			</td>

	  			<td>

					
					03/29/2025
					
					
	  			</td>

				<td>
					to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])
				</td>
			
  			<td>
  				Partner Therapeutics, Inc.
  			</td>
  			<td>
  				19 Muzzey Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				541816
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				blinatumomab
  			</td>
  			<td>
  				Blincyto
  			</td>
  			<td>
  				05/16/2008
  			</td>
  			<td>
  				Treatment of acute lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				BLINCYTO® is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.
	  			</td>
				
	  			<td>
					
						03/29/2018
					
	  			</td>

	  			<td>

					
					03/29/2025
					
					
	  			</td>

				<td>
					For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Dr.
  			</td>
  			<td>
  				Mail Stop 17-2-A
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				255707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				peginterferon alfa-2b
  			</td>
  			<td>
  				Sylatron
  			</td>
  			<td>
  				04/09/2008
  			</td>
  			<td>
  				Treatment of malignant melanoma stages IIb through IV. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy
	  			</td>
				
	  			<td>
					
						03/29/2011
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Merck, Sharpe & Dohme Corp.
  			</td>
  			<td>
  				1 Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				249507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tacrolimus
  			</td>
  			<td>
  				Prograf
  			</td>
  			<td>
  				06/06/2005
  			</td>
  			<td>
  				Prophylaxis of organ rejection in patients receiving heart transplants.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prophylaxis of organ rejection in patients receiving allogenic heart transplants. 
	  			</td>
				
	  			<td>
					
						03/29/2006
					
	  			</td>

	  			<td>

					
					03/29/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Astellas Pharma US, Inc.
  			</td>
  			<td>
  				Three Parkway North
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Deerfield
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60015
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				203305
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ecallantide; ecallantide
  			</td>
  			<td>
  				Kalbitor; Kalbitor
  			</td>
  			<td>
  				02/04/2003
  			</td>
  			<td>
  				Treatment of angioedema
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older
	  			</td>
				
	  			<td>
					
						03/28/2014
					
	  			</td>

	  			<td>

					
					03/28/2021
					
					
	  			</td>

				<td>
					Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.
				</td>
			
  			<td>
  				Takeda Pharmaceuticals USA, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				160802
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor IX (recombinant), Fc fusion protein
  			</td>
  			<td>
  				ALPROLIX
  			</td>
  			<td>
  				10/30/2008
  			</td>
  			<td>
  				Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.  
	  			</td>
				
	  			<td>
					
						03/28/2014
					
	  			</td>

	  			<td>

					
					03/28/2021
					
					
	  			</td>

				<td>
					Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.  
				</td>
			
  			<td>
  				Bioverativ Therapeutics, Inc.
  			</td>
  			<td>
  				225 2nd Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				261508
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				durvalumab
  			</td>
  			<td>
  				IMFINZI
  			</td>
  			<td>
  				07/10/2019
  			</td>
  			<td>
  				Treatment of small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
	  			</td>
				
	  			<td>
					
						03/27/2020
					
	  			</td>

	  			<td>

					
					03/27/2027
					
					
	  			</td>

				<td>
					Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
				</td>
			
  			<td>
  				AstraZeneca Pharmaceuticals LP
  			</td>
  			<td>
  				1800 Concord Pike
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19803
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				691319
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				niraparib
  			</td>
  			<td>
  				Zejula
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of ovarian cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
	  			</td>
				
	  			<td>
					
						03/27/2017
					
	  			</td>

	  			<td>

					
					03/27/2024
					
					
	  			</td>

				<td>
					Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in a complete or partial response to platinum-based chemotherapy
				</td>
			
  			<td>
  				GlaxoSmithKline, LLC.
  			</td>
  			<td>
  				1000 Winter St.
  			</td>
  			<td>
  				Suite 3300
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02451
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				306510
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				idecabtagene vicleucel
  			</td>
  			<td>
  				Abecma
  			</td>
  			<td>
  				05/11/2016
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
	  			</td>
				
	  			<td>
					
						03/26/2021
					
	  			</td>

	  			<td>

					
					03/26/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
				</td>
			
  			<td>
  				Celgene Corporation, a Bristol-Myers Squibb Company
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				520416
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fenfluramine
  			</td>
  			<td>
  				Fintepla
  			</td>
  			<td>
  				06/19/2017
  			</td>
  			<td>
  				Treatment of Lennox-Gastaut syndrome
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older
	  			</td>
				
	  			<td>
					
						03/25/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Zogenix Inc.
  			</td>
  			<td>
  				5858 Horton Street
  			</td>
  			<td>
  				Suite 455
  			</td>
  			<td>
  				Emeryville
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94608
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				584217
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ipilimumab
  			</td>
  			<td>
  				Yervoy
  			</td>
  			<td>
  				06/03/2004
  			</td>
  			<td>
  				Treatment of high risk Stage II, Stage III, and Stage IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of unresectable or metastatic melanoma
	  			</td>
				
	  			<td>
					
						03/25/2011
					
	  			</td>

	  			<td>

					
					03/25/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177703
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				bortezomib
  			</td>
  			<td>
  				Velcade
  			</td>
  			<td>
  				01/15/2003
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of multiple myeloma patients who have received at least  one prior therapy 
	  			</td>
				
	  			<td>
					
						03/25/2005
					
	  			</td>

	  			<td>

					
					03/25/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Millennium Pharmaceuticals, Inc.
  			</td>
  			<td>
  				40 Landsdowne Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				163002
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pegvisomant
  			</td>
  			<td>
  				Somavert
  			</td>
  			<td>
  				06/24/1997
  			</td>
  			<td>
  				Treatment of acromegaly.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate
	  			</td>
				
	  			<td>
					
						03/25/2003
					
	  			</td>

	  			<td>

					
					03/25/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Sensus Corporation
  			</td>
  			<td>
  				Suite 430,
  			</td>
  			<td>
  				98 San Jacinto Boulevard
  			</td>
  			<td>
  				Austin
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				78701
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				105097
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation factor VIIa (recombinant)
  			</td>
  			<td>
  				NovoSeven
  			</td>
  			<td>
  				06/06/1988
  			</td>
  			<td>
  				Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.  
	  			</td>
				
	  			<td>
					
						03/25/1999
					
	  			</td>

	  			<td>

					
					03/25/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novo Nordisk, Inc.
  			</td>
  			<td>
  				100 Overlook Center
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				026588
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Iobenguane Sulfate I 131
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				11/14/1984
  			</td>
  			<td>
  				For use as a diagnostic adjunct in patients with pheochromocytoma.
  			</td>
  			<td>
  				Designated/Approved/Withdrawn
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas.
	  			</td>
				
	  			<td>
					
						03/25/1994
					
	  			</td>

	  			<td>

					
					03/25/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				University of Michigan
  			</td>
  			<td>
  				UH B1 H410/0028
  			</td>
  			<td>
  				1500 E. Medical Center Drive
  			</td>
  			<td>
  				Ann Arbor
  			</td>
  			<td>
  				Michigan
  			</td>
  			<td>
  				48109
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				002284
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				anthrax immune globulin (human)
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				07/29/2008
  			</td>
  			<td>
  				Treatment of inhalational anthrax
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate  antibacterial drugs
	  			</td>
				
	  			<td>
					
						03/24/2015
					
	  			</td>

	  			<td>

					
					03/24/2022
					
					
	  			</td>

				<td>
					Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate  antibacterial drugs
				</td>
			
  			<td>
  				Cangene Corp. - Emergent Biosolutions
  			</td>
  			<td>
  				155 Innovation Drive
  			</td>
  			<td>
  				R3T 5Y3
  			</td>
  			<td>
  				Winnipeg, MB
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				263008
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rifaximin
  			</td>
  			<td>
  				Xifaxan
  			</td>
  			<td>
  				02/10/1998
  			</td>
  			<td>
  				Treatment of hepatic encephalopathy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age
	  			</td>
				
	  			<td>
					
						03/24/2010
					
	  			</td>

	  			<td>

					
					03/24/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Salix Pharmaceuticals, Inc.
  			</td>
  			<td>
  				400 Somerset Corporate Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Somerset
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				109497
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tenofovir 
  			</td>
  			<td>
  				Viread
  			</td>
  			<td>
  				03/17/2009
  			</td>
  			<td>
  				Treatment of pediatric HIV infection.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age
	  			</td>
				
	  			<td>
					
						03/24/2010
					
	  			</td>

	  			<td>

					
					03/24/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster city
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				276209
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Rho (D) immune globulin intravenous (human)
  			</td>
  			<td>
  				WinRho SD
  			</td>
  			<td>
  				11/09/1993
  			</td>
  			<td>
  				Treatment of immune thrombocytopenic purpura.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults and children with chronic and acute immune thrombocytopenic purpura.
	  			</td>
				
	  			<td>
					
						03/24/1995
					
	  			</td>

	  			<td>

					
					03/24/2002
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Rh Pharmaceuticals, Inc.
  			</td>
  			<td>
  				104 Chancellor Matheson Road
  			</td>
  			<td>
  				U of Manitoba
  			</td>
  			<td>
  				Winnipeg
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				074993
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1)
  			</td>
  			<td>
  				Bavencio
  			</td>
  			<td>
  				09/21/2015
  			</td>
  			<td>
  				Treatment of merkel cell carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma
	  			</td>
				
	  			<td>
					
						03/23/2017
					
	  			</td>

	  			<td>

					
					03/23/2024
					
					
	  			</td>

				<td>
					Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma
				</td>
			
  			<td>
  				EMD Serono Research and Development Institute, Inc. 
  			</td>
  			<td>
  				45A Middlesex Turnpike
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Billerica
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				01821
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				491815
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sirolimus 
  			</td>
  			<td>
  				Hyftor
  			</td>
  			<td>
  				05/17/2017
  			</td>
  			<td>
  				Treatment of angiofibroma associated with tuberous sclerosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older
	  			</td>
				
	  			<td>
					
						03/22/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				NobelPharma Co., LTD
  			</td>
  			<td>
  				12-10 Nihonbashi-kobunacho
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Chuo-ku
  			</td>
  			<td>
  				Tokyo-to
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Japan
  			</td>
			<td>
  				568416
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				Keytruda
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of esophageal carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:- in combination with platinum- and fluoropyrimidine-based chemotherapy, or- as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >/=10) as determined by an FD
	  			</td>
				
	  			<td>
					
						03/22/2021
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.
  			</td>
  			<td>
  				1 Merck Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Whitehouse Station
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08889
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				578717
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nilotinib; nilotinib; nilotinib
  			</td>
  			<td>
  				Tasigna; Tasigna; Tasigna 
  			</td>
  			<td>
  				04/27/2006
  			</td>
  			<td>
  				Treatment of chronic myelogenous leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.
	  			</td>
				
	  			<td>
					
						03/22/2018
					
	  			</td>

	  			<td>

					
					03/22/2025
					
					
	  			</td>

				<td>
					TASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				220806
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				06/29/2011
  			</td>
  			<td>
  				Treatment of botulism.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F or G in adults and pediatric patients. 
	  			</td>
				
	  			<td>
					
						03/22/2013
					
	  			</td>

	  			<td>

					
					03/22/2020
					
					
	  			</td>

				<td>
					Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients  
				</td>
			
  			<td>
  				Cangene Corporation
  			</td>
  			<td>
  				155 Innovation Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Winnipeg
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				345011
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pilocarpine
  			</td>
  			<td>
  				Salagen
  			</td>
  			<td>
  				09/24/1990
  			</td>
  			<td>
  				Treatment of xerostomia induced by radiation therapy for head and neck cancer.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.
	  			</td>
				
	  			<td>
					
						03/22/1994
					
	  			</td>

	  			<td>

					
					03/22/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				MGI Pharma, Inc.
  			</td>
  			<td>
  				5775 West Old Shakoppe Rd.
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Bloomington
  			</td>
  			<td>
  				Minnesota
  			</td>
  			<td>
  				55437
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				045990
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pegademase bovine
  			</td>
  			<td>
  				Adagen
  			</td>
  			<td>
  				05/29/1984
  			</td>
  			<td>
  				For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						03/21/1990
					
	  			</td>

	  			<td>

					
					03/21/1997
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Sigma-tau Pharmaceuticals, Inc.
  			</td>
  			<td>
  				9841 Washingtonian Blvd
  			</td>
  			<td>
  				Suite 500
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20878
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				002084
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				brentuximab vedotin
  			</td>
  			<td>
  				Adcetris
  			</td>
  			<td>
  				01/30/2007
  			</td>
  			<td>
  				Treatment of Hodgkin's lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.
	  			</td>
				
	  			<td>
					
						03/20/2018
					
	  			</td>

	  			<td>

					
					03/20/2025
					
					
	  			</td>

				<td>
					ADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.
				</td>
			
  			<td>
  				Seagen Inc.
  			</td>
  			<td>
  				21823 30th Drive Southeast
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bothell
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98021
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				235606
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Bendamustine hydrochloride
  			</td>
  			<td>
  				Treanda
  			</td>
  			<td>
  				08/17/2007
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with chronic lymphocytic leukemia
	  			</td>
				
	  			<td>
					
						03/20/2008
					
	  			</td>

	  			<td>

					
					03/20/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cephalon, Inc.
  			</td>
  			<td>
  				41 Moores Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Frazer
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				244807
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sofosbuvir/velpatasvir
  			</td>
  			<td>
  				Epclusa
  			</td>
  			<td>
  				02/22/2017
  			</td>
  			<td>
  				Treatment of pediatric patients with chronic hepatitis C virus infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				EPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for use in combination with ribavirin.                      
	  			</td>
				
	  			<td>
					
						03/19/2020
					
	  			</td>

	  			<td>

					
					03/19/2027
					
					
	  			</td>

				<td>
					For the treatment of pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for use in combination with ribavirin.
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				554816
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				miltefosine
  			</td>
  			<td>
  				IMPAVIDO
  			</td>
  			<td>
  				10/10/2006
  			</td>
  			<td>
  				Treatment of leishmaniasis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.  
	  			</td>
				
	  			<td>
					
						03/19/2014
					
	  			</td>

	  			<td>

					
					03/19/2021
					
					
	  			</td>

				<td>
					Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.  
				</td>
			
  			<td>
  				Knight Therapeutics (USA)
  			</td>
  			<td>
  				Corporation Trust Center
  			</td>
  			<td>
  				1209 Orange Street
  			</td>
  			<td>
  				Wilmington
  			</td>
  			<td>
  				Delaware
  			</td>
  			<td>
  				19801
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				229406
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Lidocaine patch 5%
  			</td>
  			<td>
  				Lidoderm Patch
  			</td>
  			<td>
  				10/24/1995
  			</td>
  			<td>
  				For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						03/19/1999
					
	  			</td>

	  			<td>

					
					03/19/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Teikoku Pharma USA, Inc.
  			</td>
  			<td>
  				745-D Camden Ave.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Campbell
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				95008
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				092395
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				zidovudine
  			</td>
  			<td>
  				Retrovir
  			</td>
  			<td>
  				07/17/1985
  			</td>
  			<td>
  				Treatment of AIDS
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun
	  			</td>
				
	  			<td>
					
						03/19/1987
					
	  			</td>

	  			<td>

					
					03/19/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Inc.
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				008185
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab and relatlimab-rmbw
  			</td>
  			<td>
  				Opdualag
  			</td>
  			<td>
  				08/18/2017
  			</td>
  			<td>
  				Treatment of stage IIb to IV melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma
	  			</td>
				
	  			<td>
					
						03/18/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Co.
  			</td>
  			<td>
  				5 Research Parkway
  			</td>
  			<td>
  				P.O. Box 5100
  			</td>
  			<td>
  				Wallingford
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06492
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				595017
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rilonacept
  			</td>
  			<td>
  				Arcalyst
  			</td>
  			<td>
  				07/14/2020
  			</td>
  			<td>
  				Treatment of pericarditis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older
	  			</td>
				
	  			<td>
					
						03/18/2021
					
	  			</td>

	  			<td>

					
					03/18/2028
					
					
	  			</td>

				<td>
					Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older
				</td>
			
  			<td>
  				Kiniksa Pharmaceuticals, Ltd.
  			</td>
  			<td>
  				c/o Kiniksa Pharmaceuticals Corp.
  			</td>
  			<td>
  				100 Hayden Avenue
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				649718
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				atezolizumab
  			</td>
  			<td>
  				TECENTRIQ
  			</td>
  			<td>
  				10/13/2016
  			</td>
  			<td>
  				Treatment of small cell lung cancer (SCLC)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TECENTRIQ®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
	  			</td>
				
	  			<td>
					
						03/18/2019
					
	  			</td>

	  			<td>

					
					03/18/2026
					
					
	  			</td>

				<td>
					TECENTRIQ®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				541216
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				obiltoxaximab
  			</td>
  			<td>
  				Anthim
  			</td>
  			<td>
  				06/09/2006
  			</td>
  			<td>
  				Treatment of exposure to B. anthracis spores
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate.
	  			</td>
				
	  			<td>
					
						03/18/2016
					
	  			</td>

	  			<td>

					
					03/18/2023
					
					
	  			</td>

				<td>
					1) Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and (2) for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
				</td>
			
  			<td>
  				Elusys Therapeutics, Inc.
  			</td>
  			<td>
  				25 Riverside Drive
  			</td>
  			<td>
  				P.O. Box 102
  			</td>
  			<td>
  				Pine Brook
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07058
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				224306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				carglumic acid
  			</td>
  			<td>
  				Carbaglu
  			</td>
  			<td>
  				01/20/1998
  			</td>
  			<td>
  				Treatment of N-acetylglutamate synthetase deficiency. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As an adjunctive therapy for  the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency
	  			</td>
				
	  			<td>
					
						03/18/2010
					
	  			</td>

	  			<td>

					
					03/18/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Orphan Europe SARL
  			</td>
  			<td>
  				Immeuble Le Wilson
  			</td>
  			<td>
  				70 avenue du General de Gaulle
  			</td>
  			<td>
  				Puteaux
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				109997
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R ; and treatment of CF in patients age 2 years and older who have an R117H mutation in the CFTR gene.  
	  			</td>
				
	  			<td>
					
						03/17/2015
					
	  			</td>

	  			<td>

					
					03/17/2022
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis (CF) in patients ages 2 to less than 6 years who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, and R117H.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cholic acid 
  			</td>
  			<td>
  				Cholbam
  			</td>
  			<td>
  				07/18/2003
  			</td>
  			<td>
  				Treatment of inborn errors of cholesterol and bile acid synthesis and  metabolism
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of bile acid synthesis disorders due to single enzyme defects 
	  			</td>
				
	  			<td>
					
						03/17/2015
					
	  			</td>

	  			<td>

					
					03/17/2022
					
					
	  			</td>

				<td>
					Treatment of bile acid synthesis disorders due to single enzyme defects 
				</td>
			
  			<td>
  				Retrophin, Inc.
  			</td>
  			<td>
  				777 Third Avenue
  			</td>
  			<td>
  				22nd Floor
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				170503
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eculizumab
  			</td>
  			<td>
  				Soliris
  			</td>
  			<td>
  				08/20/2003
  			</td>
  			<td>
  				Treatment of paroxysmal nocturnal hemoglobinuria
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis
	  			</td>
				
	  			<td>
					
						03/16/2007
					
	  			</td>

	  			<td>

					
					03/16/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Alexion Pharmaceuticals, Inc.
  			</td>
  			<td>
  				121 Seaport Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				173203
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Immune Globulin Subcutaneous (Human), 20% Liquid
  			</td>
  			<td>
  				Hizentra
  			</td>
  			<td>
  				08/18/2014
  			</td>
  			<td>
  				Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
	  			</td>
				
	  			<td>
					
						03/15/2018
					
	  			</td>

	  			<td>

					
					03/15/2025
					
					
	  			</td>

				<td>
					Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment
				</td>
			
  			<td>
  				CSL Behring
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				439914
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				temozolomide
  			</td>
  			<td>
  				Temodar
  			</td>
  			<td>
  				10/05/1998
  			</td>
  			<td>
  				Treatment of recurrent malignant glioma.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment
	  			</td>
				
	  			<td>
					
						03/15/2005
					
	  			</td>

	  			<td>

					
					03/15/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Schering-Plough Research Institute
  			</td>
  			<td>
  				2000 Galloping Hill Rd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kenilworth
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07033
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				116798
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				KEYTRUDA
  			</td>
  			<td>
  				12/30/2015
  			</td>
  			<td>
  				Treatment of Hodgkin lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.
	  			</td>
				
	  			<td>
					
						03/14/2017
					
	  			</td>

	  			<td>

					
					03/14/2024
					
					
	  			</td>

				<td>
					Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.
				</td>
			
  			<td>
  				Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc
  			</td>
  			<td>
  				126 E. Lincoln Avenue
  			</td>
  			<td>
  				P. O. Box 2000
  			</td>
  			<td>
  				Rathway
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				07065
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				502415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				propranolol 
  			</td>
  			<td>
  				HEMANGEOL
  			</td>
  			<td>
  				09/05/2008
  			</td>
  			<td>
  				Treatment of proliferating infantile hemangiomas requiring systemic therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of proliferating infantile hemangioma requiring systemic therapy.  
	  			</td>
				
	  			<td>
					
						03/14/2014
					
	  			</td>

	  			<td>

					
					03/14/2021
					
					
	  			</td>

				<td>
					Treatment of proliferating infantile hemangioma requiring systemic therapy.  
				</td>
			
  			<td>
  				Pierre Fabre Dermatologie
  			</td>
  			<td>
  				8 Campus Drive, 2nd Floor
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Parsippany
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07054
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				266708
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Anagrelide
  			</td>
  			<td>
  				Agrylin
  			</td>
  			<td>
  				01/27/1988
  			</td>
  			<td>
  				Treatment of essential thrombocythemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.
	  			</td>
				
	  			<td>
					
						03/14/1997
					
	  			</td>

	  			<td>

					
					03/14/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				020887
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				agalsidase beta
  			</td>
  			<td>
  				Fabrazyme
  			</td>
  			<td>
  				01/19/1988
  			</td>
  			<td>
  				Treatment of Fabry's disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease
	  			</td>
				
	  			<td>
					
						03/11/2021
					
	  			</td>

	  			<td>

					
					03/11/2028
					
					
	  			</td>

				<td>
					treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease
				</td>
			
  			<td>
  				Genzyme Corporation
  			</td>
  			<td>
  				50 Binney Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				015286
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				crizotinib
  			</td>
  			<td>
  				Xalkori
  			</td>
  			<td>
  				09/13/2010
  			</td>
  			<td>
  				Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive
	  			</td>
				
	  			<td>
					
						03/11/2016
					
	  			</td>

	  			<td>

					
					03/11/2023
					
					
	  			</td>

				<td>
					Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				10646 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				310610
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				nivolumab
  			</td>
  			<td>
  				OPDIVO
  			</td>
  			<td>
  				09/02/2015
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
	  			</td>
				
	  			<td>
					
						03/10/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Company
  			</td>
  			<td>
  				P. O. Box 5326
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				489915
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				melphalan 
  			</td>
  			<td>
  				EVOMELA
  			</td>
  			<td>
  				11/24/2008
  			</td>
  			<td>
  				High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
	  			</td>
				
	  			<td>
					
						03/10/2016
					
	  			</td>

	  			<td>

					
					03/10/2023
					
					
	  			</td>

				<td>
					for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma
				</td>
			
  			<td>
  				Acrotech Biopharma LLC
  			</td>
  			<td>
  				279 Princeton Hightstown Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Windsor
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				270008
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dinutuximab
  			</td>
  			<td>
  				Unituxin
  			</td>
  			<td>
  				12/20/2010
  			</td>
  			<td>
  				Treatment of neuroblastoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy
	  			</td>
				
	  			<td>
					
						03/10/2015
					
	  			</td>

	  			<td>

					
					03/10/2022
					
					
	  			</td>

				<td>
					For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy
				</td>
			
  			<td>
  				United Therapeutics Corporation
  			</td>
  			<td>
  				55 TW Alexander Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				324210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				immune globulin intravenous (human)
  			</td>
  			<td>
  				Gammaplex
  			</td>
  			<td>
  				04/29/2011
  			</td>
  			<td>
  				Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Idiopathic thrombocytopenic purpura
	  			</td>
				
	  			<td>
					
						03/08/2013
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bio Products Laboratory
  			</td>
  			<td>
  				Dagger Lane
  			</td>
  			<td>
  				Hertfordshire
  			</td>
  			<td>
  				England
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				335211
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cinacalcet
  			</td>
  			<td>
  				Sensipar
  			</td>
  			<td>
  				05/12/2003
  			</td>
  			<td>
  				Treatment of hypercalcemia in patients with parathyroid carcinoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of hypercalcemia in patients with parathyroid carcinoma
	  			</td>
				
	  			<td>
					
						03/08/2004
					
	  			</td>

	  			<td>

					
					03/08/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				 
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				163402
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Somatropin for injection
  			</td>
  			<td>
  				Humatrope
  			</td>
  			<td>
  				06/12/1986
  			</td>
  			<td>
  				For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						03/08/1987
					
	  			</td>

	  			<td>

					
					03/08/1994
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				011285
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Levoleucovorin
  			</td>
  			<td>
  				Fusilev
  			</td>
  			<td>
  				08/01/1991
  			</td>
  			<td>
  				For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists
	  			</td>
				
	  			<td>
					
						03/07/2008
					
	  			</td>

	  			<td>

					
					03/07/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Acrotech Biopharma LLC
  			</td>
  			<td>
  				279 Princeton Hightstown Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Windsor
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				048490
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Desmopressin acetate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				01/22/1991
  			</td>
  			<td>
  				Treatment of mild hemophilia A and von Willebrand's disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.
	  			</td>
				
	  			<td>
					
						03/07/1994
					
	  			</td>

	  			<td>

					
					03/07/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Ferring Pharmaceuticals, Inc.
  			</td>
  			<td>
  				100 Interpace Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Parsippany-Troy Hills
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07054
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				051490
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				osilodrostat
  			</td>
  			<td>
  				Isturisa
  			</td>
  			<td>
  				09/13/2013
  			</td>
  			<td>
  				Treatment of Cushing's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
	  			</td>
				
	  			<td>
					
						03/06/2020
					
	  			</td>

	  			<td>

					
					03/06/2027
					
					
	  			</td>

				<td>
					For the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
				</td>
			
  			<td>
  				Recordati Rare Diseases, Inc
  			</td>
  			<td>
  				100 Corporate Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lebanon
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08833
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				405113
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibalizumab
  			</td>
  			<td>
  				Trogarzo
  			</td>
  			<td>
  				10/20/2014
  			</td>
  			<td>
  				Treatment of HIV-1 infection in  treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
	  			</td>
				
	  			<td>
					
						03/06/2018
					
	  			</td>

	  			<td>

					
					03/06/2025
					
					
	  			</td>

				<td>
					TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
				</td>
			
  			<td>
  				Theratechnologies Inc.
  			</td>
  			<td>
  				2015 Peel Street
  			</td>
  			<td>
  				5th Floor
  			</td>
  			<td>
  				Montreal
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Canada
  			</td>
			<td>
  				321910
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				isavuconazonium sulfate
  			</td>
  			<td>
  				Cresemba
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of invasive aspergillosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of invasive aspergillosis in patients 18 years of age and older
	  			</td>
				
	  			<td>
					
						03/06/2015
					
	  			</td>

	  			<td>

					
					03/06/2022
					
					
	  			</td>

				<td>
					Treatment of invasive aspergillosis in patients 18 years of age and older
				</td>
			
  			<td>
  				Astellas Pharma Global Development Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				394913
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				isavuconazonium sulfate
  			</td>
  			<td>
  				Cresemba
  			</td>
  			<td>
  				10/25/2013
  			</td>
  			<td>
  				Treatment of zygomycosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of invasive mucormycosis in patients 18 years of age and older
	  			</td>
				
	  			<td>
					
						03/06/2015
					
	  			</td>

	  			<td>

					
					03/06/2022
					
					
	  			</td>

				<td>
					Treatment of invasive mucormycosis in patients 18 years of age and older
				</td>
			
  			<td>
  				Astellas Pharma Global Development Inc.
  			</td>
  			<td>
  				1 Astellas Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Northbrook
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60062
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				395013
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antihemophilic factor (recombinant)
  			</td>
  			<td>
  				ReFacto, Xyntha
  			</td>
  			<td>
  				02/08/1996
  			</td>
  			<td>
  				For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						03/06/2000
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals, Inc.
  			</td>
  			<td>
  				P. O. Box 8299
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Philadelphia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				094495
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Lepirudin
  			</td>
  			<td>
  				Refluden
  			</td>
  			<td>
  				02/13/1997
  			</td>
  			<td>
  				Treatment of heparin-associated thrombocytopenia type II.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.
	  			</td>
				
	  			<td>
					
						03/06/1998
					
	  			</td>

	  			<td>

					
					03/06/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hoechst Marion Roussel
  			</td>
  			<td>
  				Frankfurt am Main
  			</td>
  			<td>
  				P.O. Box 1140
  			</td>
  			<td>
  				Marburg
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Germany
  			</td>
			<td>
  				102796
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				axicabtagene ciloleucel
  			</td>
  			<td>
  				Yescarta
  			</td>
  			<td>
  				04/25/2016
  			</td>
  			<td>
  				Treatment of follicular lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
	  			</td>
				
	  			<td>
					
						03/05/2021
					
	  			</td>

	  			<td>

					
					03/05/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, excluding patients with diffuse large B-cell lymphoma arising from follicular lymphoma.
				</td>
			
  			<td>
  				Kite Pharma Inc.
  			</td>
  			<td>
  				2400 Broadway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Santa Monica
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				515615
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sargramostim
  			</td>
  			<td>
  				Leukine
  			</td>
  			<td>
  				05/03/1990
  			</td>
  			<td>
  				Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						03/05/1991
					
	  			</td>

	  			<td>

					
					03/05/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Immunex Corporation
  			</td>
  			<td>
  				51 University Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98101
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				044290
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tocilizumab
  			</td>
  			<td>
  				Actemra
  			</td>
  			<td>
  				04/17/2013
  			</td>
  			<td>
  				Treatment of systemic sclerosis 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease
	  			</td>
				
	  			<td>
					
						03/04/2021
					
	  			</td>

	  			<td>

					
					03/04/2028
					
					
	  			</td>

				<td>
					slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				381212
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				04/06/2012
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia (CLL)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for the treatment of patients with chronic lymphocytic leukemia 
	  			</td>
				
	  			<td>
					
						03/04/2016
					
	  			</td>

	  			<td>

					
					03/04/2023
					
					
	  			</td>

				<td>
					Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy). 
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				368012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)
  			</td>
  			<td>
  				Idelvion
  			</td>
  			<td>
  				04/27/2012
  			</td>
  			<td>
  				Treatment of patients with congenital factor IX deficiency (hemophilia B). 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated in children and adults with hemophilia B (congenital Factor IX deficiency) for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
	  			</td>
				
	  			<td>
					
						03/04/2016
					
	  			</td>

	  			<td>

					
					03/04/2023
					
					
	  			</td>

				<td>
					Indicated for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
				</td>
			
  			<td>
  				CSL Behring, LLC
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				P.O. Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				366712
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Ganciclovir intravitreal implant
  			</td>
  			<td>
  				Vitrasert Implant
  			</td>
  			<td>
  				06/07/1995
  			</td>
  			<td>
  				Treatment of cytomegalovirus retinitis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.
	  			</td>
				
	  			<td>
					
						03/04/1996
					
	  			</td>

	  			<td>

					
					03/04/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bausch & Lomb Surgical, Chiron Vision Products
  			</td>
  			<td>
  				9342 Jeronimo Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Irvine
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92718
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				086494
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lorlatinib
  			</td>
  			<td>
  				Lorbrena
  			</td>
  			<td>
  				06/23/2015
  			</td>
  			<td>
  				Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						03/03/2021
					
	  			</td>

	  			<td>

					
					03/03/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test, excluding patients whose disease has progressed on crizotinib and at least one other ALK inhibitor; or alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				235 East 42nd Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				481015
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				isatuximab
  			</td>
  			<td>
  				Sarclisa
  			</td>
  			<td>
  				05/22/2014
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
	  			</td>
				
	  			<td>
					
						03/02/2020
					
	  			</td>

	  			<td>

					
					03/02/2027
					
					
	  			</td>

				<td>
					Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
				</td>
			
  			<td>
  				Sanofi U.S. Services, Inc.
  			</td>
  			<td>
  				50 Binney St.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				431914
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cetuximab
  			</td>
  			<td>
  				Erbitux
  			</td>
  			<td>
  				07/03/2000
  			</td>
  			<td>
  				Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed
	  			</td>
				
	  			<td>
					
						03/01/2006
					
	  			</td>

	  			<td>

					
					03/01/2013
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				ImClone Systems Incorporated
  			</td>
  			<td>
  				33 ImClone Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Branchburg
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08876
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				132700
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pacritinib
  			</td>
  			<td>
  				Vonjo
  			</td>
  			<td>
  				03/13/2008
  			</td>
  			<td>
  				Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 x 109/L
	  			</td>
				
	  			<td>
					
						02/28/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CTI BioPharma Corporation
  			</td>
  			<td>
  				3101 Western Avenue
  			</td>
  			<td>
  				Suite 600
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				245607
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ciltacabtagene autoleucel)
  			</td>
  			<td>
  				Carvykti
  			</td>
  			<td>
  				02/01/2019
  			</td>
  			<td>
  				Treatment of multiple myeloma (MM)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
	  			</td>
				
	  			<td>
					
						02/28/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Janssen Research & Development, LLC
  			</td>
  			<td>
  				920 Route 202 South
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				672118
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				telotristat etiprate
  			</td>
  			<td>
  				Xermelo
  			</td>
  			<td>
  				03/09/2012
  			</td>
  			<td>
  				Treatment of carcinoid syndrome in patients with neuroendocrine tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
	  			</td>
				
	  			<td>
					
						02/28/2017
					
	  			</td>

	  			<td>

					
					02/28/2024
					
					
	  			</td>

				<td>
					Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
				</td>
			
  			<td>
  				Lexicon Pharmaceuticals, Inc.
  			</td>
  			<td>
  				8800 Technology Forest Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				The Woodlands
  			</td>
  			<td>
  				Texas
  			</td>
  			<td>
  				77381
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				266308
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Rilonacept 
  			</td>
  			<td>
  				Arcalyst
  			</td>
  			<td>
  				12/20/2004
  			</td>
  			<td>
  				Treatment of CIAS1-Associated Periodic Syndromes
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS)
	  			</td>
				
	  			<td>
					
						02/27/2008
					
	  			</td>

	  			<td>

					
					02/27/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Regeneron Pharmaceuticals, Inc.
  			</td>
  			<td>
  				777 Old Saw Mill River Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tarrytown
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10591
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				196904
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fosdenopterin
  			</td>
  			<td>
  				Nulibry
  			</td>
  			<td>
  				11/05/2009
  			</td>
  			<td>
  				Treatment of molybdenum cofactor deficiency type A (MoCD)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A

	  			</td>
				
	  			<td>
					
						02/26/2021
					
	  			</td>

	  			<td>

					
					02/26/2028
					
					
	  			</td>

				<td>
					to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A

				</td>
			
  			<td>
  				Origin Biosciences, Inc.
  			</td>
  			<td>
  				75 Park Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02116
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				291209
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				melphalan flufenamide
  			</td>
  			<td>
  				Pepaxto
  			</td>
  			<td>
  				03/16/2015
  			</td>
  			<td>
  				Treatment of plasma cell myeloma, also referred to as multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment, in combination with dexamethasone, of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.
	  			</td>
				
	  			<td>
					
						02/26/2021
					
	  			</td>

	  			<td>

					
					02/26/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.
				</td>
			
  			<td>
  				Oncopeptides AB
  			</td>
  			<td>
  				Vastra Tradgardsgatan 15
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Stockholm
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				465314
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				obinutuzumab
  			</td>
  			<td>
  				GAZYVA
  			</td>
  			<td>
  				04/15/2015
  			</td>
  			<td>
  				Treatment of follicular lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen
	  			</td>
				
	  			<td>
					
						02/26/2016
					
	  			</td>

	  			<td>

					
					02/26/2023
					
					
	  			</td>

				<td>
					in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.
				</td>
			
  			<td>
  				Genentech Inc., a member of the Roche Group
  			</td>
  			<td>
  				1 DNA Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				473415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				everolimus
  			</td>
  			<td>
  				Afinitor
  			</td>
  			<td>
  				02/14/2008
  			</td>
  			<td>
  				Treatment of neuroendocrine tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease; and treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, with unresectable, locally advanced or metastatic disease.
	  			</td>
				
	  			<td>
					
						02/26/2016
					
	  			</td>

	  			<td>

					
					02/26/2023
					
					
	  			</td>

				<td>
					Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) (excluding pancreatic) or lung origin,  with unresectable, locally advanced or metastatic disease.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza, 315/5450A
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				254107
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				velaglucerase-alfa
  			</td>
  			<td>
  				VPRIV
  			</td>
  			<td>
  				06/08/2009
  			</td>
  			<td>
  				Treatment of Gaucher disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Type I Gaucher Disease
	  			</td>
				
	  			<td>
					
						02/26/2010
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Takeda Development Center Americas, Inc.
  			</td>
  			<td>
  				95 Hayden Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				283509
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Cladribine
  			</td>
  			<td>
  				Leustatin Injection
  			</td>
  			<td>
  				11/15/1990
  			</td>
  			<td>
  				Treatment of hairy cell leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						02/26/1993
					
	  			</td>

	  			<td>

					
					02/26/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				R. W. Johnson Pharmaceutical Research Institute
  			</td>
  			<td>
  				Route 202, P.O. Box 300
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Raritan
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08869
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				051690
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Nafarelin acetate
  			</td>
  			<td>
  				Synarel Nasal Solution
  			</td>
  			<td>
  				07/20/1988
  			</td>
  			<td>
  				Treatment of central precocious puberty.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.
	  			</td>
				
	  			<td>
					
						02/26/1992
					
	  			</td>

	  			<td>

					
					02/26/1999
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Syntex (USA), Inc.
  			</td>
  			<td>
  				3401 Hillview Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Palo Alto
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94303
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				029888
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				casimersen
  			</td>
  			<td>
  				Amondys 45 
  			</td>
  			<td>
  				06/04/2019
  			</td>
  			<td>
  				Treatment of Duchenne muscular dystrophy 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping
	  			</td>
				
	  			<td>
					
						02/25/2021
					
	  			</td>

	  			<td>

					
					02/25/2028
					
					
	  			</td>

				<td>
					treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping
				</td>
			
  			<td>
  				Sarepta Therapeutics, Inc.
  			</td>
  			<td>
  				215 First Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				690019
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				regorafenib
  			</td>
  			<td>
  				Stivarga 
  			</td>
  			<td>
  				01/12/2011
  			</td>
  			<td>
  				Treatment gastrointestinal stromal tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
	  			</td>
				
	  			<td>
					
						02/25/2013
					
	  			</td>

	  			<td>

					
					02/25/2020
					
					
	  			</td>

				<td>
					Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
				</td>
			
  			<td>
  				Bayer HealthCare Pharmaceuticals, Inc.
  			</td>
  			<td>
  				P. O. Box 1000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Montvale
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07045
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				329410
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cinacalcet
  			</td>
  			<td>
  				Sensipar
  			</td>
  			<td>
  				04/30/2010
  			</td>
  			<td>
  				Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy
	  			</td>
				
	  			<td>
					
						02/25/2011
					
	  			</td>

	  			<td>

					
					02/25/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Amgen, Inc.
  			</td>
  			<td>
  				One Amgen Center Drive
  			</td>
  			<td>
  				Bldg 17, 1A-4-4, Mail Stop 17-1-B
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				165102
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				polifeprosan 20 with carmustine
  			</td>
  			<td>
  				Gliadel
  			</td>
  			<td>
  				12/13/1989
  			</td>
  			<td>
  				Treatment of malignant glioma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Expanding the indication to include patients with malignant glioma undergoing primary surgical resection.
	  			</td>
				
	  			<td>
					
						02/25/2003
					
	  			</td>

	  			<td>

					
					02/25/2010
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Guilford Pharmaceuticals, Inc.
  			</td>
  			<td>
  				6611 Tributary Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Baltimore
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				21224
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				037089
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Hydroxyurea
  			</td>
  			<td>
  				Droxia
  			</td>
  			<td>
  				10/01/1990
  			</td>
  			<td>
  				Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).  
	  			</td>
				
	  			<td>
					
						02/25/1998
					
	  			</td>

	  			<td>

					
					02/25/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Pharmaceutical Research Institute
  			</td>
  			<td>
  				P.O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				049590
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antihemophilic factor (recombinant)
  			</td>
  			<td>
  				Kogenate
  			</td>
  			<td>
  				09/25/1989
  			</td>
  			<td>
  				Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)
	  			</td>
				
	  			<td>
					
						02/25/1993
					
	  			</td>

	  			<td>

					
					02/25/2000
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bayer Corporation
  			</td>
  			<td>
  				1884 Miles Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Elkhart
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46515
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				039289
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				Humira
  			</td>
  			<td>
  				05/11/2011
  			</td>
  			<td>
  				Treatment of pediatric patients with ulcerative colitis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.

 


	  			</td>
				
	  			<td>
					
						02/24/2021
					
	  			</td>

	  			<td>

					
					02/24/2028
					
					
	  			</td>

				<td>
					treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.

 


				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 North Waukegan Rd
  			</td>
  			<td>
  				Dept PA72; Bldg AP30-4
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				340911
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				metreleptin
  			</td>
  			<td>
  				MYALEPT
  			</td>
  			<td>
  				08/22/2001
  			</td>
  			<td>
  				Treatment of metabolic disorders secondary to lipodystrophy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.  
	  			</td>
				
	  			<td>
					
						02/24/2014
					
	  			</td>

	  			<td>

					
					02/24/2021
					
					
	  			</td>

				<td>
					Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.  
				</td>
			
  			<td>
  				Amryt Pharmaceutical DAC
  			</td>
  			<td>
  				45 Mespil Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Dublin
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				4
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				146701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				panobinostat
  			</td>
  			<td>
  				Farydak
  			</td>
  			<td>
  				08/20/2012
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent
	  			</td>
				
	  			<td>
					
						02/23/2015
					
	  			</td>

	  			<td>

					
					02/23/2022
					
					
	  			</td>

				<td>
					FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent
				</td>
			
  			<td>
  				Secura Bio, Inc.
  			</td>
  			<td>
  				11988 El Camino Real
  			</td>
  			<td>
  				Suite 650
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92130
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				376212
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trifluridine/tipiracil 
  			</td>
  			<td>
  				LONSURF
  			</td>
  			<td>
  				04/17/2017
  			</td>
  			<td>
  				Treatment of gastric cancer including cancer of the gastroesophageal junction
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
	  			</td>
				
	  			<td>
					
						02/22/2019
					
	  			</td>

	  			<td>

					
					02/22/2026
					
					
	  			</td>

				<td>
					LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
				</td>
			
  			<td>
  				Taiho Oncology, Inc.
  			</td>
  			<td>
  				101 Carnegie Center
  			</td>
  			<td>
  				Suite 101
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08540
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				564116
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid 
  			</td>
  			<td>
  				09/20/2001
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
	  			</td>
				
	  			<td>
					
						02/22/2017
					
	  			</td>

	  			<td>

					
					02/22/2024
					
					
	  			</td>

				<td>
					Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				147701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				aztreonam
  			</td>
  			<td>
  				Cayston
  			</td>
  			<td>
  				03/12/2002
  			</td>
  			<td>
  				Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa
	  			</td>
				
	  			<td>
					
						02/22/2010
					
	  			</td>

	  			<td>

					
					02/22/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Gilead Sciences (formerly Corus Pharma)
  			</td>
  			<td>
  				199 East Blaine St
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				155002
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.
	  			</td>
				
	  			<td>
					
						02/21/2014
					
	  			</td>

	  			<td>

					
					02/21/2021
					
					
	  			</td>

				<td>
					Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				adalimumab
  			</td>
  			<td>
  				Humira
  			</td>
  			<td>
  				03/21/2005
  			</td>
  			<td>
  				Treatment of juvenile rheumatoid arthritis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.  
	  			</td>
				
	  			<td>
					
						02/21/2008
					
	  			</td>

	  			<td>

					
					02/21/2015
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AbbVie Inc.
  			</td>
  			<td>
  				1 North Waukegan Road
  			</td>
  			<td>
  				Bldg. AP-30
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				200905
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Trypan blue
  			</td>
  			<td>
  				MembraneBlue
  			</td>
  			<td>
  				08/02/2006
  			</td>
  			<td>
  				Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue
	  			</td>
				
	  			<td>
					
						02/20/2009
					
	  			</td>

	  			<td>

					
					02/20/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Dutch Ophthalmic Research Center International BV
  			</td>
  			<td>
  				P.O. Box 43 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Zuidland
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Netherlands
  			</td>
			<td>
  				207505
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Bleomycin sulfate
  			</td>
  			<td>
  				Blenoxane
  			</td>
  			<td>
  				09/17/1993
  			</td>
  			<td>
  				Treatment of malignant pleural effusion.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of malignant pleural effusion.
	  			</td>
				
	  			<td>
					
						02/20/1996
					
	  			</td>

	  			<td>

					
					02/20/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bristol-Myers Squibb Pharmaceutical Research Institute
  			</td>
  			<td>
  				P.O. Box 4000
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Princeton
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08543
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				076193
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibritumomab tiuxetan
  			</td>
  			<td>
  				Zevalin
  			</td>
  			<td>
  				09/06/1994
  			</td>
  			<td>
  				Treatment of B-cell non-Hodgkin's lymphoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma
	  			</td>
				
	  			<td>
					
						02/19/2002
					
	  			</td>

	  			<td>

					
					02/19/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Acrotech Biopharma LLC
  			</td>
  			<td>
  				279 Princeton Hightstown Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Windsor
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08520
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				084894
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				droxidopa
  			</td>
  			<td>
  				NORTHERA
  			</td>
  			<td>
  				01/17/2007
  			</td>
  			<td>
  				Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.  
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.  
	  			</td>
				
	  			<td>
					
						02/18/2014
					
	  			</td>

	  			<td>

					
					02/18/2021
					
					
	  			</td>

				<td>
					Treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.  
				</td>
			
  			<td>
  				Lundbeck LLC
  			</td>
  			<td>
  				3530 Toringdon Way, Suite 200
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Charlotte
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				28277
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				229506
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				rituximab
  			</td>
  			<td>
  				Rituxan
  			</td>
  			<td>
  				01/29/2004
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide
	  			</td>
				
	  			<td>
					
						02/18/2010
					
	  			</td>

	  			<td>

					
					02/18/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Genentech, Inc.
  			</td>
  			<td>
  				1DNA Way
  			</td>
  			<td>
  				MS 241A
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				177603
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Vaccinia Immune Globulin (Human) Intravenous
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				06/18/2004
  			</td>
  			<td>
  				Treatment of severe complications from the smallpox vaccine
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment and modification of aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard; eczema vaccinatum; progressive vaccinia; severe generalized vaccinia, and vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because o
	  			</td>
				
	  			<td>
					
						02/18/2005
					
	  			</td>

	  			<td>

					
					02/18/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				DynPort Vaccine Company LLC
  			</td>
  			<td>
  				64 Thomas Johnson Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Frederick
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				21702
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				184204
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mitapivat
  			</td>
  			<td>
  				Pyrukynd
  			</td>
  			<td>
  				03/24/2015
  			</td>
  			<td>
  				Treatment of pyruvate kinase deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency
	  			</td>
				
	  			<td>
					
						02/17/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Agios Pharmaceuticals, Inc.
  			</td>
  			<td>
  				88 Sidney Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				442814
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenalidomide
  			</td>
  			<td>
  				Revlimid 
  			</td>
  			<td>
  				09/20/2001
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).
	  			</td>
				
	  			<td>
					
						02/17/2015
					
	  			</td>

	  			<td>

					
					02/17/2022
					
					
	  			</td>

				<td>
					For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first-line therapy).
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				147701
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mifepristone
  			</td>
  			<td>
  				Korlym
  			</td>
  			<td>
  				07/05/2007
  			</td>
  			<td>
  				Treatment of the clinical manifestations of endogenous Cushing's syndrone
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.   
	  			</td>
				
	  			<td>
					
						02/17/2012
					
	  			</td>

	  			<td>

					
					02/17/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Corcept Therapeutics, Inc.
  			</td>
  			<td>
  				149 Commonwealth Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Menlo Park
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94025
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				239507
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				factor XIII concentrate (human)
  			</td>
  			<td>
  				Corifact
  			</td>
  			<td>
  				01/16/1985
  			</td>
  			<td>
  				Treatment of congenital factor XIII deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the routine prophylactic treatment of congenital factor XIII deficiency
	  			</td>
				
	  			<td>
					
						02/17/2011
					
	  			</td>

	  			<td>

					
					02/17/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CSL Behring LLC
  			</td>
  			<td>
  				1020 First Ave.
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				004484
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				benzoate/phenylacetate
  			</td>
  			<td>
  				Ammonul
  			</td>
  			<td>
  				11/22/1993
  			</td>
  			<td>
  				Treatment of acute hyperammonemia and associated  encephalopathy in patients with deficiencies in enzymes of the urea cycle.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.
	  			</td>
				
	  			<td>
					
						02/17/2005
					
	  			</td>

	  			<td>

					
					02/17/2012
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Medicis Pharmaceutical Corp.
  			</td>
  			<td>
  				8125 N. Hayden Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Scottsdale
  			</td>
  			<td>
  				Alaska
  			</td>
  			<td>
  				85258
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				077993
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pembrolizumab
  			</td>
  			<td>
  				KEYTRUDA
  			</td>
  			<td>
  				11/19/2012
  			</td>
  			<td>
  				Treatment of Stage IIB through IV malignant melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
	  			</td>
				
	  			<td>
					
						02/15/2019
					
	  			</td>

	  			<td>

					
					02/15/2026
					
					
	  			</td>

				<td>
					KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
				</td>
			
  			<td>
  				Merck, Sharp & Dohme Corp.
  			</td>
  			<td>
  				351 North Sumneytown Pike 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				North Wales
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19454
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				381012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cysteamine enteric coated
  			</td>
  			<td>
  				PROCYSBI
  			</td>
  			<td>
  				10/24/2006
  			</td>
  			<td>
  				Treatment of cystinosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
	  			</td>
				
	  			<td>
					
						02/14/2020
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Horizon Therapeutics USA, Inc.
  			</td>
  			<td>
  				150 S. Saunders Road
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Lake Forest
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60045
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				231006
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				hydroxyprogesterone caproate
  			</td>
  			<td>
  				Makena
  			</td>
  			<td>
  				01/25/2007
  			</td>
  			<td>
  				Prevention of preterm birth in singleton pregnancies
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Makena auto-injector for subcutaneous injection is indicated to reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth.
	  			</td>
				
	  			<td>
					
						02/14/2018
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AMAG Pharma USA, Inc.
  			</td>
  			<td>
  				1100 Winter Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02154
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				218706
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				elosulfase alfa
  			</td>
  			<td>
  				Vimizim
  			</td>
  			<td>
  				05/15/2009
  			</td>
  			<td>
  				Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)
	  			</td>
				
	  			<td>
					
						02/14/2014
					
	  			</td>

	  			<td>

					
					02/14/2021
					
					
	  			</td>

				<td>
					Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)
				</td>
			
  			<td>
  				BioMarin Pharmaceutical Inc.
  			</td>
  			<td>
  				105 Digital Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Novato
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94949
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				280809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				triclabendazole
  			</td>
  			<td>
  				Egaten
  			</td>
  			<td>
  				04/17/2017
  			</td>
  			<td>
  				Treatment of fascioliasis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				EGATEN™ is indicated for the treatment of fascioliasis in patients 6 years of age and older.
	  			</td>
				
	  			<td>
					
						02/13/2019
					
	  			</td>

	  			<td>

					
					02/13/2026
					
					
	  			</td>

				<td>
					EGATEN™ is indicated for the treatment of fascioliasis in patients 6 years of age and older.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				1 Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				564216
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lenvatinib
  			</td>
  			<td>
  				Lenvima
  			</td>
  			<td>
  				12/27/2012
  			</td>
  			<td>
  				Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer
	  			</td>
				
	  			<td>
					
						02/13/2015
					
	  			</td>

	  			<td>

					
					02/13/2022
					
					
	  			</td>

				<td>
					Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer
				</td>
			
  			<td>
  				Eisai, Inc.
  			</td>
  			<td>
  				200 Metro Blvd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110-6102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				378412
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Tezacaftor and Ivacaftor combination therapy
  			</td>
  			<td>
  				SYMDEKO
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of cystic fibrosis (CF)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence
	  			</td>
				
	  			<td>
					
						02/12/2018
					
	  			</td>

	  			<td>

					
					02/12/2025
					
					
	  			</td>

				<td>
					SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence
				</td>
			
  			<td>
  				Vertex Pharmaceuticals Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				577517
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				04/06/2012
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia (CLL)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
	  			</td>
				
	  			<td>
					
						02/12/2014
					
	  			</td>

	  			<td>

					
					02/12/2021
					
					
	  			</td>

				<td>
					Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				368012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				evinacumab-dgnb
  			</td>
  			<td>
  				Evkeeza
  			</td>
  			<td>
  				02/08/2016
  			</td>
  			<td>
  				Treatment of homozygous familial hypercholesterolemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)
	  			</td>
				
	  			<td>
					
						02/11/2021
					
	  			</td>

	  			<td>

					
					02/11/2028
					
					
	  			</td>

				<td>
					adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)
				</td>
			
  			<td>
  				Regeneron Pharmaceuticals, Inc.
  			</td>
  			<td>
  				777 Old Saw Mill River Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tarrytown
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10591-0707
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				507815
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pilocarpine HCl
  			</td>
  			<td>
  				Salagen
  			</td>
  			<td>
  				02/28/1992
  			</td>
  			<td>
  				Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of dry mouth in patients with Sjogren's syndrome.
	  			</td>
				
	  			<td>
					
						02/11/1998
					
	  			</td>

	  			<td>

					
					02/11/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				MGI Pharma, Inc.
  			</td>
  			<td>
  				5775 West Old Shakoppe Rd.
  			</td>
  			<td>
  				Suite 100
  			</td>
  			<td>
  				Bloomington
  			</td>
  			<td>
  				Minnesota
  			</td>
  			<td>
  				55437
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				062091
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Coagulation Factor IX (recombinant)
  			</td>
  			<td>
  				BeneFix
  			</td>
  			<td>
  				10/03/1994
  			</td>
  			<td>
  				Treatment of hemophilia B.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings.
	  			</td>
				
	  			<td>
					
						02/11/1997
					
	  			</td>

	  			<td>

					
					02/11/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
  			</td>
  			<td>
  				35 E. 42nd St 219/9/1
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10017
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				082294
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Interferon gamma-1b
  			</td>
  			<td>
  				Actimmune
  			</td>
  			<td>
  				09/30/1996
  			</td>
  			<td>
  				Delaying time to disease progression in patients with severe, malignant osteopetrosis.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Delaying time to disease progression in patients with severe, malignant osteopetrosis.
	  			</td>
				
	  			<td>
					
						02/10/2000
					
	  			</td>

	  			<td>

					
					02/10/2007
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Horizon Therapeutic Ireland DAC
  			</td>
  			<td>
  				Connaught House, 1st Floor
  			</td>
  			<td>
  				1 Burlington Road
  			</td>
  			<td>
  				Dublin 4
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				098796
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deflazacort
  			</td>
  			<td>
  				Emflaza
  			</td>
  			<td>
  				08/16/2013
  			</td>
  			<td>
  				Treatment of Duchenne muscular dystrophy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older
	  			</td>
				
	  			<td>
					
						02/09/2017
					
	  			</td>

	  			<td>

					
					02/09/2024
					
					
	  			</td>

				<td>
					Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older
				</td>
			
  			<td>
  				PTC Therapeutics, Inc.
  			</td>
  			<td>
  				100 Corporate Court
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South Plainfield
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				403413
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pomalidomide
  			</td>
  			<td>
  				Pomalyst
  			</td>
  			<td>
  				01/15/2003
  			</td>
  			<td>
  				Treatment of multiple myeloma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.  
	  			</td>
				
	  			<td>
					
						02/08/2013
					
	  			</td>

	  			<td>

					
					02/08/2020
					
					
	  			</td>

				<td>
					Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.  
				</td>
			
  			<td>
  				Celgene Corporation
  			</td>
  			<td>
  				86 Morris Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Summit
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07901
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				161402
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mitomycin-C
  			</td>
  			<td>
  				Mitosol
  			</td>
  			<td>
  				01/08/2008
  			</td>
  			<td>
  				Treatment of refractory glaucoma as an adjunct to surgery
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				An adjunct to ab externo glaucoma surgery.
	  			</td>
				
	  			<td>
					
						02/07/2012
					
	  			</td>

	  			<td>

					
					02/07/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Mobius Therapeutics, LLC
  			</td>
  			<td>
  				1141 South 7th Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				St. Louis
  			</td>
  			<td>
  				Missouri
  			</td>
  			<td>
  				63104
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				251407
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Caplacizumab
  			</td>
  			<td>
  				CABLIVI
  			</td>
  			<td>
  				04/14/2009
  			</td>
  			<td>
  				Treatment of thrombotic thrombocytopenic purpura
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
	  			</td>
				
	  			<td>
					
						02/06/2019
					
	  			</td>

	  			<td>

					
					02/06/2026
					
					
	  			</td>

				<td>
					CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
				</td>
			
  			<td>
  				Ablynx, a wholly owned subsidiary of Sanofi Group
  			</td>
  			<td>
  				55 Corporate Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Bridgewater
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08807
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				277909
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				recombinant human antithrombin
  			</td>
  			<td>
  				ATryn
  			</td>
  			<td>
  				12/07/2007
  			</td>
  			<td>
  				Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.
	  			</td>
				
	  			<td>
					
						02/06/2009
					
	  			</td>

	  			<td>

					
					02/06/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				GTC Biotherapeutics, Inc.
  			</td>
  			<td>
  				175 Crossing Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Framingham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				01702
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				246807
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				umbralisib
  			</td>
  			<td>
  				Ukoniq
  			</td>
  			<td>
  				03/04/2020
  			</td>
  			<td>
  				Treatment of Follicular Lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
	  			</td>
				
	  			<td>
					
						02/05/2021
					
	  			</td>

	  			<td>

					
					02/05/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
				</td>
			
  			<td>
  				TG Therapeutics, Inc.
  			</td>
  			<td>
  				343 Thornall Street, Suite 740
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Edison
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08837
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				726819
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				umbralisib
  			</td>
  			<td>
  				Ukoniq
  			</td>
  			<td>
  				04/11/2019
  			</td>
  			<td>
  				Treatment of nodal marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen 
	  			</td>
				
	  			<td>
					
						02/05/2021
					
	  			</td>

	  			<td>

					
					02/05/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen 
				</td>
			
  			<td>
  				TG Therapeutics, Inc.
  			</td>
  			<td>
  				343 Thornall Street, Suite 740
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Edison
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08837
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				687519
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				umbralisib
  			</td>
  			<td>
  				Ukoniq
  			</td>
  			<td>
  				04/11/2019
  			</td>
  			<td>
  				Treatment of extranodal marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
	  			</td>
				
	  			<td>
					
						02/05/2021
					
	  			</td>

	  			<td>

					
					02/05/2028
					
					
	  			</td>

				<td>
					Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
				</td>
			
  			<td>
  				TG Therapeutics, Inc.
  			</td>
  			<td>
  				343 Thornall Street, Suite 740
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Edison
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08837
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				687419
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				umbralisib
  			</td>
  			<td>
  				Ukoniq 
  			</td>
  			<td>
  				04/11/2019
  			</td>
  			<td>
  				Treatment of splenic marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen 
	  			</td>
				
	  			<td>
					
						02/05/2021
					
	  			</td>

	  			<td>

					
					02/05/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen 
				</td>
			
  			<td>
  				TG Therapeutics, Inc.
  			</td>
  			<td>
  				343 Thornall Street, Suite 740
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Edison
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				08837
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				680019
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lisocabtagene maraleucel
  			</td>
  			<td>
  				Breyanzi
  			</td>
  			<td>
  				07/12/2018
  			</td>
  			<td>
  				Treatment of primary mediastinal large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				 treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B
	  			</td>
				
	  			<td>
					
						02/05/2021
					
	  			</td>

	  			<td>

					
					02/05/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy 

				</td>
			
  			<td>
  				Juno Therapeutics, Inc.
  			</td>
  			<td>
  				400 Dexter Avenue N 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98109
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				644018
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lisocabtagene maraleucel
  			</td>
  			<td>
  				Breyanzi
  			</td>
  			<td>
  				09/07/2017
  			</td>
  			<td>
  				Treatment of follicular lymphoma (FL)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B
	  			</td>
				
	  			<td>
					
						02/05/2021
					
	  			</td>

	  			<td>

					
					02/05/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy
				</td>
			
  			<td>
  				Juno Therapeutics, Inc.
  			</td>
  			<td>
  				400 Dexter Avenue N 
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98109
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				600517
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lisocabtagene maraleucel
  			</td>
  			<td>
  				Breyanzi
  			</td>
  			<td>
  				04/27/2016
  			</td>
  			<td>
  				Treatment of diffuse large B-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B
	  			</td>
				
	  			<td>
					
						02/05/2021
					
	  			</td>

	  			<td>

					
					02/05/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy
				</td>
			
  			<td>
  				Juno Therapeutics, Inc.
  			</td>
  			<td>
  				400 Dexter Avenue North
  			</td>
  			<td>
  				Suite 1200
  			</td>
  			<td>
  				Seattle
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				98109
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				516115
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				denileukin diftitox
  			</td>
  			<td>
  				Ontak
  			</td>
  			<td>
  				08/21/1996
  			</td>
  			<td>
  				Treatment of patients with cutaneous T-cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.
	  			</td>
				
	  			<td>
					
						02/05/1999
					
	  			</td>

	  			<td>

					
					02/05/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eisai, Inc.
  			</td>
  			<td>
  				300 Tice Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Woodcliff Lake
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07677
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				099396
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sutimlimab-jome
  			</td>
  			<td>
  				Enjaymo
  			</td>
  			<td>
  				07/27/2016
  			</td>
  			<td>
  				Treatment of autoimmune hemolytic anemia 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)
	  			</td>
				
	  			<td>
					
						02/04/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bioverativ USA Inc. (a fully owned subsidiary of Sanofi)
  			</td>
  			<td>
  				951 Gateway Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				South San Francisco
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94080
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				506115
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				pemetrexed disodium
  			</td>
  			<td>
  				Alimta
  			</td>
  			<td>
  				08/28/2001
  			</td>
  			<td>
  				Treatment of malignant pleural mesothelioma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery
	  			</td>
				
	  			<td>
					
						02/04/2004
					
	  			</td>

	  			<td>

					
					02/04/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Eli Lilly and Company
  			</td>
  			<td>
  				Lilly Corporate Center
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Indianapolis
  			</td>
  			<td>
  				Indiana
  			</td>
  			<td>
  				46285
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				145101
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Busulfan
  			</td>
  			<td>
  				Busulfex
  			</td>
  			<td>
  				07/28/1994
  			</td>
  			<td>
  				As preparative therapy in the treatment of malignancies with bone marrow transplantation.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.  
	  			</td>
				
	  			<td>
					
						02/04/1999
					
	  			</td>

	  			<td>

					
					02/04/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Otsuka Pharmaceutical Company, Ltd
  			</td>
  			<td>
  				 2-9, Kanda-Tsukasamachi
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Tokyo
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Japan
  			</td>
			<td>
  				083094
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tepotinib
  			</td>
  			<td>
  				Tepmetko
  			</td>
  			<td>
  				10/26/2020
  			</td>
  			<td>
  				Treatment of non-small cell lung cancer with MET genomic tumor aberrations
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
	  			</td>
				
	  			<td>
					
						02/03/2021
					
	  			</td>

	  			<td>

					
					02/03/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations
				</td>
			
  			<td>
  				EMD Serono, Inc. 
  			</td>
  			<td>
  				One Technology Place
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Rockland
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02370
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				679719
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				hydroxyprogesterone caproate
  			</td>
  			<td>
  				Makena
  			</td>
  			<td>
  				01/25/2007
  			</td>
  			<td>
  				Prevention of preterm birth in singleton pregnancies
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth
	  			</td>
				
	  			<td>
					
						02/03/2011
					
	  			</td>

	  			<td>

					
					02/03/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				AMAG Pharma USA, Inc.
  			</td>
  			<td>
  				1100 Winter Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Waltham
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02154
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				218706
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				collagenase clostridium histolyticum
  			</td>
  			<td>
  				Xiaflex
  			</td>
  			<td>
  				05/23/1996
  			</td>
  			<td>
  				Treatment of advanced (involutional or residual stage) Dupuytren's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adult patients with Dupuytren's contracture with a palpable cord
	  			</td>
				
	  			<td>
					
						02/02/2010
					
	  			</td>

	  			<td>

					
					02/02/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Auxilium Pharmaceuticals, Inc.
  			</td>
  			<td>
  				40 Valley Stream Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Malvern
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19335
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				092595
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Alitretinoin
  			</td>
  			<td>
  				Panretin
  			</td>
  			<td>
  				03/24/1998
  			</td>
  			<td>
  				Treatment of AIDS-related Kaposi's sarcoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
	  			</td>
				
	  			<td>
					
						02/02/1999
					
	  			</td>

	  			<td>

					
					02/02/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Concordia Pharmaceuticals Inc.
  			</td>
  			<td>
  				Canewood Business Centre
  			</td>
  			<td>
  				5 Canewood Industrial Park
  			</td>
  			<td>
  				St Michael
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				BB11005
  			</td>
  			<td>
  				Barbados
  			</td>
			<td>
  				110998
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				glycerol phenylbutyrate
  			</td>
  			<td>
  				RAVICTI
  			</td>
  			<td>
  				04/27/2009
  			</td>
  			<td>
  				Maintenance treatment of patients with deficiencies in enzymes of the urea cycle 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).
	  			</td>
				
	  			<td>
					
						02/01/2013
					
	  			</td>

	  			<td>

					
					02/01/2020
					
					
	  			</td>

				<td>
					Use as a nitrogen-binding adjunctive therapy for chronic management of adult and pediatric patients at least 2 years of age with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).  
				</td>
			
  			<td>
  				Horizon Pharma USA, INc.
  			</td>
  			<td>
  				150 South Saunders Road
  			</td>
  			<td>
  				Suite 400
  			</td>
  			<td>
  				Lake Forest
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60045
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				203505
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				imatinib mesylate
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				11/01/2001
  			</td>
  			<td>
  				Treatment of gastrointestinal  stromal tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)
	  			</td>
				
	  			<td>
					
						02/01/2002
					
	  			</td>

	  			<td>

					
					02/01/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corp.
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				149201
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Pegaspargase
  			</td>
  			<td>
  				Oncaspar; Asparlas
  			</td>
  			<td>
  				10/20/1989
  			</td>
  			<td>
  				Treatment of acute lymphocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.
	  			</td>
				
	  			<td>
					
						02/01/1994
					
	  			</td>

	  			<td>

					
					02/01/2001
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Servier Pharmaceuticals LLC
  			</td>
  			<td>
  				200 Pier Four Blvd
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				039589
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tasimelteon
  			</td>
  			<td>
  				HETLIOZ
  			</td>
  			<td>
  				01/19/2010
  			</td>
  			<td>
  				Non-24-hour sleepwake disorder in blind individuals without light perception
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of non-24-hour sleep-wake disorder
	  			</td>
				
	  			<td>
					
						01/31/2014
					
	  			</td>

	  			<td>

					
					01/31/2021
					
					
	  			</td>

				<td>
					Treatment of non-24-hour sleep-wake disorder
				</td>
			
  			<td>
  				Vanda Pharmaceuticals, Inc.
  			</td>
  			<td>
  				2200 Penn. Ave., NW
  			</td>
  			<td>
  				Suite 300 E
  			</td>
  			<td>
  				Washington
  			</td>
  			<td>
  				District of Columbia
  			</td>
  			<td>
  				20037
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				297409
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ivacaftor
  			</td>
  			<td>
  				Kalydeco
  			</td>
  			<td>
  				12/20/2006
  			</td>
  			<td>
  				Treatment of patients with cystic fibrosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.  
	  			</td>
				
	  			<td>
					
						01/31/2012
					
	  			</td>

	  			<td>

					
					01/31/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Vertex Pharmaceuticals, Inc.
  			</td>
  			<td>
  				50 Northern Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Boston
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02210
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				228306
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Antihemophilic factor (human)
  			</td>
  			<td>
  				Alphanate
  			</td>
  			<td>
  				01/05/1996
  			</td>
  			<td>
  				Treatment of von Willebrand's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For surgical and/or invasive procedures in patients with von Willebrand Disease (VWD) in whom desmopressin is either ineffective or contraindicated.  It is not indicated for patients with severe VWD (Type 3) undergoing major surgery
	  			</td>
				
	  			<td>
					
						01/31/2007
					
	  			</td>

	  			<td>

					
					01/31/2014
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Grifols Biologicals Inc.
  			</td>
  			<td>
  				5555 Valley Boulevard
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Los Angeles
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				90032
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				093895
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Succimer
  			</td>
  			<td>
  				Chemet capsules
  			</td>
  			<td>
  				05/09/1984
  			</td>
  			<td>
  				Treatment of lead poisoning in children.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						01/30/1991
					
	  			</td>

	  			<td>

					
					01/30/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Bock Pharmacal Company
  			</td>
  			<td>
  				P.O. Box 419056
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Saint Louis
  			</td>
  			<td>
  				Missouri
  			</td>
  			<td>
  				63141
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				001984
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				acetylcysteine effervescent tablets for oral solution
  			</td>
  			<td>
  				Cetylev
  			</td>
  			<td>
  				02/24/2015
  			</td>
  			<td>
  				Preventing hepatic injury from acetaminophin overdose
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion
	  			</td>
				
	  			<td>
					
						01/29/2016
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Arbor Pharmaceuticals, Inc.
  			</td>
  			<td>
  				6 Concourse Parkway
  			</td>
  			<td>
  				Suite 1800
  			</td>
  			<td>
  				Atlanta
  			</td>
  			<td>
  				Georgia
  			</td>
  			<td>
  				30328
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				401713
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				10/15/2013
  			</td>
  			<td>
  				Treatment of Waldenstrom's macroglobulinemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with Waldenstrom's macroglobulinemia
	  			</td>
				
	  			<td>
					
						01/29/2015
					
	  			</td>

	  			<td>

					
					01/29/2022
					
					
	  			</td>

				<td>
					Treatment of patients with Waldenstrom's macroglobulinemia
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				407413
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				mipomersen
  			</td>
  			<td>
  				KYNAMRO
  			</td>
  			<td>
  				05/23/2006
  			</td>
  			<td>
  				Treatment of homozygous familial hypercholesterolemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
	  			</td>
				
	  			<td>
					
						01/29/2013
					
	  			</td>

	  			<td>

					
					01/29/2020
					
					
	  			</td>

				<td>
					Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
				</td>
			
  			<td>
  				Kastle Therapeutics, LLC
  			</td>
  			<td>
  				181 West Madison Street
  			</td>
  			<td>
  				Suite 3745
  			</td>
  			<td>
  				Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60602
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				221406
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				von Willebrand factor (recombinant)
  			</td>
  			<td>
  				Vonvendi
  			</td>
  			<td>
  				11/23/2010
  			</td>
  			<td>
  				Treatment of von Willebrand disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy
	  			</td>
				
	  			<td>
					
						01/28/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Baxalta US, Inc.
  			</td>
  			<td>
  				650 E. Kendall Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02142
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				322210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				romiplostim
  			</td>
  			<td>
  				Nplate
  			</td>
  			<td>
  				05/24/2018
  			</td>
  			<td>
  				Treatment of patients acutely exposed to myelosuppressive doses of radiation following radiological/nuclear incident
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS])
	  			</td>
				
	  			<td>
					
						01/28/2021
					
	  			</td>

	  			<td>

					
					01/28/2028
					
					
	  			</td>

				<td>
					to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS])
				</td>
			
  			<td>
  				Amgen Inc.
  			</td>
  			<td>
  				1 Amgen Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Thousand Oaks
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				91320
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				639818
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				eribulin mesylate
  			</td>
  			<td>
  				Halaven
  			</td>
  			<td>
  				05/14/2012
  			</td>
  			<td>
  				Treatment of soft tissue sarcoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
	  			</td>
				
	  			<td>
					
						01/28/2016
					
	  			</td>

	  			<td>

					
					01/28/2023
					
					
	  			</td>

				<td>
					Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen
				</td>
			
  			<td>
  				Eisai Inc.
  			</td>
  			<td>
  				200 Metro Blvd.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Nutley
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07110-6102
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				367112
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				gabapentin
  			</td>
  			<td>
  				Gralise
  			</td>
  			<td>
  				11/08/2010
  			</td>
  			<td>
  				Management of postherpetic neuralgia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the management of postherpetic neuralgia
	  			</td>
				
	  			<td>
					
						01/28/2011
					
	  			</td>

	  			<td>

					
					01/28/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Golf Acquiror LLC
  			</td>
  			<td>
  				44 Whippany Road
  			</td>
  			<td>
  				Suite 300
  			</td>
  			<td>
  				Morristown
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07960
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				236506
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Zinc acetate
  			</td>
  			<td>
  				Galzin
  			</td>
  			<td>
  				11/06/1985
  			</td>
  			<td>
  				Treatment of Wilson's disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.
	  			</td>
				
	  			<td>
					
						01/28/1997
					
	  			</td>

	  			<td>

					
					01/28/2004
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Lemmon Company
  			</td>
  			<td>
  				1510 Delp Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Kulpsville
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19443
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				011185
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				lutetium Lu 177 dotatate
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				01/12/2009
  			</td>
  			<td>
  				Treatment of gastro-entero-pancreatic neuroendocrine tumors 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults
	  			</td>
				
	  			<td>
					
						01/26/2018
					
	  			</td>

	  			<td>

					
					01/26/2025
					
					
	  			</td>

				<td>
					Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults
				</td>
			
  			<td>
  				Advanced Accelerator Applications
  			</td>
  			<td>
  				57 East Willow Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Millburn
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07041
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				271008
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Thiotepa
  			</td>
  			<td>
  				Tepadina
  			</td>
  			<td>
  				04/02/2007
  			</td>
  			<td>
  				Conditioning treatment prior to hematopoietic stem cell transplantation
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogenic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-thalassemia
	  			</td>
				
	  			<td>
					
						01/26/2017
					
	  			</td>

	  			<td>

					
					01/26/2024
					
					
	  			</td>

				<td>
					Indicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogenic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-thalassemia
				</td>
			
  			<td>
  				ADIENNE S.A.
  			</td>
  			<td>
  				Via Zurigo, 46
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lugano
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				237807
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tebentafusp-tebn
  			</td>
  			<td>
  				Kimmtrak
  			</td>
  			<td>
  				01/21/2016
  			</td>
  			<td>
  				Treatment of uveal melanoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma
	  			</td>
				
	  			<td>
					
						01/25/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Immunocore Ltd
  			</td>
  			<td>
  				Milton Park
  			</td>
  			<td>
  				90 Park Drive
  			</td>
  			<td>
  				Milton
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				United Kingdom
  			</td>
			<td>
  				503615
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				imatinib
  			</td>
  			<td>
  				Gleevec
  			</td>
  			<td>
  				10/11/2005
  			</td>
  			<td>
  				Treatment of Philadelphia-positive acute lymphoblastic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
	  			</td>
				
	  			<td>
					
						01/25/2013
					
	  			</td>

	  			<td>

					
					01/25/2020
					
					
	  			</td>

				<td>
					Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Mail Code 105/1E870D
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				208905
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fidaxomicin
  			</td>
  			<td>
  				Dificid
  			</td>
  			<td>
  				12/13/2010
  			</td>
  			<td>
  				Treatment of pediatric Clostridium difficile infection
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				DIFICID® is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).
	  			</td>
				
	  			<td>
					
						01/24/2020
					
	  			</td>

	  			<td>

					
					01/24/2027
					
					
	  			</td>

				<td>
					Dificid (fidaxomicin) is indicated for pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).
				</td>
			
  			<td>
  				Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.
  			</td>
  			<td>
  				20 Weystrasse
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Luzern
  			</td>
  			<td>
  				Luzern
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Switzerland
  			</td>
			<td>
  				325210
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				factor XIII concentrate (human)
  			</td>
  			<td>
  				Corifact
  			</td>
  			<td>
  				01/16/1985
  			</td>
  			<td>
  				Treatment of congenital factor XIII deficiency
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.
	  			</td>
				
	  			<td>
					
						01/24/2013
					
	  			</td>

	  			<td>

					
					01/24/2020
					
					
	  			</td>

				<td>
					Peri-operative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.  
				</td>
			
  			<td>
  				CSL Behring LLC
  			</td>
  			<td>
  				1020 First Ave.
  			</td>
  			<td>
  				PO Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				004484
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				tazemetostat
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				06/15/2017
  			</td>
  			<td>
  				Treatment of soft tissue sarcoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
	  			</td>
				
	  			<td>
					
						01/23/2020
					
	  			</td>

	  			<td>

					
					01/23/2027
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Epizyme, Inc.
  			</td>
  			<td>
  				400 Technology Square
  			</td>
  			<td>
  				4th Floor
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				578417
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				parathyroid hormone
  			</td>
  			<td>
  				Natpara
  			</td>
  			<td>
  				08/31/2007
  			</td>
  			<td>
  				Treatment of hypoparathyroidism
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
	  			</td>
				
	  			<td>
					
						01/23/2015
					
	  			</td>

	  			<td>

					
					01/23/2022
					
					
	  			</td>

				<td>
					An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
				</td>
			
  			<td>
  				Shire-NPS Pharmaceuticals, Inc.
  			</td>
  			<td>
  				300 Shire Way
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Lexington
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02421
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				246707
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				deferasirox
  			</td>
  			<td>
  				Exjade; Jadenu Sprinkles
  			</td>
  			<td>
  				02/24/2015
  			</td>
  			<td>
  				Treatment of chronic iron overload in alpha-thalassemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.
	  			</td>
				
	  			<td>
					
						01/23/2013
					
	  			</td>

	  			<td>

					
					01/23/2020
					
					
	  			</td>

				<td>
					Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				354411
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				acetylcysteine
  			</td>
  			<td>
  				Acetadote
  			</td>
  			<td>
  				10/19/2001
  			</td>
  			<td>
  				For the intravenous treatment of moderate to severe acetaminophen overdose
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur
	  			</td>
				
	  			<td>
					
						01/23/2004
					
	  			</td>

	  			<td>

					
					01/23/2011
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Cumberland Pharmaceuticals, Inc.
  			</td>
  			<td>
  				209 10th Street South
  			</td>
  			<td>
  				Suite 332
  			</td>
  			<td>
  				Nashville
  			</td>
  			<td>
  				Tennessee
  			</td>
  			<td>
  				37203
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				148401
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				carglumic acid
  			</td>
  			<td>
  				Carbaglu
  			</td>
  			<td>
  				06/17/2014
  			</td>
  			<td>
  				Treatment of organic acidemias
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)
	  			</td>
				
	  			<td>
					
						01/22/2021
					
	  			</td>

	  			<td>

					
					01/22/2028
					
					
	  			</td>

				<td>
					in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)
				</td>
			
  			<td>
  				Recordati Rare Diseases
  			</td>
  			<td>
  				Immeuble Le Wilson
  			</td>
  			<td>
  				70 avenue du General de Gaulle
  			</td>
  			<td>
  				Puteaux
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				France
  			</td>
			<td>
  				352111
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				dalfampridine
  			</td>
  			<td>
  				Ampyra
  			</td>
  			<td>
  				06/02/1987
  			</td>
  			<td>
  				Relief of symptoms of multiple sclerosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment to improve walking in patients with multiple sclerosis 
	  			</td>
				
	  			<td>
					
						01/22/2010
					
	  			</td>

	  			<td>

					
					01/22/2017
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Acorda Therapeutics
  			</td>
  			<td>
  				15 Skyline Dr.
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Hawthorne
  			</td>
  			<td>
  				New York
  			</td>
  			<td>
  				10532
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				018186
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				teprotumumab
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				05/06/2013
  			</td>
  			<td>
  				Treatment of active thyroid eye disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TEPEZZA is indicated for the treatment of Thyroid Eye Disease.
	  			</td>
				
	  			<td>
					
						01/21/2020
					
	  			</td>

	  			<td>

					
					01/21/2027
					
					
	  			</td>

				<td>
					For the treatment of active Thyroid Eye Disease
				</td>
			
  			<td>
  				Horizon Therapeutics Ireland DAC
  			</td>
  			<td>
  				Connaught House, 1st Floor  
  			</td>
  			<td>
  				1 Burlington Road 
  			</td>
  			<td>
  				Dublin 
  			</td>
  			<td>
  				Ireland 
  			</td>
  			<td>
  				DO4 C5Y6
  			</td>
  			<td>
  				Ireland
  			</td>
			<td>
  				387812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ofatumumab
  			</td>
  			<td>
  				ARZERRA
  			</td>
  			<td>
  				03/10/2009
  			</td>
  			<td>
  				Treatment of chronic lymphocytic leukemia
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. 
	  			</td>
				
	  			<td>
					
						01/19/2016
					
	  			</td>

	  			<td>

					
					01/19/2023
					
					
	  			</td>

				<td>
					For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. 
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				275809
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				02/02/2016
  			</td>
  			<td>
  				Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. 
	  			</td>
				
	  			<td>
					
						01/18/2017
					
	  			</td>

	  			<td>

					
					01/18/2024
					
					
	  			</td>

				<td>
					Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. 
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				462114
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				02/05/2015
  			</td>
  			<td>
  				Treatment of splenic marginal zone lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. 
	  			</td>
				
	  			<td>
					
						01/18/2017
					
	  			</td>

	  			<td>

					
					01/18/2024
					
					
	  			</td>

				<td>
					Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. 
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				462314
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				ibrutinib
  			</td>
  			<td>
  				Imbruvica
  			</td>
  			<td>
  				02/05/2015
  			</td>
  			<td>
  				Treatment of nodal marginal zone lymphoma 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. 
	  			</td>
				
	  			<td>
					
						01/18/2017
					
	  			</td>

	  			<td>

					
					01/18/2024
					
					
	  			</td>

				<td>
					Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. 
				</td>
			
  			<td>
  				Pharmacyclics, LLC
  			</td>
  			<td>
  				995 E. Arques Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sunnyvale
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94085
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				462214
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Nitisinone
  			</td>
  			<td>
  				Orfadin
  			</td>
  			<td>
  				05/16/1995
  			</td>
  			<td>
  				Treatment of tyrosinemia type 1.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1
	  			</td>
				
	  			<td>
					
						01/18/2002
					
	  			</td>

	  			<td>

					
					01/18/2009
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Swedish Orphan Biovitrum AB 
  			</td>
  			<td>
  				SE-112
  			</td>
  			<td>
  				75 Stockholm
  			</td>
  			<td>
  				Stockholm
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Sweden
  			</td>
			<td>
  				089095
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Respiratory syncytial virus immune globulin (Human)
  			</td>
  			<td>
  				Respigam
  			</td>
  			<td>
  				09/27/1990
  			</td>
  			<td>
  				Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).
	  			</td>
				
	  			<td>
					
						01/18/1996
					
	  			</td>

	  			<td>

					
					01/18/2003
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				MedImmune & Massachussetts Public Health Biologics Labs.
  			</td>
  			<td>
  				35 West Watkins Mill Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Gaithersburg
  			</td>
  			<td>
  				Maryland
  			</td>
  			<td>
  				20878
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				051190
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				glucarpidase
  			</td>
  			<td>
  				Voraxaze
  			</td>
  			<td>
  				08/19/2003
  			</td>
  			<td>
  				Treatment of patients at risk of methotrexate toxicity
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.  
	  			</td>
				
	  			<td>
					
						01/17/2012
					
	  			</td>

	  			<td>

					
					01/17/2019
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				BTG International Inc.
  			</td>
  			<td>
  				5214 Maryland Way
  			</td>
  			<td>
  				Suite 405
  			</td>
  			<td>
  				Brentwood
  			</td>
  			<td>
  				Tennessee
  			</td>
  			<td>
  				37027
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				163702
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Gallium nitrate injection
  			</td>
  			<td>
  				Ganite
  			</td>
  			<td>
  				12/05/1988
  			</td>
  			<td>
  				Treatment of hypercalcemia of malignancy.
  			</td>
  			<td>
  				Designated/Approved/Withdrawn
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				
	  			</td>
				
	  			<td>
					
						01/17/1991
					
	  			</td>

	  			<td>

					
					01/17/1998
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Solopak Pharmaceutical Co.
  			</td>
  			<td>
  				1845 Tonne Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Elk Grove Village
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60007
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				024487
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				human fibrinogen concentrate, pasteurized
  			</td>
  			<td>
  				RiaSTAP
  			</td>
  			<td>
  				03/13/2008
  			</td>
  			<td>
  				Treatment of fibrinogen deficient patients.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia)
	  			</td>
				
	  			<td>
					
						01/16/2009
					
	  			</td>

	  			<td>

					
					01/16/2016
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				CSL Behring, LLC
  			</td>
  			<td>
  				1020 First Avenue
  			</td>
  			<td>
  				P.O. Box 61501
  			</td>
  			<td>
  				King of Prussia
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19406
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				245107
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				fam-trastuzumab deruxtecan-nxki
  			</td>
  			<td>
  				Enhertu
  			</td>
  			<td>
  				05/20/2020
  			</td>
  			<td>
  				Treatment of gastric cancer, including gastroesophageal junction cancer
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen
	  			</td>
				
	  			<td>
					
						01/15/2021
					
	  			</td>

	  			<td>

					
					01/15/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen
				</td>
			
  			<td>
  				Daiichi Sankyo, Inc.
  			</td>
  			<td>
  				211 Mount Airy Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Basking Ridge
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07920
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				738420
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				daratumumab and hyaluronidase-fihj
  			</td>
  			<td>
  				Darzalex Faspro
  			</td>
  			<td>
  				10/06/2020
  			</td>
  			<td>
  				treatment of light-chain (AL) amyloidosis
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis
	  			</td>
				
	  			<td>
					
						01/15/2021
					
	  			</td>

	  			<td>

					
					01/15/2028
					
					
	  			</td>

				<td>
					treatment of adult patients with newly diagnosed light chain (AL) amyloidosis
				</td>
			
  			<td>
  				Janssen Research & Development, LLC
  			</td>
  			<td>
  				1400 McKean Road
  			</td>
  			<td>
  				PO Box 776
  			</td>
  			<td>
  				Spring House
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19477
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				769220
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				crizotinib
  			</td>
  			<td>
  				Xalkori
  			</td>
  			<td>
  				09/28/2012
  			</td>
  			<td>
  				Treatment of anaplastic large cell lymphoma
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive
	  			</td>
				
	  			<td>
					
						01/14/2021
					
	  			</td>

	  			<td>

					
					01/14/2028
					
					
	  			</td>

				<td>
					treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
				</td>
			
  			<td>
  				Pfizer, Inc.
  			</td>
  			<td>
  				10646 Science Center Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92121
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				379712
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				cabozantinib
  			</td>
  			<td>
  				CABOMETYX
  			</td>
  			<td>
  				03/02/2017
  			</td>
  			<td>
  				Treatment of hepatocellular carcinoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
	  			</td>
				
	  			<td>
					
						01/14/2019
					
	  			</td>

	  			<td>

					
					01/14/2026
					
					
	  			</td>

				<td>
					CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
				</td>
			
  			<td>
  				Exelixis, Inc.
  			</td>
  			<td>
  				1851 Harbor Bay Parkway
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Alameda
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94502
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				552916
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				sodium nitrite and sodium thiosulfate
  			</td>
  			<td>
  				Nithiodote
  			</td>
  			<td>
  				04/09/2008
  			</td>
  			<td>
  				Treatment of known or suspected cyanide poisoning
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening
	  			</td>
				
	  			<td>
					
						01/14/2011
					
	  			</td>

	  			<td>

					
					01/14/2018
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Hope Pharmaceuticals
  			</td>
  			<td>
  				16416 North 92nd Street
  			</td>
  			<td>
  				Suite 125
  			</td>
  			<td>
  				Scottsdale
  			</td>
  			<td>
  				Arizona
  			</td>
  			<td>
  				85260
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				244207
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				phoxillum
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				02/14/2014
  			</td>
  			<td>
  				For use as a replacement solution in patients undergoing continuous renal replacement therapy
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialzable substances
	  			</td>
				
	  			<td>
					
						01/13/2015
					
	  			</td>

	  			<td>

					
					01/13/2022
					
					
	  			</td>

				<td>
					As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialzable substances
				</td>
			
  			<td>
  				Gambro Renal Products, Inc.
  			</td>
  			<td>
  				1845 Mason Avenue
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Daytona Beach
  			</td>
  			<td>
  				Florida
  			</td>
  			<td>
  				32117
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				382012
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				afatinib
  			</td>
  			<td>
  				Gilotrif 
  			</td>
  			<td>
  				12/03/2012
  			</td>
  			<td>
  				Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
	  			</td>
				
	  			<td>
					
						01/12/2018
					
	  			</td>

	  			<td>

					
					01/12/2025
					
					
	  			</td>

				<td>
					GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations other than exon 19 deletions or exon 21 (L858R) substiution mutationas as detected by an FDA-approved test.
				</td>
			
  			<td>
  				Boehringer Ingelheim Pharmaceuticals, Inc.
  			</td>
  			<td>
  				900 Ridgebury Road
  			</td>
  			<td>
  				P. O. Box 368
  			</td>
  			<td>
  				Ridgefield
  			</td>
  			<td>
  				Connecticut
  			</td>
  			<td>
  				06877
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				375712
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Arsenic trioxide
  			</td>
  			<td>
  				Trisenox
  			</td>
  			<td>
  				03/03/1998
  			</td>
  			<td>
  				Treatment of acute promyelocytic leukemia.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
	  			</td>
				
	  			<td>
					
						01/12/2018
					
	  			</td>

	  			<td>

					
					01/12/2025
					
					
	  			</td>

				<td>
					In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
				</td>
			
  			<td>
  				Teva Branded Pharmaceutical Products R&D, Inc.
  			</td>
  			<td>
  				41 Moores Road
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Frazer
  			</td>
  			<td>
  				Pennsylvania
  			</td>
  			<td>
  				19355
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				109697
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Potassium Iodide Oral Solution 
  			</td>
  			<td>
  				ThyroShield
  			</td>
  			<td>
  				11/17/2004
  			</td>
  			<td>
  				For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine 
	  			</td>
				
	  			<td>
					
						01/12/2005
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Fleming & Company, Pharmaceuticals
  			</td>
  			<td>
  				1733 Gilsinn Lane
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Fenton
  			</td>
  			<td>
  				Missouri
  			</td>
  			<td>
  				63026
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				190304
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				diazepam (intranasal)
  			</td>
  			<td>
  				VALTOCO
  			</td>
  			<td>
  				11/16/2015
  			</td>
  			<td>
  				Management of acute repetitive seizures
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
	  			</td>
				
	  			<td>
					
						01/10/2020
					
	  			</td>

	  			<td>

					
					01/10/2027
					
					
	  			</td>

				<td>
					Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
				</td>
			
  			<td>
  				Neurelis Pharmaceuticals, Inc.
  			</td>
  			<td>
  				11682 El Camino Reall
  			</td>
  			<td>
  				Suite 255
  			</td>
  			<td>
  				San Diego
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				92130
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				382512
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				avapritinib
  			</td>
  			<td>
  				Ayvakit
  			</td>
  			<td>
  				01/06/2016
  			</td>
  			<td>
  				Treatment of gastrointestinal stromal tumors
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
	  			</td>
				
	  			<td>
					
						01/09/2020
					
	  			</td>

	  			<td>

					
					01/09/2027
					
					
	  			</td>

				<td>
					Treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
				</td>
			
  			<td>
  				Blueprint Medicines Corporation
  			</td>
  			<td>
  				45 Sidney Street
  			</td>
  			<td>
  				Suite 200
  			</td>
  			<td>
  				Cambridge
  			</td>
  			<td>
  				Massachusetts
  			</td>
  			<td>
  				02139
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				500415
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				levodopa and carbidopa
  			</td>
  			<td>
  				Duopa
  			</td>
  			<td>
  				01/18/2000
  			</td>
  			<td>
  				Treatment of late stage Parkinson's disease
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of motor flucuations in patients with advanced Parkinson's disease
	  			</td>
				
	  			<td>
					
						01/09/2015
					
	  			</td>

	  			<td>

					
					01/09/2022
					
					
	  			</td>

				<td>
					Treatment of motor flucuations in patients with advanced Parkinson's disease
				</td>
			
  			<td>
  				AbbVie, Inc.
  			</td>
  			<td>
  				1 N. Waukegan Road
  			</td>
  			<td>
  				Building AP30-1
  			</td>
  			<td>
  				North Chicago
  			</td>
  			<td>
  				Illinois
  			</td>
  			<td>
  				60064
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				129499
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Aldesleukin
  			</td>
  			<td>
  				Proleukin
  			</td>
  			<td>
  				09/10/1996
  			</td>
  			<td>
  				Treatment of metastatic melanoma.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of adults with metastatic melanoma.
	  			</td>
				
	  			<td>
					
						01/09/1998
					
	  			</td>

	  			<td>

					
					01/09/2005
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Chiron Corporation
  			</td>
  			<td>
  				4560 Horton Street
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Emeryville
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94608
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				100696
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trametinib and dabrafenib
  			</td>
  			<td>
  				MEKINIST and TAFINLAR
  			</td>
  			<td>
  				09/20/2012
  			</td>
  			<td>
  				Treatment of Stage IIb through IV melanoma. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.
	  			</td>
				
	  			<td>
					
						01/08/2014
					
	  			</td>

	  			<td>

					
					01/08/2021
					
					
	  			</td>

				<td>
					TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Office 337 A13.5B
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				376812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				trametinib and dabrafenib
  			</td>
  			<td>
  				MEKINIST and TAFINLAR
  			</td>
  			<td>
  				09/20/2012
  			</td>
  			<td>
  				Treatment of Stage IIb through IV melanoma. 
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate.  Improvement in disease-related symptoms or overall survival has not been demonstrated for MEKINIST in combination with dabrafenib.
	  			</td>
				
	  			<td>
					
						01/08/2014
					
	  			</td>

	  			<td>

					
					01/08/2021
					
					
	  			</td>

				<td>
					MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate.  Improvement in disease-related symptoms or overall survival has not been demonstrated for MEKINIST in combination with dabrafenib.
				</td>
			
  			<td>
  				Novartis Pharmaceuticals Corporation
  			</td>
  			<td>
  				One Health Plaza
  			</td>
  			<td>
  				Office 337 A13.5B
  			</td>
  			<td>
  				East Hanover
  			</td>
  			<td>
  				New Jersey
  			</td>
  			<td>
  				07936
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				376812
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				emtricitabine and tenofovir alafenamide
  			</td>
  			<td>
  				Descovy
  			</td>
  			<td>
  				06/06/2017
  			</td>
  			<td>
  				Treatment of HIV-1 infection in pediatric patients under 12 years of age
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg in combination with other antiretroviral agents other than
protease inhibitors that require a CYP3A inhibitor
	  			</td>
				
	  			<td>
					
						01/07/2022
					
	  			</td>

	  			<td>

					
					
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Gilead Sciences, Inc.
  			</td>
  			<td>
  				333 Lakeside Drive
  			</td>
  			<td>
  				
  			</td>
  			<td>
  				Foster City
  			</td>
  			<td>
  				California
  			</td>
  			<td>
  				94404
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				569716
  			</td>
	
  		</tr>
	   

	
	
  		<tr>
  			<td>
  				Atovaquone
  			</td>
  			<td>
  				Mepron
  			</td>
  			<td>
  				08/14/1991
  			</td>
  			<td>
  				Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.
  			</td>
  			<td>
  				Designated/Approved
  			</td>
  			<td>
  				
  			</td>
			
	  			<td>
	  				Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.
	  			</td>
				
	  			<td>
					
						01/05/1999
					
	  			</td>

	  			<td>

					
					01/05/2006
					
					
	  			</td>

				<td>
					
				</td>
			
  			<td>
  				Glaxo Wellcome Research and Development
  			</td>
  			<td>
  				5 Moore Drive
  			</td>
  			<td>
  				PO Box 13398
  			</td>
  			<td>
  				Research Triangle Park
  			</td>
  			<td>
  				North Carolina
  			</td>
  			<td>
  				27709
  			</td>
  			<td>
  				United States
  			</td>
			<td>
  				048990
  			</td>
	
  		</tr>
	   

	</table>
		Note: Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
	 